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Summary
Human cytomegalovirus (HCMV) frequently reactivates after hematopoietic stem cell transplant-
ation (HSCT). Antiviral medication is not universally effective and has side effects that prohibit
prophylaxis and limit pre-emptive use. Adoptive transfer of HCMV-specific T lymphocytes can
protect patients at risk of HCMV disease, but such T cells are difficult to obtain if the HSC donor
is HCMV-negative. Transferring the T cell receptor (TCR) genes of HCMV-specific T cell clones
to donor T cells will convey HCMV specificity to those cells. But if αβ T cells are engineered to
co-express a second αβ TCR, mixed αβ TCR heterodimers of unknown and potentially hazardous
specificity may form. This problem can be solved by expressing αβ TCRs in γδ T cells from the
donor.
HCMV-specific CD8+ T cells limit HCMV infection, but presentation of their antigenic pep-
tides is effectively impaired by HCMV’s immunoevasins, especially in case of human leukocyte
antigen (HLA)-A and -B allotypes. In contrast, CD8+ T cells restricted by HLA-C*07:02 resist
the immunoevasins. In this study, the genes of eight HLA-C*07:02-restricted TCRs specific for
immediate-early protein 1 (IE-1) or UL28 protein were derived from CD8+ T cell clones and ret-
rovirally transferred into T cells from HCMV-negative donors. While all of those TCRs mediated
strong recognition of an HCMV strain that is devoid of the four immunoevasins, their response to
target cells infected with wild-type HCMV strains was weaker. Transduction experiments with
different variations of the TCRs pointed to the existence of additional T cell-endogenous factors
that contribute to recognition of infected cells.
HCMV-specific CD4+ T cells are known to play a critical role in controlling HCMV and maintain-
ing immunity. Nonetheless, possibilities of their transgenic generation have not been explored.
In this study, HCMV-specific TCRs from CD4+ T cell clones were expressed in T cells from
HCMV-negative donors. A panel of ten HCMV-specific, HLA class II-restricted TCRs was es-
tablished that target seven distinct epitopes of phosphoprotein 65 (pp65) and IE-1 presented by
a wide range of HLA class II allotypes. These TCR genes were retrovirally transferred into αβ
T cells and γδ T cells from HCMV-negative donors. The resulting T cells specifically recognised
HLA-matched, HCMV-infected dendritic cells. TCR-transduced αβ and γδ T cells were simil-
arly effective, but backgrounds due to alloreactivity were even lower in γδ T cells than in αβ
T cells. Experiments with inactivated virus showed that pp65-specific, HLA class II-restricted
TCRs conveyed similar sensitivity towards HCMV-infected target cells and target cells that had
acquired viral proteins through ingestion of extracellular material. In contrast, IE-1-specific,
HLA class II-restricted TCRs mediated selective recognition of bona fide infected target cells.
These results identify γδ T cells that transgenically express HLA class II-restricted TCRs as




Humans are constantly exposed to infectious agents as a result of their interactions with the
environment and uptake of material from it. Considering the multitude and omnipresence of
different pathogens – bacteria, fungi, viruses, protozoa and helminths – it is fascinating that
people rarely suffer from disease. This is due to the human immune system, which has evolved
to defend its host against pathogens. It is comprised of various molecules and cells, organised
in a complex network involving different tissues and spread throughout the human body. In the
mid 20th century, Macfarlane Burnet hypothesised that the immune system is able to recognise
pathogens while generally maintaining the integrity of innocent cells or tissues by distinguish-
ing between agents originating from the host (“self”) and agents being foreign to the human
body (“non-self”, Macfarlane Burnet, 1954). However, several observations, such as reactivity
of the immune system directed against “self” (“autoimmunity”), could not be explained by the
“self/non-self” model. In contrast, Matzinger (1994) proposed that the immune system is far less
concerned with things that are foreign, but with the detection of damage and danger signals that
are usually accompanied by pathogens or injured host tissue. Since then, the “danger model”
has been adapted to accommodate the immunobiology of phenomena, such as transplantation,
allergy, autoimmunity and cancer, but still “explains most of what the immune system seems to
do right, as well as most of what it appears to do wrong” (Matzinger, 2012).
Once a pathogen has bypassed the chemical and physical barriers of the human body, such
as the skin, it will immediately encounter molecules and cells of the innate immune system that
serve as the first line of defence. These molecules and cells will counteract the pathogen by
attacking it directly or indirectly, trapping it and recruiting more immune effectors to the site
of infection. While the actions of the innate immune system are very quick and intense, they
are rather unspecific and similarly applied to a broad range of pathogens. In order to efficiently
fight and potentially clear a certain pathogen from the human body, however, a specific immune
response is often required. This second line of defence is provided by the adaptive immune system,
which is initiated by innate molecules and/or cells. Adaptive immune cells need several days to
mount a counter-attack, but develop an immunologic memory, which will be re-activated by a
second encounter of the same pathogen and will result in an increased and quicker response. The
defence mechanisms of both the innate and the adaptive immune system encompass the secretion
of molecules (“humoral response”), as well as direct cellular interactions (“cellular response”).
1.1 Cellular immune responses
All immune cells arise from pluripotent hematopoietic stem cells (HSCs) that differentiate into
common myeloid and common lymphoid progenitor cells in the bone marrow. Granulocytes,
monocytes and dendritic cells (DCs), but also megakaryocytes and erythroblasts, are derived
from common myeloid progenitor cells. In contrast, the common lymphoid progenitor cells give
rise to B cells, T cells, natural killer (NK) cells and also DCs. The innate immune cells, namely
granulocytes, monocytes/macrophages, DCs and NK cells, rely on pattern recognition recept-
ors (PRRs) to recognise invading microbes. These PRRs are invariant receptors that bind to
conserved microbial molecules or patterns of molecular structures generalised under the term of
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pathogen-associated molecular patterns (PAMPs).
Upon recognition of a PAMP or an alarm signal such as tissue damage, tissue-resident macro-
phages and immature DCs will release cytokines and chemokines that convey crucial informations
to other cells and guide other immune cells towards the site of infection. As a result, an inflamma-
tion is triggered that aims to immobilise and destroy the pathogens, to hamper their replication,
to recruit more immune molecules and cells, as well as to promote repair of injured tissue. The
first cells that are attracted to a site of inflammation are neutrophils – a type of granulocyte – and
monocytes. During their migration, monocytes can differentiate into macrophages if triggered
by macrophage colony-stimulating factor (M-CSF), or into immature DCs if interleukin (IL)-4
and granulocyte-macrophage colony-stimulating factor (GM-CSF) are present.
Phagocytic cells, such as DCs, macrophages and neutrophils, do not only drive inflammation
after encountering pathogens or associated alarm signals, but also possess a variety of different
cell surface receptors to bind and engulf microbes, their metabolites and cellular debris from the
environment. Their phagocytic activity, however, depends on their activation status. Immature
DCs, for example, capture antigens in the periphery, but gradually lose their ability to take up
antigens by phagocytosis during maturation (Moutaftsi et al., 2002). The obtained material is
processed and presented to T cells that will be activated if they can recognise the antigen with
their own T cell receptors and if the presenting cell simultaneously provides co-stimulation. The
expression of co-stimulatory molecules, such as CD86 (B7.2), is triggered by PAMPs and sup-
ports the activation of T cells. Co-stimulation is essential for effective T cell activation because
if absent, the T cell will die, become anergic – i.e. “non-responsive” to its specific antigen – or
induce tolerance concerning the specific antigen.
B and T lymphocytes are the key players of the adaptive immune system. Their specificity
is determined by the B cell receptor (BCR) or T cell receptor (TCR), respectively. While the
BCR can recognise a conformational polypeptide substructure, the TCR binds to linear peptides
only if presented by major histocompatibility complex (MHC) proteins. Importantly, B and T
cells differ greatly in function: upon activation, B cells can differentiate into plasma cells and
strongly enhance their capacity to produce antibodies, which are a soluble form of their specific
BCR. Thus, B cells contribute to the humoral immune response by the secretion of antibodies
that can specifically bind to a certain structure of a pathogen. Moreover, B cells can also serve
as antigen-presenting cells (APCs) after binding to antigenic material via the BCR, engulfing
the material and digesting it.
In contrast to B cells, T cells exert their functions by direct or indirect interactions with host
cells. They can be grouped into the two major categories of cytotoxic T lymphocytes (CTLs) and
T helper (TH) cells, most of which express either the TCR co-receptor CD8 or CD4, respectively.
CTLs eliminate pathogen-infected host cells thereby preventing further replication and dissem-
ination of the pathogen. In contrast, TH cells control immune responses by orchestrating and
regulating various immune cells, such as B cells, CTLs and macrophages. Thus, CD4-positive
(CD4+) TH cells are of vital importance for the generation of appropriate and effective immune
responses. B cells, for example, present fragments of processed antigens to TH cells of corres-
ponding specificity, which in turn stimulate the B cells if the TH cells recognised the presented
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antigen with their TCRs – a process that is required for establishing effective humoral immunity.
During an infection, a small number of antigen-specific T cells expands by several orders of mag-
nitude in order to combat the infection. After the acute immune response has subsided and the
infection is resolved, most of the antigen-specific T cells die, but a small proportion persists.
These T cells will react more quickly and strongly if they encounter their antigen again in case
of re-infection with the same pathogen. This kind of T cells is called memory T cells and their
formation depends on TH cells. After primary infection with certain persistent pathogens, such
as HCMV, has been resolved, the number of T cells that are maintained is relatively high. Also,
there is a debate whether such T cells should be considered “memory” T cells because there is
periodic or continuous challenge with at least low-level antigen in such infections (reviewed in
Virgin et al., 2009).
1.1.1 Composition and diversity of the T cell receptor
Every T cell expresses a unique T cell receptor (TCR) that defines its specificity and enables it to
survey a small part of the molecular universe within the human body. A TCR is a heterodimer
composed either of a TCRα and a TCRβ chain or a TCRγ and a TCRδ chain, which are linked
by a disulfide bond. Each TCR chain consists of a variable (V) and a constant (C) domain, both
of which are extracellular and immunoglobulin-like, a short hinge, a transmembrane domain and
a cytoplasmic tail. The specificity of a TCR is defined by the combined protein surface formed
by the extracellular V domains of both TCR chains. Each of these V domains has three pro-
truding loops that mediate most of the binding to the antigen and the molecule presenting it.
Accordingly, the loops are called complementarity determining regions (CDRs).
While the CDRs 1 and 2 are encoded within the V gene segment of a given TCR chain, the
CDR3 is located at the junctions of V(D)J segments (fig. 1.1). Due to the diverse, partially
random events during V(D)J recombination, the CDR3 is highly variable (fig. 1.1). In contrast,
the germline-encoded CDR1 and CDR2 are less variable, because there are at most as many
different versions of them as there are corresponding V gene segments to choose from in the
genome (e.g. ≈60 for TCRβ), and their genome-encoded sequences are not altered. This fits
the binding properties of these loops well, since CDR1 and CDR2 bind the less variable MHC
molecule(s) and CDR3 binds to the highly variable peptide antigen that is being presented on
MHC molecule(s) (see fig. 1.4 & 1.5).
In the cell membrane, the TCR heterodimer associates with and is stabilised by a ζζ homodi-
mer and the CD3 complex that consists of two heterodimers, namely εγ and εδ. Like the TCR
chains, these proteins are membrane-anchored by transmembrane domains. Their intracellular
tails contain immunoreceptor tyrosine-based activation motifs (ITAMs) that are essential for
TCR signal transmission.
The interaction of an αβ T cell with a peptide antigen presented on MHC class I or class II
molecules (peptide/MHC complex) is mediated by its TCR and can be stabilised by the co-
receptor CD8 or CD4, respectively. Both co-receptors are transmembrane proteins and directly
bind to MHC molecules thus increasing the overall strength of the TCR-MHC binding. CD8
can either be expressed as αα homodimer or as αβ heterodimer. The latter is pre-dominant on
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CTLs and binds to the α2 and α3 domain of MHC class I molecules, while it does not interfere
with TCR recognition. CD4 is a single chain protein mainly found on TH cells and binds to a
crevice between MHC class II α2 and β2 domains. The interaction of a single TCR with a pep-
tide/MHC complex is not sufficient to fully activate the T cell even if supported by CD4 or CD8
co-receptor and co-stimulatory molecule binding. In order to activate the T cell, a multitude
of TCR-peptide/MHC interactions has to occur, usually in an arrangement of molecules termed
the immunological synapse. The affinity of each interaction contributes to the overall avidity of
the interaction between the T cell and an APC. This synapse is further stabilised by interactions
of adhesion molecules (e.g. integrins) expressed by the APC and the T cell.
TCRs have a tremendous variability, which is estimated to encompass more than 108 unique
TCRβ sequences in naïve CD4 and CD8 T cell repertoires of young adults (Qi et al., 2014). This
is a result of (I) many different gene segments of one TCR chain that can be combined in various
ways (combinatorial diversity), (II) imprecise processing of DNA ends during the rearrangement
(junctional diversity) and (III) different combinations of TCRα and TCRβ or TCRγ and TCRδ
chains. Each of the TCR chains is created separately by rearrangement of TCR genes in the T
cell precursor (somatic recombination) during its maturation in the thymus.
In order to understand the combinatorial diversity, we must take a look at the composition of the
TCR chains and their genetic loci (fig. 1.2): Human TCRα chains are comprised of a variable
(V), a joining (J) and a constant (C) region each encoded by respective gene segments. While
there is only one Cα gene segment, there are 59 Vα and 61 Jα gene segments. Similarly, human
TCRβ chains are also composed of one V, J and C region, each, but additionally contain a di-










Figure 1.1. mRNA structure of TCRα (top) and TCRβ chain (bottom). The complementarity
determining regions (CDRs) 1 and 2 are germline-encoded within the respective V gene
segment. However, the CDR3 spans across the junction of the rearranged V (red) and J
(cyan) gene segments (TCRα) or V, D (yellow) and J gene segments (TCRβ). At the junc-
tions between V, D (if available) and J segments, nucleotides are randomly added or deleted
(purple) by the terminal deoxynucleotidyl transferase (TdT) or exonucleases, respectively.
This greatly contributes to CDR3 diversity. C gene segments are displayed in blue. Modified
from Attaf et al. (2015).
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Figure 1.2. TCR gene rearrangement at the TR loci. A: The TRA locus contains 59 Vα, 61 Jα
and 1 Cα gene segment and includes the whole TRD locus (3 Vδ, 3 Dδ, 4 Jδ and 1 Cδ). V
to J recombination joins one Vα gene segment with one Jα gene segment, while intervening
gene segments are excised. The final TCRα transcript is generated by splicing. B: The
TRB locus contains 68 Vβ, 2 Dβ, 14 Jα and 2 Cβ gene segments, with two separate DJC
clusters. Firstly, one Dβ gene segment is fused to one Jβ gene segment and intervening gene
segments are excised (D to J recombination). Secondly, one Vβ gene segment is joined with
the rearranged DJβ, excluding intervening gene segments again (V to DJ recombination).
The final TCRβ transcript is generated by splicing. Modified from Attaf et al. (2015).
in contrast to the high number of Jα gene segments, fewer Jβ gene segments exist (14). While
the TCRα locus contains no D and only one C gene segment, the TRB locus offers two, each.
Human TCRγ and TCRδ chains are composed similarly to human TCRα (V-J-C) and TCRβ
chains (V-D-J-C), respectively, but the number of germline encoded Vγ and Vδ genes is a lot
lower than that of Vα and Vβ: 13 Vγ, 5 Jγ, 2 Cγ, 3 Vδ, 3 Dδ, 4 Jδ and 1 Cδ gene segment
exist. However, T cells expressing a γδ TCR (γδ T cells) may compensate for this by junctional
diversity (reviewed in Carding and Egan, 2002). The TRD locus is part of the TRA locus with
Vδ gene segments being interspersed with Vα gene segments and Dδ, Jδ and Cδ gene segments
being located between Vα/δ and Jα gene segments.
During TCR gene rearrangement, one V, one D (only for TCRβ and TCRδ) and one J gene
segment are linked together and subsequently connected to one C gene segment, while all other
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intervening V and J gene segments between the chosen V and J gene segments are excised (see
fig. 1.2). Any TCRα rearrangement results in the loss of the complete TRD locus. While gene
rearrangement is taking place, junctional diversity comes into play, too: When V, (D,) and J
gene segments are joined, the enzyme terminal deoxynucleotidyl transferase (TdT) adds short,
random stretches of nucleotides to the coding ends and exonucleases may delete nucleotides at
gene segment junctions (fig. 1.1). Both processes greatly contribute to CDR3 diversity of both
TCR chains, but come at the cost of many non-productive rearrangements due to random DNA
sequence alterations that can induce a frame shift or stop codon. However, the development of
a T cell does not necessarily fail in case of a non-productive TCR gene rearrangement, since
at most loci remaining gene segments allow for successive rearrangements on the same chromo-
some (see fig. 1.2). Also, if TCR gene rearrangement on one chromosome is unsuccessful, the
process may be repeated on the other chromosome in order to create a functional TCR chain gene.
After successful rearrangements of TCRα and TCRβ genes that are able to successfully pair
with each other and create a TCR signal, a developing αβ T cell will simultaneously express
both CD4 and CD8 co-receptors and undergo a TCR-driven selection process in the thymus,
during which its capability to recognise self-peptides on self-MHC proteins is tested. CD4- and
CD8-double-positive (DP) T cells bind to self-peptide/self-MHC complexes presented by cortical
epithelial cells in the thymic cortex, which triggers their proliferation (a process called “positive
selection”). Thus, a DP T cell that is able to bind to any of the offered MHC class I or class II
molecules survives and will subsequently become CD4- or CD8-single-positive (SP). If the devel-
oping T cell binds too strongly to self-peptide/self-MHC complexes, however, it may possess a
TCR that is specific for a self-peptide and thus has to be deleted in order to avoid autoimmune
reactivity. This is a process known as “negative selection”, which can happen during both DP
and SP stages of T cell development. On the contrary, if the T cell binds too weakly or not at
all to self-peptide/self-MHC complexes, it may not be able to bind to any peptide-presenting
self-MHC at all and thus will be of no immunologic use. Indeed, the vast majority of αβ T cells
succumbs to these selection processes and dies or becomes anergic. Having successfully passed
thymic selection, a T cell emerging from the thymus will express either CD4 or CD8, depending
on the MHC class its TCR binds to.
Whether and to which extent thymic selection shapes the γδ T cell repertoire is less well under-
stood. γδ T cells do not necessarily undergo thymic selection the way that αβ T cells do. At least
in the mouse, normal γδ T cell development requires proper intrathymic localisation (Reinhardt
et al., 2014) and thymic selection was shown to determine the effector fate of γδ T cells rather
than constrain their antigen specificities (Jensen et al., 2008).
1.1.2 γδ T cells
On average, about 4% of T cells in peripheral blood of healthy adults are γδ T cells (Groh et al.,
1989; Pitard et al., 2008). They constitute a phenotypically diverse T cell population and most
of them do not express CD4 or CD8 (Groh et al., 1989), so they are not sub-grouped like αβ T
cells, but according to their Vδ expression. Vδ1 T cells and Vδ3 T cells make up about 1% and
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less than 0.5% of peripheral blood T cells, respectively, but are enriched in mucosal epithelia
and the spleen (Pitard et al., 2008). The majority of γδ T cells found in peripheral blood are
Vδ2 T cells (3% among peripheral blood T cells). In the 1990s, Vδ2 T cells were identified to be
activated by non-peptidic mycobacterial antigens (Constant et al., 1994; Davodeau et al., 1993)
that were characterised as prenyl pyrophosphates and included isopentenyl pyrophosphate (IPP
Tanaka et al., 1995). Later, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) of the
2-C-methyl-D-erythritol 4-phosphate (MEP) pathway, which is not present in eukaryotes, was
found to be 104× more potent than IPP (Hintz et al., 2001). IPP is produced by the MEP path-
way, but also by the mevalonate pathway of eukaryotes. In a macaque model, Vδ2 T cells were
shown to respond to infection with Mycobacterium tuberculosis in vivo, to mount memory re-
sponses on re-infection and to confer protective immunity to macaques that had been vaccinated
with Mycobacterium bovis Bacille Calmette-Guérin (Shen et al., 2002). In humans, numerous
pathogenic bacteria and protozoan parasites were reported to drive immune responses of Vδ2 T
cells (reviewed in Morita et al., 2007).
In vitro and in vivo, aminobisphosphonates, like pamidronate or zoledronate, have been shown
to trigger human Vδ2 T cell activation and proliferation (Gober et al., 2003; Khan et al., 2014;
Wilhelm et al., 2003) as a result of the inhibition of farnesyl pyrophosphate synthesis in the
mevalonate pathway. This inhibition causes the accumulation of IPP (Gober et al., 2003). Miy-
agawa et al. (2001) reported that stimulation of Vδ2 T cells by pamidronate strictly depended
on the presence of cells from the monocyte lineage in vitro. The sensitivity for phosphoantigens
can be conferred to other T cells by transfer of Vγ9Vδ2 TCR genes (Bukowski et al., 1995; Das
et al., 2001). The membrane-expressed butyrophilin (BTN) 3A1 molecule has been identified
to play a key role in target cells that activate Vδ2 T cells (Harly et al., 2012). More precisely,
phosphoantigens directly bind to BTN3A1’s intracellular B30.2 domain, causing immobilisation
of BTN3A1 in the plasma membrane. Subsequently, BTN3A1 either recruits an additional factor
and/or changes the conformation of its extracellular domain thereby generating a structure that
can directly be detected by the Vγ9Vδ2 TCR (Sandstrom et al., 2014; Vavassori et al., 2013).
Sebestyen et al. (2016) support both notions adding the small GTPase RhoB to the model:
RhoB, which is activated and relocated for example by dysregulation of the mevalonate pathway,
induces immobilisation of BTN3A1, but ultimately dissociates from BTN3A1 most likely after
phosphoantigen binding and the conformational change of the extracellular domain of BTN3A1.
Vδ2 T cells can be activated by certain cancer cells (Gober et al., 2003; Morita et al., 2007),
probably due to dysregulation of metabolism in cancer cells leading to the accumulation of
phosphoantigens, and thus can be used in cancer therapy (reviewed in Scheper et al., 2014).
Recently, Vδ2 T cells and Vγ9Vδ2 TCRs (Hoeres et al., 2018; Straetemans et al., 2018) were
developed for cancer therapy and their function was assessed in clinical trials. In general, the
administration of γδ T cells was safe regardless of in vitro or in vivo stimulation, but clinical
responses varied and showed limited success (reviewed in Scheper et al., 2014).
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1.1.3 Antigen presentation and the major histocompatibility complex
An αβ T cell will be activated if its TCR binds to a peptidic antigen that is presented on major
histocompatibility complex (MHC) class I or class II molecules. In humans, these proteins are
also called human leukocyte antigens (HLAs). The human MHC locus on chromosome number
6 contains three MHC class I α genes, one HLA-A, -B and -C gene each, and three pairs of
MHC class II α and β genes, one pair of HLA-DR, -DQ and -DP genes each. Additionally, the
MHC locus can contain an extra HLA-DRβ chain gene (fig. 1.3). The particular set of HLA
alleles that is found on a single chromosome is called the HLA haplotype. This polygeny and the
polymorphism of most of those HLA genes have evolved to at least partially match the enormous
diversity of peptides. Thus, being heterozygous for the genes encoding HLA class I and II mo-
lecules is likely advantageous and since HLA alleles are expressed co-dominantly, an individual
can express 3 to 6 and 3 to 12 different HLA class I and class II molecules, respectively.
While HLA class I molecules are expressed on almost every cell of the human body, HLA
class II molecules are mainly present on the surface of immune cells, such as DCs, mono-
cytes/macrophages, B and T cells. In addition, HLA class II molecules can also be expressed by
non-hematopoietic cells, like fibroblasts and endothelial cells, if induced by interferon (IFN)-γ
(Collins et al., 1984; Pober et al., 1983; Stevanovic et al., 2013).
HLA class I molecules consist of an α chain (also termed “heavy chain”) that includes a trans-
membrane domain and forms a heterodimer with the invariant β2-microglobulin (β2-m). Peptides
bound to the extracellular domains of an HLA class I molecule are typically 8 to 10 amino acids
Class II Class IClass III
AB C EMIC F GTNFC4 Bf C2DRDQDODO
TAP
LMPDMDP
Classical class I molecules
Non-classical class I molecules
Classical class II molecules
Non-classical class II molecules
Molecules associated with
antigen processing
Complement factors and cytokines
Figure 1.3. Organisation of the human major histocompatibility complex (MHC) locus on
chromosome 6. The human MHC (also called HLA) locus is divided in three regions:
class I, class II and class III. Class I encodes the genes of HLA-A, -B and -C (the classical
HLA class I molecules), as well as the genes of HLA-E, -F, -G and MHC class I chain-related
(MIC) proteins (the non-classical HLA class I molecules). Class II encodes the genes for α
and β chains of HLA-DR, -DQ and -DP (the classical HLA class II molecules), as well as
the genes of transporter associated with antigen-processing (TAP), HLA-DO and -DM (the
non-classical HLA class II molecules). Class III encodes the genes of tumour necrosis factor
(TNF) and the complement proteins Bf, C2 and C4. Only some of the genes located at the
MHC locus are shown. Distances between genes are not in scale. According to Trowsdale
(2002).
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in length and binding is almost always stabilised by an anchor residue at the carboxy (C) ter-
minus of the peptide. Additional anchor residues can be in other positions of the peptide, this
depends on the HLA in question. The binding cleft of the HLA class I α chain provides limited
space for the accommodation of a peptide, so long or bulky peptides protrude from the cleft in
order to fit (fig. 1.4). The loading of HLA class I molecules with antigenic peptides takes place in
the endoplasmic reticulum (ER). During translation of HLA class I chains, they are translocated
to the ER lumen, where they fold, form a heterodimer together with β2-m, and associate with
proteins that stabilise them and support peptide loading. The majority of peptides loaded onto
HLA class I molecules is produced by the proteasome by degradation of proteins translated in the
same cell. These peptides are continually transported from the cytosol into the ER by transport-
ers associated with antigen processing (TAP), which are proteins of the ATP binding cassette
family that prefer peptides of 8 to 16 amino acids harbouring hydrophobic or basic residues at
the C terminus (van Endert, 1999; Peters et al., 2003). However, peptides translocated by TAP
are often too long at the amino (N) terminus to bind to HLA class I molecules. The N terminus
can be shortened by the ER aminopeptidases ERAP1 and ERAP2 which act in concert in order
to produce peptides that can fit into the HLA molecule’s binding cleft (Saveanu et al., 2005).
HLA class II molecules are heterodimers consisting of an α and a β chain, both of which encom-
pass a transmembrane domain. Together the two chains form a peptide binding cleft, which is
not closed at the ends, like that of HLA class I α chain, and can thus accommodate longer pep-
tides that protrude from the binding cleft (fig. 1.5). Peptides bound to HLA class II molecules
are usually 13 to 17 amino acids long. Most of those peptides are produced by intravesicular
proteases that degrade extracellular pathogens and proteins after their internalisation by endo-
cytosis. Newly synthesised HLA class II heterodimers are bound by the invariant chain (“Ii”),
which blocks the peptide-binding cleft to prevent premature binding of peptides. Ii targets the
delivery of HLA class II heterodimers from the ER to endosomes, where Ii is degraded and HLA
class II heterodimers are loaded with peptides, which is mediated by HLA-DM. After peptide
loading, peptide/HLA class II complexes are transported to the cell surface (the whole process
is reviewed in Kropshofer et al., 1999; Schulze and Wucherpfennig, 2012).
In the absence of peptides, HLA molecules that are expressed on the cell surface are unstable res-
ulting in their internalisation and degradation. The presentation of peptides from extracellular
sources on HLA class I molecules is also possible in some cell types and is of special import-
ance in professional antigen-presenting cells. This process is called cross-presentation (Burgdorf
and Kurts, 2008; Mantegazza et al., 2013). On the other hand, peptides derived from cytosolic
proteins may be presented on HLA class II molecules if they have been degraded by autophagy
(Nimmerjahn et al., 2003).
Individuals express different sets of HLA molecules. If “foreign” tissues are transplanted into a
recipient, the immune system can exert strong alloreactivity due to recognition of non-self HLA
molecules and other antigens. After solid organ transplantation (SOT), the immune system of the
recipient can cause graft rejection, which is usually inhibited by immunosuppressive medication.
However, immunosuppression always needs to be balanced with the accompanied increase in
risk of infection. After hematopoietic stem cell transplantation (HSCT), T lymphocytes that













Figure 1.4. Structure of the extracellular domains of αβ TCR and HLA class I complex.
A TCR consists of an α chain (pink) and a β chain (purple) and interacts with a peptide
(red) that is bound to the HLA class I complex, which is composed of the HLA class I α
chain (cyan) and the invariant β2-microglobulin (blue). Typically, HLA class I complexes
accommodate peptides of 8 to 10 amino acids length. In this case, the peptide is 10 amino
acids long and bound to an HLA-B*44:05. FiguresA and B show the same structure of TCR
and HLA class I complex, in B rotated by 90°. The CDR3 forms a loop that mediates most
of the contact to the peptide (nicely visible in A). Figure C only shows the peptide/HLA
class I complex viewed from the top. Disulfide bonds are shown in yellow. Modified from
Archbold et al. (2009, NCBI Protein Data Bank ID: 3DXA, accessed on 21.05.2019).
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Figure 1.5. Structure of the extracellular domains of αβ TCR and HLA class II complex. A
TCR consists of an α chain (pink) and a β chain (purple) and interacts with a peptide (red)
that is bound to the HLA class II complex, which is composed of the HLA class II α chain
(cyan) and β chain (blue). Typically, HLA class II complexes accommodate peptides of 13
to 17 amino acids length. In this case, the peptide is 13 amino acids long and bound to
an HLA-DRA1*01:01/DRB1*04:01 complex. Figures A and B show the same structure of
TCR and HLA class II complex, in B rotated by 90°. The CDR3 forms a loop that mediates
most of the contact to the peptide. Figure C only shows the peptide/HLA class II complex
viewed from the top. Disulfide bonds are shown in yellow. Modified from Hennecke and
Wiley (2002, NCBI Protein Data Bank ID: 1J8H, accessed on 21.05.2019).
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trigger an immune reaction towards them. This graft-versus-host disease (GvHD) is a major
complication after allogeneic transplantation of hematopoietic stem cells (HSCs) that can be
reduced in incidence by matching the recipient’s HLA type with the donor. This alloreactivity
can even be employed to kill remaining tumour cells (graft-versus-leukemia, GvL), which is part
of the therapeutic principle of allogeneic HSCT. Apart from HLA molecules, genetically different
proteins that are called minor histocompatibility antigens may also trigger GvHD. If the reaction
cannot be controlled by immunosuppression, the recipient suffers from tissue damage that may
result in fever, pain, diarrhea, erythema and even death.
1.2 Human cytomegalovirus
Human cytomegalovirus (HCMV), also known as human herpesvirus 5 (HHV-5), is an oppor-
tunistic and widespread pathogen with a seroprevalence ranging from 50–100 % depending on
socio-economic status, geography and ethnicity (reviewed in Cannon et al., 2010). The other
human herpesviruses are herpes simplex virus type 1 and 2, varicella zoster virus, Epstein-Barr
virus (EBV), HHV-6A and -6B, HHV-7 and Kaposi’s sarcoma-associated herpesvirus. HCMV
carries a linear, double-stranded, ≈235 kb DNA genome that was estimated to harbour 164 to
167 protein-coding open reading frames (ORFs, Davison et al., 2003). Later, wild-type (WT)
HCMV was reported to harbour about 170 genes (Murphy and Shenk, 2008; Sijmons et al., 2014).
In comparison to clinical isolates, the genome of laboratory HCMV strains, such as AD169, con-
tains mutations, deletions and rearrangements (Bradley et al., 2009), which likely are the result
of prolonged in vitro passaging. HCMV’s genome consists of a unique long (UL) and a unique
short (US) region that are both flanked by a pair of inverted repeats (Sijmons et al., 2014). Viral
genes are labelled with the region they are located in and a sequential number (e.g. UL55).
The viral genome is contained in an icosahedral capsid structure that is surrounded by a mat-
rix of proteins (the tegument) and a lipid bilayer envelope (Chen et al., 1999) with membrane-
anchored glycoproteins. The tegument is comprised of many viral proteins, of which the 65 kDa
phosphoprotein (pp65, gene product of UL83) is the most abundant protein of virions, at least
in some HCMV strains such as AD169 (Reyda et al., 2014; Varnum et al., 2004). pp65 plays
an important structural role and participates in the assembly of new virions. Glycoprotein B
(gB), gH, gL, gM, gN and gO are also part of the viral proteome (Varnum et al., 2004) and form
gH/gL complexes that are involved in cell attachment and penetration (Kinzler and Compton,
2005). In contrast, other proteins such as the 72 kDa immediate-early protein 1 (IE-1), which is
the gene product of UL123, play a largely intracellular role in HCMV replication. IE-1 was not
identified as a component of virions (Büscher et al., 2015; Varnum et al., 2004) or was contained
at very low levels only (Reyda et al., 2014).
Except for the viral DNA, HCMV particles also contain various RNAs that allow for the expres-
sion of viral genes in an infected cell immediately after virus entry and independent of the viral
genome (Bresnahan and Shenk, 2000).
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1.2.1 Human cytomegalovirus infection and disease
HCMV can be transmitted via bodily fluids (e.g. saliva, breast milk, urine, blood) of infected
persons with active virus replication and can also be transmitted from mother to fetus (con-
genital infection) or through solid organ transplantation (SOT) and hematopoietic stem cell
transplantation (HSCT). Primary HCMV infection of immunocompetent individuals is usually
asymptomatic and rarely causes severe complications (reviewed in Gandhi and Khanna, 2004),
since the virus is controlled by the host’s immune system. In contrast, the immature immune
system of perinatal and postnatal infants often cannot cope with the infection on its own. HCMV
is one of the most frequent congenital infections and can lead to severe developmental abnormal-
ities and fetal death (reviewed in Gandhi and Khanna, 2004; Manicklal et al., 2013; Ross and
Boppana, 2005). Also, patients that are immunosuppressed after SOT or HSCT and patients
that are infected with human immunodeficiency virus (HIV) and suffer from the acquired im-
munodeficiency syndrome (AIDS) are at risk because their immune system is compromised and
can therefore not sufficiently control HCMV infection. Since HCMV has a broad cell tropism, it
infects and replicates in cells of many different tissues (reviewed in Sinzger et al., 2008a) causing
inflammation and dysfunction of various organs (e.g. lung, gastro-intestinal tract, liver, retina
and central nervous system) if infection is not held in check by the immune system.
In allogeneic HSCT (allo-HSCT), human cytomegalovirus is one of the most significant infec-
tious pathogens causing substantial morbidity and mortality after transplantation (Boeckh et al.,
2003; Boeckh and Nichols, 2004; Walker et al., 2007). If both donor and recipient are HCMV-
seronegative (HCMV–) before transplantation, the risk of viral reactivation can be excluded, but
primary infection with HCMV occurs in 30% of HSCT recipients after transplantation (D– R–,
reviewed in Ljungman, 2007). In contrast, viral reactivation occurs in 80% of cases if the HSCT
recipient was HCMV-seropositive (HCMV+) before transplantation.
In SOT, HCMV– patients who received an organ from an HCMV+ donor (D+ R–) are at high
risk of HCMV infection by viral reactivation from the graft (reviewed in Rubin, 2007) because
they do not possess a pre-established HCMV-specific immunity that may prevent dissemination
of the virus. Infection with HCMV also increases the risk of chronic graft rejection (Evans et al.,
2000).
HCMV enters a host cell by direct fusion with its cell membrane (Compton et al., 1992), which
is promoted by gH/gL complexes on the virion surface (Kinzler and Compton, 2005). Virus entry
is mediated by the cellular receptor neuropilin-2 (Martinez-Martin et al., 2018). Two types of
viral gH/gL complexes are known: gH/gL/gO and gH/gL/pUL(128,130,131A) (Scrivano et al.,
2011). Many laboratory HCMV strains, such as AD169 (Ryckman et al., 2010), only express
gH/gL/gO complexes which restricts virus entry to a few cell types including fibroblasts (Hahn
et al., 2004; Scrivano et al., 2011; Wang and Shenk, 2005). Clinical HCMV isolates, however, also
express gH/gL/pUL(128,130,131A) complexes (Baldanti et al., 2006; Grazia Revello et al., 2001;
Ryckman et al., 2010) and are therefore able to infect leukocytes, DCs, and endothelial cells, too
(Gerna et al., 2005; Hahn et al., 2004). Interestingly, HCMV virions display different selectivity




After fusion of the HCMV virus envelope with the cell membrane, the tegument and capsid enter
the cytoplasm. Tegument proteins deliver the capsid to the nucleus and initiate viral gene expres-
sion (reviewed in Kalejta, 2008). In the cell nucleus, the viral genome is released from the capsid
and viral genes are transcribed, whose products orchestrate the translation of other viral proteins
and the replication of viral DNA. Viral gene products can be grouped according to the time of
synthesis after productive infection, however, these phases overlap with each other: immediate-
early (IE, 0–2 h), early (E, 0–15 h), late (L, >15 h, Stinski, 1978). The immediate-early proteins
1 (IE-1, product of UL123) and 2 (IE-2, product of UL122) function as transcriptional regulators
and trigger the expression of viral early proteins, which drive viral DNA replication (Greaves
and Mocarski, 1998; Marchini et al., 2001). Viral late proteins participate in virus assembly or
represent structural components of the virion. The viral capsid is formed in the nucleus and
translocated to the cytosol, where it associates with tegument proteins. Subsequently, the viral
envelope and its glycoproteins are acquired by budding into intracellular vesicles of the ER, Golgi
apparatus and endosomal machinery. Finally, enveloped infectious virus particles are released
into the extracellular space (the whole viral “life” cycle is reviewed in Jean Beltran and Cristea,
2014) after 72–96 hours (Loewendorf and Benedict, 2010).
In vitro, HCMV-infected fibroblasts release infectious virions but also two types of particles
that lack viral DNA and are not infectious: dense bodies and non-infectious enveloped particles
(NIEPs, Irmiere and Gibson, 1983). NIEPs contain the full complement of virion proteins in
approximately the same relative amounts, but dense bodies lack all of the capsid and most of the
tegument proteins of the virion (Gibson and Irmiere, 1984). Dense bodies are being developed
as a form of HCMV vaccine (Pepperl et al., 2000; Pepperl-Klindworth et al., 2003).
After initial infection, HCMV, like all other herpesviruses, can establish persistence for a life-
time despite the strong antiviral immunity developed by a healthy host (see section below).
During the subsequent phase known as latency, viral gene expression is strongly decreased and
viral replication is shut off, which hampers immunological detection of latently infected cells.
The latency reservoir of HCMV is formed by CD34-positive (CD34+) hematopoietic progenitor
cells and cells of the myeloid lineage (Kondo et al., 1994; Sinclair and Sissons, 2006; Sindre et al.,
1996). Periodically HCMV is reactivated from latently infected cells particularly in response to
immunosuppression, inflammation or stress (Kutza et al., 1998; Mutimer et al., 1997; Prösch
et al., 2000), which causes the transcription of viral IE genes of HCMV and ultimately leads
to lytic viral replication (Prösch et al., 1995; Stein et al., 1993). Tumour necrosis factor alpha
(TNF-α) is one of the key mediators of HCMV reactivation by induction of NFκB (nuclear factor
kappa-light-chain-enhancer of activated B cells) in latently infected cells (Prösch et al., 1995).
Prostaglandin E2 (PGE2) that acts via the cyclic adenosine monophosphate (cAMP) pathway
and IL-1β were also reported to trigger HCMV reactivation (Kline et al., 1998). Reactivation of
HCMV often goes unnoticed in immunocompetent individuals, since virus replication is rapidly
controlled by effector functions of memory T cells that were previously established in response to
primary infection. In contrast, these effective defence mechanisms are impaired in immunocom-
promised persons, such as AIDS patients and HSCT recipients or immunosuppressed patients
after SOT. They cannot be protected from pathogens that reside within their body by isolation in
a germ-free environment. Due to their deficient or impaired immune system HCMV replication
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may not be controlled, eventually resulting in HCMV disease.
1.2.2 Immune response towards human cytomegalovirus
Innate immune cells can sense and attack HCMV infection early on. The PRR Toll-like receptor
2 (TLR2) can detect the viral surface glycoproteins gB and gH and trigger inflammatory cytokine
production in response (Compton et al., 2003) even before the cell is infected. As a result, more
effector cells of the innate immune system, like DCs, macrophages and NK cells, are attracted
to the site of infection. Recruitment of DCs is very important because they possess the unique
ability to prime antigen-inexperienced (“naïve”) T cells, but are also able to reactivate memory
T cells. However, DCs can be infected by HCMV themselves (Jahn et al., 1999; Sénéchal et al.,
2004) and the virus encodes mechanisms that impair DC function, such as stimulation of T cells
(Moutaftsi et al., 2002; Raftery et al., 2001, also see section 1.2.3). Recovery of NK cell activity
was associated with survival from HCMV disease after HSCT (Quinnan et al., 1982) and pa-
tients who lack functional NK cells may suffer from recurrent episodes of HCMV disease (Biron
et al., 1989). The importance of NK cell activity is indirectly highlighted by the large array of
mechanisms that HCMV employs to prevent activation of NK cells (reviewed in Jackson et al.,
2011, also see section 1.2.3).
Infection with HCMV induces a strong humoral and cellular response of the adaptive immune
system. But at least in the mouse, antibodies specific for murine cytomegalovirus (MCMV) are
not essential for controlling infection but rather limit viral dissemination (Jonjić et al., 1994). In
humans, pre-existing anti-HCMV antibodies can prevent congenital infection of the fetus during
pregnancy (Fowler et al., 1992). Although numerous antigens of HCMV are targeted by antibod-
ies, those that are specific for the gH/gL/pUL(128,130,131A) complex show superior neutralising
activity regarding HCMV infection of endothelial, epithelial, and myeloid cells in comparison to
antibodies specific for gB or gH (Macagno et al., 2010). This further illustrates the major role of
gH/gL/pUL(128,130,131A) complexes in HCMV infection of leukocytes, DCs, and endothelial
cells as described by Gerna et al. (2005) and Hahn et al. (2004). Therefore, some current vaccine
approaches aim at generating an antibody response against this pentameric complex (Plotkin
and Boppana, 2018).
1.2.2.1 HCMV-specific CD8+ cytotoxic T lymphocytes
The proportion of HCMV-specific T cells among peripheral blood T cells of an HCMV+ person
is high: it was described that, on average, 10% of the blood memory T cell population is specific
for HCMV in healthy carriers (Sylwester et al., 2005). The frequency of HCMV-specific T cells
gradually increases with age (“memory inflation”) and this phenomenon may contribute to im-
mune system exhaustion and dysfunction in the elderly (Moss, 2010). This profound expansion
of HCMV-specific T cell populations is likely due to continuous expression and presentation,
although at low levels, of HCMV antigens during latency.
As patients without detectable HCMV-specific CTL activity are at risk of developing severe
HCMV disease, these effector T cells were proposed to mediate recovery from HCMV infection
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already more than three decades ago (Quinnan et al., 1982; Reusser et al., 1991). In fact, CD8+
CTLs were identified to be crucial for limiting replication of HCMV (Einsele et al., 2002; Redde-
hase, 2002) by killing infected target cells and their efficacy was demonstrated by reconstitution of
HCMV-specific CTL immunity in immunocompromised patients after HSCT (see section 1.2.4).
CD8+ T cell responses were reported against many HCMV antigens regardless of their function:
transcription factors, like IE-1 and IE-2, immunomodulatory proteins, like glycoprotein (gp) US3
(see section 1.2.3), and structural proteins, like gB, gH or pp65 (Elkington et al., 2003; Sylwester
et al., 2005). Within these studies and others (Khan et al., 2007; Nastke et al., 2005; Slezak
et al., 2007) a large number of CD8+ T cell epitopes derived from many different antigens of
HCMV were identified.
The T cell responses to the immunodominant antigens pp65 (Kern et al., 2002) and IE-1 (Kern
et al., 1999) were studied in greater detail than those to most other HCMV antigens, since CD8+
T cell responses to both antigens were detected in a majority of HCMV+ donors (see Khan et al.,
2005; Sylwester et al., 2005). Strikingly, CTLs specific for IE-1, but not CTLs specific for pp65,
were found to correlate with protection from HCMV disease (Bunde et al., 2005). Moreover, a
delay in reconstituting IE-1-specific CD8+ T cells in the first 3 months after HSCT was shown to
correlate with a lack of protection from HCMV disease (Sacre et al., 2008). The protective effect
of IE-1-specific CD8+ T cells was confirmed by adoptive transfer of murine IE-1-specific CD8+
T cells into mice challenged with MCMV (Pahl-Seibert et al., 2005). However, protection is
not necessarily mediated by immunodominant viral epitopes, as the latter did not correlate with
antiviral efficacy of epitope-specific CD8+ T cell immunotherapy in murine models (reviewed in
Lemmermann and Reddehase, 2016).
Since IE-1 is expressed very early during infection and reactivation, IE-1-specific T cells may be
able to detect productively infected host cells at an early stage of the viral “life” cycle and may
thus be able to prevent shedding of virus by killing the infected cell before the release of progeny
virus. pp65-specific T cells may also be able to detect primary infection at an early time point
because pp65 is contained in HCMV particles in large quantities (Varnum et al., 2004) and thus
abundantly available for presentation via HLA class I molecules. In contrast, pp65-specific T
cells will not be able to detect HCMV reactivation from cellular latency as early as IE-1-specific
T cells because in this case no exogenous source of pp65 or other structural proteins is available,
and to prevent new virion synthesis targeting of IE/E regulatory factors will be necessary. The
same is likely to apply to T cells specific for other late antigens, too. This makes IE-1 an at-
tractive target in immunotherapy or prophylaxis of HCMV infection and reactivation.
Recently, CD8+ T cell clones restricted by HLA-C*07:02 and specific for the epitope IE-1309-317
(CRV) were shown to strongly recognise AD169-infected fibroblasts despite the presence of the
four immunoevasive proteins (“immunoevasins”) gpUS2, gpUS3, gpUS6 and gpUS11 (Ameres
et al., 2014, 2013). In contrast, IE-1-specific CD8+ T cell clones restricted by several HLA-
A and -B allotypes did not elicit a significant IFN-γ secretion in response to AD1619-infected
fibroblasts. If fibroblasts were infected with the AD169-derived variant CMV-Δall that lacks
immunoevasins US2, US3, US6 and US11 (Besold et al., 2009, originally named RV-KB6), all
IE-1-specific CD8+ T cell clones strongly recognised the virus infected target cells irrespective
of HLA restriction (Ameres et al., 2013). Since HLA-C*07:02 is less affected by these four im-
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munoevasins in comparison to other HLA molecules, it may play an important role in controlling
HCMV infection in individuals that possess this HLA allele.
1.2.2.2 HCMV-specific γδ T cells
Vδ2– γδ T cells are likely involved in the immune response directed against HCMV, too. Vδ2– γδ
T cells, but not Vδ2+ T cells, were significantly expanded due to HCMV reactivation after SOT
or HSCT, which suggests that Vδ2– γδ T cells participate in the anti-HCMV immune response
(Déchanet et al., 1999; Knight et al., 2010, respectively). In vitro, Vδ2– γδ T cells, but not Vδ2+
T cells, killed HCMV-infected target cells through a mechanism involving TCR engagement, but
not HLA presentation by target cells (Halary et al., 2005). Moreover, higher numbers of Vδ2–
γδ T cells were observed in HCMV+ healthy persons compared with HCMV– persons in the
aforementioned study. Some of these Vδ2– γδ T cells appear to be specific for endothelial protein
C receptor (EPCR), a stress-induced molecule (Khairallah et al., 2017; Willcox et al., 2012).
Pitard et al. (2008) showed that HCMV+ persons possess a slightly but significantly increased
proportion of Vδ1+ T cells (≈1.2%) in comparison to HCMV– persons (≈0.9%), while Vδ2+ and
Vδ3+ T cells did not differ between the two groups. They also found that Vδ1+ T cells are more
likely to express memory markers in HCMV carriers. Thus, Vδ2– γδ T cells show consistent
changes in their phenotype and frequency in HCMV carriers, which indicates that they are part
of the adaptive immune response to infection (Gerna and Lilleri, 2019).
1.2.2.3 HCMV-specific CD4+ T helper cells
Functional CD4+ T cells play important roles in the surveillance and control of HCMV infection:
1. The maintenance of HCMV-specific CD8+ T cells depends on recovery of CD4+ T cell
function after HSCT (Riddell and Greenberg, 1995; Walter et al., 1995). Immunosuppressed
patients after SOT are only protected from HCMV reactivation if HCMV-specific CD4+
cells reconstitute their functions and provide help to CD8+ T cells (Gabanti et al., 2014).
2. Functional CD4+ T cells are required for resolution of symptomatic HCMV disease (Lilleri
et al., 2008; Rentenaar et al., 2000) with IFN-γ playing a critical role as antiviral mediator
(Gamadia et al., 2003).
3. HCMV-specific CD4+ T cells attack the viral infection through direct effector functions,
such as cytotoxicity and secretion of pro-inflammatory molecules (Crompton et al., 2008;
Pachnio et al., 2016), and thus contribute to virus clearance and prevent dissemination
(Jackson et al., 2017). Although CD4+ T cells are not cytotoxic effectors in many other
situations, some HCMV-specific CD4+ T cells were found to have direct cytotoxic function
(Crompton et al., 2008; Elkington et al., 2004; Hopkins et al., 1996; Le Roy et al., 2002;
Pachnio et al., 2016; Weekes et al., 2004).
4. A lack of HCMV-specific CD4+ T cells was associated with persistent shedding of virus in
immunocompetent young children (Tu et al., 2004) and with an increased risk for HCMV
disease after HSCT (Boeckh et al., 2003; Krause et al., 1997; Ljungman et al., 1993) and
in AIDS patients (Komanduri et al., 1998).
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These observations are supported by findings in mouse models: MCMV-specific CD4+ T cells can
prevent infection of salivary glands and thus shedding of virus (Lucin et al., 1992; Yunis et al.,
2018). Additionally, murine CD4+ T cells were found to successfully control MCMV infection in
the absence of CD8+ T cells in vivo (Jonjić et al., 1990). In vaccinated HLA-A*02:01-transgenic
mice, pp65495-503 (NLV)-specific CD8+ T cells critically depend on CD4+ T cell help (Reiser
et al., 2011).
Similar to CD8+ CTLs, human CD4+ T cells are specific for epitopes from various HCMV an-
tigens including the transcription factors IE-1 and IE-2, the immunomodulatory protein gpUS3,
and the structural proteins gB, gH or pp65 (Sylwester et al., 2005). Elkington et al. (2004)
identified CD4+ T cell epitopes from gB and gH. Several CD4+ T cell epitopes from pp65 were
published almost two decades ago (Gallot et al., 2001; Khattab et al., 1997; Li Pira et al., 2004;
Wiesner et al., 2005). pp65 apparently is an immunodominant antigen of HCMV in both the
CD8+ and the CD4+ T cell repertoire. In contrast, low numbers of IE-1-specific CD4+ T cells
were reported (Bunde et al., 2005; Gratama et al., 2008; Kern et al., 2002), although IE-1-specific
CD4+ T cell clones and some of their epitopes had been described early, too (Alp et al., 1991;
Davignon et al., 1996). Recently, the CD4+ T cell repertoire directed against IE-1 was analysed
and many IE-1 epitopes and their HLA restrictions were identified in great detail (Ameres et al.,
2015; Braendstrup et al., 2014). The problem of generally low numbers of IE-1-specific CD4+ T
cells was overcome by expansion with peptides and subsequent multimer staining (Braendstrup
et al., 2014) or by mini-LCL expansion (see sections 2.3.2 & 3.3.5) and single-cell cloning followed
by functional testing of the T cell clones (Ameres et al., 2015). In summary, CD4+ T cells are a
key component of an HCMV-specific immune response.
1.2.3 Viral immune evasion
Due to their long-term co-evolution with their host species, CMV species are intricately ad-
apted to their host’s immune responses and have developed many mechanisms to escape and
counteract them. For this purpose, HCMV codes for several micro-RNAs (miRNAs) and im-
munomodulatory proteins. miRNAs are small non-coding RNAs that can post-transcriptionally
regulate gene expression by interfering with 3’ untranslated regions of mRNA. HCMV’s miRNAs
target the expression of both viral and cellular genes and thus regulate viral replication, cell
survival, establishment and maintenance of viral latency, but also affect innate and adaptive
immunity (reviewed in Hook et al., 2014). For example, the miRNA US4-1 of HCMV specifically
down-regulates ERAP1 expression thereby inhibiting the trimming of peptides in the ER and
leading to reduced susceptibility of infected cells to HCMV-specific CTLs (Kim et al., 2011b).
HCMV down-regulates expression of HLA class I molecules on the surface of infected cells (Barnes
and Grundy, 1992), which is a mechanism to evade detection of viral peptides by T cells. The
viral genes US2-US11 are involved in this process (Jones et al., 1995). The relevant glycopro-
teins encoded by this genomic region are gpUS2, gpUS3, gpUS6, gpUS10 and gpUS11. These
glycoproteins are immunoevasins since they help infected cells evade the attention of virus-specific
T cells, in particular HLA class I-restricted CD8+ T cells. gpUS2 and gpUS11 are early proteins
and promote the dislocation of HLA class I α chains from the ER to the cytosol where they are
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degraded (Jones and Sun, 1997; Wiertz et al., 1996). gpUS3 is an IE protein and retains HLA
class I complexes in the ER (Jones et al., 1996; Zhao and Biegalke, 2003). gpUS3 interacts with
components of the peptide loading complex and prevents loading of susceptible HLA molecules
with optimal peptides (Park et al., 2004, 2006). gpUS6 is an early/late protein and inhibits
peptide translocation by TAP into the ER, which impairs loading of HLA class I molecules with
peptide (Ahn et al., 1997). gpUS10 selectively down-regulates cell surface expression of HLA-G,
but not that of classical HLA class I molecules (Park et al., 2010).
Taken together, recognition of HCMV-infected cells by CD8+ CTLs is strongly impaired by the
immunoevasins (Ameres et al., 2014, 2013) that decrease the amount of peptide/HLA class I
complexes on the surface of an infected cell. Down-regulation of the expression of peptide/HLA
class I complexes by US2 and US11 was reported to be allele specific (Barel et al., 2003a,b;
Schust et al., 1999, 1998). HLA-C, however, was uniquely resistant to the effects of both im-
munoevasins. The functional relevance of HLA-C for T cell recognition of HCMV infection was
shown by Ameres et al. (2014) who confirmed the resistance of HLA-C*07:02 to US2 and US11
while all HLA-A and -B allotypes that were analysed in this study were heavily affected by the
immunoevasins. Thus, HLA-C*07:02 is a promising HLA restriction to target in T cell therapy
of HCMV infection.
Down-regulation of HLA class I molecules enables HCMV to evade T cell detection, but is accom-
panied by an increased susceptibility to recognition by NK cells due to low HLA class I expression
levels. Thus, HCMV employs other mechanisms of NK cell inhibition. Viral glycoproteins reduce
the expression of ligands for NK cell activating receptors thereby decreasing susceptibility to NK
cell recognition. For example, gpUL16 and gpUL142 reduce cell surface levels of MHC class I
chain-related protein A (MICA), MICB, UL16-binding protein 1 (ULBP1), and ULBP2 to avoid
NK cell recognition via NKG2D (Chalupny et al., 2006; Dunn et al., 2003). In parallel, HCMV
also enhances the expression of ligands for inhibitory NK cell receptors to compensate for the
lack of HLA class I molecules on the surface of the infected cell. The HCMV-encoded UL18 and
UL40 proteins promote surface expression of leukocyte immunoglobulin-like receptor subfamily
B member 1 (LILRB1, Chapman et al., 1999) and HLA-E (Tomasec et al., 2000), respectively,
to prevent NK cell activation.
It has been proposed that HCMV immunoevasins affect peptide presentation by HLA class
II molecules, too. US2 was reported to degrade HLA-DRα and HLA-DMα chains (Hegde and
Johnson, 2003; Tomazin et al., 1999) thereby affecting peptide loading and stability of all HLA-
DR allotypes. US3 supposedly binds to HLA class II αβ complexes in the ER and reduces
their association with Ii. As a result, HLA class II complexes were not loaded with peptides
efficiently and formation of peptide-loaded HLA class II complexes was reduced (Hegde et al.,
2002). However, others presented evidence that interference of HCMV immunoevasins with HLA
class II levels was weak or absent (Odeberg and Söderberg-Nauclér, 2001; Rehm et al., 2002).
It has remained unclear how this interference would operate, since the recognition sequences of
US2 and US11 on HLA class I molecules are precisely known (Barel et al., 2006, 2003a,b), are
even greatly variable in HLA class I allotypes, and are unlikely to be broadly conserved in HLA
class II molecules. However, it remains possible that such effects operate on certain specific HLA
class II allotypes that remain to be defined.
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Since DCs can be infected with HCMV and are critical immune cells that initiate and maintain
immune responses, it is not surprising that HCMV tampers with the functions of DCs. HCMV
infection alters the expression of adhesion molecules, which may contribute to an impairment
of DC migration (Beck et al., 2003). Immature DCs that were infected with HCMV showed a
decreased expression of HLA molecules and co-stimulatory molecules and their maturation as
well as cytokine production was inhibited (Moutaftsi et al., 2002). The same study found reduced
proliferation and cytotoxicity of T cells specific to a recall antigen if presented by HCMV-infected
DCs. Mature DCs that were infected with HCMV lose surface expression of CD83 while soluble
CD83 accumulates in the supernatant and inhibits stimulation of T cell proliferation (Sénéchal
et al., 2004). If soluble CD83 was removed, T cell stimulation by DCs could be restored.
1.2.4 Therapy for human cytomegalovirus infection
After HSCT or SOT, the immune system of the recipient is heavily compromised due to the
necessary myeloablative treatment in HSCT and the resulting immunosuppression after trans-
plantation. As a result, the recipient is susceptible to infections, especially to those that are
caused by pathogens that reside within the body, because the patient cannot be shielded from
them.
1.2.4.1 Antivirals
Standard antiviral therapy using inhibitors, such as foscarnet, ganciclovir or cidofovir, target
viral DNA polymerases to impair viral replication. However, these inhibitors also affect human
DNA polymerases, but to a lesser degree. HCMV disease in the immunocompromised host can be
successfully prevented by antiviral treatment with these compounds, but their administration is
often accompanied by serious side effects, such as myelotoxicity, neutropenia and nephrotoxicity
(Broers et al., 2000; Sharland and Khare, 2001). Moreover, antiviral drug resistance has been
reported for each of the three DNA polymerase inhibitors (Lurain and Chou, 2010).
Recently, the novel anti-HCMV drug letermovir was reported to successfully reduce the risk of
HCMV infection after HSCT if applied as a prophylactic treatment in a phase III clinical trial
(Marty et al., 2017). Letermovir has a different mechanism of action than established anti-HCMV
drugs: it targets the viral terminase complex, which is involved in processing of the concatenated
HCMV genome and transfer of a single-unit genome into procapsids (reviewed in Foolad et al.,
2018). Importantly, the frequency and severity of adverse events (including myelotoxicity and
nephrotoxicity) as a result of letermovir treatment were reported to be similar to treatment with
placebo. Whether letermovir will be less susceptible to resistance mutations by HCMV than
foscarnet, ganciclovir or cidofovir and whether letermovir will uphold its superior safety profile
remains to be evaluated.
While the risk of HCMV infections can be reduced by administration of antivirals early after
transplantation (typically 3 months), late-onset HCMV disease (>100 days after transplantation)




Vaccination against HCMV should provide efficient prevention of HCMV infection or reactiv-
ation, especially in immunocompromised patients, without causing side effects. According to
developers, a protective HCMV vaccine should induce both humoral and cellular immunity that
is not restricted only to a single structural antigen, such as gB or pp65, because those antigens
may not confer protection from HCMV infection or reactivation (Bunde et al., 2005). Although
numerous clinical trials are ongoing (reviewed in Diamond et al., 2018), no vaccine has yet been
licensed (Schleiss, 2016).
Before recombinant vaccines were developed, live attenuated vaccines based on fibroblast-pas-
saged HCMV laboratory strains, such as AD169 or Towne, were evaluated, but they could not
provide satisfactory results in clinical trials or animal models (reviewed in Gerna and Lilleri,
2019). A potential reason is their loss of genes encoding elements of the pentameric glycoprotein
complex. As a result, these virus strains may not have been able to infect natural HCMV host
cells such as endothelial or myeloid cells, resulting in premature abortion of infection and non-
immunogenicity.
A recombinant MF59-adjuvanted vaccine that contained only gB as HCMV antigen protected
HCMV– pregnant women from primary infection with an intermediate efficacy of 50% (Pass
et al., 2009). The same gB-MF59 vaccine was able to boost antibody responses and IFN-γ secre-
tion by CD4+ T cells in HCMV+ women (Sabbaj et al., 2011). However, the clinical evaluation
of this vaccine was halted and its efficacy was not evaluated in a phase III study (Diamond et al.,
2018) after it was discovered that antibodies specific for the gH/gL/pUL(128,130,131A) complex
show superior neutralising activity in comparison to antibodies specific for gB (Freed et al., 2013;
Macagno et al., 2010).
A number of different HCMV vaccines is now in clinical trials. Candidate vaccines for patients
after allo-HSCT include recombinant modified vaccinia Ankara (MVA) encoding pp65, IE-1, and
IE-2, pp65/HLA-A2 (NLV) peptide vaccines, and the gB subunit vaccine (reviewed in Diamond
et al., 2018). Vaccines in development for prevention of infection for different patient groups
are based on dense bodies, virus-like particles, heterologous viral vectors (such as vesicular sto-
matitis virus, MVA and canarypox), protein vaccines with gB or the pentameric complex, and
new attenuated forms of HCMV (reviewed in Plotkin and Boppana, 2018). Thus, there is a great
diversity of concepts for a HCMV vaccine, but it cannot be predicted at the moment which of
these will be successful.
1.2.4.3 Antibodies
Earlier studies described that adoptively transferred immunoglobulin preparations which con-
tain HCMV-specific antibodies from HCMV+ donors can prevent congenital infection of the
fetus during pregnancy (Nigro et al., 2005), but a more recent study has contested the efficacy of
this treatment (Revello et al., 2014). Some evidence supports the administration of anti-HCMV
antibodies to prevent HCMV reactivation and disease after SOT (Falagas et al., 1997; Snydman
et al., 1987) and HSCT (Messori et al., 1994). Other studies, however, found no beneficial ef-
fect of HCMV immunoglobulins in patients at risk of developing HCMV infection after HSCT
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(Muñoz et al., 2001; Ringdén et al., 1987).
Antibodies that are specific for the gH/gL/pUL(128,130,131A) complex showed superior neutral-
ising activity regarding HCMV infection of endothelial, epithelial, and myeloid cells in comparison
to antibodies specific for gB or gH (Macagno et al., 2010). Thus, the efficacy of treatment with
HCMV-specific antibodies likely depends on antibodies that are specific for antigens which are
critical for HCMV infection, such as gH/gL/pUL(128,130,131A) complexes (as described in sec-
tion 1.2.2).
1.2.4.4 Adoptive T cell transfer
The standard therapy to fight HCMV reactivation is antiviral medication, which is of limited
efficacy, shows severe side effects and is counteracted by increasing viral resistance (see section
1.2.4). Adoptive T cell transfer offers an alternative that provides HCMV-specific T cells for the
patient at risk, which has been shown to prevent disease and death.
Several studies have shown that adoptive transfer of HCMV-specific CD8+ T cells restores
cellular immunity against HCMV after HSCT (Cobbold et al., 2005; Einsele et al., 2002; Riddell
et al., 1992; Schmitt et al., 2011; Walter et al., 1995, also see section 1.2.2). However, the ex
vivo expansion of T cell clones from an HCMV+ HSCT donor (as done by Riddell et al., 1992;
Walter et al., 1995) is laborious, time-consuming and thus expensive. Consequently, this method
is not suited well to provide a large number of patients with individual HCMV-specific CTLs
and was not established as clinical routine. Moreover, adoptive T cell transfer of HCMV-specific
T cells should include CD4+ and CD8+ T cells (Einsele et al., 2002; Sellar and Peggs, 2012) to
ensure T cell help and maintenance of T cell memory (see section 1.2.2).
An approach that targets multiple epitopes simultaneously is considered an advantage in the
field of adoptive T cell transfer against viral disease (Papadopoulou et al., 2014; Peggs et al.,
2003) because a broad immune response may provide a better chance of controlling viral infec-
tion (Braendstrup et al., 2014) and minimise the risk of viral escape. Earlier protocols used DCs
pulsed with HCMV antigens (Peggs et al., 2001) or PBMCs pulsed with libraries of overlapping
peptides that spanned the entire sequence of viral proteins (pp65 & IE-1, Papadopoulou et al.,
2014) to generate polyclonal T cell lines specific for multiple HCMV epitopes. In 2010, Moos-
mann et al. generated EBV-specific T cells for adoptive transfer to patients after allo-HSCT by
stimulating leukapheresis products from the HSC donor with a peptide mix that consisted of 23
defined peptides with various HLA class I and class II restrictions. After 12 hours of stimulation,
IFN-γ-secreting cells were isolated by IFN-γ capture and magnetic separation. The multi-epitope
EBV-specific T cells were administered to the patients as a single transfusion and caused a rapid
and sustained reconstitution of protective EBV-specific T cell memory.
Gary et al. (2018) recently published a good manufacturing practice (GMP) protocol to generate
HCMV-/EBV-peptide-stimulated T cells from leukapheresis products of HSC donors using a
pool of 34 HCMV and EBV peptides that represent well-defined dominant T cell epitopes with
various HLA restrictions. Virus-specific CD8+ and CD4+ T cells are expanded over 9 days and
can be administered early after HSCT (>day 30) as a preventive approach. This protocol allows
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for rapid and cost-efficient production of HCMV- and EBV-specific T cells and is currently eval-
uated in a phase I/IIa clinical trial (https://clinicaltrials.gov, identifier: NCT02227641, accessed
on 07.05.19). Other clinical trials (NCT01325636 and NCT02985775, accessed on 07.05.19) also
intend to provide the patient with HCMV-specific T cells from HSCT donors by stimulating
donor-derived PBMCs with HCMV peptides. However, in all of these clinical trials, there is the
prerequisite that the donor is HCMV+ and therefore has an established repertoire of HCMV-
specific T cells.
Donor immunity may be transferred from an HCMV+ HSC donor to an HCMV– recipient
(D+ R–), but an HCMV– HSC donor cannot provide HCMV-specific T cells. As a surrogate,
HCMV-specific T cells derived from a third-party donor that is partially HLA-matched with
the recipient may be administered, but in a study from Neuenhahn et al. (2017) these cells
failed to persist and proliferate in 7 out of 8 cases after their adoptive transfer to an HSCT
patient. Instead, virus-specific T cells can be produced and subsequently administered to the
patient by transferring the genes of HCMV-specific TCRs into T cells from the HCMV– HSC
donor. This strategy was originally developed for tumour immunotherapy, but was adapted to
HCMV (Schub et al., 2009). Still, applications in HCMV disease have been very limited. There
is only one registered clinical trial (NCT02988258, accessed on 07.05.19) at present that aims
to introduce a pp65-specific, HLA-A*02:01-restricted TCR into donor T cells via ex vivo GMP-
compliant retroviral transduction. However, endowing an αβ T cell with a transgenic αβ TCR
harbours two major disadvantages: (I) After TCR transfer, the T cell will express two TCRα
and two TCRβ chains, which can potentially form four different TCR heterodimers. One will be
the original TCR of the T cell, another TCR will be the transgenic one, but the two remaining
mis-paired TCR dimers are of unknown specificity and could thus be harmful. This threat is not
just hypothetical, as well-defined neo-reactivity due to TCR chain mis-pairing has been reported
in vitro (van Loenen et al., 2010). (II) TCR transfer into bulk T cells will generate a multitude
of different T cells with at least two specificities per T cell. Such T cells could lead to toxicity
in the patient if the endogenous TCR is autoreactive. Since an αβ TCR cannot exchange chains
with a γδ TCR (Koning et al., 1987; Saito et al., 1988), γδ T cells may be a safer alternative to
αβ T cells in adoptive T cell therapy if effector cells are equipped with a transgenic αβ TCR.
This concept was successfully employed to generate anti-leukemic γδ T cells that were modified
to express an αβ TCR and the relevant co-receptor. These genetically modified γδ T cells exerted
high levels of antigen-specific cytotoxicity and produced IFN-γ in response to antigen-expressing
target cells in vitro (van der Veken et al., 2006). In vivo, murine γδ T cells that expressed an
αβ TCR specific for the model antigen ovalbumin proliferated in an antigen-specific manner,
showed prolonged persistence and had the capacity to mount recall responses (van der Veken
et al., 2009). Interestingly, the murine TCR-engineered γδ T cells did not show a preferential
homing towards intestinal epithelial sites but resided in peripheral blood. Therefore, there is
the chance that γδ T cells are an effective alternative to αβ T cells as effector cells to express
transgenic TCRs for immunotherapy.
No randomised, controlled clinical trial on HCMV-specific T cell transfer was ever completed
and published. Apart from evaluating the efficacy of adoptively transferred HCMV-specific CD4+
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or CD8+ T cells, it would be interesting to see whether application of both HCMV-specific
CD4+ and CD8+ T cells have a synergistic effect. In a humanised mouse model, HLA-A*02:01-
transgenic NOD/SCID/IL-2rg-/- mice were challenged with a chimeric MCMV that was modified
to express the NLV-peptide epitope of HCMV (Thomas et al., 2015). The infectious virus load
was significantly reduced in spleen and lungs by CD8+ T cells that were engineered to express
an NLV-specific TCR, but not by equivalent CD4+ T cells expressing the same TCR. If the
same TCR-transgenic CD4+ T cells were co-administered with TCR-transgenic CD8+ T cells
– both expressing the same NLV-specific TCR – at a ratio of 1 to 4, the viral load in spleen
and lungs dropped to markedly lower levels than TCR-transgenic CD8+ T cells alone. Thus,
the TCR-transgenic CD4+ T cells enhanced the antiviral function of TCR-transgenic CD8+ T
cells. This strikingly illustrates the benefit through virus-specific CD4+ T cell help, but does
not reflect the physiologic situation, in which CD4+ T cells respond to virus-infected target cells
that express HLA class II and not HLA class I.
Most of the HCMV-specific, HLA class II-restricted TCRs, whose TCRβ sequences were pub-
lished, are specific for gB (Abana et al., 2017; Crompton et al., 2008), pp65 (Schwele et al.,
2012; Simon et al., 2014) or of unknown specificity (Abana et al., 2017; van Leeuwen et al.,
2006). Only few TCRβ sequences of IE-1-specific, HLA class II-restricted TCRs were published
(Schwele et al., 2012). Most of those studies analysed the TCRβ repertoire of HCMV-specific T
cells from HCMV+ donors ex vivo and none of them assessed the function of the described HLA
class II-restricted TCRs in recognising HCMV-infected target cells.
HCMV-specific, HLA class II-restricted TCRs should be made available for application in ad-
optive T cell transfer in order to be able to supply HCMV+ transplant recipients with HCMV-
specific, HLA class II-restricted T cells. Nevertheless, the efficacy of HCMV-specific, HLA class
II-restricted TCRs that are specific for different antigens in recognition of HCMV infection was
neglected to date.
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1.3 Aims of this study
HCMV remains a great threat and health burden especially for immunocompromised patients
who do not possess HCMV-specific T cells. Adoptive transfer of HCMV-specific, HLA class
I-restricted (CD8+) T cells can restore immunity to HCMV and protect patients from HCMV
disease. However, many HLA class I molecules succumb to the combined effects of HCMV’s
immunoevasins resulting in poor recognition of virus infection by HCMV-specific CD8+ T cells.
In contrast, T cell clones restricted by HLA-C*07:02 were able to strongly recognise HCMV-
infected target cells despite the presence of immunoevasins. Thus, the therapeutic potential of
T cells with this HLA restriction needs to be further explored.
HCMV-specific, HLA class II-restricted (CD4+) T cells were identified as important effector cells
to control HCMV infection and maintain immunity to HCMV. Since HCMV latently resides in
cells of the myeloid lineage that express HLA class II, HCMV-specific CD4+ T cells may be key
to detecting viral reactivation from latency early on and to prevent dissemination of the virus
and subsequent HCMV disease. However, the efficacy of adoptively transferred HCMV-specific
CD4+ T cells alone or in combination with HCMV-specific CD8+ T cells was evaluated only
by few studies. Transferring the TCR genes derived from HCMV-specific CD4+ T cells into T
cells from the HCMV– donor (HSCT) or recipient (SOT) can provide HCMV-specific T cells for
patients with the highest need. A prerequisite is the identification and functional analysis of
HCMV-specific, HLA class II-restricted TCRs and the evaluation of their function in recognition
of HCMV infection – both of which have been neglected so far. A schematic illustration of the
experiments that were conducted for this study and how they are connected is depicted in fig.
1.6.
The aim of the present study was to address the following questions:
1. Can TCR-transgenic T cells that express an HCMV-specific, HLA-C*07:02-restricted TCR
recognise target cells infected with HCMV despite the action of immunoevasins?
2. Can HCMV-specific TCRs that are restricted by HLA class II be functionally expressed on
αβ T cells and δ2 T cells? What are the resulting functional differences between the two T
cell subsets?
3. Do TCR-transgenic T cells that express an HCMV-specific, HLA class II-restricted TCR
recognise HCMV-infected target cells? Does this recognition depend on co-expression of
the co-receptor CD4?
4. Do HCMV’s immunoevasins affect the presentation of peptides by HLA class II similarly
than peptide presentation on HLA class I molecules?
5. Do HLA class II-restricted TCRs that are specific for the HCMV antigens IE-1 or pp65
differ in their recognition of infected cells?
6. Which HCMV-specific, HLA class II-restricted TCRs may be expected to protect from
HCMV infection or reactivation and should thus be developed further for clinical applica-
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Figure 1.6. Schematic overview of T cell analyses and experiments performed in this study.
HCMV-specific T cell lines were derived from PBMCs of healthy HCMV+ donors by stimu-
lation with autologous mini-LCLs that expressed either IE-1 or pp65. HCMV-specific CD4+
and CD8+ T cell clones were obtained by limiting dilution and subjected to (I) epitope iden-
tification, (II) TCR sequencing, (III) determination of HLA restriction and (IV) analysis of
HCMV-infected target cell recognition. PBMCs from healthy HCMV– donors as substrates
for TCR gene transfer were either used in bulk (not depicted) or after sorting of subpopula-
tions by MACS. The αβ TCR+ fraction (“αβ T cells”) and the αβ TCR– fraction (“γδ T cells”)
were stimulated with anti-CD3 antibody (“αCD3”) or the aminobisphosphonate pamidron-
ate (“PAM”), respectively, prior to transduction with retroviruses coding for HCMV-specific
TCRs that were derived from T cell clones. The recognition of HCMV-infected target cells




The fibroblast adapted HCMV strain AD169 was kindly provided by Martin Messerle (Han-
nover, Germany). The Merlin strain was acquired from the National Collection of Pathogenic
Viruses (Catalogue No. 0302163v), which belongs to Public Health England (Salisbury, United
Kingdom). TB40-BAC4 was obtained from Barbara Adler (LMU Munich, Germany). CMV-
Δall (Besold et al., 2009, originally named RV-KB6) lacks the genes of the four HCMV-encoded
immunoevasive proteins gpUS2, gpUS3, gpUS6 and gpUS11 and was kindly provided by Bodo
Plachter (Mainz, Germany). This HCMV mutant was generated through BAC mutagenesis from
AD169 as described in Besold et al. (2009). Virus passages of all HCMV virus strains used in
this study are shown in table 2.1.
Table 2.1. Stocks of fibroblast supernatant containing laboratory HCMV strains. Super-
natants were stored at −80 ◦C. Producer, date of aliquotation, passage number and virus
titer given in TCID50 units per ml (see section 3.5.2) are shown.
HCMV strain AD169 Merlin TB40-BAC4 CMV-Δall
Passage W22 P4 p5 p5
Date 04.06.2014 04.08.2015 27.07.2015 14.09.2012
Producer X. Liang X. Liang X. Liang S. Ameres
Titer [TCID50/ml] 3.2× 106 1.8× 107 8.3× 106 8.3× 106
For gene transfer purposes, MP71 retroviral vectors (Engels et al., 2003) were produced by
packaging recombinant, modified MPSV (Myeloproliferative sarcomavirus)-derived vector DNA
through co-expression of MuLV (murine leukemia virus)-10A1-env and Mo-MuLV-gag/pol in
HEK293T cells (cells and plasmids see sections 2.3.2 and 2.4, respectively).
2.2 Prokaryotic cells
For the propagation of plasmids (see section 2.4), Escherichia coli of strain DH5α (Invitrogen,
Karlsruhe, Germany) were made chemically transformation-competent. The genotype of the
bacteria was F-, Φ80dlacZΔM15, Δ(lacZYA-argF), U169, deoR, recA1, endA1, hsdR17(rk–,
mk–), supE44, thi-I, gyrA96, relA1, λ–.
2.3 Human cells
2.3.1 Primary cells
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood donations or leuko-
cyte concentrates (“buffy coats”, obtained from the Institute for Transfusion Medicine, University
of Ulm, Germany) of healthy adult donors, all of which were anonymised for this work by a four
to eight digit and letter identifier. The institutional review board (Ethikkommission, Klinikum
der Universität München, Marchioninistr. 25, 81377 Munich, Germany) approved the study. All
work was conducted according to the principles expressed in the Helsinki Declaration. Low- or
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high-resolution HLA genotypes and HCMV serostatus of the PBMC donors are listed in table
2.2.
Table 2.2. HLA type and HCMV serostatus of PBMC donors. Each donor is identified by
a unique three to six digit and letter code (1st column). If PBMCs were isolated from a
buffy coat instead of whole blood, the additional identifier “BC” was inserted into a four
digit and letter identifier (new nomenclature) or “F” was added in front of two digits (old
nomenclature). HCMV serostatus (IgG) of the donor is indicated by “+” or “–” (2nd column).
For some donors HCMV serostatus or HLA alleles have not been determined (“n.d.”). In one
case, no HLA-DRB3, DRB4 and DRB5 allele was present in the donor (“a”). Other donors
were not analysed for HLA-DRB3/4/5 alleles (“b”) although such alleles may be present.
Ambiguities of HLA alleles that were not further resolved are depicted by HLA allele codes
as published by the National Marrow Donor Program (NMDP, see https://bioinformatics.
bethematchclinical.org/hla/alpha.v3.html, accessed on 18.01.2019):
AB = 01/02; AF = 01/09; AFCTE = 02:01/416:01; CKP = 02/04/11;









































































































07:02 n.d. n.d. n.d. n.d. n.d.
Continued on next page
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n.d. 1*03:ENWH1*03:ENWH n.d. n.d.
2.3.2 Cell lines
All human cell lines used in this work were available at the Department of Gene Vectors (AGV)
of the Helmholtz Zentrum München (Germany). A description of each cell line including HLA
typing is given in table 2.3. Mini-lymphoblastoid cell lines (mini-LCLs), T cell clones and T cell
lines derived from PBMCs, which were isolated from donors listed in table 2.2, are not included
in table 2.3.
T cell clones specific for HCMV antigens pp65 or IE-1 were established by Andreas Moos-
mann, Martina Wiesner (2005), Andrea Schub (2010) and Stefanie Ameres (2012) from PBMCs
of the blood donors shown in table 2.2 (also see section 3.3.5). The nomenclature of these T
cell clones indicates the anonymised donor by three to six digits and letters, followed by P or M
depending on the target antigen (pp65 or IE-1, respectively), the number of the T cell clone and
a three (CD8+ T cell clone) or four letter (CD4+ T cell clone) abbreviation of the recognised
peptide in single letter amino acid code. Thus, 1220M #22 EFFT is a CD4+ T cell clone derived
from donor 1220 recognising the peptide EFFT KNSA FPKT TNG of IE-1 (see section 2.6). If the
clone was established from PBMCs of a buffy coat, the sample was coded either by “F” and a
number or by XYBC#, with XY being the preparator and # a number.
For the generation of mini-lymphoblastoid cell lines (mini-LCL), PBMCs were infected
with a mini-Epstein-Barr Virus (mini-EBV), as described in Moosmann et al. (2002). This
mini-EBV contains a reduced set of viral genes, but harbours all necessary viral genes and
elements for transformation of primary B cells (Kempkes et al., 1995, plasmid 1495.A). In order
to generate mini-LCLs that stably express HCMV’s pp65 or immediate-early (IE) protein 1, the
mini-EBV 1495.A was genetically modified to additionally express the cDNA sequence of either
pp65 (Moosmann et al., 2002, plasmid 4014) or IE-1 (Wiesner, 2005, plasmid 3457) under the
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simian virus 40 (SV40) promoter derived from the expression plasmid pSG-5 (Stratagene, La
Jolla, USA). Mini-LCLs were assigned code names in addition to the donor code: “P” for pp65,
“M” for IE-1 and “W” for negative control (no transgene).
Table 2.3. Description and HLA type of other cell lines. Some HLA alleles were not determined
(“n.d.”). Ambiguities of HLA alleles that were not resolved by sequencing are presented as
HLA allele codes as published by the National Marrow Donor Program (NMDP, see https:
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2.3.3 Cell culture media and additives
The media and additives that were used for cultivation of human cells are shown in table 2.4.
The cytokines that were used for stimulation, differentiation and cultivation of specific cell types
are shown in table 2.5.
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Table 2.4. Media and additives that were used for cultivation of human cells.
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Table 2.5. Cytokines used in human cell culture.
Cytokine Application Manufacturer












Recombinant human IL-1β Maturation of DCs Miltenyi Biotec (BergischGladbach, Germany)
Recombinant human IL-2
(Proleukin S) Cultivation of T cells Novartis (Nürnberg, Germany)
Recombinant human IL-4 Establishment of DCs R&D Systems (Minneapolis, USA)
Recombinant human IL-6 Maturation of DCs Miltenyi Biotec (BergischGladbach, Germany)
Recombinant human IL-7 Cultivation of T cells Miltenyi Biotec (BergischGladbach, Germany)
Recombinant human IL-15 Cultivation of T cells Miltenyi Biotec (BergischGladbach, Germany)
Recombinant human




All plasmids containing the cDNA of a recombinant HLA allele that were used in this study are
shown in table 2.6 and were kindly provided by Josef Mautner (Helmholtz Zentrum München,
Germany). The expression of the HLA allele was under the control of the immediate-early en-
hancer and promoter of HCMV (pCMV).
Tables 2.7 and 2.8 show all plasmids that were used for the generation of MP71 retroviral
vectors (see section 3.5.1), which carried different genetic cargo, such as genes coding for CD4,
CD8αβ, GFP or TCRα and TCRβ chains.
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Table 2.6. Expression plasmids encoding recombinant HLA class II molecules, all of which
are controlled by the immediate-early enhancer and promoter of HCMV (pCMV) and were
kindly provided by Josef Mautner (Helmholtz Zentrum München, Germany).














Table 2.7. Plasmids used for the generation of MP71 retroviral vectors carrying GFP, CD4
or CD8 as genetic cargo. Plasmids that carry a TCRβ–P2A–TCRα construct instead can




Vector for the eukaryotic expression of viral envelope protein of the
murine leukemia virus (MuLV) 10A1 (kindly provided by Stitz et al.,
2000; Uckert et al., 2000).
pcDNA3.1MLVg/p
(gag/pol)
Vector for the eukaryotic expression of group-specific antigens and
polymerases of the Mo-MLV retrovirus (Leisegang et al., 2008,
originally produced by Christopher Baum (Hannover, Germany)).
Kindly provided by Wolfgang Uckert (Berlin, Germany).
MP71Gpre
Retroviral vector with GFP marker gene under MPSV-LTR control.
Additionally, a posttranscriptional regulatory element (PRE) of the
woodchuck hepatitis virus and a modified mRNA splice site (mSS)
have been added (Engels et al., 2003).
MP71-CD4
Retroviral vector based on MP71Gpre, of which the GFP marker gene
was replaced by cDNA coding for CD4 (derived from UniProt.org,
accession number P01730, accessed 06.03.2017).
MP71-CD8_FYK
Retroviral vector based on MP71Gpre, of which the GFP marker gene
was replaced by cDNA coding for CD8α (derived from UniProt.org,
acession number P01732, isoform 1, accessed 06.03.2017) and CD8β
(derived from UniProt.org, accession number P10966 (accessed
06.03.2017), isoform 1, which is identical to NCBI Gene ID 926




Table 2.8. Plasmids encoding for HCMV-specific TCRα and TCRβ chains based on
MP71Gpre. The original GFP marker gene of MP71Gpre (see table 2.7) was replaced
by cDNA coding for a TCRβ–P2A–TCRα construct (see section 3.2.3). For each construct,
the table shows the parental T cell clone, from which the TCRα and TCRβ chains were isol-
ated, and its specificity. The epitope is abbreviated by the first three or four amino acids of
the peptide that is recognised by the CD8+ or CD4+ T cell clone, respectively. The origin of
each T cell clone is displayed in the last column. Also, if TCR sequences have been identified
or modified by someone else, it is indicated in the last column.









MP71pre/AGIL19 F46P #19and #45 pp65 123 AGIL
T cell clones from Wiesner
(2005)
MP71pre/EFFT22 1220M #22 IE-1 54 EFFT T cell clone from Ameres(2012)
MP71pre/EFFT50 1826M #50 IE-1 54 EFFT T cell clone from Ameres(2012)
MP71pre/EIMA236 0664M #236 IE-1 62 EIMA T cell clone from Ameres(2012)
MP71pre/EPDV21 1304P #21 pp65 45 EPDV
T cell clone and TCRβ
sequence from A. Schub
(2010, plasmid 4054),
incorrectly labelled “KVYL”
MP71pre/KYQE16 0662P #16 pp65 128 KYQE T cell clone from Wiesner(2005)
MP71pre/MSIY40 F46P #40 pp65 28 MSIY T cell clone from Wiesner(2005)
MP71pre/QPFM17 F46P #17 pp65 66 QPFM
T cell clone from Wiesner
(2005) and TCRα & TCRβ
sequences from A. Schub
(2010, plasmids 4051 and
4052), incorrectly labelled
“RPHE”







T cell clone from Ameres
(2012)
MP71pre/SVMK6 1021M #6and #90 IE-1 85 SVMK
T cell clones from Ameres
(2012)
MP71pre/SVMK27 1826M #27 IE-1 85 SVMK T cell clone from Ameres(2012)




T cell clone from Wiesner
(2005)




T cell clone from Wiesner
(2005)
MP71pre/CRV1 F46M #165 IE-1 — CRV
T cell clone and TCRα &
TCRβ sequences from X.
Liang (unpublished)
Continued on next page
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Table 2.8. Retroviral vectors expressing HCMV-specific TCRα and TCRβ chains based on the plasmid
MP71Gpre (continued from previous page)









MP71pre/CRV1mu Same as MP71pre/CRV1, but C region has beenreplaced by the murine counterpart
Murinisation by F. Lorenz
(MDC, Berlin)
MP71pre/CRV2 1021M #75 IE-1 — CRV
T cell clone and TCRα &
TCRβ sequences from X.
Liang (unpublished)
MP71pre/CRV2mu Same as MP71pre/CRV2, but C region has beenreplaced by the murine counterpart
Murinisation by F. Lorenz
(MDC, Berlin)
MP71pre/CRV2α Same as MP71pre/CRV2, but only coding for TCRα chain
MP71pre/CRV2β Same as MP71pre/CRV2, but only coding for TCRβ chain
MP71pre/CRV3 F46M #36 IE-1 — CRV T cell clone from X. Liang(unpublished)





UL28 — FRC T cell clone from X. Liang(unpublished)
MP71pre/FRC6 XLBC13 6# UL28 — FRC T cell clone from X. Liang(unpublished)
MP71pre/FRC32 XLBC1832# UL28 — FRC






UL28 — FRC T cell clone from X. Liang(unpublished)
MP71pre/YSE 1304P #19 pp65 — YSE
T cell clone and TCRα &
TCRβ sequences from A.
Schub (2010, plasmids 4045
and 4046)
2.5 Oligonucleotides
All oligonucleotides used in this study were synthesised by Metabion (Martinsried, Germany).
Their sequences are displayed in tables 2.9 and 2.10.
2.5.1 Primers for the identification of T cell receptor chains
The primers shown in tables 2.9 and 2.10 were used for amplifying parts of the cDNA that coded
for TCRα or TCRβ chains. The primers shown in table 2.9 have been synthesised as listed by
Schuster (2008) and Schub (2010), who derived the primer sequences from Steinle et al. (1995)
and Zhou et al. (2006). Steinle et al. (1995) stated that they had deduced the sequences of the
primers for Vα1 to Vα12 and Vα17 to Vα21 from Davies et al. (1991). However, no primers
for Vα19 to Vα21 were listed in that publication and their Vα8 primer (GGAGAGAATGTGGAGCAG-
CATC, binding nucleotide positions 61 to 82 of TRAV13) was different from the one used by
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Schuster (2008) and Schub (2010, TGTGGCTGCAGGTGGACT, binding nucleotide positions 32 to 49 of
TRAV13). The origin of the latter primer could not be determined, but this primer was found
to encompass an error at nucleotide position 12 of its sequence (5’ → 3’) showing G instead of C
(see section 4.3.2.2), as verified by using the primer TRAV13-2 (tab. 2.10) and comparing the
PCR product to IMGT’s gene tables of TRAV13-2 (Scaviner and Lefranc, 2000b). Therefore,
the primer was corrected (“Vα8corr”, G→C in position 12, see table 2.9, marked in red) replacing
the erroneous Vα8 primer. The primer names refer to the TCR nomenclature by Arden et al.
(1995).
Table 2.9. Primers for identification of T cell receptor chains by PCR as listed by Schuster
(2008) and Schub (2010) (see original publications Davies et al., 1991; Steinle et al.,
1995; Zhou et al., 2006). Nomenclature of TCR chains is according to Arden et al. (1995).
Nucleobases are abbreviated as A = adenosine, C = cytidine, G = guanosine, I = inosine and
T = thymidine. Degenerate bases (“wobbles”) are displayed as K = G or T, M = A or C, R
= A or G, S = C or G, W = A or T and Y = C or T. The original primer Vα8 was replaced
by Vα8corr (see description above).
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Table 2.9. Primers for identification of T cell receptor chains by PCR (continued from previous page)
















All peptides used in this study were synthesised by JPT (Berlin, Germany) to >70% purity.
Peptides were resuspended in 100% dimethy sulfoxide (DMSO) at various concentrations ranging
from 1 to 12 mg/ml and stored at −20 ◦C. For pulsing target cells, peptide concentrations of
1 or 5 µg/ml were used. Peptides used in this study are YSEHPTFTSQY (pp65363-373), CRVLCCYVL
(IE-1309-317), FRCPRRFCF (UL28327-335) or listed in tables 2.11 and 2.12. Peptides are abbreviated
by their first three or four amino acids in single letter code indicating whether the peptide is
recognised by an HLA class I-restricted TCR or an HLA class II-restricted TCR, respectively.
In all T cell effector assays, DMSO was either washed away before co-cultivation of effector and
target cells or the DMSO concentration was kept below 0.5% (vol/vol).
For identifying the specificity of pp65- or IE-1-specific T cells, two separate peptide libraries
were used. Each library contains of a set of peptides that span the entire sequence either of the
Table 2.10. Primers for resolving ambiguity of V region alleles of T cell receptor chains by
PCR. The primers listed below were designed using MacVector to produce an amplicon
that covers more of the V region than the primers of table 2.9 by binding the cDNA further
upstream (i.e. closer to the 5’ end). Nomenclature of TCR chains is according to IMGT
(Lefranc et al., 1999). The primer names (left column) also show which ambiguities they
were designed to resolve. The last column shows which nucleotide positions (“nt pos.”) of
the respective V region are bound by each primer counting from the first nucleotide of the
start codon.










Table 2.11. The IE-1 peptide library consists of 129 peptides and covers the whole amino acid
sequence of HCMV’s immediate-early (IE) protein 1, strain AD169 (Peptides no. 1 to 120),
and some sequence variants of strains Toledo and TB40. From no. 1 to 120, each peptide is
15 amino acids long and overlaps with the last 11 amino acids of the previous peptide. The
peptides no. 121 to 129 contain sequence variants that are found in HCMV strains Toledo
and TB40. Each peptide was dissolved in 100% DMSO to 12 mg/ml. Modified from Ameres
(2012).
No. Sequence No. Sequence No. Sequence
1 MESS AKRK MDPD NPD 44 ELHD VSKG AANK LGG 87 EICM KVFA QYIL GAD
2 AKRK MDPD NPDE GPS 45 VSKG AANK LGGA LQA 88 KVFA QYIL GADP LRV
3 MDPD NPDE GPSS KVP 46 AANK LGGA LQAK ARA 89 QYIL GADP LRVC SPS
4 NPDE GPSS KVPR PET 47 LGGA LQAK ARAK KDE 90 GADP LRVC SPSV DDL
5 GPSS KVPR PETP VTK 48 LQAK ARAK KDEL RRK 91 LRVC SPSV DDLR AIA
6 KVPR PETP VTKA TTF 49 ARAK KDEL RRKM MYM 92 SPSV DDLR AIAE ESD
7 PETP VTKA TTFL QTM 50 KDEL RRKM MYMC YRN 93 DDLR AIAE ESDE EEA
8 VTKA TTFL QTML RKE 51 RRKM MYMC YRNI EFF 94 AIAE ESDE EEAI VAY
9 TTFL QTML RKEV NSQ 52 MYMC YRNI EFFT KNS 95 ESDE EEAI VAYT LAT
10 QTML RKEV NSQL SLG 53 YRNI EFFT KNSA FPK 96 EEAI VAYT LATA GVS
11 RKEV NSQL SLGD PLF 54 EFFT KNSA FPKT TNG 97 VAYT LATA GVSS SDS
12 NSQL SLGD PLFP ELA 55 KNSA FPKT TNGC SQA 98 LATA GVSS SDSL VSP
13 SLGD PLFP ELAE ESL 56 FPKT TNGC SQAM AAL 99 GVSS SDSL VSPP ESP
14 PLFP ELAE ESLK TFE 57 TNGC SQAM AALQ NLP 100 SDSL VSPP ESPV PAT
15 ELAE ESLK TFEQ VTE 58 SQAM AALQ NLPQ CSP 101 VSPP ESPV PATI PLS
16 ESLK TFEQ VTED CNE 59 AALQ NLPQ CSPD EIM 102 ESPV PATI PLSS VIV
17 TFEQ VTED CNEN PEK 60 NLPQ CSPD EIMA YAQ 103 PATI PLSS VIVA ENS
18 VTED CNEN PEKD VLA 61 CSPD EIMA YAQK IFK 104 PLSS VIVA ENSD QEE
19 CNEN PEKD VLAE LVK 62 EIMA YAQK IFKI LDE 105 VIVA ENSD QEES EQS
20 PEKD VLAE LVKQ IKV 63 YAQK IFKI LDEE RDK 106 ENSD QEES EQSD EEE
21 VLAE LVKQ IKVR VDM 64 IFKI LDEE RDKV LTH 107 QEES EQSD EEEE EGA
22 LVKQ IKVR VDMV RHR 65 LDEE RDKV LTHI DHI 108 EQSD EEEE EGAQ EER
23 IKVR VDMV RHRI KEH 66 RDKV LTHI DHIF MDI 109 EEEE EGAQ EERE DTV
24 VDMV RHRI KEHM LKK 67 LTHI DHIF MDIL TTC 110 EGAQ EERE DTVS VKS
25 RHRI KEHM LKKY TQT 68 DHIF MDIL TTCV ETM 111 EERE DTVS VKSE PVS
26 KEHM LKKY TQTE EKF 69 MDIL TTCV ETMC NEY 112 DTVS VKSE PVSE IEE
27 LKKY TQTE EKFT GAF 70 TTCV ETMC NEYK VTS 113 VKSE PVSE IEEV APE
28 TQTE EKFT GAFN MMG 71 ETMC NEYK VTSD ACM 114 PVSE IEEV APEE EED
29 EKFT GAFN MMGG CLQ 72 NEYK VTSD ACMM TMY 115 IEEV APEE EEDG AEE
30 GAFN MMGG CLQN ALD 73 VTSD ACMM TMYG GIS 116 APEE EEDG AEEP TAS
31 MMGG CLQN ALDI LDK 74 ACMM TMYG GISL LSE 117 EEDG AEEP TASG GKS
32 CLQN ALDI LDKV HEP 75 TMYG GISL LSEF CRV 118 AEEP TASG GKST HPM
33 ALDI LDKV HEPF EEM 76 GISL LSEF CRVL CCY 119 TASG GKST HPMV TRS
34 LDKV HEPF EEMK CIG 77 LSEF CRVL CCYV LEE 120 GKST HPMV TRSK ADQ
35 HEPF EEMK CIGL TMQ 78 CRVL CCYV LEET SVM 121 LKAK ARAK KDEL KRK
36 EEMK CIGL TMQS MYE 79 CCYV LEET SVML AKR 122 ARAK KDEL KRKM IYM
37 CIGL TMQS MYEN YIV 80 LEET SVML AKRP LIT 123 KDEL KRKM IYMC YRN
38 TMQS MYEN YIVP EDK 81 SVML AKRP LITK PEV 124 KRKM IYMC YRNV EFF
39 MYEN YIVP EDKR EMW 82 AKRP LITK PEVI SVM 125 LTEF CRVL CCYI LEE
40 YIVP EDKR EMWM ACI 83 LITK PEVI SVMK RRI 126 CRVL CCYI LEET SVL
41 EDKR EMWM ACIK ELH 84 PEVI SVMK RRIE EIC 127 CCYI LEET SVLL AKR
42 EMWM ACIK ELHD VSK 85 SVMK RRIE EICM KVF 128 LEET SVLL AKRP LIT
43 ACIK ELHD VSKG AAN 86 RRIE EICM KVFA QYI 129 ESDE EDAI AAYT LAT
40
2.6 Peptides
Table 2.12. The pp65 peptide library consists of 138 peptides and covers the whole amino acid
sequence of HCMV’s phosphoprotein 65 (pp65), strain AD169. Each peptide is 15 amino
acids long and overlaps with the last 11 amino acids of the previous peptide (Kern et al.,
2002). Each peptide was dissolved in 100% DMSO to 4 mg/ml. Modified from Schub (2010).
No. Sequence No. Sequence No. Sequence
1 MESR GRRC PEMI SVL 47 AFVF PTKD VALR HVV 93 FTSQ YRIQ GKLE YRH
2 GRRC PEMI SVLG PIS 48 PTKD VALR HVVC AHE 94 YRIQ GKLE YRHT WDR
3 PEMI SVLG PISG HVL 49 VALR HVVC AHEL VCS 95 GKLE YRHT WDRH DEG
4 SVLG PISG HVLK AVF 50 HVVC AHEL VCSM ENT 96 YRHT WDRH DEGA AQG
5 PISG HVLK AVFS RGD 51 AHEL VCSM ENTR ATK 97 WDRH DEGA AQGD DDV
6 HVLK AVFS RGDT PVL 52 VCSM ENTR ATKM QVI 98 DEGA AQGD DDVW TSG
7 AVFS RGDT PVLP HET 53 ENTR ATKM QVIG DQY 99 AQGD DDVW TSGS DSD
8 RGDT PVLP HETR LLQ 54 ATKM QVIG DQYV KVY 100 DDVW TSGS DSDE ELV
9 PVLP HETR LLQT GIH 55 QVIG DQYV KVYL ESF 101 TSGS DSDE ELVT TER
10 HETR LLQT GIHV RVS 56 DQYV KVYL ESFC EDV 102 DSDE ELVT TERK TPR
11 LLQT GIHV RVSQ PSL 57 KVYL ESFC EDVP SGK 103 ELVT TERK TPRV TGG
12 GIHV RVSQ PSLI LVS 58 ESFC EDVP SGKL FMH 104 TERK TPRV TGGG AMA
13 RVSQ PSLI LVSQ YTP 59 EDVP SGKL FMHV TLG 105 TPRV TGGG AMAG AST
14 PSLI LVSQ YTPD STP 60 SGKL FMHV TLGS DVE 106 TGGG AMAG ASTS AGR
15 LVSQ YTPD STPC HRG 61 FMHV TLGS DVEE DLT 107 AMAG ASTS AGRK RKS
16 YTPD STPC HRGD NQL 62 TLGS DVEE DLTM TRN 108 ASTS AGRK RKSA SSA
17 STPC HRGD NQLQ VQH 63 DVEE DLTM TRNP QPF 109 AGRK RKSA SSAT ACT
18 HRGD NQLQ VQHT YFT 64 DLTM TRNP QPFM RPH 110 RKSA SSAT ACTS GVM
19 NQLQ VQHT YFTG SEV 65 TRNP QPFM RPHE RNG 111 SSAT ACTS GVMT RGR
20 VQHT YFTG SEVE NVS 66 QPFM RPHE RNGF TVL 112 ACTS GVMT RGRL KAE
21 YFTG SEVE NVSV NVH 67 RPHE RNGF TVLC PKN 113 GVMT RGRL KAES TVA
22 SEVE NVSV NVHN PTG 68 RNGF TVLC PKNM IIK 114 RGRL KAES TVAP EED
23 NVSV NVHN PTGR SIC 69 TVLC PKNM IIKP GKI 115 KAES TVAP EEDT DED
24 NVHN PTGR SICP SQE 70 PKNM IIKP GKIS HIM 116 TVAP EEDT DEDS DNE
25 PTGR SICP SQEP MSI 71 IIKP GKIS HIML DVA 117 EEDT DEDS DNEI HNP
26 SICP SQEP MSIY VYA 72 GKIS HIML DVAF TSH 118 DEDS DNEI HNPA VFT
27 SQEP MSIY VYAL PLK 73 HIML DVAF TSHE HFG 119 DNEI HNPA VFTW PPW
28 MSIY VYAL PLKM LNI 74 DVAF TSHE HFGL LCP 120 HNPA VFTW PPWQ AGI
29 VYAL PLKM LNIP SIN 75 TSHE HFGL LCPK SIP 121 VFTW PPWQ AGIL ARN
30 PLKM LNIP SINV HHY 76 HFGL LCPK SIPG LSI 122 PPWQ AGIL ARNL VPM
31 LNIP SINV HHYP SAA 77 LCPK SIPG LSIS GNL 123 AGIL ARNL VPMV ATV
32 SINV HHYP SAAE RKH 78 SIPG LSIS GNLL MNG 124 ARNL VPMV ATVQ GQN
33 HHYP SAAE RKHR HLP 79 LSIS GNLL MNGQ QIF 125 VPMV ATVQ GQNL KYQ
34 SAAE RKHR HLPV ADA 80 GNLL MNGQ QIFL EVQ 126 ATVQ GQNL KYQE FFW
35 RKHR HLPV ADAV IHA 81 MNGQ QIFL EVQA IRE 127 GQNL KYQE FFWD AND
36 HLPV ADAV IHAS GKQ 82 QIFL EVQA IRET VEL 128 KYQE FFWD ANDI YRI
37 ADAV IHAS GKQM WQA 83 EVQA IRET VELR QYD 129 FFWD ANDI YRIF AEL
38 IHAS GKQM WQAR LTV 84 IRET VELR QYDP VAA 130 ANDI YRIF AELE GVW
39 GKQM WQAR LTVS GLA 85 VELR QYDP VAAL FFF 131 YRIF AELE GVWQ PAA
40 WQAR LTVS GLAW TRQ 86 QYDP VAAL FFFD IDL 132 AELE GVWQ PAAQ PKR
41 LTVS GLAW TRQQ NQW 87 VAAL FFFD IDLL LQR 133 GVWQ PAAQ PKRR RHR
42 GLAW TRQQ NQWK EPD 88 FFFD IDLL LQRG PQY 134 PAAQ PKRR RHRY DAL
43 TRQQ NQWK EPDV YYT 89 IDLL LQRG PQYS EHP 135 PKRR RHRY DALP GPC
44 NQWK EPDV YYTS AFV 90 LQRG PQYS EHPT FTS 136 RHRY DALP GPCI AST
45 EPDV YYTS AFVF PTK 91 PQYS EHPT FTSQ YRI 137 DALP GPCI ASTP KKH
46 YYTS AFVF PTKD VAL 92 EHPT FTSQ YRIQ GKL 138 GPCI ASTP KKHR G
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antigen pp65 or IE-1 of the HCMV strain AD169. Each of these peptides has a length of 15
amino acids and overlaps in 11 amino acids with the subsequent peptide.
The IE-1 peptide library (see table 2.11) is comprised of 120 peptides covering AD169’s IE-1
sequence and nine additional peptides, which contain sequence variants that are found in HCMV
strains Toledo and TB40 (peptides no. 121-129, see Ameres, 2012). For handling purposes,
the 129 peptides were subpooled in a cross-matrix fashion as described by Kern et al. (1999)
and depicted in table 2.13 so that every single peptide was contained within one of the vertical
subpools (from 1 to 12) and within one horizontal subpool (from 13 to 23) at 1 mg/ml (Ameres,
2012).
The pp65 peptide library (see table 2.12) is comprised of 138 peptides covering AD169’s pp65
sequence (Kern et al., 2002). Similar to the IE-1 peptides, the pp65 peptides were subpooled
in a cross-matrix fashion so that every single peptide was contained within one of the vertical
subpools (from 1 to 12) and within one horizontal subpool (from 13 to 24) at 0.33 mg/ml (see
table 2.13; Kern et al., 2002; Schub, 2010).
Table 2.13. Vertical and horizontal peptide subpools of pp65 or IE-1 peptide libraries. All
peptides either of the pp65 library (tab. 2.12) or the IE-1 peptide library (tab. 2.11) were
pooled according to the scheme shown in this table. As a result, 12 vertical subpools (bold,
numbered 1 to 12) and 12 horizontal subpools (bold, numbered 13 to 24) for pp65 were
obtained. Separately, 12 vertical subpools and 11 horizontal subpools were created from
the IE-1 peptide library. Each peptide pool contains 12 peptides, except for IE-1 pool no.
23 and pp65 pool no. 24, both of which contain fewer peptides. IE-1 and pp65 peptide
numbers (non-bold) refer to the numbers shown in tables 2.11 and 2.12, respectively.
Vertical subpool
1 2 3 4 5 6 7 8 9 10 11 12
Horizontal
subpool
13 1 2 3 4 5 6 7 8 9 10 11 12
14 13 14 15 16 17 18 19 20 21 22 23 24
15 25 26 27 28 29 30 31 32 33 34 35 36
16 37 38 39 40 41 42 43 44 45 46 47 48
17 49 50 51 52 53 54 55 56 57 58 59 60
18 61 62 63 64 65 66 67 68 69 70 71 72
19 73 74 75 76 77 78 79 80 81 82 83 84
20 85 86 87 88 89 90 91 92 93 94 95 96
21 97 98 99 100 101 102 103 104 105 106 107 108
22 109 110 111 112 113 114 115 116 117 118 119 120
23 121 122 123 124 125 126 127 128 129 130 131 132
24 133 134 135 136 137 138
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Biolegend (San Diego, USA) 300324 HIT3a 500.0 1:100
CD3 APC Biolegend (San Diego, USA) 300312 HIT3a 25.0 1:50
CD3 PE Biolegend (San Diego, USA) 300308 HIT3a 50.0 1:100





Biolegend (San Diego, USA) 300519 RPA-T4 50.0 1:50
CD4 APC Biolegend (San Diego, USA) 300514 RPA-T4 12.5 1:50
CD4 PE Biolegend (San Diego, USA) 300514 RPA-T4 12.5 1:50







Biolegend (San Diego, USA) 300916 HIT8a 100.0 1:100
CD8 APC-Cy7 Biolegend (San Diego, USA) 301016
RPA-
T8 200.0 1:250
CD8 PacificBlue Biolegend (San Diego, USA) 301033
RPA-
T8 200.0 1:100
CD8 PerCp-Cy5.5 Biolegend (San Diego, USA) 301032
RPA-
T8 200.0 1:100
CD11c PerCp Biolegend (San Diego, USA) 337233 Bu15 100.0 1:100
CD14 APC-Cy7 Biolegend (San Diego, USA) 301819 M5E2 400.0 1:100






CD19 BV605 Biolegend (San Diego, USA) 302244 HIB19 80.0 1:100
Continued on next page
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CD25 PacificBlue Biolegend (San Diego, USA) 356129
M-
A251 50.0 1:50
CD45RA APC Biolegend (San Diego, USA) 304112 HI100 25.0 1:50
CD45RA PE Biolegend (San Diego, USA) 304108 HI100 1.5 1:50
CD62L PE-Cy7 Biolegend (San Diego, USA) 304822 DREG-56 200.0 1:50
CD83 FITC BD Biosciences (Heidelberg,Germany) 556910 HB15e 3:50




FITC BD Biosciences (Heidelberg,Germany) 559784 CH-L 3:50
CD158b










Biolegend (San Diego, USA) 353206 G043H7 400.0 1:50
CD314
(NKG2D) PE-Cy7 Biolegend (San Diego, USA) 320812 1D11 200.0 3:100
HLA-DP notlabelled
Leinco Technologies (St.







L3 1,000.0 10 µg/ml
HLA-DR notlabelled Biolegend (San Diego, USA) 307612 L243 1,000.0 40 µg/ml
TCRαβ APC Biolegend (San Diego, USA) 306718 IP26 100.0 1:50
TCR Vβ1 FITC Beckman Coulter (Krefeld,Germany) IM2406 BL37.2 1:50
TCR Vβ2 FITC Beckman Coulter (Krefeld,Germany) IM2407 MPB2D5 3:50
TCR Vβ3 FITC Beckman Coulter (Krefeld,Germany) IM2372 CH92 7:50
Continued on next page
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TCR Vβ5.1 FITC Beckman Coulter (Krefeld,Germany) IM1552
IMMU
157 1:10
TCR Vβ5.2 FITC Beckman Coulter (Krefeld,Germany) IM1482 36213 1:10
TCR Vβ11 PE Beckman Coulter (Krefeld,Germany) IM2290 C21 3:50
TCR Vβ13.1 PE Beckman Coulter (Krefeld,Germany) IM2292
IMMU
222 7:50
TCR Vβ13.2 PE Beckman Coulter (Krefeld,Germany) IM3603 H132 1:50
TCR Vβ17 PE Beckman Coulter (Krefeld,Germany) IM2048
E17.5F
3.15.13 1:10
TCR Vβ21.3 FITC Beckman Coulter (Krefeld,Germany) IM1483 IG125 3:50
TCR Vδ2 PacificBlue Biolegend (San Diego, USA) 331414 B6 100.0 1:100
TCR Vδ2 PerCp Biolegend (San Diego, USA) 331410 B6 200.0 1:100
For immunomagnetic separation of cell populations, anti-human CD8 MicroBeads (Order No.:
130-045-201), anti-APC MicroBeads (Order No.: 130-090-855) or anti-FITC MicroBeads (Order
No. 130-048-701) by Miltenyi Biotec (Bergisch Gladbach, Germany) have been used.
PE-labelled Calibrite beads (Cat.No. 349502) from BD Biosciences (Heidelberg, Germany) were
used to normalise cell counts acquired by flow cytometry.
2.8 Major histocompatibility complex multimers
YSE/HLA-A*01:01 pentamers (unlabelled) and associated R-PE Pro5 fluorotags were purchased
from ProImmune (Oxford, United Kingdom).
CRV/HLA-C*07:02 monomers and FRC/HLA-C*07:02 monomers were generated and provided
by Fabian Schlott, Michael Neuenhahn and Dirk Busch (Institute for Medical Microbiology, Im-
munology and Hygiene, TUM, Munich, Germany; see Schlott et al., 2018). Peptide/HLA class
I monomers were assembled using MHC OneSTrEPtag-Strep-Tactin (IBA Göttingen, Germany)
to generate streptamers (see section 3.4.2 and Knabel et al., 2002; Neudorfer et al., 2007).
Recombinant peptide/HLA class II αβ complexes (hereafter referred to as peptide/HLA class II
monomers) were purchased from Immunaware (Copenhagen, Denmark) and applied for staining
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Table 2.15. Recombinant peptide/HLA class II monomers (purchased from Immunaware, Copen-
hagen, Denmark).
Peptide HLA class II αβ heterodimer
Concentration [nM]
of stock applied
QPFM RPHE RNGF TVL HLA-DRA1*01:01 / HLA-DRB1*13:02 1,675 nM failed
YRIQ GKLE YRHT WDR HLA-DRA1*01:01 / HLA-DRB1*13:02 1,800 nM 60 nM
AGIL ARNL VPMV ATV HLA-DRA1*01:01 / HLA-DRB3*03:01 2,900 nM 30 nM
MSIY VYAL PLKM LNI HLA-DRA1*01:01 / HLA-DRB1*15:01 1,600 nM failed
EFFT KNSA FPKT T HLA-DRA1*01:01 / HLA-DRB5*01:01 2,870 nM 30 nM
of T cells at concentrations indicated in table 2.15. For QPFM and MSIY monomers sub-optimal
folding was reported by Immunaware (70 and 60%, respectively), and indeed, these monomers
failed to detect QPFM- or MSIY-specific T cells after tetramerisation, respectively (see table 2.15
and section 4.4.2). Unfortunately, KRKM IYMC YRNV EFF/HLA-DRB3*02:02 monomers failed to
fold entirely and were thus not available for staining of RRKM-specific T cells.
Peptide/HLA class II monomers were assembled using PE- (Cat.No. 554061) or APC-labelled
streptavidin (Cat.No. 554067) from BD Biosciences (Heidelberg, Germany) to generate tetramers
(see section 3.4.2 and Braendstrup et al., 2013, 2014).
2.9 Commercial kits
Table 2.16. Commercial kits.
Name Manufacturer
Cytofix/Cytoperm BD Biosciences (Heidelberg, Germany)
Endofree Plasmid Maxi Kit Qiagen (Hilden, Germany)
HiPure Plasmid Maxiprep Kit Thermo Fisher Scientific (Waltham, USA)
Human IFN-γELISA Kit (ALP) Mabtech (Nacka Strand, Sweden)
Human IL-10 ELISA Kit (DuoSet) R&D Systems (Minneapolis, USA)
NucleoSpin Gel and PCR Clean-up Kit Macherey-Nagel (Düren, Germany)
QIAshredder Qiagen (Hilden, Germany)
QuantiTect Reverse Transcription Kit Qiagen (Hilden, Germany)
RNeasy Mini Kit Qiagen (Hilden, Germany)
2.10 Chemicals, reagents, enzymes and buffers






Ampicillin Carl Roth (Karlsruhe, Germany)
Continued on next page
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Aqua ad iniectabilia Berlin-Chemie (Berlin, Germany)
Cell Trace Violet 5 mM Thermo Fisher Scientific (Waltham, USA)
Comp Beads, anti-mouse
Igκ BD Biosciences (Heidelberg, Germany)
Dimethyl sulfoxide
(DMSO) ≥99.8% p.a. Carl Roth (Karlsruhe, Germany)
DNA agarose, ultra pure Life Technologies (Paisley, UnitedKingdom)
DNA loading dye 6× Thermo Fisher Scientific (Waltham, USA)
dNTPs 10 mM Thermo Fisher Scientific (Waltham, USA)
ELISA washing buffer 0.05% Tween 20 in1× PBS Freshly produced
Ethanol ≥99.8% p.a. Carl Roth (Karlsruhe, Germany)
Ethidium bromide 10 mg/ml Carl Roth (Karlsruhe, Germany)
FACS buffer 2% FCS in 1× PBS Freshly produced
FACS Clean BD Biosciences (Heidelberg, Germany)
FACS Flow BD Biosciences (Heidelberg, Germany)
FACS fixation solution 2% PFA in 1× PBS Freshly produced or stored at 4 ◦C
GeneRuler DNA Ladder
Mix 1 kb Fermentas (St. Leon-Rot, Germany)
HCl ≥32% Merck (Darmstadt, Germany)
Heparin-Natrium 5,000 I E /ml Rotexmedica (Trittau, Germany)
Ionomycin calcium salt Tocris Bioscience (Bristol, UK)
Isopropanol 99.9% p.a. Carl Roth (Karlsruhe, Germany)
MgSO4 25 mM Thermo Fisher Scientific (Waltham, USA)




3 mg/ml medac (Wedel, Germany)
Pancoll 1.077 g/ml PAN Biotech (Aidenbach, Germany)
Paraformaldehyde Carl Roth (Karlsruhe, Germany)
Para-nitrophenyl
phosphate (pNPP) Carl Roth (Karlsruhe, Germany)
Continued on next page
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amine and 5 mg/ml
pNPP in sterile
water at pH 9.5)
Freshly produced or stored at −20 ◦C
PBS Dulbecco (without
Mg2+ & Ca2+)
1×, dissolved Sigma-Aldrich (St. Louis, USA)
PBS Dulbecco (without
Mg2+ & Ca2+)
10×, solid AppliChem (Darmstadt, Germany)
Protamine sulfate MP Biomedicals (Illkirch, France)
Protamine sulfate
solution
1 mg/ml in sterile
H2O
Freshly produced or stored at 4 ◦C
RetroNectin 1 mg/ml Takara Bio Europe (St. Germain en Laye,France)
RetroNectin solution 12.5 µg/ml in sterileH2O
Freshly produced or stored at −20 ◦C
Rnase ZAP Sigma-Aldrich (St. Louis, USA)
TAE (Tris, acetate,
EDTA) 10× Carl Roth (Karlsruhe, Germany)
Taq reaction buffer 10× New England BioLabs (Ipswich, USA)
Taq DNA polymerase 5,000 U/ml New England BioLabs (Ipswich, USA)
Tetradecanoylphorbol
acetate (TPA) Sigma-Aldrich (St. Louis, USA)
TransIT-293 transfection
reagent Mirus Bio LLC (Madison, USA)
Tris/HCl 1M Carl Roth (Karlsruhe, Germany)
Trypan blue Merck (Darmstadt, Germany)
Tween 20 Carl Roth (Karlsruhe, Germany)
2.11 Consumables
Table 2.18. Consumables.
Name Brand name,concentration or size Manufacturer




96-wells Nunc A/S (Roskilde, Denmark)
Continued on next page
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Table 2.18. Consumables (continued from previous page).
Name Brand name,concentration or size Manufacturer
Cell culture multiwell
plate, flat-bottom 6-, 12-, 48- or 96-wells Corning Inc. (Corning, USA)
Cell culture multiwell
plate, round-bottom 96-wells Nunc A/S (Roskilde, Denmark)
Cell culture multiwell
plate, V-bottom 96-wells Hartenstein (Würzburg, Germany)
Cell scraper 20 mm width, 30 cm length TPP Techno Plastic Products(Trasadingen, Switzerland)
Cell strainer Falcon, 100 µm Corning Inc. (Corning, USA)
Counting chamber Neubauer Improved NanoEnTek (Seoul, Korea)
Cryo tube vial 1.8 ml Nunc A/S (Roskilde, Denmark)
Electroporation cuvette GenePulser, 0.4 cm Bio-Rad (München, Germany)
MACS column LD Miltenyi Biotec (BergischGladbach, Germany)
Needle Multifly, 21G, 240 mm Sarstedt (Nümbrecht, Germany)
Pasteur pipette
(sterile, single use) 3.2 ml Carl Roth (Karlsruhe, Germany)
Petri dishes 60×15 or 100×20 mm Corning Inc. (Corning, USA)
Pipette tip Diamond TowerPack,2–200 µl or 100–1,000 µl Gilson Inc. (Middleton, USA)
Pipette tip epT.I.P.S. Reloads 0.1–10 µl Eppendorf (Hamburg, Germany)
Pipette tip with filter MultiGuard Barrier Tips,10 µl, 20 µl, 200 µl or 1,000 µl
Sorenson BioScience (Salt Lake
City, USA)
Plastic pipette 5, 10 or 25 ml Greiner Bio-One (Kremsmünster,Austria)
Reagent reservoir Costar, 50 ml Corning Inc. (Corning, USA)
Reaction tube 0.5, 1.5 or 2.0 ml Eppendorf (Hamburg, Germany)
Reaction tube for PCR 0.2 µl single tubes or stips Thermo Fisher Scientific(Waltham, USA)
Syringe Infuject, 50 ml Dispomed Witt oHG (Gelnhausen,Germany)
Syringe filter 0.45 µm, SFCA Thermo Fisher Scientific(Waltham, USA)
Syringe with needle 1 ml, 25G Terumo (Binan, Philippines)
Tube, conical Falcon, 15 or 50 ml Corning Inc. (Corning, USA)
Tube, round-bottom Falcon, 5 ml (Polystyrene) Corning Inc. (Corning, USA)
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2.12 Laboratory equipment and devices
Table 2.19. Laboratory equipment and devices.
Device / Equipment Manufacturer / Distributor
Bacteria incubator/shaker innova 4400 New Brunswick Scientific (Enfield, USA)
Centrifuge Avanti J-26 XP Beckman Coulter (Krefeld, Germany)
Centrifuge 5415 R Eppendorf (Hamburg, Germany)
Centrifuge Heraeus Pico 21 Thermo Fisher Scientific (Waltham, USA)
Centrifuge Rotanta 46 RSC Hettich (Bäch, Switzerland)
Centrifuge Rotanta 460 R Hettich (Bäch, Switzerland)
Centrifuge Rotina 38 R Hettich (Bäch, Switzerland)
Counting chamber Neubauer Improved Paul Marienfeld (Lauda-Königshofen,Germany)
Cytofluorometer Canto BD Biosciences (Heidelberg, Germany)
Cytofluorometer LSR Fortessa BD Biosciences (Heidelberg, Germany)
Electroporation system GenePulser II Bio-Rad (München, Germany)
Freezer −20 ◦C Liebherr (Biberach an der Riss, Germany)
Freezer −80 ◦C Igloo Green Line 830L Telstar (Terrassa, Spain)
Fridge 2–8 ◦C Bosch (Gerlingen-Schillerhöhe, Germany)
Gel documentation system
Quantum ST4-1100/26LMX Vilber Lourmat (Eberhardzell, Germany)
Gel electrophoresis chambers Peqlab Biotechnologie (Erlangen, Germany)
Gel electrophoresis power supply
PowerPac 200 Bio-Rad (München, Germany)
Glassware Schott (Mainz, Germany)
Ice machine AF 206 Scotsman (Milan, Italy)
Incubator Binder (Tuttlingen, Germany)
Irradiator CIX2, X-ray xstrahl (Camberley, United Kingdom)
Irradiator Gammacell 40, 137Cs Atomic Energy of Canada Limited(Ottawa, Canada)
Laminar flow hoods BDK (Sonnenbühl-Genkingen, Germany)
MACS MultiStand Miltenyi Biotec (Bergisch Gladbach, Germany)
MACS separator Quadro Miltenyi Biotec (Bergisch Gladbach, Germany)
Magnetic stirrer Monotherm Variomag (Daytona Beach, USA)
Microplate reader EL-800 BIO-TEK Instruments (Winooski, USA)
Microplate reader Infinite F200 Pro Tecan (Männedorf, Switzerland)
Microplate washer hydroSPEED Tecan (Männedorf, Switzerland)
Continued on next page
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Table 2.19. Laboratory equipment and devices (continued from previous page)
Device / Equipment Manufacturer / Distributor
Microscope (fluorescence) Axiovert 200M Zeiss (Jena, Germany)
Microscope (inverted) Axiovert 25 Zeiss (Jena, Germany)
Microwave oven R-202 Sharp (Osaka, Japan)
pH-meter pH 526 WTW (Xylem Analytics Germany, Weilheim, Ger-many)
Pipetboy acu Integra Biosciences (Fernwald, Germany)
Pipette Transferpette
(multichannel, 20–200 µl) Brand (Wertheim, Germany)
Pipettes (0.1–2.0 µl, 2–20 µl, 20–200 µl,
200–1,000 µl) Gilson (Mettmenstetten, Switzerland)
Precision scales SPB 55 Scaltec instruments (Göttingen, Germany)
Spectrophotometer Nanodrop ND-1000 Peqlab Biotechnologie (Erlangen, Germany)
Thermocycler Biometra T gradient Biometra (Göttingen, Germany)
Thermomixer compact eppendorf (Hamburg, Germany)
Tumble roller mixer TRM-50 IDL (Nidderau, Germany)
Ultra pure water device Aquintus membraPure (Hennigsdorf, Germany)
UV crosslinker CL-1, 254 nm Herolab (Wiesloch, Germany)
UV transilluminator UVT 400 M International Biotechnologies Inc.(New Haven, USA)
Vacuum pump Fröbel Labortechnik (Lindau, Germany)
Vortex mixer Vortex-Genie 2 Scientific Industries (Bohemia, USA)
Water bath GFL (Burgwedel, Germany)
2.13 Services
• The EBV and HCMV IgG serostatus of blood donors was determined by the Max von
Pettenkofer Institute (München, Germany).
• High resolution HLA typing of blood donors was performed by the “Zentrum für Human-
genetik und Laboratoriumsdiagnostik, Dr. Klein, Dr. Rost und Kollegen” (Martinsried,
Germany) using whole blood, isolated PBMCs or established cell lines.
• SangerDNA sequencing of purified PCR products was done by GATC Biotech AG (Kon-
stanz, Germany) and Eurofins Genomics (Ebersberg, Germany).
• Gene synthesis and human codon optimisation of TCR constructs as well as cloning of
the constructs into pMP71 was done by Thermo Fisher Scientific (Regensburg, Germany).
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• Oligonucleotides were synthesised by Metabion (Martinsried, Germany).
• Buffy coats were obtained from the Institute for Transfusion Medicine of the University
of Ulm (Germany)
2.14 Software and databases
For identification of V, CDR3, (D), J and C regions of sequenced TCRα or TCRβ chains the
international ImMunoGeneTics information system (IMGT, Lefranc et al., 1999) was used. In
particular, the V-QUEST tool (Brochet et al., 2008; Giudicelli et al., 2011, http://www.imgt.
org/IMGT_vquest/vquest) was employed and reference sequences were obtained from the TCR
repertoire (http://www.imgt.org/IMGTrepertoire/) concerning human TRAV (Scaviner and Le-
franc, 2000b) and TRBV (Folch and Lefranc, 2000).
The UniProt database (The UniProt Consortium, 2017, https://www.uniprot.org/) served as
source for protein sequences, like that of 65 kDa phosphoprotein (pp65) of HCMV strain AD169
(accession number P06725, accessed 06.03.2017). Additionally, the genetic sequence database
Table 2.20. Software.
Name Version Application Producer
Diva 8.0.1 FACS data analysis &compensation BD Biosciences (Heidelberg, Germany)
Excel 2016 15.32 Data analysis and tabledesign Microsoft (Redmond, USA)
FlowJo 10.5.3 FACS data analysis &compensation TreeStar Inc. (Ashland, USA)
i-control 1.10 ELISA measurement Tecan (Männedorf, Switzerland)









MacVector Inc. (Cary, USA)
Mendeley 1.19.2 Reference management Elsevier Limited (Oxford, UnitedKingdom)
PowerPoint
2016 15.32 Illustration Microsoft (Redmond, USA)
Prism 6.0h Data analysis and display GraphPad Software (La Jolla, USA)
TeXstudio 2.12.14 Writing
Benito van der Zander, Jan
Sundermeyer, Daniel Braun, Tim
Hoffmann (https://www.texstudio.org)
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GenBank (Benson et al., 2012, https://www.ncbi.nlm.nih.gov/genbank/) of the National Insti-
tutes of Health was used to gather nucleic acid sequences, such as the genome of AD169 (accession
number FJ527563, accessed 03.06.2019).
All other software, which has been used in this study for experimental design, data analysis and





3.1.1 Cultivation and storage of bacteria
Escherichia coli (E. coli) strain DH5α (Invitrogen, Karlsruhe, Germany) was used for propagation
of plasmids (see section 2.4). They were cultured at 37 ◦C overnight on LB agar plates or in LB
medium under constant agitation at 200 rpm. If the bacteria carried a plasmid, the respective
antibiotic was added to the LB agar or medium (100 µg/ml ampicillin, 30 µg/ml chloramphenicol,
30 µg/ml kanamycin) in order to select for bacteria harbouring the plasmid’s resistance gene.
After overnight incubation, LB plates were stored at 4 ◦C for up to 7 days.
3.1.2 Transformation of bacteria
For transforming E. coli DH5α, a vial of highly concentrated, chemically competent bacteria that
had been prepared by L. Schirrmann was thawed on ice. 1 µg of plasmid DNA was added to
50 µl of bacteria, incubating the mixture for 10 to 20 minutes on ice. After a heat shock of 45
seconds at 42 ◦C, the bacteria suspension was cooled on ice for another 1 to 2 minutes. Next,
1 ml of LB medium without antibiotics was added and the suspension was shaken at 37 ◦C and
900 rpm. After an hour, the suspension was centrifuged at 3,000 × g for 3 minutes, the majority
of the supernatant was discarded and the remaining volume (ca. 50 µl) was used to resuspend the
pelleted bacteria and plate them on a pre-warmed LB plate containing the respective antibiotic.
Finally, plates were incubated at 37 ◦C overnight. Well grown, single colonies were used for
further propagation.
3.1.3 Propagation of transformed bacteria
One well grown and well separated colony was picked from an overnight LB plate and incubated
in 400 ml sterile LB medium including the necessary antibiotic (see section 3.1.1) for selection of
transformed bacteria.
3.2 Molecular biology methods
3.2.1 Plasmid DNA purification from E. coli
Large scale purification of plasmid DNA for transfection of human cells was performed using the
HiPure Plasmid Maxiprep Kit (Thermo Fisher Scientific, Waltham, USA) or Endofree Plasmid
Maxi Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. 400 ml of sat-
urated overnight bacteria culture were used for a single preparation providing yields of up to
1 mg DNA. Concentration and purity of the preparation were assessed by absorbency readings




Table 3.1. Primer pools of TCR Vα primers (listed in section 2.5.1, from Davies et al., 1991; Steinle
et al., 1995) for amplification of TCRα cDNA.
Pool Primers included
A Pan Vα1, Pan Vα1.1, Vα2, Vα3, Vα4
B Vα5, Vα6, Vα7, Vα8corr
C Vα9, Vα10, Vα11, Vα12
D Vα13, Vα14.1, Vα14, Vα15, Vα16
E Vα17, Vα18, Vα19, Vα20
F Vα21, Vα22, Vα23, Vα24
G Vα25, Vα26, Vα27, Vα28
H Vα29, Vα30, Vα31NEU, Vα32
3.2.2 T cell receptor analysis
Total RNA was isolated from T cell clones by using QIAshredder kit and RNeasy mini kit (Qia-
gen, Hilden, Germany) following the instructions of the manufacturer. T cells were either freshly
pelleted or had been frozen at −80 ◦C and were thawed for RNA extraction. RNA concentration
was assessed by absorbency readings at 260 nm with the Nanodrop ND-1000 spectrophotometer
(Peqlab Biotechnologie, Erlangen, Germany). cDNA was generated from extracted RNA using
the QuantiTect reverse transcription kit (Qiagen, Hilden, Germany). If RNA concentration was
higher than or equal to 30 ng/ml, 6 µl were used for reverse transcription. If RNA concentration
was lower, 12 µl were used.
For amplification of TCRα cDNA by polymerase chain reaction (PCR), 34 forward primers
(see Davies et al., 1991; Steinle et al., 1995) were pooled into eight groups as shown in table
3.1. With the forward primer binding in the V region of the TCRα chain and the reverse primer
3’T-Cα specifically binding to the C region of TCRα cDNA, the resulting amplicon was of ap-
proximately 400 bp length. Additionally, the primers P-5’αST (forward) and P-3’αST (reverse)
generated an amplicon of 547 bp spanning from the C region to the 3’ untranslated region (UTR)
of TCRα cDNA serving as positive control.
TCRα PCR was carried out on a Biometra T gradient thermocycler (Biometra, Göttingen, Ger-
many). The composition of the PCR mixture is shown in table 3.2. The PCR program consisted
of 2 minutes initial denaturation at 95 ◦C, 38 cycles of (I) 30 seconds at 95 ◦C, (II) 30 seconds at
56 ◦C and (III) 60 seconds at 72 ◦C, followed by a final extension at 72 ◦C for 10 minutes to allow
for the completion of abortive elongation reactions. In the end, the PCR samples were kept at
4 ◦C until further processing or they were stored at −20 ◦C.
For amplification of TCRβ cDNA, the two degenerate forward primers VP1 and VP2 were
used (see Zhou et al., 2006). While VP1 is able to bind to 42 different V regions of TCRβ chains,
VP2 is able to bind to 11 additional TCRβ V regions, leaving only Vβ16.1 and Vβ10.1 not to
be covered by these two primers. The reverse primer CP1 specifically binds both alleles of the
C region of the TCRβ chain (Cβ1 or Cβ2), resulting in an amplicon of approximately 400 bp
length.
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TCRβ PCR was carried out on a Biometra T gradient thermocycler (Biometra, Göttingen,
Germany). The composition of the PCR mixture is shown in table 3.2. The PCR program
consisted of 2 minutes initial denaturation at 95 ◦C, 40 cycles of (I) 30 seconds at 95 ◦C, (II)
30 seconds at 50 ◦C and (III) 30 seconds at 72 ◦C, followed by a final extension at 72 ◦C for 10
minutes. In the end, the PCR samples were kept at 4 ◦C until further processing or they were
stored at −20 ◦C.
Table 3.2. Compositions of TCRα and TCRβ PCR mixtures.
PCR component
concentration required amountfor PCR [µl]
stock final Vα Vβ
Vα and Vβ
cDNA - - 1.0 - 2.0 1.5
dNTP 2.0 mM 0.2 mM 4.0 4.0
Taq Buffer 10× 1× 4.0 4.0
DMSO 100% 5% 2.0 2.0
Taq polymerase 5.0 U/µl 2.5 U/40 µl 0.5 0.5
H2O - - 7.9 - 8.9 19.2
Vα
5’ primer subpool
A, B, C, ... or H 0.8 µM each 0.2 µM each 10.0 -
3’ primer 3’T-Cα 5.0 µM 0.5 µM 4.0 -
P-5’αST 2.5 µM 0.175 µM 2.8 -
P-3’αST 2.5 µM 0.175 µM 2.8 -
Vβ
5’ primer VP1 or VP2 10.0 µM 2.0 µM - 8.0
3’ primer CP1 10.0 µM 0.2 µM - 0.8
Sum - - 40.0 40.0
PCR products were separated according to their size by agarose gel electrophoresis.
Agarose gels were prepared using 1× TAE buffer, 2% (w/v) ultra pure agarose (Life Technolo-
gies, Paisley, UK) and 0.1 µg/ml ethidium bromide (Carl Roth GmbH, Karlsruhe, Germany) for
visualisation of the DNA. While all of the sample volume was consumed for gel electrophoresis
of from TCRα PCR samples, only 10 µl of the TCRβ PCR samples were used. The samples
were mixed with 6× loading dye (Thermo Fisher Scientific, Waltham, USA) and run on a 2%
(w/v) agarose gel at 110 V for 45 to 60 minutes using 1× TAE as a running buffer and 1 kb
GeneRuler DNA Ladder Mix (Fermentas, St. Leon-Rot, Germany) to determine DNA fragment
size. The gel was viewed and documented employing the gel documentation system Quantum
ST4-1100/26LMX (Vilber Lourmat, Eberhardzell, Germany). In case of TCRα PCR samples,
the gel was additionally viewed on an ultraviolet (UV) transilluminator (UVT 400 M, Interna-
tional Biotechnologies Inc., New Haven, USA) allowing for gel cutting. Cut TCRα bands were
extracted from the gel and their DNA was purified using NucleoSpin Gel and PCR Clean-up kit
(Macherey-Nagel, Düren, Germany) following the manufacturer’s instructions. Similarly, DNA
products contained in the remaining 30 µl of the TCRβ PCR sample volume were purified using
this kit. The DNA concentration of each sample was measured by the Nanodrop ND-1000 spec-
trophotometer (260 nm) and set to 5 ng/µl for Sanger sequencing by either GATC Biotech AG
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(Konstanz, Germany) or Eurofins Genomics GmbH (Ebersberg, Germany).
For identification of V, J and C regions, as well as complementarity determining region
3 (CDR3), sequencing results were analysed using IMGT’s V-QUEST tool (Brochet et al., 2008;
Giudicelli et al., 2011, http://www.imgt.org/IMGT_vquest/vquest). Any ambiguities were re-
solved by newly amplifying and resequencing the TCR chain using the forward primer specific
for the relevant Vα or Vβ region.
3.2.3 Gene synthesis
In order to be able to produce retroviral vectors to transfer HCMV-specific TCR genes into
receiving T cells, complete TCRα and TCRβ chains of a T cell clone were assembled in silico
including the necessary elements for retroviral packaging and strong, equimolar eukaryotic ex-
pression. Since the TCRα and TCRβ sequences obtained from the Sanger sequencing service
only spanned from the primer binding sites within the V region to the beginning of the C region,
but did not fully cover both those regions, the missing parts of the sequences were completed
by using IMGT’s TCR repertoire (http://www.imgt.org/IMGTrepertoire/) as source for human
TRAV (Scaviner and Lefranc, 2000b), TRAC, TRBV (Folch and Lefranc, 2000) and TRBC gene
tables (Lefranc et al., 1999). A NotI restriction site (GCGGCCGC) and a Kozak sequence (CACC)
were put in front of the start codon of the complemented TCRβ chain. The stop codon of the
TCRβ chain was replaced by a Gly-Ser-Gly linker (GGCAGCGGC) and a Picornavirus 2A peptide
(P2A) sequence (GCCACCAACTTCAGCCTGCTGAAACAGGCCGGCGACGTGGAAGAGAACCCTGGGCCC translat-
ing to ATNFSLLKQAGDVEENPGP).
The ’self-cleaving’ 2A peptide induces a ribosomal ’skip’ mechanism between its second to last
amino acid (Gly) and its last amino acid (Pro) without affecting the translation of the gene
immediately downstream of it, thus allowing for an approximately equimolar separate expression
of both the gene upstream and the gene downstream of the 2A peptide within the same ORF
(Donnelly et al., 2001). The “cleavage” efficiency is improved by placing the Gly-Ser-Gly linker
between NH2-terminal protein and the 2A peptide (Holst et al., 2006; Szymczak et al., 2004, ad-
dendum 01.06.2004). P2A encompassed a BmgBI restriction site in order to be able to exchange
TCRα and TCRβ chains from different constructs.
Downstream of P2A, the whole TCRα chain gene including its stop codon was added and an
EcoRI restriction site (GAATTC) was attached at the end of the sequence. Taken together, every
complete construct was of approximately 1,800 bp length and consisted of 5’—NotI–Kozak–
TCRβ–GSG–P2A–TCRα–Stop–EcoRI—3’. This order was chosen since Leisegang et al. (2008)
showed it to be superior to its counterpart (TCRα before TCRβ), probably because TCRβ ex-
pression is more limiting.
Two constructs were designed not coding for TCR chains, but co-receptors instead: The first
codes for T-cell surface glycoprotein CD4 (see table 2.7). The second codes for T-cell surface
glycoproteins CD8α and CD8β linked by P2A (see table 2.7). According to Thakral et al. (2008),
CD8β can be spliced into different variants: M-1 is dominant on most thymocytes, peripheral
blood CD8+ T cells and naïve CD8+ T cells, M-2 is mainly withheld in internal vesicles, M-3 is
barely expressed/found and M-4 is predominant on effector memory CD8+ T cells. The CD8β
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splice variant M-1, which is identical to NCBI, Gene ID 926, isoform 5, was chosen. However, a
SalI restriction site (GTCGAC) at nucleotide position 1373 of the CD8α–P2A–CD8β construct has
been included, so that splice variants of CD8β could potentially be edited by PCR and cloning.
Each complete, in silico assembled construct was sent to Thermo Fisher Scientific (Regens-
burg, Germany, formerly “GeneArt”) for commercial gene synthesis and cloning into plas-
mid MP71Gpre. Prior to synthesis, however, the construct was subjected to GeneArt’s gene
optimisation process to allow high and stable expression rates in Homo sapiens. During this
process the codon usage was adapted to the codon bias of Homo sapiens genes, while protecting
the intended NotI, EcoRI & BmgBI restriction sites from sequence alteration, but avoiding or
removing unintended NotI, EcoRI & BmgBI restriction sites elsewhere. In addition, negative cis-
acting sites (such as splice sites, TATA-boxes, etc.), which may negatively influence expression,
were avoided where possible and GC content was adjusted to prolong mRNA half life. The syn-
thetic gene was assembled from synthetic oligonucleotides and/or PCR products and cloned into
MP71Gpre thereby replacing the GFP marker gene. The sequence congruence within the inser-
tion sites was 100%, as verified by sequencing. The plasmid DNA was purified from transformed
bacteria and 5 µg of it were lyophilised and shipped.
3.3 Cell culture methods
3.3.1 Cell culture conditions
All human cells used in this study were cultivated in an incubator at 37 ◦C, 5% CO2 and a
humidified atmosphere. Handling of the cells was performed in laminar flow hoods, only. In
general, for washing and concentration purposes, all cells were pelleted by centrifugation at 300
× g and room temperature for 10 minutes. Before determining the cell count using a Neubauer
Improved counting chamber, the cell suspension was diluted 2- to 10-fold with a 0.5% trypan
blue solution in order to discriminate live and dead cells. Living cells repel the dye, whereas
dead cells take up the dye due to their damaged cell membrane and thus appear in a blue colour
when viewed through the microscope.
The standard cell culture medium for Raji and lymphoblastoid cell lines that were created using
mini-EBV (mini-LCLs) was RPMI 1650 supplemented with 7% fetal calf serum (FCS), 100 U/ml
penicillin, 100 µg/ml streptomycin and 100 nM sodium selenite (henceforth called LCL medium).
These cells were cultivated in suspension and split 1:3 up to 1:10 once or twice a week depending
on their proliferation rate. DG-75 were cultured as adherent cells and had to be scraped for
passaging. Apart from that they were cultured like Raji and mini-LCLs.
Adherent HEK293T cells were cultured in DMEM supplemented with 7% FCS, 100 U/ml penicil-
lin, 100 µg/ml streptomycin and 100 nM sodium selenite, being split approximately 10 to 20-fold
once or twice a week, depending on the confluence, by flushing them off the plastic surface with
a pipette. MRC-5 human fibroblasts, which also grow adherently, were cultured likewise adding




3.3.2 Cryopreservation of human cells
For long term preservation of human cells, they were pelleted by centrifugation, the supernatant
was discarded and the cells were resuspended in pre-cooled (4 ◦C) freezing medium composed of
RPMI 1640 supplemented with 50% FCS and 10% DMSO. Alternatively, cells were resuspended
in the ready-made freezing medium Bambanker (Nippon Genetics Europe, Düren, Germany).
The cell suspension was aliquoted in 1.8 ml cryo tubes that were kept on ice for up to 30 minutes.
Next, they were stored at −80 ◦C for several days up to several weeks, after which the tubes were
finally moved to the liquid nitrogen tank and stored in the gas phase.
Frozen cells were thawed as fast as possible by pre-warmed (37 ◦C) RPMI 1640 without any
additives transferring the content of the cryo tube into a tube filled with 50 ml RPMI 1640.
The cells were pelleted by centrifugation, the supernatant was discarded and the cells were
resuspended in the respective medium.
3.3.3 Transfection of human cells with plasmid DNA
For production of HLA-transgenic cells, an excess amount of DG-75, Raji or EBV-B1.11 was
harvested after splitting the cells 1:2 the previous day. The cells were washed once in RPMI 1640
without any supplements and once in OptiMEM in order to remove any remaining serum. They
were resuspended at 16.67× 106 cells/ml in OptiMEM, of which 0.3 ml were mixed with 10 µg
of plasmid DNA in a 1.5 ml reaction tube and transferred into a 0.4 cm Gene Pulser cuvette
(Bio-Rad, München, Germany). If two plasmids were transfected simultaneously (e.g. HLA-
DQA & HLA-DQB plasmid DNA), 10 µg per plasmid were used. An equal volume of TE buffer
from Qiagen’s Endofree Plasmid Maxi Kit or 10 µg GFP plasmid DNA (MP71Gpre) served as
negative or positive electroporation control, respectively. The cuvette was placed between the
contacts of a GenePulser II (Bio-Rad, München, Germany) and electroporated at 230 V using
975 µF. The cells were immediately resuspended in 1 ml pre-warmed FCS and put into one
well of a 6-well plate that held 4 ml pre-warmed LCL medium. After overnight incubation at
37 ◦C, the GFP expression of the positive control was checked and if successful, HLA-transgenic
cells were used for determining the HLA restriction of a T cell clone or TCR-transgenic T cell line.
For production of MP71 retroviral vectors, adherent HEK293T cells were transfected
using TransIT-293 transfection reagent (Mirus Bio LLC, Madison, USA) according to the manu-
facturer’s instructions. In brief, 3× 105 HEK293T cells in 2.5 ml were plated per well into 6-well
plates the day before transfection. On the following day, 250 µl OptiMEM medium, 2.0–4.0 µg
of plasmid DNA and 2.5 µl TransIT-293 transfection reagent (pre-warmed to room temperature)
per 1.0 µg of plasmid DNA were gently mixed. The amount of total plasmid DNA varied due to
different retroviral DNA cargo: (I) 1.0 µg of TCRβ–P2A–TCRα plasmid construct (see section
3.2.3 and tab. 2.8), (II) 1.0 µg of the TCRβ–P2A–TCRα construct and 0.5 µg of co-receptor
CD4 or CD8 constructs (DNA ratio 2:1), (III) 1.0 µg of the TCRα and 1.0 µg of the TCRβ
constructs (DNA ratio 1:1, only performed with CRV2α and CRV2β), (IV) 1.0 µg of the GFP-
encoding plasmid MP71Gpre as transfection and transduction control or (V) no genetic cargo
at all (“empty” retroviral vector as mock control). Regardless of the cargo, 1.0 µg of each of
the expression plasmids encoding the moloney MLV gag/pol genes (plasmid pcDNA3.1MLVg/p,
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kindly provided by Christopher Baum, Hannover, Germany, see Leisegang et al., 2008) and the
MLV-10A1 env gene (plasmid pALF-10A1, see Uckert et al., 2000) was used (see section 2.4
and table 2.7). After 30 minutes of incubation at room temperature to allow the formation of
TransIT-293/DNA complexes, the solution was added on top of the HEK293T culture medium
in a drop-wise manner to different areas of the well while rocking the well plate back-and-forth
and side-to-side to ensure an even distribution of TransIT-293/DNA complexes. After 48 hours,
the transfection efficiency of the positive control (GFP) was checked usually showing more than
70% GFP-positive cells. Further processing of the supernatant containing the retroviral vectors
is described in section 3.5.1. In brief, the supernatant of the HEK293T cells was harvested after
48 hours, filtrated (0.45 µm pore size) and directly used for transduction (Leisegang et al., 2008).
A schematic overview of HEK293T transfection in the context of analysing the effector function
of TCR-transgenic HLA class I- or HLA class II-restricted T cells is depicted in figure 3.1.
3.3.4 Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) of healthy adult donors were isolated by density
gradient centrifugation using Pancoll (PAN Biotech, Aidenbach, Germany) either from hepar-
inised venous blood of voluntary donors or from leukocyte concentrates (“buffy coats”) shipped
by the Institute for Transfusion Medicine, University of Ulm (Germany). Buffy coats contained
enriched leukocytes from standard blood donations (500 ml) suspended in approximately 20 ml.
Whole blood samples or buffy coats were pre-diluted 6:1 or 1:1 in 1× PBS, respectively. 30
to 35 ml of diluted blood sample were transferred into 50 ml tubes and carefully underlaid with
approximately 12 ml Pancoll (density: 1.077 g/ml). During the following centrifugation for 25
minutes at 1,000 × g, room temperature, low acceleration (level 1 out of 9) and no braking
for deceleration, the various components of the blood were separated according to their density.
Erythrocytes sediment at the bottom of the tube with Pancoll layering on top, followed by a
layer of PBMCs at the interface of Pancoll and plasma. To avoid erythrocyte contamination,
PBMCs were carefully aspirated, transferred to new 50 ml tubes and diluted at least 1:5 in 1×
PBS for washing of the cells. If necessary, an aliquot of the donor’s plasma was collected for
determination of the EBV or HCMV IgG serostatus. The cells were pelleted by centrifugation
(8–10 min, 300 × g, room temperature, full acceleration and deceleration) and washing was re-
peated 3 to 4 times in order to remove remaining Pancoll and deplete thrombocytes. Freshly
isolated PBMCs were counted using a Neubauer Improved counting chamber (diluted 1:10 in
0.5% trypan blue solution) and either directly frozen or processed for cell culture as described
elsewhere in this section.
3.3.5 Establishment and maintenance of T cell clones
The production of polyclonal T cell lines and subsequent single cell cloning in order
to obtain single T cell clones were performed by Andreas Moosmann, Martina Wiesner (2005),
Andrea Schub (2010), Stefanie Ameres (2012) or Xiaoling Liang (unpublished) using PBMCs
of HCMV-seropositive (HCMV+) donors (see tab. 2.8). HCMV-specific T cells were expan-
ded in vitro by repeated stimulation for several weeks (Moosmann et al., 2002; Wiesner, 2005).
Either autologous mini-LCLs endogenously expressing pp65 or IE-1 (see section 2.3.2) or B blasts
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that were pulsed with the relevant peptide(s) were irradiated and served as antigen presenting
cells (APCs). Also, peptide pulsed, autologous PBMCs were employed. While both mini-LCLs
and pulsed APCs can present exogenously loaded antigenic peptides on HLA class I and II
molecules, only mini-LCLs can provide endogenously processed peptides of HCMV antigens on
HLA molecules. By using autologous APCs, HCMV-specific memory T cells of the donor can be
stimulated regardless of their HLA restriction without activating alloreactive T cells.
Resulting polyclonal T cell lines were subjected to limiting dilution giving rise to T cell clones. In
some cases, IFN-γ capture and immunomagnetic separation were performed before limiting dilu-
tion to further enrich antigen-specific T cells. The T cell clones were maintained and expanded in
96-well plates (round bottom, 200 µl per well) by restimulation with 1,000 U/ml IL-2, 0.1× 106
irradiated (60 Gy), autologous, antigen-expressing mini-LCL per millilitre and 1.5× 106 irradi-
ated (60 Gy), allogeneic PBMCs (mixed from at least three donors) per millilitre. The T cell
lines were cultivated in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 100 U/ml
penicillin, 100 µg/ml streptomycin and 100 nM sodium selenite (henceforth abbreviated as “10%
FCS T cell medium”). One week after restimulation, half of the medium was discarded and re-
placed by 10% FCS T cell medium supplemented with 1,000 U/ml IL-2. After another week, the
T cell lines were restimulated again with the feeder mix described above, frozen or analysed for
their epitope specificity using peptide libraries (sections 2.6 and 3.4.4), HLA restriction (section
3.4.3), TCRα and β chain usage (section 3.2.2) and recognition of HCMV-infected target cells
(section 3.5.3). As soon as the data from these analyses excluded the possibility of two or more
clones being mixed in one T cell line, it was considered a T cell clone.
3.3.6 Generation of monocyte-derived dendritic cells
The recognition of HCMV-infected target cells by CD4+ T cell clones or TCR-transgenic HLA
class II-restricted T cell lines was analysed using HLA-matched monocyte-derived dendritic cells
(moDCs). moDCs were generated largely according to the published protocol from Jonuleit
et al. (2000, 1997). Approximately 5× 107 freshly isolated PBMCs were incubated in 15 ml
RPMI 1640 supplemented with 2% human serum, 100 U/ml penicillin, 100 µg/ml streptomycin
and 100 nM sodium selenite per flask (75 cm2) for at least 2.5 hours in order to let the monocytes
adhere to the plastic surface. Next, the supernatant was discarded and the adherent monocytes
were rinsed twice using 10 ml pre-warmed RPMI 1640 without any supplements and a plastic
pipette (10 ml) to get rid of all remaining non-adherent cells. Immature dendritic cells were
generated by cultivating the monocytes for 3 days in 15 ml RPMI 1640 supplemented with 2%
human serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 nM sodium selenite, 100 ng/ml
rhuGM-CSF and 20 ng/ml rhuIL-4. For maturation of moDCs, 10 ng/ml rhuTNF-α, 10 ng/ml
rhuIL-1β, 1 µg/ml PGE2 and 15 ng/ml rhuIL-6 were directly added to the old medium and the




3.4.1 Immunomagnetic separation of cell populations
In order to separate different populations of immune cells from each other, “magnetic activated
cell sorting” (MACS) was applied according to Miltenyi Biotec’s instructions. This technique
links superparamagnetic, non-toxic and biodegradable nanoparticles (“microbeads”) to cells by
particle-bound monoclonal antibodies with a defined specificity. Thereby these nanoparticles tag
a particular cell population enabling its retention on a column that is placed into a magnetic field.
While labelled cells are retained on the column during washing procedures, the unlabelled cells
are washed out and can be collected as negative fraction. Once the column has been removed
from the magnetic field, the labelled cells can also be removed from the column by flushing and
are recovered as the positive fraction.
Freshly isolated or thawed PBMCs (section 3.3.4 or 3.3.2, respectively) were either directly la-
belled with 2 µl anti-CD8 beads (Miltenyi Biotec, Bergisch Gladbach, Germany) per 106 PBMCs
or indirectly labelled by using anti-fluorochrome microbeads after the cells had been stained
with fluorochrome-tagged antibodies. In the latter case, 106 PBMCs were stained with 2 µl
APC-labelled anti-TCRαβ antibody (Clone: IP26, Biolegend) or 0.5 µl FITC-labelled anti-TCR
Vδ2 antibody (Clone B6, Biolegend, San Diego, USA), after which 2 µl anti-APC or anti-FITC
beads (Miltenyi Biotec) were applied per 106 PBMCs, respectively. MS MACS columns (Miltenyi
Biotec) were used to positively select CD8-positive (CD8+) T cells from PBMCs. LD MACS
columns (Miltenyi Biotec) were used to deplete TCRαβ+ T cells from PBMCs resulting in a
negative fraction that contained all PBMC types, except for TCRαβ+ T cells which were eluted
as positive fraction of the separation. In order to check the purity of each fraction, they were
stained with antibodies and analysed by flow cytometry (see section 3.4.2). During all steps 2%
FCS in 1× PBS was used as equilibration, washing and elution buffer.
3.4.2 Phenotypic analysis of cells by flow cytometry
In order to analyse the expression of surface proteins on a cell population of interest, the
cells were stained using various monoclonal antibodies conjugated to a fluorochrome (such as
FITC or PE, see table 2.14). Usually 0.2–0.3× 106 cells were centrifuged at room temperature
and 1,000 × g for 5 min in 1.5 ml reaction tubes (Eppendorf, Hamburg, Germany) and the su-
pernatant was discarded. The pelleted cells were resuspended in 50 µl pre-cooled (4 ◦C) FACS
buffer (2% FCS in 1× PBS) containing fluorochrome-labelled monoclonal antibodies at defined
dilutions (see table 2.14). The cells were incubated at (4 ◦C) for 20 minutes, after which they
were washed by adding 1 ml of pre-cooled FACS buffer and pelleting the cells as described above.
Finally, the cells were resuspended in 0.2 ml pre-cooled FACS buffer for direct analysis in a flow
cytometer or fixed with 1% (v/v) paraformaldehyde (PFA) in FACS buffer and stored at 4 ◦C
for up to 7 days.
The expression of T cell receptors (TCRs) on T cell clones (section 3.3.5) or TCR-
transgenic T cells (section 3.5.1) was assessed by HLA multimers labelled with either PE or
APC. This technique employs the natural ligand of the TCR consisting of a peptide that is
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bound to an HLA class I α chain/β2m heterodimer or bound to an HLA class II αβ heterodimer.
Due to the unstable nature of a TCR-peptide/HLA interaction (Savage et al., 1999) the avidity
has to be increased by multimerisation (Altman et al., 1996) to achieve stable binding of the
reagent. All peptide/HLA monomers were stored in aliquots at −20 or −80 ◦C and thawed on
ice for multimerisation, while peptide/HLA pentamers were stored at 4 ◦C.
HLA multimers were never used together with antibodies specific for a particular TCRβ V-region
or the αβ TCR (see table 2.14) in one staining in order to avoid competition for binding and
sterical inhibition.
CRV- or FRC- specific T cells were stained using an MHC-streptagII-StrepTactin multimer
reagent (streptamer) as described in Neudorfer et al. (2007). CRV/HLA-C*07:02 monomers and
FRC/HLA-C*07:02 monomers were generated and kindly provided by Michael Neuenhahn and
Dirk Busch (Institute for Medical Microbiology, Immunology and Hygiene, TUM, Munich, Ger-
many). Per sample, 0.4 µl of CRV/HLA-C*07:02 monomers (0.93 µg/µl) or 0.7 µl of FRC/HLA-
C*07:02 monomers (0.77 µg/µl) were mixed with 0.5 µl PE-labelled StrepTactin (0.5 mg/ml, IBA
Göttingen, Germany) in a total volume of 10.0 µl pre-cooled (4 ◦C) FACS buffer. After 45 minutes
of incubation on ice to allow streptamer complexes to form, the solution was diluted 1:3 using
pre-cooled FACS buffer and 30 µl of this dilution were used to resuspend and stain 0.2–0.3× 106
pelleted cells for 20 minutes at 4 ◦C. Next, surface proteins were stained with fluorochrome-
labelled monoclonal antibodies as described previously except for two alterations: (I) no washing
of the cells was performed after streptamer staining and before surface staining and (II) anti-
bodies were diluted in 20 instead of 50 µl FACS buffer in order to achieve the intended final
concentrations as shown in table 2.14 in the total volume of 30+20 µl. The cells were incubated
for another 20 minutes at 4 ◦C to allow the monoclonal antibodies to bind thereby prolonging the
streptamer incubation, however, at a reduced concentration. Finally, cells were washed, pelleted
and resuspended either for direct or delayed flow cytometrical analysis as described above.
Likewise, YSE-specific T cells were incubated with specific multimers first and then counter-
stained with a combination of monoclonal antibodies. Differing from the protocol described
above, YSE/HLA-A*01:01 pentamers (ProImmune, Oxford, UK) did not have to be multimer-
ised beforehand. Instead, 0.5 µl of them were diluted 1:100 in FACS buffer and used to stain
the cells for 10 minutes at room temperature. Afterwards, the cells were washed once and re-
suspended in FACS buffer containing not only fluorochrome-labelled antibodies, but also 2.0 µl
pentamer-binding R-PE Pro5 fluorotag (Proimmune) per 50.0 µl total volume. Other than the
alterations described, the procedure was identical.
QPFM-, YRIQ-, AGIL-, MSIY- or EFFT-specific T cells were stained using HLA
class II tetramers similar to the protocol described in Braendstrup et al. (2013). QPFM/HLA-
DRB1*13:02, YRIQ/HLA-DRB1*13:02, AGIL/HLA-DRB3*03:01, MSIY/HLA-DRB1*15:01 and
EFFT/HLA-DRB5*01:01 monomers were purchased from Immunaware (Copenhagen, Denmark,
see section 2.8). Peptide/HLAmonomers were thawed and coupled to PE-streptavidin (0.5 mg/ml,
BD Biosciences, Heidelberg, Germany) or APC-streptavidin (0.2 mg/ml, BD Biosciences) at a
molar ratio of 4 to 1. In order to fully saturate streptavidin molecules with peptide/HLA com-
plexes, the required amount of fluorochrome-labelled streptavidin was divided into three equal
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portions that were successively added to the solution containing the peptide/HLA monomers
every 15 minutes. After each addition, the mix was incubated for 15 minutes at 4 ◦C. If less than
3 µl of fluorochrome-labelled streptavidin were required, the latter was diluted 1:10 beforehand.
Working concentration of peptide/HLA monomers ranged from approximately 1 to 3 µM during
tetramerisation (see table 2.15 for concentrations of peptide/HLA monomers). Finally, tetramer
concentration was adjusted to 30 or 60 nM and 30 µl of this dilution were applied per staining of
usually 0.2–0.3× 106 cells.
The stained cells were analysed in a Canto or an LSR Fortessa (both by BD Biosciences)
flow cytometer and the resulting data was processed using FlowJo software (Tree Star, Ash-
land, USA). Viable lymphocytes were discriminated according to their characteristic position
in the forward/sideward scatter (FSC/SSC) dot plot. The axes of the dot plot diagrams in
this study are scaled bi-exponentially, usually comprising −103 to 105 arbitrary units of fluor-
escence intensity, except for FSC and SSC diagrams showing intensities from zero to 260,000
on a linear scale. Pseudocolour dot plots indicate increasing density of signals in 2D plots by
a colour code ranging from blue (low density) over green, yellow and orange to red (high density).
In order to obtain absolute cell counts by flow cytometric measurement, 20,000 PE-labelled
Calibrite beads (BD Biosciences) were added to the cells after they had been stained as described
in the paragraphs above. Prior to the staining procedure, cells were resuspended in cell culture
plates first and then a particular volume of resuspended cells that was standardised within one
experiment to maintain comparability was taken for staining of cells (e.g. 500 µl from a well
of a 24-well plate containing 2.0 ml in total and, if applicable, 1.0 ml from a well of a 12-well
plate containing 4.0 ml in total, thereby taking 25% of the cells per well regardless of the total
volume). The absolute cell count was calculated after flow cytometric measurement according
to the following formula:
absolute cell count = cell countbead count · 20,000 (1)
3.4.3 Determination of human leukocyte antigen class II restriction
The nomenclature of HLA alleles describes (I) the gene name, (II) the allele group, (III) the
specific HLA protein, (IV) silent DNA substitutions within the coding region and (V) differ-
ences in non-coding regions (see http://hla.alleles.org/nomenclature/naming.html, accessed on
21.01.2019). As an example, the allele HLA-DRB1*13:02:01 codes for an HLA-DRβ chain of
the allele group “13”, precisely the specific HLA-DRB1 protein “13:02”, with the precise cod-
ing nucleic acid sequence “01”. Consequently, the alleles HLA-DRB1*13:02:01, DRB1*13:02:02,
DRB1*13:02:03, etc. have different coding nucleic acids sequences, but code for the same amino
acid sequence. In contrast, HLA-DRB1*13:01 and DRB1*13:02 produce slightly different pro-
teins with alterations in the amino acid sequence (in the given example at amino acid position
86: DRB1*13:01 = Val, DRB1*13:02 = Gly).
T cell clones or TCR-transgenic T cell lines (abbreviated as “effector cells” below) were co-
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cultured with HLA-genotyped APCs in three different approaches to ascertain the HLA class II
restriction of the TCR:
1. Presentation of endogenously processed antigens on HLA-DR, HLA-DQ or HLA-DP by
autologous mini-LCLs was blocked by respective anti-human HLA antibodies (see table
2.14) to see which of the three HLA class II isoforms provided the epitope.
2. Effector cells were tested on a panel of HLA-matched as well as HLA-mismatched allogeneic
mini-LCLs to narrow the variety of HLA candidates that could be presenting the epitope.
3. HLA-mismatched, transformed B cells were transfected to transiently express a certain
HLA class II molecule (see section 3.3.3 and table 2.6) and pulsed with the peptide epitope
(only possible after determining the TCR’s epitope, as described in section 3.4.4).
Different effector-to-target cell (e:t) ratios were used, depending on the kind of effector cell,
with T cell clones requiring a lower cell number for a sufficient response than TCR-transgenic
T cell lines, and depending on the expression level of the HLA transgene on a transformed B
cell line. Using T cell clones, the effector-to-target cell ratio of approach 1 and 2 usually was
10,000:20,000, whereas the ratio was 20,000:40,000 for HLA-transgenic DG-75 or 20,000:80,000
for HLA-transgenic Raji and EBV-B1.11. If TCR-transgenic T cell lines were used as effector
cells, their amount was usually doubled while target cell numbers were kept because in general
only 20 to 40% of the TCR-transgenic T cell lines are positive for the transduced TCR. If effector-
to-target cell ratio was different than stated here, it is noted in the figure caption.
Each co-culture was incubated at 37 ◦C for 16–21 hours in 200 µl 10% FCS T cell medium per well
in 96-well plates (V-bottom) in duplicates or triplicates. Secreted IFN-γ levels were analysed by
enzyme-linked immunosorbent assay (ELISA, see section 3.4.5) to quantify the activation of T
cells by recognition of their target peptide/HLA complex.
3.4.4 Epitope mapping using peptide libraries
In order to determine the epitope specificity of T cell clones or TCR-transgenic T cell lines, auto-
logous or allogeneic, HLA-matched mini-LCLs that do not express any HCMV antigen (“control
mini-LCLs”) were pulsed with synthetic peptides of 15 amino acids length derived from the
HCMV antigen pp65 (UL83). After pulsing control mini-LCLs with 24 different pp65 peptide
pools (see section 2.6 and tables 2.12 & 2.13, final concentration: 1 µg/ml per 15-mer) for 1 hour
at 37 ◦C, cells were washed three times in 1× PBS and co-cultured with T cell clones at a usual
e:t ratio of 10,000:20,000 (i.e. 10,000 effector cells and 20,000 target cells in each individual 96-
well reaction in a volume of 200 µl) in duplicates for 16–20 hours. If TCR-transgenic T cell lines
were chosen as effector cells, the e:t ratio varied from 20,000:20,000 to 40,000:40,000, depending
on availability of effector cells. Co-culture supernatants were analysed for IFN-γ secretion by
ELISA (see section 3.4.5).
Epitopes of IE-1-specific CD4+ T cell clones were determined by Stefanie Ameres (2012) using
the IE-1 peptide library (table 2.11) organised in peptide pools as shown in table 2.13.
3.4.5 Enzyme-linked immunosorbent assay (ELISA) for quantification of cytokine release
IFN-γ production by effector cells (TCR-transgenic T cells or T cell clones) was analysed
to quantify the antigen-specific recognition of target cells. Effector and target cells were co-
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cultivated at different ratios for 16–21 hours in 200 µl 10% FCS T cell medium per well in 96-well
plates (V-bottom) in duplicates or triplicates at 37 ◦C, after which the plates were either frozen
at −20 ◦C or directly used in a “sandwich” ELISA according to the manufacturer’s instructions
(Mabtech, Nacka Strand, Sweden) with a few modifications. 10% FCS T cell medium was always
used for co-cultivation of effector and target cells, because 5% HS T cell medium caused high
and irregular background levels of IFN-γ. As a positive control for IFN-γ secretion, effector T
cells were sometimes stimulated with 50 ng/ml tetradecanoylphorbol acetate (TPA) and 0.5 µM
Ionomycin (Iono). Every step of the protocol was performed at room temperature unless noted
otherwise.
Highly adsorbent, 96-well ELISA plates (MaxiSorp Immunoplate, Nunc A/S) were coated at
4 ◦C with 50 µl/well of the IFN-γ-specific monoclonal capture antibody 1-D1K diluted to 2 µg/ml
in 1× PBS overnight. The following day, plates were washed twice with 200 µl ELISA washing
buffer (0.05% Tween 20 in 1× PBS) per well to remove excess antibody, and were blocked for
one hour at 37 ◦C using 100 µl 10% FCS T cell medium per well to cover non-specific binding
sites. Plates were washed twice with 200 µl ELISA washing buffer per well before applying 50 µl
of the co-culture supernatant to be analysed per well and incubating the plates for two hours
to allow the plate-bound antibody to bind soluble IFN-γ. In parallel, a blank reaction and a
cytokine standard series (Mabtech) spanning from 20 to 20,000 pg/ml were also set up in each of
the plates to allow for quantification. Next, the plates were washed four times with 300 µl ELISA
washing buffer per well and incubated with 50 µl/well of the biotinylated monoclonal detection
antibody 7-B6-1 diluted to 1 µg/ml in 1× PBS. After one hour incubation, during which the
antibody 7-B6-1 bound to IFN-γ, the plates were washed four times with 300 µl ELISA wash-
ing buffer per well and incubated for another hour with 50 µl/well of Streptavidin-ALP (diluted
1:1000 in 1× PBS) that attached to 7-B6-1 via biotin. Once again, the plates were washed four
times with 300 µl ELISA washing buffer per well and 100 µl/well of alkaline phosphatase (ALP)
substrate solution were added. The ALP substrate solution was freshly prepared by diluting 5×
pNPP stock solution (50% diethanolamine and 5 mg/ml pNPP in sterile water at pH 9.5, stored
at −20 ◦C) to 1× solution with sterile water, and adding MgSO4 solution (stock concentration
200 mM; final concentration 0.8 mM), as a co-factor of ALP. ALP catalyses the hydrolysis of
colorless pNPP to yellow para-nitrophenol, which has a maximum of absorbance at 405 nm that
is measured by a spetrophotometer. The standard curve for calculating the concentration of
each sample as well as the calculation itself were performed with Prism (GraphPad Software, La
Jolla, USA) employing a sigmoidal four parameter logistic curve fit with the average blank value
serving as lower asymptote of the curve fit.
The ELISA for quantification of IL-10 secretion (R&D Systems, Minneapolis, USA) in the
co-culture supernatant was performed analogously to that of IFN-γ, except that the biotinylated
goat anti-human IL-10 detection antibody was diluted to 150 ng/ml in 1× PBS, and the cytokine




3.5.1 Gene transfer via retroviral vectors
On day zero of the protocol, PBMCs were isolated from whole blood (section 3.3.4) of HCMV-
seronegative (HCMV–) donors and resuspended at 5× 105 cells per millilitre in RPMI 1640
supplemented with 5% human serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 nM so-
dium selenite, 50 U/ml interleukin (IL)-2, 5 ng/ml IL-7 and 5 ng/ml IL-15. Bulk PBMCs were
stimulated by either 50 ng/ml anti-CD3 antibody (Clone: OKT3, Biolegend, San Diego, USA)
or 10 µM pamidronate (medac, Wedel, Germany) to trigger proliferation of total T cells or of δ2
T cells, respectively. Depending on the required number of stimulated T cells, 8, 4 or 2 ml of the
resuspended cells were seeded into 6-, 12- or 24-well plates, respectively, and incubated for 72
hours at 37 ◦C.
In order to transduce selected T cell subpopulations, PBMCs were separated by MACS using
an αβ TCR-specific antibody (section 3.4.1). The αβ T cells of the αβ TCR-enriched (positive)
MACS fraction and Vδ2+ T cells of the αβ TCR-depleted (negative) MACS fraction were stim-
ulated with anti-CD3 antibody and pamidronate, respectively, as described above.
On day one, adherent HEK293T cells were transfected with plasmids encoding for the moloney
MLV gag/pol genes, the MLV-10A1 env gene and MP71 retroviral vector plasmids coding either
for a TCRβ–P2A–TCRα construct, CD4, CD8 or the GFP marker gene (see section 3.3.3). As a
negative (“mock”) control the plasmid carrying the TCR, co-receptor or GFP was omitted. 48
hours after transfection (i.e. on day three of the workflow), the supernatant of the HEK293T
cells was harvested, filtrated (0.45 µm pore size) and directly used for transduction (Leisegang
et al., 2008). If identical retrovirus supernatant was harvested from more than one well, the
volume was pooled and mixed before filtration.
To prepare T cell transduction by spinoculation (centrifugal inoculation), on day two, non-tissue
culture treated 24-well plates (tab. 2.18) were coated with 400 µl per well of retronectin (Takara
Bio Europe, St. Germain en Laye, France) diluted in sterile H2O to 12.5 µg/ml. After overnight
incubation at 4 ◦C, the retronectin solution was discarded, the wells were blocked for 30 minutes
at 37 ◦C using 500 µl per well of 2% FCS in 1× PBS and washed using 1.5 ml per well of 2.5%
(v/v) HEPES in 1× PBS. Next, the washing solution was discarded, 1 ml of each filtrated ret-
rovirus supernatant was added per well into the retronectin-coated 24-well plate and each well
was supplemented with 4 µg/ml protamine sulfate, 1% (v/v) HEPES, 100 U/ml IL-2, 5 ng/ml
IL-7 and 5 ng/ml IL-15 (all concentrations calculated for a final volume of 2 ml per well). In
order to mix, the plate was carefully rocked back-and-forth and from side-to-side. Anti-CD3- or
pamidronate-stimulated cell cultures were harvested, pooled, pelleted by centrifugation, counted
and resuspended in RPMI 1640 without any supplements at a defined cell concentration in order
to match the multiplicity of infection (MOI) for both stimulations. Finally, 1 ml of resuspended
cell suspension per well was added drop-wise on top of the virus supernatant. After centrifuging
the plate for 90 minutes at 1,000 × g in a pre-warmed (32 ◦C) centrifuge with low acceleration
(level 1 out of 9) and switched-off brakes, the cells were incubated overnight at 37 ◦C.
On day four, each of the different transduction reactions was harvested, pooled if applicable, and
the cells were pelleted and resuspended in the same amount of medium than before using RPMI
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1640 supplemented with 5% human serum (HS), 100 U/ml penicillin, 100 µg/ml streptomycin,
100 nM sodium selenite and 100 U/ml IL-2 (henceforth abbreviated as “5% HS T cell medium”).
The cells were incubated in 12- or 24-well plates at 37 ◦C for up to 8 days. Every three to four
days, half of the cell culture medium was replaced by fresh medium or the cells were expanded
1:2 (i.e. from one to two wells) if rapid acidification was noticed (orange to yellow discolouration
of the medium).
In order to assess the expression of the transgene, cells were usually stained with multimers and
fluorochrome-labelled monoclonal antibodies and analysed by flow cytometry on day nine or ten.
Testing of the transduced cells in any kind of cellular assay was generally done on day ten (7
days after transduction). If no assay was performed, the cells were either frozen as described in
section 3.3.2 or restimulated by using an autologous or HLA-matched mini-LCL expressing the
relevant HCMV antigen. For this purpose, the pp65- or IE-1-expressing mini-LCL was harvested
and irradiated with 60 Gray, and 0.5× 106 of them were combined with 1.5× 106 transduced T
cells per well of a 24-well plate. Cells were co-cultured in 2 ml 5% HS T cell medium per well at
37 ◦C for up to 8 days replacing cell culture medium or expanding the cells as described above.
If the number of cells was higher, the cell counts were 2-fold up-scaled for 12-well plates, keeping
the cell concentrations constant (4 ml/well).
A schematic overview of the whole process is depicted in figure 3.1.
3.5.2 Stocks of human cytomegalovirus
Stocks of HCMV strains AD169, TB40-BAC4, Merlin or CMV-Δall (see section 2.1) were gen-
erated by virus passage on human MRC-5 fibroblasts. Semi-confluent fibroblasts were infected
with HCMV at a MOI of 0.1. HCMV replicates lytically in fibroblasts causing the release of
virus progeny, NIEPs and dense bodies into the cell culture supernatant. 14-18 days later, when
most cells displayed a cytopathic effect, cell culture supernatant was harvested. After clearing
aspirated cells and cellular debris from the supernatant by two rounds of centrifugation at 300
× g and room temperature for 10 minutes, virus stocks were aliquoted and frozen at −80 ◦C.
The concentration of infectious virus particles in HCMV stock preparations (“virus titer”) was
determined by calculation of the tissue culture infection dose 50 (TCID50), describing the amount
of virus required to infect and pathologically change 50% of the wells in limiting dilution. Virus
titers typically ranged from 106 to 107 TCID50/ml. Multiplicity of infection (MOI) was defined
as TCID50 units per cell.
Well grown MRC-5 fibroblasts were diluted 1:3, 1:6 and 1:9 and seeded in 96-well plates (flat
bottom) in 100 µl/well DMEM supplemented with 7% FCS, 100 U/ml penicillin, 100 µg/ml
streptomycin, 100 nM sodium selenite and 1% non-essential amino acids. Virus stocks were
serially diluted from 10−2–10−9 using the same medium and 100 µl/well of diluted virus super-
natant were applied to each dilution of MRC-5 fibroblast cells (12 wells per virus dilution for
each MRC-5 dilution). Cytopathic effect of MRC-5 fibroblasts was evaluated no earlier than two
weeks after infection by microscopic examination. TCID50 per millilitre was calculated according
to the Spearman-Kärber method (1908; 1931) using the following formula:
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positive value of the exponent of the highest dilution, at which all test objects
react positively
d = dose distance (factor separating dilutions given as log10; in this case for10× 10−2, 10× 10−3, 10× 10−4, etc. it is log1010 = 1)
n = amount of test objects per dilution (in this case 12)∑
xi = sum of all test objects reacting positively starting from and including x0
v = volume of virus supernatant applied per test object given in the same unit asTCID50 (in this case millilitre)
3.5.3 Recognition of HCMV-infected target cells by T cell clones or transduced T cell lines
In order to test the capability of T cell clones or TCR-transgenic T cell lines to recognise
HCMV-infected target cells, either MRC-5 fibroblasts or mature monocyte-derived dendritic
cells (moDCs) were used as target cells. Prior to infection, MRC-5 fibroblasts were treated with
300 U/ml IFN-γ for 72 hours and moDCs were differentiated from monocytes and matured (sec-
tion 3.3.6). Target cells were infected with various strains of HCMV (table 2.1) at an MOI of 5.
After 48 hours, infected target cells were washed three times in 1× PBS in order to remove resid-
ual free virus, cytokines, etc. Typically, 20,000 effector cells were co-incubated with 10,000 target
cells for 16–21 hours in 200 µl 10% FCS T cell medium per well in 96-well plates (V-bottom) in
duplicates or triplicates at 37 ◦C. Co-culture supernatants were analysed for IFN-γ secretion
by effector cells in an ELISA (section 3.4.5). If T cell clones were tested, e:t ratio usually was
10,000:10,000, instead. As positive or negative control, non-infected target cells were peptide-
pulsed with 1 or 5 µg/ml at 37 ◦C for one hour or were likewise incubated without applying any
peptides, respectively. If two or more peptides were restricted by the same HLA, such as CRV
and FRC both of which are HLA-C*07:02-restricted, control target cells were split and loaded
with each peptide separately. If a different e:t ratio was chosen or any other parameter was
altered, it is indicated in the caption of the respective figure.
Figure 3.1 provides a schematic overview of target cell preparations in the context of analysing
the effector function of TCR-transgenic HLA class I- or HLA class II-restricted T cells.
Since DCs actively take up extracellular material, they may present viral peptides by ingesting
and processing cellular debris, virus-like particles or defective virions without being infected
themselves. As a result, these DCs could trigger IFN-γ release by HCMV-specific effector T
cells just like truly HCMV-infected DCs. In order to discriminate between the recognition of
viral antigens newly synthesised in the infected host cell and antigens that were introduced
into the host cell by uptake of virions and their materials (e.g. structural proteins), control
cells were infected with UV-inactivated HCMV supernatant. The UV irradiation damages viral
DNA rendering it defective in translation and replication. UV inactivation of virus supernatant
was performed at room temperature using the CL-1 Crosslinker (Herolab, Wiesloch, Germany)
applying 1 J/cm2. Virus supernatant was irradiated for 231 seconds in 6 well plates (max. 1.5 ml
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per well) without the lid covering the plate.
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Figure 3.1. Schematic timeline of retroviral transduction of T cell lines and subsequent
analysis of their function on HCMV-infected target cells. The timeline shows (I)
production of retroviral vectors in HEK293T cells (left), (II) generation and use of TCR-
transgenic effector cells (centre), and (III) generation and use of HCMV-infected target
cells (MRC-5 fibroblasts or moDCs, right). More detailed information can be found within




HCMV-specific CD8+ CTLs kill HCMV-infected target cells and play a crucial role in limiting
replication of the virus (Einsele et al., 2002; Reddehase, 2002). If HCMV-specific CD8+ im-
munity is restored by adoptive T cell transfer in immunocompromised patients after HSCT, they
are protected from HCMV disease (Cobbold et al., 2005; Einsele et al., 2002; Riddell et al., 1992;
Schmitt et al., 2011; Walter et al., 1995). Recently, IE-1309-317 (CRV)-specific T cell clones re-
stricted by HLA-C*07:02 were reported to strongly recognise HCMV-infected target cells despite
the presence of immunoevasins, while other IE-1-specific T cell clones restricted by HLA-A or
-B failed to recognise infection (Ameres et al., 2014, 2013). Thus, the TCRs from such T cells
are clearly of interest for therapy development. Consequently, here the TCRs of HCMV-specific,
HLA-C*07:02-restricted T cell clones were sequenced, transferred into primary T cells via ret-
roviral vectors and their efficiency in mediating recognition of HCMV-infected target cells was
assessed.
HCMV-specific CD4+ T cells also play an important role in immunity against HCMV. They
maintain the HCMV-specific CD8+ T cell response (Riddell and Greenberg, 1995; Walter et al.,
1995), provide help to CD8+ T cells (Gabanti et al., 2014) thereby contributing to memory forma-
tion, and directly control HCMV infection by cytotoxic activity and secretion of pro-inflammatory
molecules (Crompton et al., 2008; Jackson et al., 2017; Pachnio et al., 2016). Therefore, it is gen-
erally believed that they should be included in adoptive T cell transfer (Einsele et al., 2002; Sellar
and Peggs, 2012). There is little published information on HCMV-specific, HLA class II-restricted
TCRs, and none of them has been tested on HCMV-infected target cells. In the present study, a
set of pp65-specific or IE-1-specific TCRs restricted by HLA class II was sequenced, transferred
into primary T cells via retroviral vectors, and the TCRs’ efficacy in mediating recognition of
HCMV-infected target cells was assessed.
4.1 Analysis of HCMV-specific T cell clones
The CD4+ and CD8+ T cell repertoires against HCMV have been intensively studied (Ameres
et al., 2015; Elkington et al., 2003; Khan et al., 2007; Nastke et al., 2005; Slezak et al., 2007;
Sylwester et al., 2005, to name but a few). Nevertheless, HCMV-specific T cell clones were often
characterised incompletely, and occasionally they seem to have been assigned an incorrect HLA
restriction or epitope specificity, as will become clear in the following description. Some IE-1-
specific CD4+ T cells have been analysed in detail by Ameres et al. (2015) including epitopes
and HLA-restrictions, but their TCR sequences were not determined.
In earlier work of this group, pp65-specific CD4+ T cell clones were characterised (Schub, 2010;
Wiesner, 2005), but with some lack of detail of their epitope specificity and HLA restriction and




Figure 4.1. Epitope mapping of pp65-specific CD4+ T cell clones F46P #18 (A), #36 (B) &
#45 (C). After pulsing autologous mini-LCLs with 24 different pools of pp65 peptides (see
tab. 2.12 & 2.13) they were co-incubated overnight with three different pp65-specific T cell
clones derived from donor F46 at an effector-to-target (e:t) ratio of 10,000:20,000 (i.e. 10,000
T cells and 20,000 B cells in each individual 96-well reaction in a volume of 200 µl). The
graphs show the concentration of secreted IFN-γ in the supernatant as evaluated by ELISA.
The mean and standard deviation of duplicate samples are shown. As positive controls,
mini-LCLs were pulsed with a peptide mixture containing all pp65 peptides of the pp65
library (“pp65 mix”) and T cell clones were stimulated by TPA & ionomycin in the absence
of target cells. Effector and target cells were incubated separately from each other to serve
as negative controls (“effector only” and “target only”).
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4.1.1 Epitope determination of T cell clones
All HCMV-specific T cell clones analysed and used in this study were generated by Andreas
Moosmann and Martina Wiesner (2005), Andrea Schub (2010), Stefanie Ameres (2012) or Xiao-
ling Liang (unpublished). As described in section 3.3.5, they isolated PBMCs from HCMV+
donors and stimulated them with autologous mini-LCLs endogenously expressing either pp65
or IE-1. Resulting T cell lines were subjected to limiting dilution resulting in numerous T cell
clones. The epitope specificity of T cell clones was determined by co-incubation with autolog-
ous or HLA-matched mini-LCLs that do not express any HCMV antigen, but had been pulsed
with synthetic peptides before (see section 3.4.4). These peptides were derived from HCMV
strain AD169’s pp65 (UL83, tab. 2.12) or IE-1 (UL123, tab. 2.11) protein and were pooled in
a cross-matrix fashion as described by Kern et al. (1999) and as depicted in table 2.13. Every
single peptide was contained within one of the vertical subpools (from 1 to 12) and within one
horizontal subpool (from 13 to 23 for pp65 or from 13 to 24 for IE-1). After overnight incuba-
tion, IFN-γ secretion by T cell clones was analysed by ELISA to quantify their antigen-specific
recognition of target cells (see section 3.4.5).
The epitopes of all CD8+ T cell clones were identified by Martina Wiesner (2005), Andrea Schub
(2010) or Xiaoling Liang (unpublished).
Figure 4.1 shows examples of this epitope determination for three pp65-specific CD4+ T cell
clones. The CD4+ T cell clones F46P #18 and #36 reacted to pools 9, 10 and 20 (fig. 4.1 A and
B, respectively). The peptide pool no. 20 shares peptides no. 93 (FTSQ YRIQ GKLE YRH) and 94
(YRIQ GKLE YRHT WDR) with pools 9 and 10, respectively, so both clones recognised the 11-mer
YRIQ GKLE YRH and were hence tagged with the abbreviation YRIQ. While F46P #18 secreted
a similar amount of IFN-γ in response to each of these three peptide pools, F46P #36 showed an
approximately 2-fold reduced IFN-γ secretion in response to pool no. 9 in comparison to pool no.
10 indicating a preference for peptide no 94 that was later confirmed using TCR-transgenic T
cells (data not shown). F46P #45 reacted to pools 2, 3 and 23 (fig. 4.1 C), which share peptides
no. 122 (PPWQ AGIL ARNL VPM) and 123 (AGIL ARNL VPMV ATV). While the 11-mer AGIL ARNL
VPM contained in both peptides seems to be sufficient for recognition of pulsed mini-LCLs by the
T cell clone, peptide no. 123 provoked an approximately 3-fold increased IFN-γ secretion. As a
result, F46P #45 was tagged with the epitope specificity abbreviated as AGIL.
The epitopes of all IE-1-specific CD4+ T cell clones shown in this work (see tab. 4.2) have
been identified by Stefanie Ameres (2012).
Martina Wiesner (2005) determined the epitopes of the pp65-specific T cell clones F46P #17,
#19, #40 and F62P #16 as (QPFM) RPHE RNGF TVL (CPKN), (AGIL) ARNL VPMV ATV (QGQN), MSIY
VYAL PLKM LNI and (GQNL) KYQE FFWD AND (IYRI), respectively. Except F46P # 40, these T cell
clones each recognised two peptides overlapping in 11 amino acids (shown between the brackets).
The epitope specificity of F46P #17 had to be corrected later to (TRNP) QPFM RPHE RNG (FTVL),
as demonstrated later in this section (fig. 4.7 A). Also, the epitope specificity of F46P #19
had to be corrected because this T cell clone was shown to express the identical TCR chains as
F46P #45 (tab. 4.2) and F46P #45 recognised (PPWQ) AGIL ARNL VPM (VATV), but not peptide
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Figure 4.2. Epitope mapping of the TCR from pp65-specific CD4+ T cell clone 1304P #21
using TCR-transgenic αβ T cell lines. After pulsing control (ctrl) mini-LCLs from
donor 1304 that do not express any HCMV antigen with one of 11 single peptides (tab. 2.12)
or one of 7 peptide pools of pp65 peptides (tab. 2.13) they were co-incubated overnight with
αβ T cells from donor 1107 that had either been TCR-transduced (black bars) or mock-
transduced (grey bars) 7 days before this assay. Effector cells have also been tested on mini-
LCLs from donor 1304 endogenously expressing pp65 (“pp65”) or not expressing any HCMV
antigen (“ctrl”). The graphs show the concentration of secreted IFN-γ in the supernatant
as evaluated by ELISA. e:t ratio was 30,000:20,000. The mean and standard deviation of
duplicate samples are shown.
no. 124 (fig. 4.1 C) as suggested by Wiesner (2005) for F46P #19. Since both T cell clones
express the same TCR, F46P #19 certainly recognises the same epitope as F45P #45 and was
consequently re-labelled as AGIL-specific. F46P #40 could not be established after thawing the
last remaining aliquot of it, hence the epitope specificity of this T cell clone could not be checked.
The specificity of F62P #16 for peptide no. 128 could be verified in this study (fig. 4.8 A).
Andrea Schub (2010) generated and analysed the CD4+ T cell clone 1304P #21, but tested its
reactivity against a selection of pp65 peptides only, using APCs pulsed with peptide pools 1-9,
11, 12, 14, 15 and 17-22. She found this T cell clone to strongly react to pool no. 9 and very
weakly to pool no. 17, which share peptide no. 57 (KVYL ESFC EDVP SGK), and consequently
reported peptide no. 57 as the epitope.
Due to the scarcity of frozen clone aliquots, further analyses of 1304P #21 within the present
study, except for HLA blocking (fig. 4.3 F) and HLA mismatch (fig. 4.6 B), were performed
using TCR-transgenic T cell lines. For this purpose, the gene sequences of the TCRα and TCRβ
chains that were expressed by this T cell clone were analysed (section 4.1.3) and assembled in
silico to construct a retroviral vector plasmid, which coded for both TCR chains within a single
gene (section 4.1.4). Recombinant retroviruses were produced by HEK293T cells and carried the
designated TCR construct as cargo DNA (section 3.5.1). PBMCs were isolated from healthy,
HCMV– adults and the T cells were stimulated to become susceptible for transduction with a
retrovirus encoding the TCRα and TCRβ chains that had been isolated from T cell clone 1304P
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#21. As a control for unspecific reactivity, such as allogeneic recognition of peptide-loaded
APCs by the transduced T cell line, another T cell line was tested simultaneously that had been
transduced with “empty” MP71 retrovirus (no genetic cargo DNA = “mock-transduced”). The
same procedure was performed to analyse other HCMV-specific TCRs if the T cell clones from
which the TCRs had been isolated were scarce or not available any more. T cells that had
been transduced with a retrovirus encoding the TCR isolated from 1304P #21 only recognised
peptide no. 45 (EPDV YYTS AFVF PTK) out of eleven peptides contained in pool no. 9 well above
background recognition by mock-transduced T cells (fig. 4.2). Also peptide pools no. 9, 10
and 16 were recognised by TCR-transgenic T cells above background, while pools no. 13, 17,
23 and 24 did not elicit a specific response. Pool no. 16 shares peptides no. 45 (EPDV YYTS
AFVF PTK) and 46 (YYTS AFVF PTKD VAL) with pools no. 9 and 10, respectively. Since pool no.
9 was recognised about twice as strong as pool no. 10 and peptide no. 46 failed to activate
TCR-transgenic T cells in a separate experiment (data not shown), the T cell clone and its TCR
were tagged with the abbreviation of epitope 45 (i.e. EPDV).
4.1.2 HLA restriction of T cell clones
T cells can become active when their TCR recognises their cognate antigen, which is a complex
of specific peptide bound to a particular HLA. Binding of both elements by the TCR is required.
Therefore, in adoptive T cell therapy, the patient must have the appropriate HLA for the T cells
to work. This makes it important to precisely identify the required HLA – in other words, the
HLA restriction of the TCR.
The HLA class I restriction of CD8+ T cell clone MDP #19 YSE was identified as HLA-
A*01:01 by Andrea Schub (2010). IE-1309-317 (CRV)-specific and UL28327-335 (FRC)-specific T
cell clones were found to be restricted by HLA-C*07:02 (Ameres et al., 2013; Kim et al., 2011b,
respectively).
There are three different isoforms of HLA class II, namely HLA-DR, HLA-DQ and HLA-DP.
Each isoform consists of two different polypeptide chains, α and β, that are encoded by separate
genes in the HLA class II region and are very polymorphic except for HLA-DRA (= HLA-DRα).
In contrast to HLA class I molecules, both chains of an HLA class II heterodimer participate
in the presentation of antigenic peptides and are thus relevant for determining HLA restriction.
The HLA class II restriction of CD4+ T cell clones was identified in a three step consecutive
process.
First, the restriction was narrowed down to one of the three HLA class II isoforms. Anti-HLA-
DR, -HLA-DQ or -HLA-DP antibodies were used to block interactions of the peptide/HLA
complexes on autologous antigen-expressing mini-LCLs with TCRs of CD4+ T cell clones. Block-
ing of an irrelevant HLA class II isoform did not affect the recognition of presented epitopes by
a T cell clone, whereas blocking the particular HLA class II isoform that can present the epitope
of a T cell clone strongly decreased or obviated the IFN-γ secretion. In this manner, F46P #17,
#18, #40 and #45 were identified as HLA-DR-restricted, while F62P #16 and 1304P #21 were
restricted by HLA-DQ (fig. 4.3). F46P #36 could not be tested because the clone died before
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Figure 4.3. Blocking of HLA-DR, -DQ or -DP on pp65-expressing mini-LCLs to narrow HLA
restriction of CD4+ T cell clones. After blocking autologous pp65-expressing mini-LCLs
with anti-human HLA antibodies for 30 minutes at 37 ◦C, they were co-incubated overnight
with T cell clones at an e:t ratio of 10,000:20,000. Stimulation by TPA and ionomycin
served as positive control, while effector cells in the absence of mini-LCLs were evaluated
as negative control (“effector only”). The graphs show the concentration of secreted IFN-γ
in the supernatant as evaluated by ELISA. The mean and standard deviation of duplicate
samples are shown. Each experiment has been repeated once with equivalent results.
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any assay could be performed.
Next, T cell clones were challenged by a panel of HLA-matched as well as HLA-
mismatched allogeneic mini-LCLs in order to identify HLA molecule candidates that could
be presenting the epitope. Apart from pp65-expressing mini-LCLs, control mini-LCLs from
the same donors were also included in the panel as negative controls and to identify potential
alloreactivity of T cell clones. No reactivity against control mini-LCLs, whether matched or
mismatched, was observed for the T cell clones described in this section.
The HLA-DR-restricted T cell clone F46P #17 reacted to pp65-expressing mini-LCLs from
donors F46 (autologous), F64, 1107 and 1223 (fig. 4.4 A). 1223 matches F46 in DRB1*13:02 and
F64 harbours HLA-DRB1*13:01, which is very similar in amino acid sequence to DRB1*13:02
(>99% homology, Marsh et al., 2000). 1107 matches F46 in HLA-DRB1*15:01 and DRB5*01:01,
but two other donors (F65 and 1220) with the same HLA alleles did not elicit a response.
While recognition of mini-LCLs from donor 1107 could not be explained, HLA-DRB1*13:01 and
DRB1*13:02 were identified as the most likely restricting HLA alleles for F46P #17.
Similar to F46P #17, T cell clone F46P #18 responded to pp65-expressing mini-LCLs from
donors F46 (autologous), F64 and 1223 (fig. 4.4 B). Thus, HLA-DRB1*13:01 and DRB1*13:02
are most likely the restricting HLA alleles for F46P #18, too.
In contrast, F46P #45 secreted IFN-γ after encountering pp65-expressing mini-LCLs from donors
F46 (autologous), F65, 1107 and 1223 (fig. 4.4 C). The donor 1223 matches F46 in HLA-
DRB3*03:01. F46, F65 and 1107 share HLA-DRB1*15:01 and DRB5*01:01, but 1220 argues
against this HLA restriction because 1220 also harbours these two alleles, but has not been
recognised by F46P #45. F65 and 1107 both have HLA-DRB3*02:02, which is similar to HLA-
DRB3*03:01 (>95% homology, Marsh et al., 2000). Thus, T cell clone F46P #45 is likely
restricted by HLA-DRB3*03:01 and DRB3*02:02.
Due to a lack of frozen aliquots of T cell clone F46P #40, further analyses of its HLA restriction
were performed using TCR-transgenic T cell lines. For this purpose, αβ T cells had been trans-
duced with the retrovirus MP71 carrying the TCRα and TCRβ genes isolated from F46P #40
(MSIY40, tab. 4.2). These TCR-transgenic T cells from donor 0112 recognised pp65-expressing
mini-LCLs from two donors that were positive for HLA-DRB1*15:01 and DRB5*01:01 (F46 &
F65, fig. 4.5). The pp65-expressing mini-LCL from donor F64 was also recognised by TCR-
transgenic T cells despite the fact that it does not share any HLA-DRB allele with F46. In an-
other experiment using the same effector cells, a pp65-expressing mini-LCL from donor 1626 that
is positive for HLA-DRB1*15:01 and DRB5*01:01 was also recognised (data not shown). Again,
pp65-expressing mini-LCLs from donor F64 were recognised despite the HLA mismatch, whereas
HLA-mismatched mini-LCLs from donor 1223 were not recognised by MSIY40-transgenic T cells.
While recognition of mini-LCLs from donor F64 could not be explained, HLA-DRB1*15:01 or
DRB5*01:01 were identified as the most likely restricting HLA alleles for F46P #40.
The HLA-DQ-restricted T cell clone F62P #16 recognised four out of four pp65-expressing
mini-LCLs, all from different donors that were positive for HLA-DQB1*05:01 (fig. 4.6 A). pp65-
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no control mini-LCL was recognised. Therefore, the experiment strongly suggested that the T
cell clone was restricted through HLA-DQB1*05:01, and its specificity for pp65 and absence of
alloreactivity was confirmed. Because HLA-DQA was not known for all target cells, the restrict-
ing DQA chain was not identified with the same high level of confidence, but the results were
consistent with restriction through DQA1*01:01. Since most HLA haplotypes with DQB1*05:01
have DQA1*01:01 (Klitz et al., 2003), the T cell clone and TCR are likely to recognise pp65 in
a majority of donors who express this DQB1 chain.
T cell clone 1304P #21 recognised the autologous and two HLA-matched pp65-expressing mini-
LCLs, all of which shared HLA-DQB1*03:01 (fig. 4.6 B). In this experiment, the transformed
B cell lines Raji and EBV-B1.11 were pulsed with the wrong peptide (pp65 peptide no. 57 =
KVYL, tab. 2.12) because the error in epitope determination of 1304P #21 was identified and
corrected later (pp65 peptide no. 45 = EPDV, see section 4.1.1). As a result, neither Raji nor
EBV-B1.11 could be recognised by the T cell clone after peptide loading despite the fact that
EBV-B1.11 cells have HLA-DQB1*03:01. HLA-DQA1*05:01 is most likely the corresponding
DQA1 chain that presents the peptide to T cell clone 1304P #21 along with DQB1*03:01, since
no other HLA-DQA allele was found to be expressed by donor 1304. As two thirds of HLA
haplotypes with DQB1*03:01 have DQA1*05:01 (Klitz et al., 2003), this TCR is likely to recog-
nise pp65 in the majority of donors who express this DQB1 chain. However, EPDV peptides
may also be presented by DQB1*03:01 in association with other DQA1 molecules, since donors
0519 and 1220 do not possess DQA1*05:01 but DQA1*01:02 & DQA1*05:05 and DQA1*01:02
& DQA1*03:03, respectively (fig. 4.6 B).
Certain HLA alleles, such as HLA-DRB1*13:02 and HLA-DRB3*03:01, are often in close
linkage disequilibrium as elements of the same HLA haplotype, making these HLA restrictions
difficult to distinguish in a match/mismatch setting. Thus, HLA candidates were individually
studied by transfection of HLA-mismatched, transformed B cells with plasmids cod-
ing for recombinant HLA molecules. B cell lines Raji, DG-75 and EBV-B1.11 were used.
After externally loading (also called “pulsing”) the transiently HLA-transfected B cells with the
chemically synthesised peptide epitope, T cell clones or TCR-transgenic T cell lines were co-
incubated and IFN-γ secretion was analysed in order to ascertain the HLA restriction. Since
HLA-DRA is not polymorphic, it was assumed that endogenous DRA would be sufficient, and
recombinant DRA was not co-transfected together with plasmids coding for HLA-DRB chains.
Figure 4.7 C shows an experiment that confirmed this assumption, since there was similarly good
recognition of targets when transfected with DRB regardless of DRA co-transfection.
Figure 4.4 . (displayed on preceding page)
Recognition of HLA-matched and -mismatched mini-LCLs by the CD4+ T cell
clones F46P #17 (A), #18 (B) and #45 (C). pp65-expressing mini-LCLs (“+”) and
respective control mini-LCLs (“–”) from several donors were co-incubated overnight with T
cell clones at an e:t ratio of 10,000:20,000. “autolog.” marks the donor from which the T cell
clone originated. Stimulation by TPA and ionomycin served as positive control, effector
cells in the absence of mini-LCLs as negative control (“effector only”). The HLA-DRB
type of each donor is given below each graph (blanks indicate absence of HLA alleles). The
graphs show the concentration of secreted IFN-γ in the supernatant as evaluated by ELISA.
The mean and standard deviation of duplicate samples are shown.
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Figure 4.5. Recognition of HLA-matched and -mismatched mini-LCLs by a TCR-transgenic
αβ T cell line that expressed the TCR from pp65-specific CD4+ T cell clone
F46P #40. pp65-expressing mini-LCLs (“+”) and respective control mini-LCLs (“–”)
from three donors were co-incubated overnight with αβ T cells from donor 0112 that had
been transduced with a retrovirus coding for MSIY40 seven days before this assay. e:t ratio
was 40,000:40,000. The HLA-DRB type of each donor is given below each graph (blanks
indicate absence of HLA alleles). The graphs show the concentration of secreted IFN-γ
in the supernatant as evaluated by ELISA. The mean and standard deviation of duplicate
samples are shown.
The T cell clone F46P #17 was reported to be specific for overlapping peptides no. 66 (QPFM
RPHE RNGF TVL) and 67 (RPHE RNGF TVLC PKN) of the pp65 library (tab. 2.12), which overlap in
the sequence RPHE RNGF TVL (Wiesner, 2005). However, multiple re-evaluations of the specificity
of F46P #17 using autologous control mini-LCLs pulsed with peptides no. 65 (TRNP QPFM RPHE
RNG), 66 or 67 contradicted this and suggested a somewhat different specificity: Peptide no. 65
caused a profound IFN-γ secretion by the T cell clone F46P #17 (2,200 pg/ml), peptide no. 66
provoked a strong secretion (19,000 pg/ml) and peptide no. 67 resulted in negligible secretion
(10 pg/ml, fig. 4.7 A). Thus, the epitope of this T cell clone centres on the sequence QPFM RPHE
RNG with a clear preference for peptide no. 66 over 65 and consequently F46P #17 was tagged
with the epitope’s abbreviation QPFM.
The T cell clone F46P #17 QPFM responded to HLA-mismatched Raji cells transfected with
HLA-DRB1*13:01, but not to Raji cells transfected with HLA-DRB1*13:02 (fig. 4.7 A). The
experiment was repeated four times using different aliquots of the T cell clone and different target
cells with equivalent results. The amino acid sequence of mature HLA proteins DRB1*13:01 and
DRB1*13:02 is identical except for a single amino acid which is located within the β1 domain:
DRB1*13:01 has valine at amino acid position 86, whereas DRB1*13:02 has glycine (Bondinas
et al., 2007; Marsh et al., 2000). Amino acid no. 86 of HLA-DRB contributes to peptide binding
and is located close to the end of the α-helix that lines the binding cleft of the αβ HLA-DR
heterodimer. Due to the high homology of both HLAs and because DRB1*13:02 was the mo-
lecule expressed by the original T cell donor, it seemed unlikely that this lack of responsiveness
of the T cell clone to HLA-DRB1*13:02-transfected and peptide-loaded target cells meant that
the epitope could only be presented by its close allogeneic variant HLA-DRB1*13:01. Instead,
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it seemed more plausible that expression of transfected HLA-DRB1*13:02 or its peptide binding
were corrupted. Sequencing data from Josef Mautner revealed that the plasmid that was used
for transfection (tab. 2.6) coded for an Asp-to-Tyr mutation at amino acid position 70 of HLA-
DRB1*13:02. Since the amino acid at position 70 of mature HLA-DRB1 protein contributes to
peptide and TCR binding simultaneously (Bondinas et al., 2007; Marsh et al., 2000), any amino
acid replacement is likely to affect both. Replacement of an acidic residue by a bulky aromatic
residue will likely have a strong effect on the binding of peptides and TCRs that usually inter-
act with HLA-DRB1*13:02. Further analyses were conducted without transfection of erroneous
HLA-DRB1*13:02 and HLA-DRB1*13:01 was used as a surrogate due to high sequence simil-
arity. Nevertheless, F46P #17 is likely restricted by both HLA-DRB1*13:01 and DRB1*13:02
because two target cell lines with endogenous expression of DRB1*13:02, but not DRB1*13:01
were recognised, and DRB1*13:01-transfected target cells were recognised as well (fig. 4.4 A and
4.7 A, respectively).
At the time of performing the HLA transfections, F46P #18 and #36 T cell clones were not
available any more. So TCR-transgenic αβ T cell lines from donor 0112 were used as effector
cells for determination of HLA restriction, instead. DG-75 cells were transfected with HLA-
DRB1*15:01 or DRB5*01:01 and Raji cells were transfected with DRB1*13:01 or DRB3*03:01,
covering all HLA-DRB alleles of donor F46 except for DRB*13:02. Both YRIQ18- and YRIQ36-
transgenic T cell lines only responded to HLA-DRB1*13:01-transfected, peptide-pulsed cells
(fig. 4.7 B). For reasons explained in the above paragraph, DRB1*13:02 could not be tested,
but because of the close similarity between autologous DRB1*13:02 and the related molecule
DRB1*13:01, it is likely that either HLA presents the peptide to the T cell clone.
The putative HLA restriction of F46P #40 MSIY was HLA-DRB1*15:01 (Wiesner, 2005), but
TCR-transgenic T cells that expressed the TCR MSIY40, which was isolated from F46P #40,
were not activated by target cells transfected with HLA-DRB1*15:01 and loaded with pp65 pep-
tide no. 28 (MSIY, tab. 2.12) in three independent experiments (data not shown). Neither the
variant HLA-DRB1*15:02 of this allotype, nor the molecule DRB5*01:01, whose gene is in strong
linkage to DRB1*15:01 and therefore sometimes difficult to distinguish from it as a restriction
element, activated TCR-transgenic T cells. Since the HLA-DRB1*15:01 tetramer also failed to
bind to T cell lines transgenically expressing the TCR MSIY40 (section 4.4.2, data not shown),
several lines of evidence indicate that HLA-DRB1*15:01 is probably not the restriction element
for this T cell clone. As strong binding of MSIY peptide to HLA-DRB1*15:01 was reported in an
artificial in vitro assay (Muixí et al., 2008), it is also possible that MSIY is not the epitope which
is recognised by T cell clone F46P #40. Thus, the HLA restriction of TCR MSIY40 remains
elusive and its epitope specificity should be reviewed.
For determining the HLA restriction of the T cell clone F46P #45 AGIL, EBV-B1.11 cells
were transfected with HLA-DRB3*01:01, DRB3*02:02 or DRB3*03:01. As a separate condition,
HLA-DRA1*01:01 and HLA-DRB3*03:01 were transfected simultaneously to assess the effect of
co-transfected HLA-DRA on antigen recognition by F46P #45. The T cell clone produced IFN-γ
in response to peptide-pulsed EBV-B1.11 cells if they were transfected with HLA-DRB3*02:02
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Figure 4.6. Recognition of HLA-matched and -mismatched mini-LCLs by the CD4+ T cell
clones F62P #16 (A) and 1304P #21 (B). pp65-expressing mini-LCLs (“+”) and
respective control mini-LCLs (“–”) from several donors were co-incubated overnight with T
cell clones at an e:t ratio of 10,000:20,000. Raji and EBV-B1.11 cells had been loaded with
peptide no. 57 (“+”, tab. 2.12) or were left untreated to serve as negative control (“–”) prior
to co-incubation with effector cells. “autolog.” marks the donor from which the T cell clone
originated. Stimulation by TPA and ionomycin served as positive control, effector cells in
the absence of mini-LCLs as negative control (“effector only”). The HLA-DQB and -DQA
type of each donor is given below each graph (blanks indicate absence of HLA alleles; “n.d.”
marks HLA alleles that have not been determined by HLA typing). The graphs show the
concentration of secreted IFN-γ in the supernatant as evaluated by ELISA. The mean and
standard deviation of duplicate samples are shown.
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or DRB3*03:01, but not DRB3*01:01 (fig. 4.7 C). While the amount of secreted IFN-γ was
not notably changed by HLA-DRA co-transfection (2,500 pg/ml), presentation of the peptide by
HLA-DRB3*03:01 (2,300 pg/ml) resulted in more than twice the amount of cytokine as present-
ation by DRB3*02:02 (1,000 pg/ml). This experiment was independently reproduced four times,
providing equivalent results. Thus, F46P #45 AGIL is restricted by HLA-DRB3*03:01 (auto-
logous allele), but is also able to bind its epitope when presented by DRB3*02:02. The amino
acid sequence of both HLA-DRB chains differs in ten amino acids (Marsh et al., 2000), four
of which participate in peptide binding (amino acid positions 30, 37, 57 & 86, Bondinas et al.,
2007). Although amino acid exchanges at positions 30, 57 and 86 are non-conservative (His–Tyr,
Asp–Val and Gly–Val, respectively), AGIL peptide was presented by HLA-DRB3*02:02 as well
as DRB3*03:01 and was recognised well despite differences in HLA-DRB sequence.
In contrast to HLA-DR, the analysis of HLA-DQ restrictions requires identification of
the restricting DQA and DQB chains, since both are polymorphic. The T cell clone F62P
#16 KYQE and EPDV21-transgenic δ2 T cell lines were tested in such experiments. Donor
F62 has HLA-DQA1*01:01 and DQB1*05:01, as well as DQA1*01:03 and DQB1*06:01; these
two pairings represent frequent HLA haplotypes (Klitz et al., 2003). EBV-B1.11 cells that
had been transfected with DQA1*01:01 & HLA-DQB1*06:01 or DQA1*01:03 & DQB1*06:01
and that had been loaded with KYQE peptide were not recognised by the T cell clone F62P
#16 (data not shown). If EBV-B1.11 cells had been transfected with DQB1*05:01, however,
F62P #16 clearly recognised peptide-loaded target cells (fig. 4.8 A). Transfecting EBV-B1.11
cells with HLA-DQB1*05:01 alone and loading them with antigenic peptide resulted in robust
IFN-γ production by the T cell clone (4,000 pg/ml), but co-transfections of the same DQB mo-
lecule together with either DQA1*01:01 (16,000 pg/ml) or DQA1*01:03 (14,000 pg/ml) resulted
in a more than 3.5-fold increase of IFN-γ levels. The endogenous HLA haplotypes of EBV-
B1.11 cells were identified as DQA1*01:02 & DQB1*06:02 and DQA1*05:FE & DQB1*03:01
(tab. 2.3). As noted earlier, two thirds of HLA haplotypes with DQB1*03:01 have DQA1*05:01
and the other third has DQA1*03:02 apart from a few other less frequent combinations (Klitz
et al., 2003). Thus, EBV-B1.11 cells very likely expressed DQA1*05:01 apart from DQA1*01:02,
neither of which are present in donor F62. Apparently, endogenous expression of DQA1*01:02
and DQA1*05:01 allowed presentation of the epitope to the TCR, but an even stronger re-
sponse was achieved by co-transfection of one of the other two DQA1*01 variants DQA1*01:01
or DQA1*01:03 (fig. 4.8 A). Since DQA1*05:01 shares just 87.9% of its amino acid sequence
with DQA1*01:01, whereas DQA1*01:02 and DQA1*01:03 share 99.1 and 97.9% sequence ho-
mology with DQA1*01:01 (Marsh et al., 2000), DQA1*01:02 rather than DQA1*05:01 probably
served as a substitute for presentation of KYQE peptide in EBV-B1.11 cells transfected with
DQB1*05:01 alone. Endogenous DQA1*01:02, however, may have been expressed at lower levels
than the transfected molecules or may bind the KYQE peptide or the TCR with lower affin-
ity than DQA1*01:02 and DQA1*01:03. Taken together, target cells were recognised by T cell
clone F62P #16 if KYQE peptide was presented through DQB1:05:01 together with any of the
three DQA1 chains DQA1*01:01, DQA1*01:02 or DQA1*01:03. As most HLA haplotypes with
DQB1*05:01 have DQA1*01:01 (Klitz et al., 2003), the T cell clone and the TCR derived from
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Since aliquots of the T cell clone 1304P #21 EPDV were scarce, its HLA restriction was ana-
lysed by employing TCR-transgenic T cell lines, as done for its epitope determination described
above (section 4.1.1). For this experiment, αβ TCR-depleted PBMCs from donor 0506 were
stimulated with pamidronate to expand the population of δ2 T cells (see section 4.2 for more
information on this procedure) and render them susceptible to transduction with a retrovirus
encoding the TCRα and TCRβ chains from T cell clone 1304P #21. The δ2 T cell line was
transduced with the TCR EPDV21 seven days before co-incubation with HLA-transfected DG-
75 cells that were used as target cells because they do not express HLA-DQB1*03:01, which is
the putative HLA restriction of this TCR (fig. 4.6 B). DG-75 cells were transfected with HLA-
DQB1*03:01 alone or in combination with DQA1*05:01 and loaded with antigenic peptide. The
TCR-transgenic δ2 T cells, but not GFP-transgenic δ2 T cells that were prepared in parallel
as controls, secreted a large amount of IFN-γ in response to DG-75 cells co-transfected with
HLA-DQA1*05:01 and DQB1*03:01 (fig. 4.8 B). Target cells that had been transfected with
DQB1*03:01 alone were not recognised. Thus, the endogenous HLA chains DQA1*01:03 and
DQA1*03:03 of DG-75 cells did not contribute to epitope presentation under these conditions.
As described in the paragraph above, DQA1*01:01, DQA1*01:02 and DQA1*01:03 are very sim-
ilar in amino acid sequence (≥98% homology), whereas DQA1*05:01 differs in 28 of 232 amino
acids from DQA1*01:01 (Marsh et al., 2000), which may easily explain this preference. As two
thirds of HLA haplotypes with DQB1*03:01 have DQA1*05:01 (Klitz et al., 2003), the T cell
clone and the TCR derived from it are likely to recognise pp65 in a majority of donors who
express this DQB1 chain.
Previously, the epitope EPDV was described as HLA-DR7-restricted by Li Pira et al. (2004), but
that study did not consider the possibility that CD4+ T cells may be restricted through HLA-
DQ or DP rather than DR. Thus, DR7 may represent an alternative HLA restriction of EPDV.
Alternatively, the HLA restriction may have been erroneously determined in the earlier study
(Li Pira et al., 2004). Since DR7 is linked to DQB1*03 alleles in about a quarter of haplotypes
Figure 4.7 . (displayed on preceding page)
Verifying the HLA-DR restriction of TCR-transgenic T cell lines or T cell
clones. DG-75, EBV-B1.11 or Raji cells were either transfected with HLA-encoding plas-
mids (given below each graph, also see tab. 2.6), transfected without plasmid DNA (“buf-
fer”) or not transfected (“not tf.”). Afterwards, they were pulsed with antigenic peptides
(“+”) or left untreated to serve as control (“–”). In each experiment, a target cell was
used that was negative for the HLAs to be tested. Autologous (“autolog.”) mini-LCLs or
HLA-matched allogeneic mini-LCLs either expressing pp65 endogenously (“+”) or respect-
ive control mini-LCLs (“–”) were included as controls. Stimulation by TPA and ionomycin
served as positive control for T cell clones. Concentration of secreted IFN-γ in the super-
natant as evaluated by ELISA after overnight co-incubation at an e:t ratio of 20,000:80,000
is shown. The mean and standard deviation of duplicate (A & B) or triplicate (C) samples
are shown. Each experiment was independently performed at least twice. A: T cell clone
F46P #17 QPFM was tested on Raji cells. Epitope specificity was re-checked by pulsing
autologous control mini-LCLs with peptides no. 65, 66 or 67 of the pp65 library (tab.
2.12). B: αβ T cells from donor 0112 had been transduced with TCR YRIQ18 (black bars)
or YRIQ36 (grey bars) 14 days before this assay, in which they were tested on Raji and
DG-75 cells. C: T cell clone F46P #45 AGIL was tested on EBV-B1.11 cells including a
comparison of transfecting HLA-DRB3*03:01 alone or together with HLA-DRA1*01:01.
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Figure 4.8. Verifying the HLA-DQ restriction of TCR-transgenic T cell lines or T cell clones.
DG-75 or EBV-B1.11 cells were either transfected with HLA-encoding plasmids (given be-
low each graph, also see tab. 2.6) or transfected without plasmid DNA (“buffer”). After-
wards, they were pulsed with antigenic peptides (“+”) or left untreated to serve as control
(“–”). In each experiment, a target cell was used that was negative for the HLAs to be
tested. Autologous (“autolog.”) mini-LCLs or HLA-matched allogeneic mini-LCLs either
expressing pp65 endogenously (“+”) or respective control mini-LCLs (“–”) were included as
controls. Concentration of secreted IFN-γ in the supernatant as evaluated by ELISA after
overnight co-incubation is shown as the mean and standard deviation of duplicate samples.
Each experiment was independently performed at least twice. A: T cell clone F62P #16
KYQE was tested on HLA-transfected and peptide-loaded EBV-B1.11 cells at an e:t ratio
of 20,000:40,000. IFN-γ secretion by the T cell clone in response to target cells transfected
either with HLA-DQB1*05:01 alone or in combination with DQA1*01:01 or 1*01:03 was
compared. Stimulation by TPA and ionomycin served as positive control. B: δ2 T cells
from donor 0506 had been transduced with TCR EPDV21 (black bars) or GFP (grey bars)
7 days before this assay, in which they were tested on HLA-transfected and peptide-loaded
DG-75 cells at an e:t ratio of 20,000:80,000.
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(Knipper et al., 2000), such an error does not seem unlikely. As the T cell clone 1304P #21 was
undoubtedly restricted by HLA-DQ (fig. 4.3 F) and this restriction was confirmed by expression
of recombinant HLA-DQ molecules, surely the TCR of 1304P #21 and maybe the EPDV epitope
in general are restricted by HLA-DQA1*05:01 and DQB1*03:01.
Taken together, the HLA class II restriction of six out of seven pp65-specific CD4+ T cell
clones could be determined, either by testing the original T cell clone, or, when these were no
longer available, using TCR-transduced T cells. Table 4.1 gives an overview about the HLA re-
strictions that were identified and the corresponding method that was used, as described earlier
in this section. Moreover, table 4.1 shows the population frequency of each HLA in the Caucasian
population (coverage). This percentage can be used to predict the probability that a particular
TCR may be applied for adoptive T cell therapy to a Caucasian patient.
HLA restrictions of all IE-1-specific CD4+ T cell clones, whose TCRs are described in this
Table 4.1. Summary of HLA restrictions of pp65-specific CD4+ T cell clones that were
identified in this study. Pairs of HLA α and β chains that were identified as the restricting
elements for each T cell clone are shown. For some of the analyses T cell clones were no
longer available, so experiments were performed with TCR-transgenic T cell lines (marked by
“a”). The epitope specificity and HLA restriction of F46P #40 (marked with “b”) could not
be confirmed. Restricting HLAs were either identified by testing T cells on a panel of HLA-
matched and -mismatched mini-LCLs (“match/mismatch”) or on transformed B cells that
were transiently transfected with HLA-encoding plasmids and loaded with pp65 peptides
(“HLA transfection”). Allele frequencies (AFs) of Caucasians were gathered from Gragert
et al. (2013). Percentages of phenotype coverage were calculated by assuming distribution
according to the Hardy-Weinberg equilibrium: Population coverage (i.e. probability that
a specific allele is present in both or one of the two sets of chromosomes of a person) =
(1−(1−AF)·(1−AF)). Population coverage of HLA-DQ restrictions was calculated involving
the AF of DQB only (regardless of the frequency of the respective DQA allele; marked by
“c”).
T cell clone HLA restriction Method of population
α chain β chain identification coverage [%]




DRA1*01:01 DRB1*13:01 HLA transfection 12.0
DRB1*13:02 match/mismatch 9.1
F46P #36 YRIQa DRA1*01:01 DRB1*13:01 HLA transfection 12.0
F46P #40 MSIYab DRA1*01:01 DRB1*15:01 match/mismatch 24.2
DRB5*01:01 match/mismatch 24.3
F46P #45 AGIL DRA1*01:01 DRB3*02:02 HLA transfection 36.2
DRB3*03:01 HLA transfection 9.2
F62P #16 KYQE
DQA1*01:01
DQB1*05:01 HLA transfection 21.9cDQA1*01:02
DQA1*01:03
1304P #21 EPDVa DQA1*05:01 DQB1*03:01 HLA transfection 35.4c
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work, have been analysed by Stefanie Ameres et al. (2015), by means of testing their reactivity
against HLA-matched and -mismatched target cells and, in some cases, target cells transfected
with specific HLAs. The HLA restrictions postulated by Ameres et al. (2015) were confirmed
in experiments that assessed the function of TCR-transgenic T cell lines on HLA-matched and
HCMV-infected target cells (section 4.4.5) with one exception: The TCRs that were isolated
from T cell clones 1021M #6 & #90 SVMK and 1826M #27 SVMK mediated recognition of
HCMV-infected target cells if these expressed HLA-DPB1*03:01 (donor 1613, fig. 4.28), but not
if target cells expressed HLA-DPB1*02:01 and DPB1*04:01 (donor 1022, data not shown). Since
both TCRs were only tested once on target cells from two different donors, further investigation
is required to clarify whether the postulated HLA restriction (DPB1*02:01 & DPB1*03:01) needs
to be corrected to DPB1*03:01 and possibly DPB1*14:01 & DPB1*20:01, which are very similar
to DPB1*03:01 in protein sequence (99.6% homology each, Marsh et al., 2000).
4.1.3 Determination of HCMV-specific TCRα and TCRβ sequences
Identifying the gene sequences ot both TCRα and β chains is a prerequisite for TCR gene trans-
fer. Hence, total mRNA was isolated from previously established T cell clones and reversely
transcribed into cDNA (see section 3.2.2). A fragment of TCRα-encoding cDNA was selectively
amplified by PCR using 34 primers organised in 8 primer pools covering all human TCRα V
regions and one primer specific for the Cα region. Likewise, a fragment of TCRβ-encoding cDNA
was selectively amplified by PCR using two degenerated primers covering most TCRβ V regions
and a Cβ region-specific primer that is fully complementary to each of the two possible vari-
ants of the Cβ region. This amplified fragment (“amplicon”) was expected to be sufficient to
deduce the entire TCRα or TCRβ sequence, since it covered the complete CDR3 and J region
and a sufficient part of the V region to identify the V segment that is used by the respective
TCR chain (section 3.2.2). The amplicons were sent for commercial sequencing and analysed by
utilising IMGT’s V-QUEST tool (section 2.14). These amplicons were sufficient to determine
the sequence of 36 TCR chains, but in 8 cases there were ambiguities of V region determination
listing several V region alleles that identically matched the sequence of the amplicon. Such am-
biguities were resolved through a second PCR with newly designed V region primers (tab. 2.10).
These new primers enabled the amplification of a larger part of the V region than the previously
used primers (tab. 2.9). This technique was also used to clarify amino acid mismatches between
IMGT’s reference alleles and initial sequencing results.
Table 4.2 shows the antigenic epitope, the composition of TCRα and TCRβ chains and the
HLA restriction of all T cell clones whose TCR chains were used to construct vectors for TCR
gene transfer and recombinant expression in T cells. All epitope specificities had already been
reported and most HLA restrictions were known, too (tab. 4.2, last column and notes in the
caption). HLA restrictions of the T cell clones F46P #17 QPFM & #19/#45 AGIL, F62P #16
KYQE and of the TCRs YRIQ18, YRIQ36 and EPDV21 were determined in this study, as shown
in the previous sections.
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Table 4.2. Paternal T cell clones, epitope specificities, TCR sequences and HLA restrictions of all TCRs that were cloned into retroviral
vector plasmids (see tab. 2.8). TCRs marked with “a” or “b” were sequenced by X. Liang (unpublished) or A. Schub (2010), respectively. Peptide
sequences are given as single letter amino acid code (AA). HLA restrictions identified or verified in this work are marked with “c”. References are











AV AJ BV BD BJ BC
F46M 165 CRV1a
IE-1 309-317 CRVLCCYVL
38-1*01 50*01 25-1*01 1*01 2-1*01 1
C*07:02
Kern et al. (B7, 1999);
Khan et al. (B*07:02, 2007);
Slezak et al. (C*07, 2007);
Ameres et al. (C*07:02, 2013)
1013M 75 CRV2a 12-1*01 8*01 7-8*01 2-1*01 1
F46M 36 CRV3 26-2*01 49*01 6-5*01 1*01 1-1*01 1
1013M 169 CRV4 12-1*01 50*01 25-1*01 2*01 2-1*01 2
XLBC13 1, 5,8, 13 FRC1
UL28 327-335 FRCPRRFCF
5*01 16*01 20-1*01 1*01 1-1*01 1
Kim et al. (C*07:02, 2011b)
XLBC13 6 FRC6 14/DV4*02 49*01 28*01 1*01 1-6*02 1
XLBC18 32 FRC32 12-2*01 48*01 28*01 1*01 2-1*01 2
XLBC18 86 FRC86 13-2*01 40*01 6-2*01/6-3*01 2*01 2-7*01 2
XLBC18 93, 94 FRC93 25*01 40*01 28*01 2*02 2-1*01 2
F46P 17 QPFM17b pp65 261-275 QPFMRPHERNGFTVL 36/DV7*01 32*02 5-1*01 1*01 1-1*01 1 DRB1*13:01
c
/1*13:02 Li Pira et al. (DR13, 2004)
F46P 18 YRIQ18 pp65 369-387 (FTSQ)YRIQG- 6*02 36*01 7-9*01 1*01 2-5*01 2 DRB1*13:01
c
/1*13:02
Khattab et al. (DR3, 1997); Gallot et al.
(DR1302, 2001); Li Pira et al. (DR3, 2004)F46P 36 YRIQ36 KLEYRH(TWDR) 6*02 29*01 7-9*01 2*02 2-2*01 2
F46P 40 MSIY40 pp65 109-123 MSIYVYALPLKMLNI 26-1*01 9*01 28*01 2*02 2-3*01 2 DRB1*15:01 Wiesner et al. (DRB1*15, 2005);Nastke et al. (DRB1*07, 2005)
F46P 19, 45 AGIL19 pp65 489-503 AGILARNLVPMVATV 21*02 36*01 20-1*01 2*01 2-5*01 2 DRB3*02:02
c
/3*03:01c
Khattab et al. (DR3, 1997); Gallot et al.
(DR1401, 2001); Li Pira et al. (DR3 or
DR11, 2004); Slezak et al. (DRB3*02,
2007); Pachnio et al. (DRB3*02:02, 2016)
F62P 16 KYQE16 pp65 509-523 KYQEFFWDWNDIYRI 23/DV6*01 54*01 30*01 1*01 2-7*01 2 DQB1*05:01c
Khattab et al. (DR3, 1997); Li Pira et al.
(DR1 or DR3, 2004); Slezak et al.
(DRB3*01:01 or DQB1*05:02, 2007)
1304P 21 EPDV21b pp65 177-191 EPDVYYTSAFVFPTK 20*02 35*01 5-6*01 2*02 2-7*01 2 DQB1*03:01c Li Pira et al. (DR7, 2004)
F64M 236 EIMA236 IE-1 241-259 (CSPD)EIMAYA-QKIFK(ILDE) 17*01 29*01 11-2*01 2*02 2-7*01 2 DRB1*13:01 Ameres et al. (DRB1*13:01, 2015)
F65M 18 RRKM18 IE-1 201-215 RRKMMYMCYRNIEFF 9-2*01 43*01 7-3*01 1*01 2-3*01 2 DRB3*02:02 Ameres et al. (DRB3*02:02 and possibly3*01:01, 2015)
1220M 22 EFFT22 IE-1 213-225 EFFTKNSAFPKTT 25*01 6*01 9*01 1*01 1-5*01 1 DRB5*01:01 Braendstrup et al. (DRB5*01:01, 2013);Ameres et al. (DRB5*01:01, 2015)1826M 50 EFFT50 25*01 49*01 7-2*02/*03 2*01 2-7*01 2
1021M 6, 90 SVMK6 IE-1 337-351 SVMKRRIEEICMKVF 9-2*02 40*01 19*01 1*01 1-5*01 1 DPB1*03:01 Ameres et al. (DPB1*02:01, 1*03:01,1*20:01 and possibly 1*14:01, 2015)1826M 27 SVMK27 38-1*01 40*01 6-5*01 2*02 2-4*01 291
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Analysis of the composition of these TCRs led to an interesting observation about gene seg-
ment usage of human TCRs. One T cell clone (1304P #21, specific for EPDV, tab. 4.2) used
a Jα segment called TRAJ35*01. First identified by Koop et al. (1994), TRAJ35*01 was con-
sidered “non-functional”, and annotated accordingly in IMGT, due to a non-canonical J-motif
(i.e. C-G-X-G instead of F-G-X-G, Scaviner and Lefranc, 2000a). On 23.01.2019, I informed
Marie-Paule Lefranc from IMGT of the identification of a TCRα chain using TRAJ35*01 and
recombinant proof of its function. As a result, the allele’s status was switched from “ORF”
(lacking proof of functional expression) to “functional” (see IMGT’s human TRAJ gene table
online, IMGT note no. 6, accessed on 20.02.2019). This finding has two interesting implications:
First, it demonstrates that the canonical phenylalanine within the J motif, which traditionally
defines the C-terminal end of the CDR3, is not absolutely required to form a functional TCRα
chain by gene recombination, but can be replaced by a cysteine. Second, other TCRs using the
TRAJ35*01 motif will no longer be automatically dismissed as non-functional or eliminated from
TCR analyses. This will make future analyses of human TCR repertoires more complete.
4.1.4 Generation of bicistronic vector plasmids coding for TCRα and TCRβ chains
For simultaneous transduction of TCRα and TCRβ genes and their expression in the receiving
T cell, it is advantageous when both TCR genes are encoded by the same retroviral vector. The
’self-cleaving’ 2A peptide P2A that is derived from the porcine teschovirus-1 is suited very well
for facilitating equimolar expression of both genes (Donnelly et al., 2001, also see section 3.2.3).
P2A showed the best cleavage efficiency among several variants of 2A peptides (Kim et al.,
2011a), is likely not immunogenic (Arber et al., 2013) and is short (19 amino acids), wasting no
precious DNA cargo capacity. Thus, it is reliable, effective and likely safe to apply in a clinical
context. In contrast, an internal ribosome entry site (IRES) is larger and its downsteam gene is
translated less efficient than the one upstream (Mizuguchi et al., 2000).
A Gly–Ser–Gly linker separating P2A and the gene downstream of it was shown to further
improve cleavage efficiency (Holst et al., 2006; Szymczak et al., 2004, addendum 01.06.2004) and
was therefore incorporated in the TCR constructs described in this thesis. In silico, TCRα and
TCRβ genes were fused as 5’—TCRβ–GSG-P2A–TCRα—3’, since Leisegang et al. (2008) showed
this arrangement to be superior to its reverse order. All TCR sequences except for CRV1mu and
CRV2mu (tab. 4.2) were fully human and not murinised or altered in any other way than codon
optimisation, which was done by Thermo Fisher Scientific (Regensburg, Germany) prior to gene
synthesis. The TCR constructs were commercially synthesised and cloned into MP71 (section
2.13). All plasmids that were generated for this study and that code for an HCMV-specific TCR
are shown in table 2.8.
4.2 Establishment of δ2 T cells as recipients for TCR transfer
Gammadelta (γδ) T cells are attractive targets for the transfer of an αβ TCR because they do
not express mis-paired TCR dimers (Koning et al., 1987; Saito et al., 1988). After adoptive
transfer of HCMV-specific T cells into a patient, TCR-transgenic δ2 T cells may be stimulated
by aminobisphosphonates to maintain and expand this population in the absence of stimulation
via the transgenic TCR. Moreover, γδ T cells are a convenient tool to analyse TCR function in
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the absence of co-stimulation by CD4 or CD8, both of which are not expressed by most γδ T
cells (Groh et al., 1989; Janeway, 1992; van der Veken et al., 2006). However, γδ T cells are not
as abundant in peripheral blood as αβ T cells and may not behave comparably if stimulated and
retrovirally transduced. Focussing on the largest fraction of γδ T cells in peripheral blood, the
specific enrichment, stimulation and transduction of Vγ9Vδ2 T cells (abbreviated as δ2 T cells)
was studied in order to establish a quick and easy protocol for obtaining αβ TCR-engineered δ2
T cells.
4.2.1 Optimising pamidronate concentration for the stimulation of δ2 T cells
In order to be susceptible to retroviral transduction, target cells need to be proliferating. Since
treatment of PBMCs with aminobisphosphonates was shown to drive activation and proliferation
of δ2 T cells in vitro (Gober et al., 2003; Khan et al., 2014; Morita et al., 2007), the aminobis-
phosphonate pamidronate was chosen as stimulating agent. 50 U/ml Interleukin (IL)-2 were
simultaneously administered to provide δ2 T cells with co-stimulation in addition to Vγ9Vδ2
TCR stimulation through pamidronate (Khan et al., 2014; van der Veken et al., 2006, applied
300 or 100 U/ml, respectively). Since survival and proliferation of γδ T cells were shown to bene-
fit from the presence of IL-7 (van der Veken et al., 2009, 5 ng/ml) and IL-15 (Khan et al., 2014;
van der Veken et al., 2006, 10 or 20 ng/ml, respectively), both cytokines were supplemented dur-
ing δ2 T cell stimulation and retroviral transduction at 5 ng/ml each. All PBMCs were incubated
in 5% HS T cell medium containing human instead of fetal calf serum throughout experimental
proceedings irrespective of PBMC sorting or chosen stimulation. However, all effector assays
during which T cells were co-incubated with target cells were set up in 10% FCS T cell medium
because HS contained human IFN-γ at levels that negatively affected analyses of T cell function
by ELISA.
The concentration of pamidronate (PAM) in the cell culture was titrated by stimulating bulk
PBMCs with different amounts of PAM. After an initial drop of cell numbers at days 3 and 4,
Vδ2+ T cells proliferated best at 10 or 15 µM PAM (fig. 4.9 A & B, one out of two donors
shown) leading to an increase in Vδ2+ T cell counts of at least 20-fold from day 0 to day 7. The
initial decline in Vδ2+ T cell numbers could be caused by impaired detection via FACS as a
result of down-regulation of TCR expression after stimulation. Vδ2– CD8– T cells, which mainly
consist of CD4+ αβ T cells, did not proliferate. In contrast, Vδ2– CD8+ T cells, which mostly are
composed of CD8+ αβ T cells, more than doubled in numbers from day 0 to day 7. This could
be caused by proliferation of CD8+ CTLs in response to presentation of an unknown antigen by
monocytes or even Vδ2+ T cells that may function as APCs (Khan et al., 2014).
A higher PAM concentration of 45 µM did not improve cell proliferation, but resulted in a
pronounced loss of Vδ2+ T cells (data not shown). Since PAM interferes with the mevalonate
pathway, a high concentration of PAM may be toxic for cells by preventing the synthesis of
downstream products of the pathway, such as isoprenoids, steroids and cholesterol. This may
affect δ2 T cells directly or cells, like monocytes, that are required to stimulate δ2 T cells by
PAM. Bearing this in mind, 10 µM PAM were chosen for future stimulations because δ2 T cell




4.2 Establishment of δ2 T cells as recipients for TCR transfer
if concentration was lower (1 or 5 µM).
The effect of 10 µM PAM on proliferation of Vδ2– and Vδ2+ T cells from four different donors
was evaluated. While the four donors showed a 40- to 200-fold increase of Vδ2+ T cell numbers
from day 0 to day 7 (fig. 4.9 C), the numbers of Vδ2– T cells in general stayed constant or
were reduced except for one donor (0401, 4-fold increase). As observed before, the numbers of
Vδ2+ T cells dropped from day 0 to day 3, before recovering on day 4 or 5. Taken together,
these experiments confirmed that PAM stimulation specifically and strongly expanded the Vδ2+
T cell-fraction, and established an optimal dose for their short-term in vitro expansion from
PBMCs.
4.2.2 Optimal time point for retroviral transduction of δ2 T cells after stimulation by
pamidronate
After 3, 4, 5, 6 or 7 days of PAM stimulation, PBMCs were transduced with retroviruses coding
for GFP to determine the optimal time point for retroviral transduction. Another four days after
transduction, GFP-expression of Vδ2+ and Vδ2– T cells was analysed by FACS. For all four
donors, the proportion of GFP-expressing Vδ2+ T cells was highest if PBMCs were transduced
after 3 days of PAM stimulation (fig. 4.9 D). Prolonged PAM stimulation for 4, 5, 6 or 7
days resulted in gradually decreased proportions of GFP+ Vδ2+ T cells. Since transduction
efficiency was best after 3 days of PAM stimulation, this scheme was applied in all future retroviral
transductions of δ2 T cells. Most GFP+ Vδ2+ T cells were CD8– because the large majority of
Vδ2+ T cells does not express CD8.
Although pamidronate specifically activates Vδ2+ T cells, some Vδ2– T cells were transduced
with GFP as well ranging from less than 0.6% (donor 0113) to more than 6% (donor 0401) GFP+
Vδ2– T cells. This simultaneous, non-intended transduction of Vδ2– T cells, which presumably
are mainly composed of αβ T cells, did not generally favour the CD4+ or CD8+ subpopulation
over the other: While mainly CD8– Vδ2– T cells, but few CD8+ Vδ2– T cells, expressed GFP
Figure 4.9 . (displayed on preceding page)
Characterisation of optimal conditions for stimulation and subsequent transduc-
tion of Vδ2 T cells. Bulk PBMCs from healthy donors were stimulated with pamidronate
(PAM) and analysed by FACS. Graphs A, C & D show cell numbers for Vδ2+ T cells (left
graph) and Vδ2– T cells (right graph). Absolute cell numbers were determined by FACS
using a pre-defined number of PE-labelled beads that were acquired simultaneously as a
standard. Results for CD8+, CD8– or all T cells of the respective T cell subset without
discrimination by CD8 expression are shown. All T cells were pre-gated as CD14– CD19–
CD3+. (A) Cell numbers were assessed before (day 0) and after stimulating 106 PBMCs
from donor 1107 with 0, 1, 5, 10 or 15 µM PAM for 3, 4, 5, 6 or 7 days and (B) dilu-
tion of the intracellular dye CellTrace Violet due to proliferation was followed (top row:
pseudocolour dot plots demonstrating δ2 T cell expansion; bottom row CellTrace Violet
histograms showing model sum (red line) and model components (blue line) calculated by
FlowJo). Dead cells were excluded from analysis by using a live/dead marker (TOPRO).
106 PBMCs from four additional donors were stimulated with 10 µM PAM for 3, 4, 5, 6
or 7 days. On those days, cell numbers were assessed (C). PBMCs that had been stim-
ulated with PAM for 3 to 7 days were transduced with a GFP-encoding retrovirus, and
the proportion of GFP+ T cells in the Vδ2+ or Vδ2– subset was determined by FACS (D,
the x-axis indicates the day of transduction after PAM stimulation, the measurement was
made four days after transduction in each case).
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in the PBMC culture from one donor (0401), this ratio was inverted in the PBMC culture from
another donor (1004).
4.2.3 Phenotypic analysis of δ2 T cells after stimulation by pamidronate
TCR-transgenic T cells need to possess a certain degree of proliferative capacity in order to ex-
ert desired effector functions when encountering targets. Thus, T cells produced for application
in adoptive T cell therapy of HCMV should originate from an effective T cell subpopulation,
which is capable of driving the immune response and is not terminally differentiated. αβ T cells
have been grouped into naïve (N, i.e. not antigen-experienced), central memory (CM), effector
memory (EM) and effector memory re-expressing CD45RA (EMRA) subpopulations according
to their differentiation status (N → CM → EM → EMRA, from early to late). The efficacy
of a T cell product will likely benefit from a high TCM and TEM content (Busch et al., 2016)
because transfer of less-differentiated T cell subsets was highly correlated with clinical responses
(Klebanoff et al., 2012).
One pair of surface markers to monitor T cell subpopulation distribution consists of CD45RA,
which is expressed by TN and TEMRA, and CD62L, which is expressed by TN and TCM. PB-
MCs from three healthy donors were simultaneously stained by monoclonal antibodies specific
for CD62L and CD45RA to assess the differentiation status of Vδ2 T cells before and after stim-
ulating them with 10 µM pamidronate. Upon encounter of APCs, the fraction of naïve Vδ2+ T
cells diminished in all three donors over the course of 7 days after PAM stimulation (fig. 4.10 B).
The fraction of central memory Vδ2+ T cells enlarged from day 0 to 3 and from day 3 to 5. At
the end of the evaluated time period (from day 5 to day 7), TCM Vδ2+ T cells decreased slightly,
probably resulting from continued antigen presentation driving differentiation further. Effector
memory Vδ2+ T cells made up the largest (donor 1004 & 1613) or second-to-largest (donor 0113)
fraction on day 0, declining in numbers over the next several days, but recovering at day 7. This
may also be caused by continued antigen presentation that promotes differentiation from TN to
TCM to TEM Vδ2+ T cells. Terminally differentiated TEMRA Vδ2+ T cells were found in fairly
large numbers on day 0 in two out of three donors (21.2% & 24.9%), but their numbers strongly
decreased in PBMC cultures from all three donors following PAM stimulation (<3% on days 5
and 7).
In summary, PBMCs stimulated with 10 µM pamidronate offered a favourable T cell composi-
tion of mainly TCM and TEM Vδ2 T cells that likely retain proliferative capacity and functional
efficacy. If the definitions of TN, TCM, TEM and TEMRA subpopulations originally identified on
αβ T cells can also be applied to γδ T cells (as suggested by Dieli et al., 2003), the demonstrated
composition of PAM-stimulated Vδ2+ T cells strongly supports engineering them with transgenic
TCRs and using them in adoptive T cell therapy.
4.3 Characterisation of HCMV-specific TCRs restricted by HLA class I
CD8+ CTLs are an essential part of HCMV-specific immunity that limits replication of HCMV
(Einsele et al., 2002; Reddehase, 2002) by killing infected host cells. Recently, IE-1-specific CD8+
T cell clones that are restricted by HLA-C*07:02 were shown to strongly recognise AD169-infected
target cells, which other T cell clones restricted by HLA-A or -B could not (Ameres et al., 2014,
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Figure 4.10. Differentiation phenotype of T cells after stimulation with pamidronate. 106
bulk PBMCs from healthy donors were stimulated with 10 µM pamidronate (PAM) and
analysed on day 0, 3, 5 and 7 by FACS. All T cells were pre-gated as CD14– CD19– CD3+.
A: Pseudocolour dot plots show the expression of CD62L and CD45RA on Vδ2+ (top row)
and Vδ2– (bottom row) T cells (representative data from one donor (1613) out of three).
B: Distribution of differentiation phenotypes of Vδ2+ T cells from donors 1004 (circles),
0113 (squares) & 1613 (triangles). CD45RA+ CD62L+, CD45RA– CD62L+, CD45RA–
CD62L– or CD45RA+ CD62L– Vδ2+ T cells were identified as naïve (N), central memory




Figure 4.11. Expression of CRV1, CRV1mu, CRV2 or CRV2mu by T cells four days after
transduction. Bulk PBMCs from donor 1107 were stimulated with anti-CD3 antibody
before transduction. Stainings with CRV streptamer (top row) and Vβ11 (bottom row)
against CD8 are shown as pseudocolour dot plots. Vβ6-specific antibodies for staining
CRV2 and CRV2mu were not available. Mock-transduced (using retroviruses devoid of
genetic cargo) T cells served as negative control. T cells were pre-gated as CD14– Vδ2–
CD158b– CD3+ cells.
2013).
4.3.1 Expression of HLA class I-restricted, HCMV-specific TCRs on T cells
Before evaluating the efficacy of TCR-transgenic T cell lines in recognising HCMV-infected tar-
get cells, the expression of HCMV-specific TCR genes on the cell surface was assessed by FACS
analysis four to seven days after transduction. Different levels of TCR expression were detec-
ted depending on the individual TCR (e.g. one CRV-specific TCR in comparison with another
CRV-specific TCR), but also depending on (I) co-expression of CD8 on TCR-transgenic T cells
(e.g. CD4+ vs. CD8+ T cells), (II) the T cell subpopulation that received the TCR genes (αβ
vs. δ2 T cells), and (III) the applied staining method (HLA multimer vs. Vβ-specific antibody).
Exemplary data of these observations are provided for the three TCRs CRV1, CRV2 and YSE
below.
Focussing on bulk PBMCs transduced with one of the two TCRs CRV1 or CRV2 after stimula-
tion by anti-CD3 antibody, CRV1 was functionally expressed by 6.1% of CD14– Vδ2– CD158b–
CD3+ (presumably αβ) T cells (as assessed by CRV streptamers, fig. 4.11, 1st column). Interest-
ingly, the large majority of all CRV streptamer+ T cells also expressed CD8 after transduction
with a CRV1-encoding retrovirus. The proportion of CRV streptamer+ CD8– T cells was low,
as was the intensity of CRV streptamer staining of this subpopulation. In contrast, the TCRβ
chain of the CRV1 TCR was strongly expressed by a considerable fraction of CD8– T cells, as
revealed by counter-staining with a Vβ11-specific antibody. Taken together, this implies that
the co-expression of CD8 in TCR-transgenic T cells enhances the binding of CRV1 TCR to
peptide/HLA complexes. Consequently, this property of CRV1 may affect TCR functionality
in CD8– T cells, such as recognising HCMV-infected cells (see section 4.3.2). The discrepancy
between streptamer and Vβ11 staining may be caused by mis-pairing of TCR chains in αβ T
cells, since both TCR chains of CRV1 are completely human and can therefore form mixed TCR
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Figure 4.12. Expression of YSE TCR by T cells four days after transduction. Bulk PBMCs
from donor 1223 were stimulated with anti-CD3 antibody or PAM before transduction.
Stainings with YSE pentamer (top row) and Vβ1 (bottom row) against CD8 are shown as
pseudocolour dot plots. Mock-transduced (using retroviruses devoid of genetic cargo) T
cells served as negative control. Cells were pre-gated as CD14–.
dimers together with the endogenous TCR chains of αβ T cells as reported by van Loenen et al.
(2010). When the constant region of both TCR chains of CRV1 was exchanged with the respect-
ive murine (“mu”) constant regions (a process called “murinisation”), this TCR (i.e. CRV1mu)
still relied on CD8 co-receptor for successful streptamer binding, but the difference between CRV
streptamer+ and Vβ11+ proportions became less pronounced (fig. 4.11, 2nd column), possibly
indicating less TCR mis-pairing. Despite the murinisation that should facilitate preferential TCR
binding, the large majority of CRV streptamer+ T cells expressed CD8.
In contrast to CRV1, CRV2 could be stained by CRV streptamers on 50.9% of T cells with
comparable proportions of CD8+ and CD8– cells carrying the TCR (fig. 4.11, 3rd column). Ap-
parently, CRV2 does not depend on CD8 for binding of peptide/HLA complexes. Nevertheless,
CRV steptamer+ CD8+ T cells showed a more intense staining than their CD8– counterparts,
which may be contributed to additional binding avidity provided by CD8 (also see MFIs of
CRV streptamer+ T cells in another experiment, fig. 4.14). Comparing CRV streptamer and
Vβ stainings, as done for CRV1, was not possible for CRV2 because no commercial antibody
specific for Vβ6 was available. Murinisation of CRV2 did not boost TCR expression, neither on
CD8+, nor on CD8– T cells (fig. 4.11, 4th column). Thus, only TCRs that are weakly expressed
and may suffer from TCR mis-pairing and/or TCR competition in αβ T cells (such as CRV1)
appear to benefit from murinisation. Similar results were obtained using PBMCs from another
donor (0102). Consequently, the disadvantage of introducing foreign peptide sequences into the
TCRs constructs, which ultimately could cause rejection of TCR-engineered T cells after adopt-
ive transfer, outweighs the potential gain in TCR expression by murinisation.
HLA class I-restricted TCRs, such as YSE and CRV2, could be successfully expressed on both
Vδ2– T cells, which likely contain a large majority of αβ T cells, and Vδ2+ T cells (fig. 4.15).





Figure 4.13. Effect of different immunomagnetic sorting on expression of YSE TCR prior to stimulation and retroviral transduction. αβ T
cell-depleted, bulk or δ2 T cell-depleted PBMCs from donor 1107 had been stimulated with PAM and were transduced by retroviruses that either
delivered the genes of YSE TCR or no genetic cargo (“mock”). For comparison, δ2 T cell-depleted PBMCs had been stimulated with anti-CD3
antibody and were transduced likewise. TCR expression was assessed on day 7 by YSE pentamers. Pseudocolour dot plots show the expression of
CD3 and Vδ2 on CD14– CD19– cells (top row). Expression of YSE TCR was analysed by pentamer staining on CD14– CD19– Vδ2+ T cells (centre
row) and CD14– CD19– Vδ2– T cells (bottom row) and is displayed together with expression of CD8. MFI of CRV streptamer+ populations are




















Figure 4.14. Effect of different immunomagnetic sorting on expression of CRV2 TCR prior to stimulation and retroviral transduction. αβ T
cell-depleted, bulk or δ2 T cell-depleted PBMCs from donor 1107 had been stimulated with PAM and were transduced by retroviruses that either
delivered the genes of CRV2 TCR or no genetic cargo (“mock”). For comparison, δ2 T cell-depleted PBMCs had been stimulated with anti-CD3
antibody and were transduced likewise. TCR expression was assessed on day 7 by CRV streptamers. NK cells that may bind to CRV streptamers
via CD158b, although they have not been transduced, were excluded by gating on CD158b– cells. Pseudocolour dot plots show the expression of
CD3 and Vδ2 on CD14– CD19– cells (top row). Expression of CRV2 TCR was analysed by streptamer staining on CD14– CD19– Vδ2+ T cells
(centre row) and CD14– CD19– Vδ2– T cells (bottom row) and is displayed together with expression of CD8. MFI of CRV streptamer+ populations
are displayed in red (“n/a” = not applicable).
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Figure 4.15. Effect of different immunomagnetic sorting and different stimulation on the
expression of transgenic TCRs YSE (A) and CRV2 (B). αβ T cell-depleted, bulk
or δ2 T cell-depleted PBMCs from donor 1107 had been stimulated with PAM and were
transduced by retroviruses that either delivered the genes of YSE TCR, CRV2 TCR or no
genetic cargo (“mock”). For comparison, δ2 T cell-depleted PBMCs had been stimulated
with anti-CD3 antibody and were transduced likewise. On day 10, YSE-transgenic T cell
lines were restimulated with an HLA-A*01:01-matched mini-LCL endogenously express-
ing pp65 (donor 0112) and CRV-transgenic T cell lines were restimulated with an HLA-
C*07:02-matched mini-LCL endogenously expressing IE-1 (donor 1021). TCR expression
was assessed on days 7 and 15 by YSE pentamers or CRV streptamers, respectively (see
fig. 4.13 & 4.14 for pseudocolour dot plots from day 7). NK cells that may bind to CRV
streptamers via CD158b, although they have not been transduced, were excluded by gating
on CD158b– cells. Proportions of CD3+ T cells that expressed the transgenic TCR among
Vδ2– CD4– CD8+ (bright blue), Vδ2– CD4+ CD8– (dark blue), Vδ2– CD4– CD8– (pink)
and Vδ2+ (orange) cells were normalised to total CD14– CD19– cells.
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Vδ2+ T cells (61.0% of CD4+ Vδ2– and 60.9% of CD8+ Vδ2– vs. 20.6% of Vδ2+ T cells were
CRV streptamer+, fig. 4.14), whereas the opposite held true for YSE (28.3% of CD4+ and 15.9%
of CD8+ Vδ2– vs. 40.2% of Vδ2+ T cells, fig. 4.13). This behaviour was observed in another
donor each (1613 and 1223, respectively, data not shown). These data may indicate that CRV2
is not or less affected by TCR mis-pairing, as more CD4+ Vδ2– T cells express functional CRV2
TCRs than Vδ2+ T cells, the latter of which will not form mixed TCR dimers. If CRV2 would
be subjected to TCR mis-pairing in αβ T cells, one would expect this ratio to be inverted. A
staining with an anti-Vβ6 antibody could not be performed for CRV2 because no suitable anti-
body is commercially available, as noted before. For YSE TCR, stainings of the same cells using
an anti-Vβ1 antibody have not been performed either, but in an independent experiment CD3-
stimulated or PAM-stimulated bulk PBMCs of donor 1223 were transduced with YSE TCR and
stained by both YSE pentamer and Vβ1 antibody (fig. 4.12): among CD3-stimulated PBMCs,
CD4+ and CD8+ Vδ2– T cells showed less YSE pentamer+ than Vβ1+ proportions, whereas the
proportion of YSE pentamer+ Vδ2+ T cells was higher than the one of Vβ1+ Vδ2+ T cells in
PAM-stimulated bulk PBMCs. In both experiments described above, markedly more Vδ2+ T
cells could be stained with the YSE pentamer than Vδ2– T cells. Thus, the expression of YSE
TCR may be dampened by TCR mis-pairing in αβ T cells.
Importantly, HLA class I-restricted αβ TCRs are not generally better expressed in CD8+ Vδ2–
T cells than in CD8– Vδ2– T cells or CD8– Vδ2+ T cells, as shown for YSE and CRV2 TCRs
above (fig. 4.13 & 4.14, respectively). Another reason for the low degree of dependence on
co-expression of CD8 could be that these TCRs are quite strong TCRs concerning their compet-
itiveness for CD3 proteins. Indeed, transgenic αβ TCRs seemed to suppress the endogenous TCR
of δ2 T cells. This TCR competition was especially pronounced for CRV2, but also observed
with YSE TCR (fig. 4.15).
Although depletion of αβ TCR+ cells typically reduced their frequency to 0.1% in the negative
fraction (fig. 4.19), almost 10% of CD3+ Vδ2– cells were found four days after mock-transduction
(fig. 4.13 & 4.14). This fraction could have been formed by other γδ T cells, such as δ1 T cells,
or by reappearing αβ T cells that escaped depletion during immunomagnetic separation because
they may not have expressed αβ TCRs at the time due to transient TCR down-regulation after
activation. On the other hand, these cells with a CD3+ Vδ2– phenotype may in fact be δ2 T
cells that transiently down-regulated γδ TCRs as a result of stimulation by PAM. Arguing in
favour of the latter, transduction of αβ TCR-depleted and PAM-stimulated PBMC cultures with
a CRV2-encoding retrovirus further increased a fraction of the same phenotype to 29.6% CD3+
Vδ2– cells. The majority of these cells was CD4– and CD8–, but CRV streptamer+ (fig. 4.14).
This confirmed that (I) αβ T cell depletion was efficient (see section 4.4.1) and αβ T cells did not
reappear in large numbers afterwards because most of them would strongly express either CD4
or CD8 (compared with low expression of CD4 or CD8 on a minority of δ2 T cells; exemplary
stainings see fig. 4.23 and fig. 4.14, respectively), and that (II) transgenic expression of some αβ
TCRs, such as CRV2, suppresses the endogenous γδ TCR thus converting δ2 T cells to CD3+
Vδ2– cells (fig. 4.14).
In summary, the data shown above demonstrates that HCMV-specific, HLA class I-restricted
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TCRs can be functionally expressed on both αβ and δ2 T cells, but the proportion of TCR-
transgenic T cells and the intensity of TCR expression varies depending on the individual TCR
that was transduced. Some TCRs (e.g. CRV2) are strongly expressed also in the absence of
CD8 co-receptor, while others seem to rely on expression of the latter (e.g. CRV1, fig. 4.11).
Murinisation can boost the expression of a “weak” TCR, such as CRV1, on CD8– T cells, but
does not improve expression of a “strong” TCR, such as CRV2 (fig. 4.11). While some αβ TCRs
did co-exist with Vγ9Vδ2 TCRs, others suppressed expression of γδ TCRs on the cell surface
of δ2 T cells (fig. 4.15). Due to the high efficiency of αβ T cell depletion by immunomagnetic
sorting (see section 4.4.1) and the competition of TCRs in δ2 T cells, CD3+ Vδ2– cells of αβ
TCR-depleted PBMCs likely were δ2 T cells nonetheless.
4.3.2 Recognition of HCMV-infected fibroblasts by TCR-transgenic T cells via
HLA-C*07:02
HCMV aims to deceive and escape the immune system by different mechanisms. One of them
targets the presentation of viral peptides by HLA complexes. Several proteins encoded in the
US2-11 region of the HCMV genome interfere with antigen presentation on HLA class I (Ahn
et al., 1997; Jones and Sun, 1997; Jones et al., 1996; Wiertz et al., 1996). Consequently, infected
host cells present fewer HLA molecules loaded with viral peptides. While several T cell clones
restricted by HLA-A or -B molecules were shown to suffer from the effects of these immunoevasins
on presentation of viral peptides, T cell clones that were restricted by HLA-C*07:02 were able
to recognise HCMV-infected fibroblasts despite the actions of the immunoevasins (Ameres et al.,
2013). Thus, HLA-C*07:02 may be considered an immunoprivileged restriction for HCMV-
specific T cells. This observation combined with the relative high allele frequency of HLA-C*07:02
across different human populations (e.g. 13.7% in Caucasians, Gragert et al., 2013, also see tab.
5.1), makes TCRs restricted by HLA-C*07:02 an interesting tool for adoptive T cell therapy
of HCMV. In total, genes of nine TCRs specific for two different viral epitopes presented by
HLA-C*07:02 were isolated and prepared for retroviral transfer, four TCRs specific for epitope
CRV from IE-1 and five TCRs specific for epitope FRC from UL28 (tab. 4.2).
4.3.2.1 Recognition of HCMV-infected fibroblasts mediated by CRV (IE-1309-317)-specific
TCRs
The successful gene transfer and subsequent expression of HCMV-specific TCRs in αβ and δ2 T
cells was shown in the previous section. Now, their capability of mediating the recognition of
HCMV-infected target cells was tested. For HLA-C*07:02-restricted TCRs, HLA-matched MRC-
5 fibroblasts were chosen as targets. By pre-treating the fibroblasts with IFN-γ for 72 hours before
infection, their HLA expression was enhanced (Ameres et al., 2014), thus reinforcing T cell recog-
nition (Ameres et al., 2013). 48 hours after infection with different HCMV strains, the MRC-5
fibroblasts were co-incubated with HCMV-specific T cell clones or TCR-transgenic T cell lines for
16–21 hours. Fibroblasts were infected with one of two wild type (WT) strains of HCMV, namely
AD169 and Merlin, or the genetically modified virus strain CMV-Δall, which is derived from
AD169 but lacks the four immunoevasins US2, US3, US6 and US11 (Besold et al., 2009, originally
named RV-KB6). Mock-infected or peptide-pulsed target cells were used as negative or positive
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controls, respectively. αβ T cells from PBMC donors 0112 and 1107 that had been transduced
with different TCRs recognising the same epitope (CRV1-CRV4, specific for IE-1309-317, tab. 4.2)
secreted high levels of IFN-γ in response to MRC-5 fibroblasts if these were loaded with CRV
peptide or infected with CMV-Δall (10,000 pg/ml, fig. 4.16 B). In contrast, mock-transduced
αβ T cell lines from both donors released only little IFN-γ (<800 pg/ml), when incubated with
the same target cells. Generally, fibroblasts that had not been infected or loaded with CRV pep-
tide elicited low IFN-γ levels irrespective of effector cell type (<900 pg/ml). After encountering
fibroblasts infected with one of the two WT strains AD169 or Merlin, the TCR-transgenic αβ
T cell lines secreted moderate IFN-γ levels (<1,800 pg/ml), which surmounted IFN-γ levels of
respective negative controls by no more than a factor of five. The two CRV-specific T cell clones
1010M #7 and F46M #36, however, did not only strongly recognise MRC-5 fibroblasts loaded
with CRV peptide or infected with CMV-Δall (>28,000 pg/ml), but also secreted high levels
of IFN-γ if fibroblasts had been infected with AD169 or Merlin (9,500–17,000 pg/ml, fig. 4.16
B). Intriguingly, the T cell clone F46M #36, from which the TCR CRV3 was derived, evoked a
distinct response towards AD169- or Merlin-infected fibroblasts, while αβ T cell lines expressing
CRV3 failed to do so. Although both effector cell types express the same TCR and at least
partly provide CD8 co-receptor, TCR-transgenic T cell lines cannot mimic the antiviral effector
function of the T cell clone. It seems that the presence of the four immunoevasins US2, US3,
US6 and US11 in AD169 does not impair the two HLA-C*07:02-restricted CRV-specific T cell
clones F46M #36 or 1010M #7, but prevents recognition of HCMV infection in fibroblasts by
T cell lines expressing CRV-specific TCRs. Moreover, TCR-transgenic αβ T cells showed the
same power in recognising fibroblasts infected with CMV-Δall than T cell clones did. These ob-
servations were confirmed in two other independent experiments involving T cell clones 1010M
#7 and F46M #36, as well as TCR-transgenic T cell lines derived from PBMCs of donors 0102,
1107 and 1613 (data not shown). Thus, other reasons likely are responsible for this functional
impairment of TCR-transgenic T cells.
In all the TCR constructs used in these experiments (except for CRV2α & CRV2β, tab. 2.8),
the TCRα and TCRβ chains were encoded by a single gene, separated by a P2A element. After
translation, 21 amino acids remain attached to the C terminus of the TCRβ chain and a single
proline is attached to the N terminus of the TCRα chain (Donnelly et al., 2001, also see section
3.2.3). Therefore, it was tested whether the remaining P2A amino acid sequences negatively
affected TCR pairing or signalling. For this purpose, TCRα and TCRβ chains of CRV2 were
delivered by separate retroviruses into the same T cells refraining from use of P2A (CRV2α &
CRV2β), which ensured that no additional amino acids were attached to the TCR chains, and
that their amino acid sequence was exactly identical to their native sequence in the parental T
cells. Furthermore, the effect of preferential TCR pairing was studied by employing a murinised
variant of CRV2 (CRV2mu). In both cases, the TCR-transgenic αβ T cells recognised MRC-5
fibroblasts loaded with CRV peptide or infected with CMV-Δall to the same extent than TCR-
transgenic αβ T cells that had been transduced with a retrovirus coding for the fully human
CRV2β–P2A–CRV2α bicistronic TCR construct (CRV2, fig. 4.16 B). Neither CRV2mu nor the
combination of CRV2α and CRV2β, however, could reconstitute the sensitivity for fibroblasts
infected with one of the two WT strains AD169 or Merlin.
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Figure 4.16. Expression of CRV TCRs by αβ T cells and their recognition of HCMV-infected
MRC-5 fibroblasts. αβ TCR-enriched fractions from PBMCs of healthy donors 0112 (I)
and 1107 (II) had been stimulated with anti-CD3 antibody and were transduced with
different TCRs specific for CRV (IE309-317, tab. 4.2). TCR-transgenic T cell lines were
restimulated by autologous IE-1-expressing mini-LCLs on day 12. A: Expression of CRV-
specific TCRs was assessed by CRV streptamers on day 11 and 18. Proportions of CRV
streptamer+ cells among CD8– and CD8+ αβ T cells, both of which were pre-gated as
CD14– CD19– CD3+ Vδ2– cells, are shown for all transduced cell lines from donors 0112
and 1107.
(continued on next page)
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Figure 4.16. (continued from previous page)
B: On day 14, MRC-5 fibroblasts were pre-treated with 300 U/ml IFN-γ for 72 hours. On
day 17, they were infected with HCMV strain AD169 (blue bars), Merlin (purple bars)
or CMV-Δall (brown bars) at an MOI of 5 for another 48 hours in the absence of IFN-
γ. Non-infected target cells were either loaded with CRV peptide (white bars) or left
untreated (black bars) to serve as positive or negative controls, respectively. On day 19,
TCR-transgenic T cell lines or CRV-specific T cell clones were co-incubated overnight with
target cells at an e:t ratio of 20,000:10,000 or 10,000:10,000, respectively. The graph shows
the concentration of secreted IFN-γ in the supernatant as evaluated by ELISA. The mean
and standard deviation of triplicate samples are shown.
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In summary, each TCR specific for the epitope CRV (IE-1309-317) enabled the TCR-transgenic
T cells to recognise HCMV-infected MRC-5 fibroblasts (fig. 4.16 B). Although, the proportions of
T cells expressing a functional CRV TCR varied from less than 5% to more than 40% depending
on the T cell subset (CD8+ or CD8–) and the individual CRV-specific TCR (fig. 4.16 A), similar
levels of IFN-γ were found to be secreted by these TCR-transgenic T cell lines in response to
fibroblasts loaded with CRV peptide or infected with CMV-Δall (fig. 4.16 B). At the same time,
none of the TCRs mediated unspecific reactivity. Thus, all CRV-specific TCRs are functional
and specific for the epitope CRV. However, none of the TCRs was able to confer the same sens-
itivity for AD169-infected fibroblasts that was observed for CRV-specific T cell clones (Ameres,
2012, and data presented in this study) to transgenic T cells. This deficiency was unexpected but
consistent for several independent experiments and for PBMCs derived from four different donors.
One of the plausible explanations of this unexpected effect could be found in the proportions
of TCR-expressing T cells. While all cells of a T cell clone express the CRV-specific TCR, rarely
more than 50% of the cells of TCR-transgenic T cell lines were found to express the transgenic
TCR a few days after retroviral transduction. Moreover, the intensity of TCR expression may
influence the sensitivity of the T cells, which may be key in binding to a limited amount of viral
peptides presented on HLA molecules, especially if target cells are infected with a virus strain
that expresses all immunoevasins. The CRV-specific T cell clones 1010M #7 (expressing an inde-
pendent TCR) and F46M #36 (the source of the TCR CRV3), as well as TCR-transgenic T cell
lines from donor 1107 expressing either CRV2 or CRV3 were stained with CRV steptamers and
analysed by flow cytometry. The fraction of CRV streptamer+ cells was larger for both T cell
clones (≥99%) than for TCR-transgenic T cell lines that had been restimulated with autologous,
IE-1-expressing mini-LCLs once, but nonetheless the fraction of streptamer+ cells in these trans-
genic T cell lines was quite high (85.2% of CRV2-transduced and 54.8% of CRV3-transduced
CD3+ Vδ2– T cells, fig. 4.17). The intensity of TCR expression by a CRV2-transgenic T cell
line (6,372 AU of CD14– CD19– CD158b– cells, fig. 4.17) was comparable to T cell clone F46M
#36 (7,935 AU) as judged by mean fluorescence intensity (MFI) from CRV streptamer stainings.
The T cell clone 1010M #7 showed a more intense TCR expression (21,809 AU), whereas the
CRV3-transgenic T cell line showed a less intense TCR expression (1,989 AU). Further narrowing
the focus on CD3+ Vδ2– CD8+ CRV streptamer+ T cells, revealed that the CRV2-transgenic
T cell line (10,008 AU) even outperformed the T cell clone F46M #36 (8,209 AU) concerning
intensity of TCR expression. Similar data were obtained for CRV2mu-transgenic T cell lines in
the same experiment (fig. 4.17).
The proportions of TCR-transgenic αβ T cells depicted in figure 4.16 A are substantially lower
than those from this comparative analysis (fig. 4.17). Nevertheless, when TCR-transgenic bulk T
cells were tested on HCMV-infected MRC-5 fibroblasts in the same manner than TCR-transgenic
αβ T cells (fig. 4.16 B), the resulting IFN-γ patterns were almost identical (data not shown),
confirming previous observations. The intensity of TCR expression on T cell clone F46M #36
was comparable to CRV2- or CRV2mu-transgenic T cells and the CRV streptamer+ proportions
of CRV2- or CRV2mu-transgenic T cell lines were only reduced by 14% or 18% in comparison
to F46M #36, respectively (fig. 4.17). Thus, other factors than TCR expression may be more
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Figure 4.17. Peptide/HLA streptamer staining of CRV-specific αβ T cell clones or TCR-
transgenic T cells transduced with a CRV-specific TCR. Bulk PBMCs from donor
1107 had been stimulated with anti-CD3 antibody and were transduced with one of the
three TCRs CRV2, CRV2mu or CRV3 or with CD8 as a control transgene. Transduced
PBMCs were restimulated with autologous, IE-1-expressing mini-LCLs on day 10. Six
days later, T cell clones F46M #36 and 1010M #7 were thawed, stained with CRV strep-
tamers and analysed by FACS simultaneously with the transduced T cell lines. Top row:
Expression of CD3 and Vδ2 TCR chain among CD14– CD19– CD158b– cells. MFI of
CRV streptamer staining is displayed in red for all cells on top of the graph. Bottom row:
Staining of CRV-specific TCR and CD8 of CD3+ Vδ2– T cells derived from CD14– CD19–
CD158b– cells. MFI of CRV streptamer is shown in red for CD8– and CD8+ subpopulations
within the respective gate.
important in overcoming the lack of sensitivity of TCR-transgenic T cells towards infection with
AD169.
4.3.2.2 Recognition of HCMV-infected fibroblasts mediated by FRC (UL28327-335)-specific
TCRs
Five more TCRs restricted by HLA-C*07:02, but specific for a different epitope, namely FRC
(UL28327-335), were transferred into T cells after CD3 stimulation of bulk PBMCs and evaluated
similarly (FRC1, FRC6, FRC32, FRC86 & FRC93, see tab. 4.2). FRC1, FRC6, FRC32 and
FRC93, but not FRC86, could be stained by FRC streptamers on TCR-transgenic T cells (fig.
4.18 A), indicating that four out of five TCRs were functionally expressed. FRC86’s TCRβ chain
could be stained with an anti-Vβ13.2 antibody to a similar extent than Vβ2 of FRC1 or Vβ3
of FRC6, FRC32 and FRC93 (fig. 4.18 A), indicating that transduction efficiency and TCRβ
chain integrity were not corrupted. The sequence of FRC86’s TCRα chain was reanalysed in
order to find explanations for its potential lack of expression. It was found that the cloned and
transduced version of FRC86’s TCRα sequence differed from all available reference sequences of
IMGT for TRAV13-2*01 (Scaviner and Lefranc, 2000b) in nucleotide positions (nt pos.) 43 and
68 resulting in amino acid exchanges at positions 15 and 23, respectively, of the full-length TCRα
protein.
The Vα8 (= TRAV13) primer that was used until that time as one of the 34 Vα primers to
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amplify fragments of TCRα cDNA by PCR (see section 3.2.2) contained an error: it harboured
a guanosine (G) at nt pos. 12 of the primer’s sequence (see tab. 2.9), but all TRAV13 alleles, for
which the primer was designed, harbour a cytidine (C) at the corresponding nt pos. 43 (Scaviner
and Lefranc, 2000b). Thus, amplification of the TCRα cDNA by PCR using the erroneous Vα8
primer had turned nucleotide C43 into G43 thereby turning amino acid L15 into V15, which lies
within the leader peptide. This exchange potentially affected the function of the leader peptide.
It is unlikely, however, that this exchange affected the leader peptide’s cleavage because the
cleavage site is positioned at some distance downstream between amino acid 21 and 22, and the
recognition motif of the signal peptidase (Hiller et al., 2004) was probably not affected. The
erroneous primer has long been in use in this (Schub, 2010) and collaborating research groups
(Schuster, 2008) and apparently the error was not noticed before. This may serve as a reminder
to be vigilant regarding such types of errors. At the time of in silico assembly of TCR constructs
and commercial gene synthesis, this error went unnoticed and was thus incorporated in the cloned
TCRα chain of FRC86. In order to avoid introduction of sequence errors in PCRs for TRAV13-1
or TRAV13-2 in the future, the Vα8 primer was corrected and re-synthesised (“Vα8corr”).
The other difference between IMGT’s reference sequences and the TCRα amplicon of FRC86 was
an adenosine (A) at nt pos. 68 instead of a G, as found in the reference sequences of TRAV13-2*01
and TRAV13-2*02 (Scaviner and Lefranc, 2000b). The TCRα cDNA of T cell clone XLBC18
#86 was amplified again using the same Cα-specific primer 3’T-Cα, but a different Vα-specific
primer (TRAV13-2, tab. 2.10) that binds more upstream (closer to the 5’ end) than the primer
Vα8 does. Sequencing of this amplicon confirmed that the unexpected nucleotide A68 was present
in the original TCRα chain of the parental T cell clone. Thus, this T cell clone harbours an allele
of TRAV13-2 that has not been previously described and that results in an Asn-to-Ser exchange
at amino acid position 23. Unfortunately, when the TCR was assembled in silico, the nucleotide
A68 was replaced by mistake with G68 as present in standard sequence. Consequently, amino acid
N23 may have hindered successful TCR pairing. Although the function of FRC86 likely could
have been restored by correcting both mistakes, the sequence of the TCRα chain of FRC86 was
not corrected and FRC86’s use was discontinued.
Of the remaining four FRC-specific TCRs FRC1, FRC6, FRC32 and FRC93, each TCR medi-
ated a strong release of IFN-γ by TCR-transgenic T cells in response to MRC-5 fibroblasts that
had been infected with CMV-Δall (4,300–6,000 pg/ml, fig. 4.18 B). None of the TCRs, however,
was able to drive a noteworthy IFN-γ secretion by TCR-transgenic T cells after encountering
AD169-infected MRC-5 fibroblasts (<80 pg/ml). As expected, non-infected fibroblasts were not
recognised (<20 pg/ml), whereas FRC peptide-pulsed fibroblasts also caused a marked IFN-γ se-
cretion by TCR-transgenic T cells (1,300–2,200 pg/ml). Fibroblasts that were infected with the
HCMV strain TB40-BAC4 evoked intermediate IFN-γ levels by TCR-transgenic T cells (600–
1,600 pg/ml). No FRC-specific T cell clones were available for comparison with TCR-transgenic
T cells.
Like CRV-specific TCRs, FRC-specific TCRs also failed to confer sensitivity for AD169-infected
fibroblasts to TCR-transgenic T cells. After testing 8 different HLA-C*07:02-restricted TCRs
that responded perfectly well to CMV-Δall-infected and peptide-loaded fibroblasts, it is very
unlikely that this deficiency is caused by errors contained in some of the TCR sequences. Ul-
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Figure 4.18. Expression of FRC-specific TCRs by T cells and their conveyed recognition
of HCMV-infected MRC-5 fibroblasts. Bulk PBMCs from healthy donor 1107 had
been stimulated with anti-CD3 antibody and were transduced with different retroviruses
delivering genes of an FRC-specific TCR (UL28327-335, tab. 4.2), GFP or no genetic cargo
(“mock”). Transduced T cell lines were restimulated by autologous peptide-loaded mini-
LCLs on day 11 and expression of FRC-specific TCRs was assessed by FRC streptamers
and Vβ-specific antibodies on day 16. A: Pseudocolour dot plots show the proportions of
CRV streptamer+ (top row) or Vβ+ (other rows) cells among CD8– and CD8+ T cells,
both of which were pre-gated as CD14– CD19– CD3+ Vδ2– cells. B: On day 13, MRC-
5 fibroblasts were pre-treated with 300 U/ml IFN-γ for 72 hours. On day 16, they were
infected with HCMV strain AD169 (blue bars), TB40-BAC4 (green bars) or CMV-Δall
(brown bars) at an MOI of 5 for another 48 hours in the absence of IFN-γ. Non-infected
target cells were either loaded with FRC peptide (white bars) or left untreated (black bars)
to serve as positive or negative controls, respectively. GFP- or mock-transduced T cell lines
were used as control effector cells to monitor unspecific activation through allogeneic T cell
stimulation. On day 18, transgenic T cell lines were co-incubated overnight with target
cells at an e:t ratio of 20,000:10,000. The graph shows the concentration of secreted IFN-γ




timately, the reason for this deficiency may lie in the nature of the effector cells that host the
HCMV-specific TCR or their composition, but not the TCR sequences or their expression pro-
files.
4.3.2.3 Reasons for different sensitivity of HLA-C*07:02-restricted T cell clones and
TCR-transgenic T cells towards infection with AD169
T cell clones were expanded from single cells and thereby free of other cell types that are usually
contained in PBMCs. TCR-transgenic T cells, however, may encompass several other cell types
that could interfere with the detection of HCMV-infected target cells by HCMV-specific T cells
and subsequent antiviral actions. After immunomagnetic sorting or prolonged in vitro propaga-
tion, T cell lines that had been stimulated with anti-CD3 antibody prior to transduction were
usually devoid of most other cell types, such as CD14+ monocytes, CD19+ B cells, CD158b+ NK
cells (each population <1% for all TCR-transgenic T cell lines shown in fig. 4.17 for example,
data not shown). Regulatory T (Treg) cells, on the other hand, may be conserved even through-
out prolonged in vitro cultivation. During co-cultivation with HCMV-infected fibroblasts they
may prevent antiviral effector functions. The amount of secreted IL-10 in the supernatant of
CRV1- or CRV2-transgenic T cells from CD3-stimulated, bulk PBMCs of donors 0102 and 1107
co-incubated with HCMV-infected MRC-5 fibroblasts, however, was generally low (≤110 pg/ml)
and mock-transduced T cells produced similar levels of IL-10 (<65 pg/ml).
In order to evaluate the IFN-γ secretion by CD8+ T cells alone, the same TCR-transgenic T cell
lines, as well as an FRC1- and an FRC6-transgenic T cell line from CD3-stimulated, bulk PBMCs
of donor 1107 were subjected to immunomagnetic sorting of CD8+ cells. After sorting, all cell
lines contained less than 0.7% CD14+ or CD19+ T cells and less than 3.8% CD4+ T cells. In
spite of distinct IFN-γ secretion in response to CMV-Δall-infected fibroblasts, TCR-transgenic
CD8+ T cells did not recognise AD169-infected fibroblasts any stronger than previously observed
(data not shown). Thus, Treg cells are unlikely to interfere with the recognition of infection by
HCMV stain AD169.
If not by other cells contained in the TCR-transgenic T cell lines, the deficiency must be caused
by something within the T cell subsets themselves. Since inhibitory effects of Treg cells can be
largely excluded, the differentiation status of T cell clones and TCR-transgenic T cell lines was
analysed. As previously, αβ T cells were grouped into naïve (N = CCR7+ CD45RA+), central
memory (CM = CCR7+ CD45RA–), effector memory (EM = CCR7– CD45RA–) and effector
memory re-expressing CD45RA (EMRA = CCR7– CD45RA+) subpopulations according to their
differentiation status (N → CM → EM → EMRA, from early to late). Both CRV-specific T cell
clones F46M #36 and 1010M #7 were almost exclusively comprised of TEM cells (≥97.3%), which
is the expected phenotype for long-term T cell lines and clones. In contrast, CRV2-, CRV2mu- or
CRV3-transgenic T cell lines that were derived from CD3-stimulated, bulk PBMCs (see fig. 4.17)
encompassed only 74.1%, 72.6% or 77.6% CD3+ CD8+ CD14– CD19– TEM cells, respectively.
Their second largest subset was that of TCM cells accounting for 20.0%, 18.1% or 14.6% of CD3+
CD8+ CD14– CD19– T cells, respectively. Very similar subset distributions were observed for
CD4+ T cells. Since TCM cell can replenish the pool of TEM (Sallusto et al., 2004), the analysed
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TCR-transgenic T cells are likely not at a disadvantage concerning their differentiation status in
comparison to the two CRV-specific T cell clones.
Several HLA-specific activating and inhibitory receptors are expressed on NK cells, but may also
be expressed on subsets of T cells. These receptors may co-modulate T cell recognition and may
be expressed at different levels on T cell clones in comparison to TCR-transgenic T cell lines.
Relevant receptors include killer cell immunoglobulin-like receptors (KIRs), like KIR2DL2/L3
(CD158b), and killer lectin-like receptors (KLRs), like NKG2A and NKG2D. The inhibitory re-
ceptors KIR2DL2 and KIR2DL3 bind HLA-C group 1 (C1) molecules that harbour an asparagine
at position 80 (Mandelboim et al., 1996), such as HLA-C*07 alleles. When analysed by FACS,
less than 0.3% of the cells of CRV-specific T cell clone 1010M #7 and less than 0.1% of the cells
of CRV2-, CRV2mu- or CRV3-transgenic T cell lines derived from CD3-stimulated, bulk PBMCs
(pre-gated as CD3+ CD8+ CD14– CD19– T cells, also see fig. 4.17 and above) stained positive
for CD158b. 2.8% of the cells of CRV-specific T cell clone F46M #36 expressed CD158b, but
this did not interfere with recognition of AD169-infected fibroblasts as shown in figure 4.16 B
II. NKG2A is expressed as a heterodimer together with CD94, binds to non-classical HLA class
I molecule HLA-E and transmits an inhibitory signal to prevent cytotoxicity by the NKG2A-
expressing cell (Borrego et al., 1998). NKG2A was expressed by less than 0.1% of the cells of
CRV-specific T cell clones F46M #36 or 1010M #7 and by less than 0.3% of the cells of CRV2-,
CRV2mu- or CRV3-transgenic T cell lines that were derived from CD3-stimulated, bulk PB-
MCs. NKG2D is expressed as a homodimer and binds to the stress-inducible ligands MHC class
I chain-related protein A (MICA), MICB and UL16-binding proteins 1, 2, 3 and 4 (ULBP1-4),
thereby transmitting an activating signal that promotes cytotoxicity by the NKG2D-expressing
cell (Sutherland et al., 2001). The MFI of NKG2D expression on T cell clones F46M #36 and
1010M #7 was 1,003 and 483 AU, respectively. CRV2-, CRV2mu- or CRV3-transgenic T cell lines
showed a similar intensity of NKG2D expression with MFIs of 760, 790 or 950 AU, respectively
(pre-gated as CD3+ CD8+ CD14– CD19– T cells). Thus, NKG2A was not expressed by any
of the T cells and NKG2D’s expression was negligible both on CRV-specific T cell clones and
TCR-transgenic T cell lines.
Taken together, phenotypic analysis could not resolve why both effector cell types behave dif-
ferently in their recognition of AD169-infected fibroblasts though they are both restricted by
HLA-C*07:02 and some even express the same TCR (CRV3 isolated from F46M #36). Con-
sequently, the relative functional deficiency of TCR-transgenic T cell lines equipped with an
HLA-C*07:02-restricted TCR to detect and react to AD169 infection could not be explained so
far and requires further investigation. HLA-C*07:02 remains an interesting restriction to target
in HCMV-specific T cell therapies, since the superiority over other HLA-A and -B alleles was
reported convincingly regarding recognition by naturally occurring HCMV-specific T cells from
the memory repertoire (Ameres et al., 2013).
4.4 Characterisation of HCMV-specific TCRs restricted by HLA class II
The importance of a functional HCMV-specific TH cell response has been reported by many
studies (Gamadia et al., 2003; Lilleri et al., 2008; Rentenaar et al., 2000) and is especially em-
phasised in immunocompromised patients, such as transplant recipients (Gabanti et al., 2014;
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Walter et al., 1995) and HIV+ individuals (Komanduri et al., 1998). HCMV-specific CD4+ TH
cells exert direct antiviral effector functions (Einsele et al., 2002; Jackson et al., 2017) and main-
tain HCMV-specific CD8+ CTL responses (Gabanti et al., 2014; Walter et al., 1995). Due to
the broadly acknowledged importance of HCMV-specific CD4+ TH cells in the control of HCMV
reactivation (Einsele et al., 2002; Gabanti et al., 2014; Gamadia et al., 2003; Sellar and Peggs,
2012; Sester et al., 2001), this study aimed to characterise HLA class II-restricted TCRs that
were isolated from such cells in order to establish them for application in adoptive T cell therapy.
For this purpose, a set of 13 HLA class II-restricted TCRs specific for various epitopes of either
pp65 or IE-1 were studied (tab. 4.2).
4.4.1 Immunomagnetic separation of PBMCs before stimulation with pamidronate and
subsequent TCR transfer
Some αβ T cells were rendered susceptible to retroviral transduction of GFP due to the stimu-
lation of bulk PBMCs with PAM as apparent by the emergence of GFP-expressing CD3+ Vδ2–
T cells (fig. 4.9 D, right graph). This simultaneous, non-intended transduction of αβ T cells
did also occur with TCR-encoding retroviruses (fig. 4.13 & 4.14, see results for bulk PBMCs).
Strikingly, even after experimental depletion of δ2 T cells, PAM stimulation facilitated retroviral
transduction of Vδ2– T cells that were CD4+ or CD8+ (see TCR expression of Vδ2– cells among
Vδ2-depleted PBMCs, fig. 4.15). When TCR-transgenic, unsorted PBMCs, which had been
stimulated with PAM prior to transduction, were restimulated by antigen-expressing mini-LCLs,
both TCR-transgenic αβ and TCR-transgenic δ2 T cells expanded and showed increased expres-
Figure 4.19. Composition of cell populations before and after immunomagnetic separation
of αβ TCR+ T cells. A: Proportion of CD14+ monocytes (top row) among single cells
(after exclusion of duplicates, etc.) and the proportion of αβ TCR+ Vδ2– or αβ TCR– Vδ2+
T cells (bottom row) among CD14– cells from donor 1107 before sorting (left column) or
after sorting, which resulted in an αβ T cell-depleted (centre column) and an αβ T cell-
enriched fraction (right column), are displayed. B: Analysis of the three cell populations in
six different donors (0112, 0506, 1004, 1013, 1107, 1613). The displayed proportions of αβ
TCR+ T cells (blue circles) and Vδ2+ T cells (orange squares) resulted from multiplication
of the frequency of CD14– cells with the frequency of each of the two subsets among CD14–
cells in order to achieve comparability to CD14+ monocytes (black triangles).
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sion of the transgenic TCR (fig. 4.15, see results for bulk PBMCs, day 7 vs. 15).
So bulk PBMCs that had been stimulated with PAM before retroviral transduction of an HCMV-
specific TCR contained TCR-transgenic αβ T cells and TCR-transgenic δ2 T cells. Consequently,
it was difficult to distinguish the contribution of these two subsets to HCMV-specific function.
Thus, αβ T cells were depleted by magnetic activated cell sorting (MACS) with an APC-labelled,
αβ TCR-specific antibody and anti-APC MicroBeads (see section 3.4.1) in order to assess the
potency of TCR-transgenic δ2 T cells in the absence of contribution by TCR-transgenic αβ T
cells. Two fractions were obtained by this procedure: an (αβ TCR-) positive fraction containing
at least 90% αβ T cells (94% αβ T cells among live, single cells on average, evaluated in five
donors) and an (αβ TCR-) negative fraction encompassing the majority of CD14+ monocytes,
γδ T cells (fig. 4.19 A), CD19+ B cells, and NK cells. Before immunomagnetic separation, αβ T
cells predominated bulk PBMCs (50–70 %), but afterwards less than 0.35% αβ T cells could be
detected in the αβ TCR-depleted fraction (median of 0.10% among six donors, fig. 4.19 B).
αβ TCR+ fractions were stimulated with anti-CD3 antibody prior to retroviral transduction to
produce TCR-transgenic αβ T cells. αβ TCR– fractions were treated with PAM before trans-
duction to obtain TCR-transgenic δ2 T cells. While αβ T cells do not require the presence
of additional immune cells to be activated by anti-CD3 antibodies, δ2 T cells rely on cell-cell
interactions with other cells, like monocytes, to be activated by PAM-induced phosphoantigens
(Miyagawa et al., 2001). As expected, CD14+ monocytes were enriched in the αβ TCR– fractions
after αβ T cell depletion (fig. 4.19) providing the basis for specific stimulation of δ2 T cells by
PAM treatment of this fraction.
4.4.2 Expression of HLA class II-restricted, HCMV-specific TCRs on αβ and δ2 T cells
Consistent with the previously established protocol for retroviral transduction (sections 3.5.1
& 4.2), the genes of HLA class II-restricted TCRs were transferred into αβ T cells and δ2 T
cells using the αβ TCR-enriched fraction and the αβ TCR-depleted fraction after immunomag-
netic separation, respectively. The same sorting procedure was used in all experiments described
in sections 4.4.2 and 4.4.5. Despite the presence of other T cells, such as Vδ1 T cells in αβ
TCR-depleted fractions, the T cell lines that were established by PAM stimulation from these
fractions were dominated by δ2 T cells, and therefore will be called “δ2 T cell lines” in the
following. The surface expression of transgenic αβ TCRs was assessed by staining with HLA
tetramers and/or antibodies followed by flow cytometric analysis. Peptide/HLA class II tetra-
mers (section 2.8) were available for TCRs recognising the epitopes QPFM (pp65261-275), YRIQ
(pp65369-387), AGIL (pp65489-503) and EFFT (IE-1213-225, tab. 4.2), all of them restricted by
HLA-DR molecules. The surface expression of all other TCRs on transgenic T cell lines was
more circumstantially assessed by staining with antibodies specific for the Vβ domain of each
TCR (tab. 2.14). The TCRs YRIQ18, YRIQ36, RRKM18 and EFFT50 (tab. 4.2) could not be
stained by any anti-Vβ antibody because no antibody specific for Vβ6 (= TRBV7) was available
for purchase. The expression of these TCRs could be monitored indirectly on δ2 T cells by
staining with an anti-αβ TCR antibody (Clone: IP26, tab. 2.14). Consequently, the expression
of these four TCRs could not be assessed by antibody staining on αβ T cells, since they already
expressed endogenous αβ TCRs. However, the expression of these TCRs could be assessed by
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peptide/HLA class II tetramers, except for RRKM18.
The pp65-specific TCR KYQE16 was never transferred into any T cells within the work
program of this thesis, due to the lack of an available HLA-DQB1*05:01+ PBMC donor from
which moDCs could be derived for testing TCR-transgenic effector T cells. As a result, successful
expression and function of KYQE16 remains to be shown.
As mentioned in section 4.1.2, the putative HLA restriction of the CD4+ T cell clone F46P
#40 MSIY (HLA-DRB1*15:01, Wiesner, 2005) could not be verified using a TCR-transgenic
T cell line. The MSIY/HLA-DRB1*15:01 tetramer failed to stain TCR-transgenic T cell lines
several days after their transduction with a retrovirus that encoded theMSIY40 TCR (data not
shown). This could potentially be due to deficient tetramers or errors within the TCR sequences
of MSIY40 that prevented its expression. However, the latter is not likely because approximately
20% of αβ TCR-depleted PBMCs (i.e. a δ2 T cell line) from donor 1004 that had been transduced
with MSIY40 and CD4 stained positive for αβ TCR and Vβ3, which is the specific V region en-
compassed in MSIY40’s TCRβ chain. Since TCRα and TCRβ chains of MSIY40 are not expected
to pair with TCRγ and TCRδ chains in δ2 T cells, this indicates successful pairing of both chains
of MSIY40 on the surface of transduced cells. Concerning the quality of the tetramer, its manu-
facturer Immunaware had reported sub-optimal folding for MSIY/HLA-DRB1*15:01 monomers
in the delivery notes (60%, see section 2.8). Thus, a deficiency in MSIY/HLA-DRB1*15:01 tet-
ramers is likely to have caused the failure in staining MSIY40-transgenic T cells. This raises the
question whether the putative HLA-restriction DRB1*15:01 is correct (already discussed in sec-
tion 4.1.2) or whether DRB1*15:01 is an allotype that is more difficult to correctly refold in vitro
in the presence of peptide. This would not be too surprising, since production of good-quality
HLA class II tetramers is technically challenging (Braendstrup et al., 2013). As a result, the
efficacy of MSIY40 in recognition of HCMV-infected target cells remains to be elucidated.
Functional expression of MSIY40 was verified indirectly by TCR-transgenic αβ T cells from
donor 0112 that strongly recognised HLA-matched pp65-expressing mini-LCLs from donor F46
(10,000 pg IFN-γ per ml), but produced much less IFN-γ in response to control mini-LCLs from
the same donor (1,000 pg/ml, fig. 4.5). This kind of specific recognition of pp65 was observed
for another set of HLA-matched mini-LCLs (donor F65), further supporting the integrity of
MSIY40’s TCR sequences.
In contrast, the genes of multiple other HCMV-specific, HLA class II-restricted TCRs could be
transferred into αβ as well as δ2 T cells, and expression of the respective TCRs could be detected
on the cell surface. The TCRβ chains of QPFM17, EPDV21, SVMK6 and SVMK27 (tab.
4.2) were similarly well expressed by CD4+ as well as CD4– (mainly CD8+) αβ T cells (fig. 4.20,
2nd column). The proportion of cells expressing the particular TCRβ chain and the intensity of
expression were slightly increased on CD4+ αβ T cells compared with their CD4– counterparts
for all TCRs. Except for EPDV21, each Vβ staining showed a high percentage of αβ T cells
expressing the TCRβ chain of the particular transgenic TCR (fig. 4.20, 2nd column, 32.3–41.5 %
after subtraction of the proportion of Vβ+ cells of respective mock controls, which was in a range
of 0.5% to 5.0%). The comparatively small proportion of anti-Vβ5.2-stained αβ T cells was most
likely not due to inefficient retroviral transduction of EPDV21, since more than 30% of CD14–
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Figure 4.20. Expression of HLA class II-restricted TCRs QPFM17, EPDV21, SVMK6 or
SVMK27 by αβ and δ2 T cells. αβ TCR-enriched (“αβ T cells”) or αβ TCR-depleted
(“δ2 T cells”) PBMCs were stimulated with anti-CD3 antibody or PAM, respectively, before
transduction. Mock-transduced (using retroviruses devoid of genetic cargo) T cells served
as negative control. Six days after transduction, T cell lines were stained with antibodies
specific for CD4, CD14, CD19, αβ TCR, Vδ2 TCR chain and various variable domains of
TCRβ chains and analysed by flow cytometry. All cells were pre-gated as live, CD14– and
CD19–. Representative pseudocolour dot plots from one (0506) out of two donors (the
other being 1613) are shown.
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Figure 4.21. Expression of HLA class II-restricted TCR EIMA236 by αβ and δ2 T cells.
αβ TCR-enriched (“αβ T cells”) or αβ TCR-depleted (“δ2 T cells”) PBMCs were stimu-
lated with anti-CD3 antibody or PAM, respectively, before transduction. Mock-transduced
(using retroviruses devoid of genetic cargo) or CD4-transduced T cells served as negative
control. T cell lines were stained with antibodies specific for CD4, CD14, CD19, αβ TCR,
Vδ2 TCR chain and Vβ21.3 TCR variable domain six days after transduction and ana-
lysed by flow cytometry. All cells were pre-gated as live, CD14– and CD19–. Representat-
ive pseudocolour dot plots from one (1107) out of two donors (the other being 1013) are
shown.
CD19– cells of a δ2 T cell line transduced with the same retroviral vector stained positive for αβ
TCR, while their Vβ5.2 staining intensity was also low, even lower than for TCR-transduced αβ
T cells (fig. 4.20, 3rd vs. 4th column). Due to unknown reasons, the staining with anti-Vβ5.2
antibody repeatedly underestimated expression of Vβ5.2 TCR chain by EPDV21-transgenic T
cells. Probably, the Vβ5.2-specific antibody competes with the αβ TCR-specific antibody for
binding to EPDV21’s TCRβ chain due to steric inhibition and tends to lose this competition.
Subsequent stainings of EPDV21-transgenic δ2 T cells were performed without Vβ5.2-specific
antibody because of the limited quality of staining with this antibody.
Similar to αβ T cells, a large proportion of δ2 T cells expressed the αβ TCRs QPFM17, EPDV21,
SVMK6 or SVMK27 several days after retroviral transduction (25.2–43.4 % αβ TCR+ cells among
CD14– CD19– cells after subtraction of the proportion of αβ TCR+ cells of corresponding parallel
mock controls, fig. 4.20, 3rd column). More than 90% of αβ TCR+ T cells stained positive for the
respective Vβ, except for EPDV21 (fig. 4.20, 4th column) as discussed. In a small fraction of cells
transduced with EPDV21, SVMK6 or SVMK27, αβ TCRs, but not the Vδ2 TCR chain, could
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be stained (3.4, 3.7 or 6.0% of CD14– CD19– cells, respectively, fig. 4.20, 3rd column). Since the
corresponding mock controls had much smaller proportions of such δ2–, αβ+ T cells, it is likely
that the majority of these αβ+ T cells is the transduced cultures that expressed the transgenic
TCRs. As observed with HLA class I-restricted TCRs before (section 4.3.1), the expression of
a transgenic αβ TCR converts a fraction of δ2 T cells into Vδ2– αβ TCR+ T cells. QPFM17,
however, showed at least twice the proportion of Vδ2– αβ TCR+ T cells (12.4%, fig. 4.20, 3rd
column), which indicates that some αβ TCRs, such as QPFM17, more strongly dominate over the
endogenous γδ TCR and markedly reduce surface expression of the latter. Strong competition
has also been observed with some HLA class I-restricted TCRs, such as CRV2 (section 4.3.1). A
similar set of data for QPFM17, EPDV21, SVMK6 and SVMK27 was obtained using transgenic
αβ T cell lines from donor 1613 (data not shown). Unfortunately, QPFM/HLA-DRB1*13:02
tetramers had failed to stain the parental T cell clone F46P #17 QPFM even at high concentra-
tion of 90 nM, which is why no tetramer stainings were performed using QPFM17-transgenic T
cell lines. Similar to MSIY/HLA-DRB1*15:01 monomers, Immunaware had also reported sub-
optimal folding for QPFM/HLA-DRB1*13:02 monomer in the delivery notes (70%, see section
2.8), which may cause the malfunction of QPFM/HLA-DRB1*13:02 tetramers.
Judging by the data obtained with Vβ-specific antibodies, the expression of transgenic, HLA
class II-restricted TCRs did not differ much between αβ and δ2 T cells, but the latter offered
a valuable insight into the inherent strength of each individual TCR in competition for surface
expression. However, the intensity of the particular Vβ expression by CD4+ αβ T cells appeared
to be slightly higher than that of CD4– αβ T cells and that of δ2 T cells, most of which are CD4–
by default (Groh et al., 1989), for the TCRs QPFM17, SVMK6 and SVMK27 (fig. 4.20).
The TCRs AGIL19, EFFT22, EFFT50 and RRKM18 were expressed by a large propor-
tion of δ2 T cells from donor 0112 five days after retroviral transduction (40, 32, 27 and 32% αβ
TCR+ cells among CD14– CD19– cells, respectively, fig. 4.23). In other experiments, a similar
proportion of αβ TCR+ δ2 T cells was observed in a second donor (35%, donor 0506), as well
as smaller fractions in two other donors (21 and 11% for donors 1013 and 1107, respectively)
after transduction with RRKM18-encoding retrovirus. Transfer of EFFT22’s TCR genes into δ2
T cells generated a marked proportion of Vδ2– αβ TCR+ T cells (15.1% of CD14– CD19– cells,
fig. 4.23). In contrast, AGIL19, EFFT50 and RRKM18 showed fewer Vδ2– αβ TCR+ T cells
(9.1, 5.8 and 6.6%, respectively, fig. 4.23). Thus, EFFT22 may compete exceptionally strongly
with the endogenous TCR of δ2 T cells for surface expression, as observed for other TCRs, like
QPFM17 and CRV2.
Efficient transduction and surface expression of the TCRs AGIL19, EFFT22 and EFFT50 on δ2
T cells was demonstrated by staining with specific peptide/HLA tetramers (fig. 4.24). RRKM18
could not be stained with tetramers because specific HLA-DRB3*02:02 monomers produced by
Immunaware (Copenhagen, Denmark) failed to refold correctly in presence of KRKM peptide
(no. 124 of the IE-1 library, tab. 2.11; section 2.8), and were therefore not provided by the
manufacturer. Potent suppression of endogenous γδ TCR expression on δ2 T cells that were
transduced with EFFT22 TCR was observed for four different donors in two independent ex-
periments (0506, 1107, 1613 & 0112, of which representative data is displayed for 0112 in fig.
4.24). Thus, EFFT22 may be considered a “strong” TCR due to its extraordinary dominant
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Figure 4.22. Expression of HLA class II-restricted TCRs YRIQ18 or YRIQ36 by αβ and
δ2 T cells. αβ TCR-enriched (“αβ T cells”) or αβ TCR-depleted (“δ2 T cells”) PBMCs
from donor 1107 were stimulated with anti-CD3 antibody or PAM, respectively, before
co-transduction with TCR and CD4 (ratio 2:1). Antibodies specific for αβ TCR and Vδ2
TCR chain were used to evaluate expression of YRIQ18 or YRIQ36 on δ2 T cell lines six
days after transduction by flow cytometry. δ2 T cells transduced with CD4 alone served as
negative control. Seven days after transduction, YRIQ/HLA-DRB1*13:02 tetramers were
used to assess expression of YRIQ18 by αβ and δ2 T cell lines. No negative control was
stained simultaneously. Pseudocolour dot plots of live, CD14– and CD19– cells or their
descendants are shown as indicated above the graphs.
surface expression in δ2 T cells in comparison to other αβ TCRs, such as AGIL19 or EFFT50.
In general, transduction and subsequent expression of EFFT22 in δ2 T cells was very efficient:
29 to 44% of live, CD14–, CD19– cells of δ2 T cell lines from four donors stained positive for
EFFT/HLA-DRB5*01:01 tetramers five or six days after transduction with EFFT22. Similarly,
roughly 30% of CD4+ and CD8+ αβ T cells each could be stained with EFFT tetramers six days
after transducing αβ T cells from two donors (0506 & 1613) with EFFT22. In contrast to TCR
EFFT22, the TCRs AGIL19 and EFFT50 were largely expressed in T cells that maintained their
expression of Vδ2 (fig. 4.24). Thus, bi-specific T cells were generated. It remains to be tested
whether this dual TCR expression pattern gives rise to T cell reactivity behaviours that may be
particularly desirable for immunotherapeutic application.
Overall, AGIL19 was highly expressed by transgenic δ2-expressing T cells: 40, 33, 24 or 19% of
live, CD14–, CD19– cells of δ2 T cell lines from four donors stained positive for AGIL/HLA-
DRB3*02:02 tetramers five or six days after transduction with AGIL19-encoding retrovirus
(donor 0112, 0506, 1107 or 1613, respectively, of which representative data is displayed for 0112
in fig. 4.24). In contrast, only 8 or 12% of CD4+ αβ T cells transduced with AGIL19 could be
stained with AGIL tetramer (donor 0506 or 1613, respectively). Tetramer+ CD8+ αβ T cells
could not be evaluated due to fluorochrome interferences.
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YRIQ18 and YRIQ36 were successfully expressed, but on a comparatively smaller fraction
of δ2 T cells after retroviral co-transduction of CD4 and the respective TCR (4 and 10% αβ
TCR+ cells among CD14– CD19– cells, respectively, fig. 4.22, 3rd column). Staining the CD4-
and YRIQ18-transgenic δ2 T cell line with YRIQ/HLA-DRB1*13:02 tetramers six days after
transduction revealed twice the number of cells that expressed YRIQ18 than staining with αβ
TCR-specific antibody had (fig. 4.22, 5th column). In this experiment, an αβ T cell line from the
same donor was transduced with CD4- and YRIQ18-encoding retroviruses, too. The proportion
of αβ T cells that could be positively stained with YRIQ/HLA-DRB1*13:02 tetramers six days
after transduction was similarly low (3%, fig. 4.22, 2nd column). Since the YRIQ tetramer stain-
ing was not controlled by staining cells that had been transduced with CD4-encoding retrovirus,
but not with the TCR, the results of the YRIQ tetramer staining have to be taken with caution
at this point.
Staining δ2 T cells after retroviral co-transduction of CD4 and YRIQ18 or YRIQ36 with αβ
TCR-specific antibody showed that the proportion of δ2 T cells that expressed YRIQ36 was
more than twice as large as the proportion of δ2 T cells that expressed YRIQ18 (fig. 4.22, 3rd
column). Additionally, the αβ TCR-specific antibody stained YRIQ36-transgenic δ2 T cells more
intensively than YRIQ18-transgenic δ2 T cells. This may indicate that YRIQ36 is generally
better expressed in transgenic T cells than YRIQ18 after retroviral transduction. Unfortunately,
expression of YRIQ36 was not assessed by tetramer staining, but might potentially yield better
results than YRIQ18 due to the stronger expression of YRIQ36 as evaluated by staining of αβ
TCR surface expression.
No Vβ-specific antibodies were available for YRIQ18 and YRIQ36 to directly compare expres-
sion of corresponding TCRβ chains on αβ and δ2 T cells with the previously described stainings.
But the large proportion of AGIL19- or QPFM17-transgenic T cells showed that susceptibility
of the receiving T cells from this particular donor to retroviral transduction was not generally
low: When δ2 T cells from the same donor were transduced with AGIL19- or QPFM17-encoding
retrovirus, 36 or 32% of CD14– CD19– cells (excluding αβ TCR– Vδ2– cells) expressed the TCRβ
chain of the respective TCR (Vβ2 or Vβ5.1, respectively; data not shown). Similarly, 45 or 44%
of αβ T cells expressed the TCRβ chain of TCR AGIL19 or QPFM17 after respective retroviral
transduction. Thus, the low proportion of TCR-transgenic T cells from this donor after trans-
duction with YRIQ18- or YRIQ36-encoding retrovirus (fig. 4.22) was likely caused by other
factors, such as poor quality of retroviruses or FACS staining.
In order to discuss the expression of the IE-1-specific TCR EIMA236 on αβ and δ2 T cells, its
function has to be addressed prematurely because EIMA236-transgenic T cells later turned out
to be unable to recognise HLA-matched, IE-1-expressing mini-LCLs (data not shown). Since this
failure in target cell recognition may have been caused by errors contained in the TCR sequences,
cDNA of both TCR chains that had been isolated from the parental T cell clone F64M #236
was amplified via PCR a second time. The TCRα sequence was reproduced using the primers
Vα3 and 3’T-Cα as before (tab. 2.9) and the sequence did not show any error. In contrast,
re-sequencing of TCRβ using the newly designed primer TRBV11-2*01_forward (tab. 2.10) and
CP1 (tab. 2.9) clearly showed an A at nucleotide position (nt pos.) 164, which was occupied by





Figure 4.23. Effect of CD4 co-transduction on the expression of HLA class II-restricted TCRs AGIL19, EFFT22, EFFT50, EPDV21 and
RRKM18 on δ2 T cells assessed with antibodies specific for αβ TCR, Vβ1 or Vβ2 TCR chain. αβ TCR-depleted PBMCs were
stimulated with PAM before retroviral transduction with TCR alone, CD4 alone or both in combination. Mock-transduced (using retroviruses
devoid of genetic cargo) T cells served as negative control. The resulting transgenic δ2 T cell lines (the same as in fig. 4.24) were stained with
antibodies specific for CD4, CD14, CD19, αβ TCR, Vδ2 TCR chain and Vβ1 or Vβ2 TCR chains five days after transduction and analysed by flow
cytometry. Data of all plots displayed was pre-gated on live, CD14– and CD19– cells. Pseudocolour dot plots from donor 0112 are shown. Black
numbers indicate the percentage of cells in each quadrant, red numbers indicate the mean fluorescence intensity (MFI) of the cells in the quadrant




















Figure 4.24. Effect of CD4 co-transduction on the expression of HLA class II-restricted TCRs AGIL19, EFFT22 and EFFT50 on δ2 T cells
assessed with specific peptide/HLA tetramers. αβ TCR-depleted PBMCs were stimulated with PAM before retroviral transduction with
TCR alone, CD4 alone or both in combination. Mock-transduced (using retroviruses devoid of genetic cargo) T cells served as negative control.
The resulting transgenic δ2 T cell lines (the same as in fig. 4.23) were stained with antibodies specific for CD4, CD14, CD19 and Vδ2 TCR chain
and with AGIL/HLA-DRB3*02:02 or EFFT/HLA-DRB5*01:01 tetramers five days after transduction and analysed by flow cytometry. Data of all
plots displayed was pre-gated on live, CD14– and CD19– cells. Representative pseudocolour dot plots from one (0112) out of two donors (1107)
are shown as pseudocolour dot plots. Black numbers indicate the percentage of cells in each quadrant, red numbers indicate the mean fluorescence
intensity (MFI) of the cells in the quadrant along the y-axis (tetramer staining).
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Table 4.3. Summary of expression of HCMV-specific, HLA class II-restricted TCRs by αβ
and δ2 T cell lines. Surface expression of TCRs on transgenic T cell lines was assessed
by staining with Vβ-specific antibodies, except for TCRs YRIQ18, YRIQ36, RRKM18 and
EFFT50 because no commercial Vβ6-specific antibody was available. The expression of αβ
TCRs could also be monitored on δ2 T cells, but not αβ T cells, by staining with an anti-
αβ TCR antibody. Additionally, peptide/HLA tetramers were available for TCRs specific
for the epitopes QPFM (pp65261-275), YRIQ (pp65369-387), AGIL (pp65489-503) and EFFT
(IE-1213-225). The number of different experiments during which TCRs were transduced and
successfully expressed on αβ and δ2 T cells are listed in the 3rd and 4th column, respectively.
The performance of each of these reagents in T cell staining was qualitatively evaluated and
categorised as described below. Some tests could not be performed due to reagents that were




expression in T cells Vβ staining Tetramer staining
αβ δ2 Vβ quality HLA quality
pp65
QPFM17 3 3 5.1 good DRB1*13:02 failed
YRIQ18 n.t. 2 6.4 n.a. DRB1*13:02 poor
YRIQ36 n.t. 2 6.4 n.a. DRB1*13:02 n.t.
MSIY40 n.t. 1 3 good DRB1*15:01 failed
AGIL19 3 5 2 good DRB3*03:01 good
EPDV21 2 3 5.2 poor DQB1*05:01 n.a.
KYQE16 n.t. n.t. 20 n.t. DQB1*03:01 n.a.
IE-1
EIMA236 3 2 21.3 good DRB1*13:01 n.a.
RRKM18 n.t. 4 6.1 n.a. DRB3*02:02 failed
SVMK6 2 1 17 good DPB1*03:01 n.a.
SVMK27 2 1 13.1 good DPB1*03:01 n.a.
EFFT22 4 7 1 good DRB5*01:01 very good
EFFT50 2 n.t. 6.5 n.a. DRB5*01:01 very good
exchange during in silico TCR construct assembly that was not detected before gene synthesis
of TCRs. The DNA base error was likely introduced by the degenerated TCRβ-specific primer
VP2 (tab. 2.9): VP2 binds to TCRβ cDNA from nt pos. 149 to 168 (starting to count at the
first base of the start codon) and positions an inosine (I) opposite of nt pos. 164, which has been
shown to potentially generate A→G transition (Yasui et al., 2008). In order to obtain a flawless
TCRβ sequence of EIMA236, the TCRβ chain was corrected and synthesised anew.
The TCRβ chain of corrected EIMA236 TCR could be detected on 15 or 12% of δ2 T cells and 9
or 15% of αβ T cells from donor 1013 or 1107, respectively (data for donor 1107 depicted in fig.
4.21, 2nd and 3rd column). While the corrected EIMA236 TCR conveyed sensitivity for peptide-
loaded moDCs to TCR-transgenic αβ T cells, HCMV-infected moDCs and antigen-expressing
mini-LCLs were not recognised despite matching HLAs (data not shown). Therefore, EIMA236
transduction was discontinued and other, more immediately promising TCRs were studied in
greater detail, instead.
Table 4.3 shows a summary of all data gathered on the expression of HCMV-specific, HLA
class II-restricted TCRs in αβ and δ2 T cell lines. Leaving the TCR KYQE16 aside, which
was never transferred into any T cell line, 8 out of 12 TCRs could be stained with a Vβ-
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specific antibody that confirmed the TCR gene transfer and at least the expression of the
respective TCRβ chain by transduced T cells. 3 out of 12 TCRs were stained well either by
AGIL/HLA-DRB3*03:01 tetramers or by EFFT/HLA-DRB5*01:01 tetramers thereby confirm-
ing that α and β chains of the transferred HCMV-specific TCR had paired, were present on
the cell surface and could interact with their cognate antigen (i.e. peptide/HLA complexes). In
contrast, KRKM/HLA-DRB3*02:02 tetramers could not be produced successfully, QPFM/HLA-
DRB1*13:02 tetramers and MSIY/HLA-DRB1*15:01 tetramers failed to stain specific T cells,
and YRIQ/HLA-DRB1*13:02 tetramers provided poor staining quality. Despite the lack of a Vβ-
specific antibody and/or a specific peptide/HLA tetramer, the expression of each of the αβ TCRs
could be stained with an αβ TCR-specific antibody after the TCR genes had been transferred
into δ2 T cells. Through this method or one of the two methods mentioned before, the surface
expression of 12 out of 13 HCMV-specific, HLA class II-restricted TCRs could be confirmed.
While KYQE16 was never transferred and remains to be evaluated, YRIQ18 and EIMA236 were
the only two TCRs that were only expressed by a small proportion of T cells after retroviral
transduction. The remaining 10 HCMV-specific, HLA class II-restricted TCRs were typically
expressed on 20 to 40% of T cells four to seven days after retroviral transduction.
4.4.2.1 Role of CD4 in transgenic expression of HLA class II-restricted, HCMV-specific
TCRs
In order to determine whether expression of HLA class II-restricted TCRs depended on co-
expression of CD4, δ2 T cells were transduced with TCR alone, co-receptor alone or both in
combination. Retroviral vectors were produced by HEK293T cells that had been transfected
with 1.0 µg of TCR plasmid DNA, 0.5 µg of CD4 plasmid DNA or the combination of both, in
addition to the necessary gag/pol and env plasmid DNA (1.0 µg each; plasmids are listed and
described in tab. 2.7 & 2.8, the general method is described in section 3.5.1). Thus, the genes of
TCR and CD4 were likely delivered at an approximate ratio of 2 to 1 into δ2 T cells that were
transfected with the combined retroviral vectors. Co-production of retroviruses coding for TCR
and CD4 in the same culture may not only generate single retroviral particles, but may result
in retroviral aggregates as well. Thus, susceptible T cells may simultaneously receive both kinds
of transgenes, TCR and CD4, with a higher likelihood than expected from a random distribution.
Comparing TCR-transgenic αβ T cells from donor 1013 or 1107 after transduction with an
EIMA263-encoding retrovirus, CD4+ and CD4– (i.e. mainly CD8+) αβ T cells expressed similar
proportions of Vβ21.3, which is the variable domain of the TCRβ chain of EIMA236 (about 9 or
15% Vβ21.3+ cells among CD14– CD19– αβ TCR+ Vδ2– T cells, respectively, after subtraction of
the proportion of Vβ21.3+ cells of associated mock controls, fig. 4.21, 2nd column). About 12%
of δ2 T cells, most of which are CD4– by default, expressed the αβ TCR EIMA236 irrespective
of CD4 co-transduction (fig. 4.21, 3rd column). Thus, EIMA236 did not appear to depend on
CD4 for surface expression on CD4– T cells.
After simultaneously transducing CD4 and TCR chains, the proportions of CD4– δ2 T cells
expressing one of the TCRs AGIL19, EFFT22 or EFFT50 were 32, 25 or 23%, while 48, 39 or 34%
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of CD4+ δ2 T cells expressed the respective TCR (as assessed by tetramer staining pre-gating
on live CD14– CD19– cells, fig. 4.24). Similar results were obtained for AGIL19 and EFFT22
by staining the particular TCRβ chain with a Vβ2- or Vβ1-specific antibody, respectively (fig.
4.23). δ2 T cells that were positively stained by peptide/HLA tetramers or a corresponding
Vβ-specific antibody also expressed proportionally more CD4 than δ2 T cells that could not
be stained by either of the two reagents (fig. 4.24 & 4.23). Thus, T cells expressing the TCR
transgene were overrepresented among T cells expressing the CD4 transgene and vice versa,
although this overrepresentation was moderate, and all TCRs could be expressed and stained in
CD4– T cells as well. This overrepresentation may be due to a subset of δ2 T cells that was more
susceptible to retroviral transduction than other δ2 T cells and that received both the CD4 gene
and the TCR genes. Moreover, aggregates of retroviral vectors, which would deliver both types
of transgenes to susceptible δ2 T cells may contribute to this observation, too. Since the efficacy
of retroviral transfer of TCR and CD4 genes may not be independent, subset distributions may
not be sufficient to show biological cooperation between TCR and CD4 expression. Therefore,
the mean fluorescence intensity (MFI) of TCR expression on δ2 T cells either expressing the
transgenic TCR alone or in combination with CD4 was compared by tetramer and Vβ stainings.
CD4+ δ2 T cells yielded a 1.2- to 1.5-fold increased MFI of AGIL or EFFT tetramer+ cells
than CD4– δ2 T cells (fig. 4.24, centre row). Likewise, the MFIs of Vβ2 or Vβ1 were 1.1-fold
increased on CD4+ δ2 T cells transduced with AGIL19 or EFFT22, respectively (fig. 4.23, centre
row). The increased tetramer staining intensity of CD4+ δ2 T cells may be due to increased TCR
expression owing to the presence of CD4 co-receptor, but may also be caused by enhanced avidity
of the tetramer-TCR interaction through presence of CD4 co-receptor. In contrast, the stainings
using Vβ2- or Vβ1-specific antibodies are not likely to be affected by co-expression of CD4 and
showed only a slightly increased intensity on CD4+ δ2 T cells, which argues against a critical
role of CD4 in the expression of TCRs AGIL19, EFFT22 or EFFT50. Importantly, the MFIs of
tetramer and Vβ stainings of δ2 T cells transduced with TCR alone did not differ greatly from
the MFIs of T cells that were transduced with TCR and CD4 simultaneously (fig. 4.24 and 4.23,
top vs. centre row).
Altogether, the TCRs AGIL19, EFFT22 and EFFT50 did not depend on CD4 for functional
expression on the cell surface judging from tetramer stainings, although there was some increase
in MFI and relative number of positive cells if CD4 was present. Also EDPV21 and RRKM18
were solidly expressed even in the absence of CD4 co-transduction as assessed with a αβ TCR-
specific antibody (fig. 4.23). The expression of TCRβ chains of QPFM17, EIMA236, SVMK6
or SVMK27 on TCR-transgenic CD4+ αβ T cells was comparable to CD4– analogues (assessed
by staining with Vβ-specific antibodies, fig. 4.20 & 4.21). As the absence of CD4 did not have
a profound impact on expression of nine HLA class II-restricted TCRs, co-transduction of CD4
was not regularly implemented and the expression and function of the remaining HLA class II-
restricted TCRs were analysed without CD4 co-transduction. Whether CD4 affects the function
of HLA class II-restricted TCRs will be discussed in section 4.4.5.
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Figure 4.25. FACS analysis of monocyte-derived dendritic cells (moDCs) during their gen-
eration and maturation. Bulk PBMCs were incubated at 37 ◦C for ≥2.5 hours to allow
plastic adherence of monocytes (day 0). Non-adherent cells were washed off and remaining
cells were stimulated with GM-CSF and IL-4 to generate immature moDCs until day 3.
After another 24 hours in the presence of a maturation cocktail containing IL-1β, IL-6,
TNF-α and PGE2, moDCs were matured (day 4). Subsequently, mature moDCs were
either infected with HCMV for 48 hours or not infected to serve as control targets. Rep-
resentative data of non-infected DCs from one donor (1613) out of 7 donors is shown. A:
Pseudocolour dot plots show the gating and phenotype of analysed DCs (1st column: SSC
vs. FSC; 2nd column: CD19 vs. CD14; 3rd column: CD11c vs. CD3; 4th column: CD83 vs.
CD86; CD25 staining is not shown, but was always assessed simultaneously). B: Overlaid
histograms show the staining intensity of CD25 (green), CD83 (orange) or CD86 (blue)
expression by CD14– CD19– CD3– CD11c+ DCs at the indicated time points of analysis.
MFI of the same population and time point are indicated for the respective marker within
each graph. On day 0, DC numbers and MFIs of the selected markers were low causing
small curves that are barely visible in the graphs.
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4.4.3 Monocyte-derived dendritic cells as target cells for HLA class II-restricted T cells
In order to evaluate the recognition of HCMV infection by HLA class II-restricted T cells, target
cells were required that expressed sufficient levels of HLA class II molecules and that could be
infected with fibroblast-adapted strains of HCMV. While fibroblasts can be easily infected, they
generally do not express HLA class II molecules (Pober et al., 1983; Stevanovic et al., 2013). In
contrast, mature monocyte-derived dendritic cells (moDCs) fulfil both requirements (Sénéchal
et al., 2004) and were thus selected as target cells. moDCs were always freshly prepared using
PBMCs from independent healthy adults (tab. 2.2), which were HLA-matched with the HLA
restriction of the T cell clone or TCR-transgenic T cell lines to be tested. Isolated PBMCs were
rested for at least 2.5 hours to let the monocytes adhere to the plastic surface. After washing off
all non-adherent cells, medium containing GM-CSF and IL-4 was added for three days to drive
differentiation of monocytes into immature moDCs. Mature moDCs were generated by adding a
maturation cocktail (IL-1β, IL-6, TNF-α, PGE2) for 24 hours, which corresponds to the classical
maturation cocktail published by Jonuleit et al. (2000). Next, moDCs were either infected with
HCMV for 48 hours or mock-treated to serve as controls. The composition of cultured cells
and the activation status of moDCs were monitored throughout the procedure by staining with
antibodies (tab. 2.14) prior to flow cytometric analysis.
DCs isolated from peripheral blood on day 0 had a low expression (measured as MFI) of the
activation markers CD25 and CD83 or the co-stimulatory molecule CD86 (fig. 4.25). Immature
moDCs (day 3 of the protocol) showed no or dim expression of CD25 and CD83, but showed
intermediate levels of CD86 expression. After 24 hours of maturation, all three markers were
expressed at high levels, which decreased following subsequent infection with HCMV or control
incubation in case of CD83, but CD25 and CD86 remained approximately constant. Taken
together, moDCs could be generated at a satisfactory purity (>90% of live cells) with a mature
phenotype that was mostly retained even after 48 hours of cultivation in the absence of cytokine
supplementation. This phenotype was also conserved when moDCs were infected with HCMV
(data not shown).
4.4.4 Recognition of HCMV-infected moDCs by CD4+ αβ T cell clones
Prior to testing TCR-transgenic T cell lines, the recognition of HCMV-infected moDCs by CD4+
T cells was evaluated in order to verify suitability of moDCs as target cells. These tests were
performed with CD4+ T cell clones from which the TCRs shown in table 4.2 had been isolated.
Frozen aliquots were available for T cell clones F46P #17 QPFM, F46P #45 AGIL, 1220M
#22 EFFT, F65M #18 RRKM and 1021M #6 SVMK, which were thawed and immediately co-
incubated overnight with moDCs that had been infected with different HCMV strains. moDCs
were infected with an MOI of 5, in accordance with previous work by colleagues Ameres et al.
(2013). moDCs that had not been infected served as negative controls (mock-treated) or positive
controls (peptide loaded). Since DCs are professional APCs, they do not only present endogenous
peptides on HLA class I molecules, but also take up and process extracellular material, such as
cellular debris or protein aggregates, and present the resulting peptide fragments on HLA class
II molecules. In these experiments, it was important to distinguish antigen presented after bona




















Figure 4.26. Recognition of HCMV-infected monocyte-derived dendritic cells (moDCs) by HLA class II-restricted T cell clones. The CD4+
αβ T cell clones F46P #17 QPFM, F46P #45 AGIL, 1220M #22 EFFT, F65M #18 RRKM and 1021M #6 SVMK were co-incubated overnight
with target cells at an e:t ratio of 20,000:10,000 (#22 & #18) or 10,000:10,000 (#17, #45 & #6) cells per well. Mature moDCs from donors 1022
(for F46P #17) or 1613 (for all other T cell clones) had been infected with HCMV strain AD169 (solid blue bars), Merlin (solid purple bars),
TB40-BAC4 (solid green bars), CMV-Δall (solid brown bars) at an MOI of 5 for 48 hours in the absence of cytokine supplementation or had
been treated correspondingly with UV-inactivated HCMV inoculum (hatched bars in corresponding colours). Non-infected target cells were either
loaded with corresponding antigenic peptides (white bars) or left untreated (black bars) to serve as positive or negative controls, respectively. The
graphs show concentration of secreted IFN-γ in the supernatant as evaluated by ELISA. The mean and standard deviation of triplicate samples are
shown, except for bars marked with “§”, for which duplicates were analysed. Due to scarcity of effector or target cells some combinations could not
be tested (“n.d.” = not determined). Representative data is shown for F46P #45 AGIL (results for 1 out of 2 moDC donors), 1220M #22 EFFT,
and F65M #18 RRKM (results for 1 out of 3 moDC donors, each). HLA restrictions of the T cell clones are listed in table 4.2.
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material in the virus preparation. HCMV particles contain various proteins, but in different
quantities: While pp65 (UL83) is copiously produced during the HCMV lytic cycle and is one
of the most abundant proteins in HCMV particles, IE-1 (UL123) protein has not been identi-
fied as a component of virions (Büscher et al., 2015; Varnum et al., 2004) or at very low levels
(Reyda et al., 2014). Therefore, the hypothesis to be tested was that pp65 would be taken up
and presented to CD4+ T cells from HCMV preparations (inactive viruses, virus-like particles,
debris), whereas IE-1 presentation would require bona fide infection of moDCs. In order to
distinguish these scenarios, moDCs were either treated with infectious (i.e. non-irradiated) or
UV-inactivated HCMV inoculum. UV irradiation damages viral DNA and renders it defective
for transcription thereby preventing de novo synthesis of viral proteins in cells that have taken
up virions (Borysiewicz et al., 1988). This will allow to distinguish the effects of infection from
those of mere uptake of antigenic material.
In accordance with this hypothesis, the pp65-specific T cell clones F46P # 17 QPFM and
F46P #45 AGIL secreted a similar amount of IFN-γ in response to moDCs that were treated
with infectious AD169 virus than to moDCs that were treated with UV-inactivated virus (fig.
4.26). In contrast, the IE-1-specific T cell clones 1220M #22 EFFT, F65M #18 RRKM and
1021M #6 SVMK produced at least 2.5-fold more IFN-γ after co-incubation with AD169-infected
moDCs than with moDCs that had been treated with UV-inactivated AD169 virus. Moreover,
F65M #18 RRKM and 1021M #6 SVMK produced at least 2.4-fold more IFN-γ in response to
moDCs infected with HCMV strain TB40-BAC4 than in response to moDCs treated with UV-
irradiated TB40-BAC4. 1220M #22 EFFT did not react accordingly, but secreted low IFN-γ
levels indicating no or weak recognition of TB40-BAC4 infection. F46P #45 AGIL showed better
recognition of moDCs infected with TB40-BAC4 in comparison to UV-irradiated TB40-BAC4
(factor 1.7), but could not match the selective recognition of infectious virus by IE-1-specific T
cell clones.
Infection with HCMV strain Merlin failed to elicit any IFN-γ secretion above background levels
by the two IE-1-specific T cell clones 1220M #22 EFFT and F65M #18 RRKM (fig. 4.26).
Recognition of moDCs infected with the genetically modified virus strain CMV-Δall, which is
derived from AD169 but lacks the four immunoevasins US2, US3, US6 and US11 (Besold et al.,
2009), was not stronger than that of AD169 for IE-1-specific 1021M #6 SVMK (fig. 4.26) or
F65M #18 RRKM (data not shown), but weaker or comparable, respectively. This indicated
that these four immunoevasins did not negatively affect presentation of viral peptides on HLA
class II molecules of DCs in contrast to their strong impact on peptide presentation on HLA
class I molecules. Infection with CMV-Δall and corresponding reactions of TCR-transgenic T
cell lines will be addressed in the following paragraphs.
This experiment provided evidence that newly synthesised IE-1 was presented to CD4+ T cells
after bona fide infection of moDCs, whereas presentation of pp65 was predominantly due to
uptake of non-infectious HCMV material.
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4.4.5 Recognition of HCMV-infected moDCs by T cell lines that express an
HCMV-specific, HLA class II-restricted TCR
4.4.5.1 Recognition by pp65-specific TCR-transgenic T cells
In the next step, the reactivity of TCR-transgenic, HLA class II-restricted T cells against HCMV-
infected moDCs was tested. Similar to their parental T cell clones (fig. 4.26), the pp65-specific,
HLA-DR-restricted TCRs AGIL19, QPFM17, YRIQ18, and YRIQ36 mediated distinct and com-
parable IFN-γ secretion by transgenic T cell lines in response to moDCs treated with infectious
HCMV or UV-inactivated virus (fig. 4.27). Each TCR conveyed comparable recognition of
Figure 4.27. Recognition of HCMV-infected moDCs by αβ and δ2 T cell lines that express
pp65-specific, HLA class II-restricted TCRs. After immunomagnetic separation,
the αβ TCR+ and the αβ TCR– fraction from donor 1107 had been stimulated with anti-
CD3 antibody or PAM, respectively, before they were transduced with AGIL19, QPFM17,
YRIQ18 or YRIQ36 and CD4 co-receptor at a ratio of 2 to 1. CD4 or GFP alone were used
as transgene controls and transduced likewise. 7 days after transduction, effector cells were
co-incubated overnight with differently treated moDCs at an e:t ratio of 20,000:20,000 cells
per well. Mature moDCs from donor 1022 had previously been infected with HCMV strain
AD169 (solid blue bars) or CMV-Δall (solid brown bars) at an MOI of 5 for 48 hours in
the absence of cytokine supplementation or had been treated correspondingly with UV-
inactivated HCMV inoculum (hatched bars in corresponding colours). Non-infected target
cells were either loaded with corresponding antigenic peptides (white bars) or left untreated
(black bars) to serve as positive or negative controls, respectively. The graph shows the
concentration of IFN-γ in the supernatant as evaluated by ELISA. The mean and standard
deviation of duplicate samples are shown. Some conditions were not tested (“n.d.” = not
determined). See table 4.2 for HLA restrictions of the TCRs.
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moDCs to αβ T cells and to δ2 T cells, regardless of the HCMV virus strain used for infection of
moDCs (AD169 vs. CMV-Δall). Remarkably, AGIL19 caused roughly 2- to 3-fold higher IFN-γ
levels than the other three pp65-specific TCRs QPFM17, YRIQ18 and YRIQ36 in response to
moDC infection with AD169 and CMV-Δall, irrespective of TCR-transgenic T cell subpopula-
tion (αβ vs. δ2). Since the two TCRs AGIL19 and QPFM17 were very similarly expressed (45%
or 44% Vβ2+ among CD14– CD19– αβ TCR+ Vδ2– T cells and 36% or 32% Vβ2+ among CD14–
CD19– δ2 T cells after exclusion of αβ TCR– Vδ2– cells, respectively), other properties must
be responsible for the higher activity of TCR AGIL19. The HLA type of donor 1022, whose
PBMCs were used for the generation of moDCs for this experiment (fig. 4.27) may provide an
explanation: this donor carried two HLA alleles (HLA-DRB3*02:02 and 3*03:01) both of which
probably presented the AGIL peptide to TCR AGIL19, but only one allele (HLA-DRB1*13:02)
able to present YRIQ or QPFM peptides to their respective TCRs. Several other factors, such
as differences in inherent strength of each TCR, as well as differences in peptide processing and
peptide/HLA stability, may also come into play, but were too difficult to measure at this point.
The two pp65-specific TCRs YRIQ18 and YRIQ36 conveyed IFN-γ secretion patterns to TCR-
transgenic T cells that were very similar to QPFM17 (fig. 4.27), all of which are restricted by
HLA-DRB1*13:01 and 1*13:02 (tab. 4.2). This is surprising because the detectable proportion
of αβ and δ2 T cells that expressed YRIQ18 or YRIQ36 was very low (fig. 4.22) and markedly
smaller than the proportion of T cells expressing other TCRs, like QPFM17 (see section 4.4.2),
as evaluated by staining with αβ TCR-specific antibody and YRIQ tetramers just one day before
the assay shown in figure 4.27. Possibly, the proportion of T cells expressing YRIQ18 or YRIQ36
was higher than both staining methods indicated.
In the experiment depicted in figure 4.27, δ2 T cells were of similar efficacy as their αβ T cell
counterparts in recognising HCMV-infected moDCs through one of the four tested pp65-specific
TCRs and in secreting robust levels of IFN-γ as a result of the recognition. TCR-transgenic δ2 T
cell lines secreted between 0.5-fold and 1.6-fold (median, 0.8-fold) as much IFN-γ as αβ T cell lines
confronted with the same targets. However, δ2 T cells displayed reduced non-HCMV-specific
background reactivity to the HLA-matched moDCs, which was visible in two different ways.
First, if transduced with HCMV-specific TCRs, δ2 T cell reactivity against moDCs that were
not treated with HCMV was lower than in the equivalent condition with αβ T cells. Second, in the
control condition, where δ2 T cells were not transduced with a TCR but with CD4 or GFP alone,
their reactivity against moDCs was lower than the reactivity of αβ T cells in the corresponding
condition – independent of the pre-treatment of the moDCs. Thus, this experiment suggests
that αβ and δ2 T cells are similarly capable of mediating transgenic TCR-mediated reactivity to
HCMV-infected cells, but δ2 T cells have lower background reactivity. This may be explained by
the fact that T cells and moDCs were HLA-matched, but not autologous, and there may have
been allo-HLA-specific reactivity by αβ T cells. Such reactivity is not expected for δ2 T cells due
to their conserved, donor-independent native specificity.
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4.4.5.2 Recognition by IE-1-specific TCR-transgenic T cells
Next, T cells of the two different types were transduced with IE-1-specific, HLA class II-restricted
TCRs, and reactivity against HCMV-treated moDCs was studied. moDCs were treated with
viruses AD169, TB40-BAC4, or CMV-Δall, each with or without UV inactivation. αβ T cells
and δ2 T cells were transduced with three IE-1-specific TCRs: RRKM18, SVMK6, and SVMK27.
For each TCR, there was clear evidence for HCMV-specific recognition of infected moDCs (fig.
4.28). Total reactivity against infected moDCs was generally higher for αβ than for δ2 T cells.
However, αβ T cells showed a clearly higher background reactivity against uninfected moDCs,
whereas such background was completely absent in δ2 T cells. For each of the three HCMV
variant viruses, recognition was lower when the virus had been inactivated by UV irradiation, in
Figure 4.28. Recognition of HCMV-infected moDCs by αβ and δ2 T cell lines that express
IE-1-specific, HLA class II-restricted TCRs. After immunomagnetic separation, the
αβ TCR+ and the αβ TCR– fraction from donor 0506 had been stimulated with anti-
CD3 antibody or PAM, respectively, before they were transduced with RRKM18, SVMK6
or SVMK27. GFP alone was used as transgene control and transduced likewise. See
figure 4.20 for FACS analysis of SVMK6- and SVMK27-transgenic T cells. 7 days after
transduction, effector cells were co-incubated overnight with differently treated moDCs at
an e:t ratio of 20,000:10,000. Mature moDCs from donor 1613 had previously been infected
with HCMV strain AD169 (solid blue bars), TB40-BAC4 (solid green bars) or CMV-Δall
(solid brown bars) at an MOI of 5 for 48 hours in the absence of cytokine supplementation
or had been treated correspondingly with UV-inactivated HCMV inoculum (hatched bars
in corresponding colours). Non-infected target cells were either loaded with corresponding
antigenic peptides (white bars) or left untreated (black bars) to serve as positive or negative
controls, respectively. The graph shows concentration of secreted IFN-γ in the supernatant
as evaluated by ELISA. The mean and standard deviation of triplicate samples are shown.
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accordance with the hypothesis that endogenously expressed IE-1 after bona fide HCMV infection
of moDCs was an important source of HLA class II-presented antigen. Consequently, a direct
comparison of the recognition of HCMV-infected target cells between TCR-transgenic δ2 and
αβ T cell populations in this particular case was hampered by the relatively large background
reactivity of αβ T cells. In a second experiment (not shown here), similar unspecific activation of
TCR-transgenic αβ T cells was observed: αβ T cells from donor 1013 that had been transduced
with EFFT22- or RRKM18-encoding retrovirus or “empty” (mock) retrovirus secreted large
amounts of IFN-γ in response to control moDCs from donors 0308 and 1613 (6,400–14,000 pg/ml
and 2,100–3,900 pg/ml, respectively). The issue of unspecific reactivity of TCR-transgenic αβ T
cells is further discussed in the paragraphs below taking all available results into account.
4.4.5.3 Overview of experiments with IE-1-specific and pp65-specific TCRs
The data shown in figures 4.27 and 4.28 depict results from two out of six independent experi-
ments that were performed evaluating the recognition of HCMV-infected moDCs by T cells that
had been transduced with retroviruses encoding HCMV-specific, HLA class II-restricted TCRs.
Figures 4.29 and 4.30 summarise all six experiments in the form of secreted IFN-γ levels. Figure
4.29 shows experiments with αβ and δ2 T cells that expressed one of the pp65-specific TCRs
AGIL19, QPFM17, YRIQ18, YRIQ36 and EPDV21 (see tab. 4.2 for details on the TCRs). In
most of these experiments, the same TCR-transgenic T cells were tested on moDCs from two
different HLA-matched donors; in the remainder of the experiments, only one HLA-matched
moDC donor was used. Each data set depicted in figures 4.29 and 4.30 was obtained with a
different combination of TCR-transgenic T cells and moDCs. Some of the TCR-transgenic T cell
lines that were used in these experiments had also been transduced with CD4 and some of the
transgenic T cell lines had been restimulated by HLA-matched, antigen-expressing mini-LCLs
(see section 3.5.1) prior to co-cultivation with HCMV-infected moDCs. Data sets were excluded
if the amount of secreted IFN-γ in response to control moDCs exceeded the amount of IFN-γ
secreted in response to any kind of moDCs that were infected with HCMV (occurred once using
δ2 T cells and four times using αβ T cells transduced with either RRKM18 or EFFT22).
AGIL19 differed from other pp65-specific, HLA class II-restricted TCRs in the extraordin-
ary high levels of IFN-γ secretion by TCR-transgenic αβ and δ2 T cell lines after encountering
AD169-infected or CMV-Δall-infected target cells (fig. 4.29). In δ2 T cells, TCR AGIL19 was
also tested against HCMV strain TB40-BAC4. In this situation, there was clear virus-specific
reactivity, but amounts of cytokine were clearly lower than against AD169 or its derivative
CMV-Δall (fig. 4.29). The amino acid sequences of the AGIL epitope (pp65489-503) and of 40
amino acids up- or downstream do not differ between AD169 (Bradley et al., 2009, GenBank
accession number FJ527563) and TB40-BAC4 (Sinzger et al., 2008b, GenBank accession number
EF999921). Thus, other reasons are likely responsible for AGIL19’s differential sensitivity to
HCMV virus strains AD169 and TB40-BAC4.
TCR EPDV21 was clearly HCMV-specific in δ2 T cells, but amounts of IFN-γ were lower than
for the other pp65-specific TCRs. EPDV21 was the only HLA-DQ-restricted TCR, whereas the
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others were HLA-DR-restricted. The TCR donor and the two moDC donors were all matched
for HLA-DQB1*03:01, but were not precisely matched for any HLA-DQA1 allele. This may
explain the observed relatively low reactivity. While the TCR donor (1304) was homozygous
for DQA1*05:01, the moDC donors (1613 and 0308) had other alleles of DQA1*05, and both
additionally had DQA1*01:02. The situation is relatively complex, since mini-LCL experiments
had previously shown that DQB-matched, DQA-mismatched, pp65-expressing mini-LCLs were
sometimes even more strongly recognised by this TCR than the autologous, pp65-expressing
mini-LCL (fig. 4.4 B). There was only one experiment with this TCR transduced into αβ T
cells (fig. 4.29), but its significance was limited by the high background reactivity to uninfec-
ted moDCs. Cumulatively, the data suggests that TCR EPDV21 is functional with HLA-DQ
heterodimers that contain DQB1*03:01 and one of a range of different DQA chains, but more
precise analyses will be needed to establish its exact pattern of HLA restriction.
The pp65-specific TCRsYRIQ18, YRIQ36, and QPFM17 showed consistent specific recogni-
tion of all three virus strains in αβ and in δ2 T cells, and this recognition was largely independent
of UV irradiation, consistent with the aforementioned hypothesis on pp65 presentation. The only
exception was one experiment with QPFM17 in αβ T cells that had a high background to un-
infected moDCs, probably due to alloreactivity of donor T cells; this experiment could not be
evaluated.
An analogous overview of experiments with IE-1-specific, HLA class II-restricted TCRs is
shown in figure 4.30. These TCRs were EFFT22, EFFT50, RRKM18, SVMK6 and SVMK27
(see tab. 4.2 for details). There was clear evidence that all five TCRs mediated recognition
of HCMV-infected cells by both types of TCR-transduced T cell lines, αβ and δ2. All TCRs
recognised moDCs infected with “live” virus better than UV-inactivated virus, suggesting that
IE-1 epitopes are at least partially derived from newly transcribed IE-1 in the viral replication
cycle taking place in infected DCs.
There were certain differences between the three epitope specificities regarding their recognition
of different HCMV strains. These differences seemed most pronounced for the TCRs target-
ing the epitope EFFT: such TCRs recognised AD169-infected targets much more strongly than
TB40-BAC4-infected moDCs (fig. 4.30). However, the amino acid sequence of the EFFT epitope
(IE-1213-225) does not differ between AD169 and TB40/E (fig. 4.31 B), and the nearest difference
in the surroundings of the epitope is a Met-Ile polymorphism at position 205, which is rather
unlikely to influence processing or presentation of the IE-1213-225 epitope (AD169 has Met, while
TB40/E has Ile, fig. 4.31 B). Ultimately, the reason for these differences in recognition of HCMV
strains remains to be elucidated.
RRKM18 was the only TCR that mediated preferential recognition of TB40-BAC4 over
AD169 (fig. 4.30). The RRKM epitope differs in two amino acids between these HCMV strains.
Therefore, potential differences in recognition of IE-1-derived peptides representing these HCMV
strains were investigated using RRKM18-transgenic αβ T cells (fig. 4.31). These experiments
showed that the TCR RRKM18 was about 10-fold more sensitive to IE-1 peptide no. 124, which
is similar to TB40-BAC4’s sequence, than to peptide no. 51, which represents AD169’s sequence





Figure 4.29. Summary of data on recognition of HCMV-infected moDCs by αβ and δ2 T cell lines that express pp65-specific, HLA class
II-restricted αβ TCRs. After immunomagnetic separation, αβ TCR+ and αβ TCR– fractions from donors 0112, 0506 or 1107 had been stimulated
with anti-CD3 antibody or PAM, respectively, before they were transduced with a TCR specific for one of the epitopes shown in the graph. Seven
or eight days after transduction or restimulation, effector cells were co-incubated overnight with moDCs from an HLA-matched donor (0308, 1022,
1201, 1613 or 1918). Mature moDCs had previously been infected with HCMV strain AD169 (blue), TB40-BAC4 (green) or CMV-Δall (brown).
Viruses were used untreated (dark colours) or were treated with UV irradiation (light colours). Virus was applied at an MOI of 5 for 48 hours
in the absence of cytokine supplementation. Non-infected target cells served as negative control (black). The graph shows mean concentration of
secreted IFN-γ in the supernatant as evaluated by ELISA. Data points with the same T cell line and the same moDC culture obtained in the same




















Figure 4.30. Summary of data on recognition of HCMV-infected moDCs by αβ and δ2 T cell lines that express IE-1-specific, HLA class
II-restricted αβ TCRs. After immunomagnetic separation, αβ TCR+ and αβ TCR– fractions from donors 0112, 0506 or 1107 had been stimulated
with anti-CD3 antibody or PAM, respectively, before they were transduced with a TCR specific for one of the epitopes shown in the graph. Seven
or eight days after transduction or restimulation, effector cells were co-incubated overnight with moDCs from an HLA-matched donor (0308, 1022,
1201, 1613 or 1918). Mature moDCs had previously been infected with HCMV strain AD169 (blue), TB40-BAC4 (green) or CMV-Δall (brown).
Viruses were used untreated (dark colours) or were treated with UV irradiation (light colours). Virus was applied at an MOI of 5 for 48 hours
in the absence of cytokine supplementation. Non-infected target cells served as negative control (black). The graph shows mean concentration
of secreted IFN-γ in the supernatant as evaluated by ELISA. Data points with the same T cell line and the same moDC culture obtained in the
same experiment are connected with lines. TCRs tested were EFFT22 (nine experiments), EFFT50 (two experiments with αβ T cells only; shown
together with EFFT22 as “EFFT”); RRKM18; SVMK6 and SVMK27 (one experiment each; shown together as “SVMK”).
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target cells in this experiment. F65M #18 RRKM showed the same hierarchy of recognition
as the TCR-transduced cells (peptide no. 124 was about 10-fold more sensitively recognised
than peptide no. 51) with the distinction that the original T cell clone was about 10-fold more
sensitive to each peptide than the TCR-transduced cells (data not shown). IE-1 peptide no.
51 is identical to the amino acid sequence of IE-1201-215 from HCMV strain AD169, which is
RRKM MYMC YRNI EFF. Peptide no 124 differs from the former in three amino acids (KRKM IYMC
YRNV EFF) and is found in IE-1 protein from HCMV strain Davis (fig. 4.31 B). HCMV strain
TB40/E has the sequence KRKM IYMC YRNI EFF in this region. Thus, it covers only two (R201K,
M205I) of the three amino acid exchanges that distinguish AD169 from Davis. Unfortunately, a
peptide precisely corresponding to TB40-BAC4 was not available at the time of the experiment.
It is nontheless likely that exchanges R201K and M205I contributed to superior recognition of the
epitope, because peptides partially overlapping the RRKM epitope that are truncated immedi-
ately before the position of the third polymorphism (I212V) were also better recognised in the
TB40-BAC4/Davis variant than in the AD169 variant (fig. 4.31 A).
The function of the HLA-DP-restricted TCRs SVMK6 and SVMK27 was tested in one
experiment that included, for each of the two TCRs, an αβ and a δ2 T cell line transduced
with the TCR (fig. 4.30). Both TCRs recognised the three virus strains tested (AD169, TB40-
BAC4, and the AD169 derivative CMV-Δall). The response was somewhat stronger against
AD169 than against TB40-BAC4. SVMK6 conveyed similar sensitivity for HCMV-infected tar-
get cells to TCR-transgenic T cell lines than SVMK27. Among the IE-1-specific TCRs, SVMK6
and SVMK27 produced the strongest response towards target cells infected with AD169, TB40-
BAC4 or CMV-Δall regardless of the T cell type that received the transgenic TCR (αβ vs. δ2
T cells). Thus, SVMK-specific TCRs are promising candidates for an application in adoptive T
cell therapy of HCMV, but require verification of this result in independent experiments.
Looking at the overall picture, TCR-transgenic δ2 T cells were as effective as αβ T cells in
recognising HCMV infection when they had been transduced with retrovirus encoding a pp65-
specific, HLA class II-restricted TCR (fig. 4.29). If they expressed an IE-1-specific TCR after
retroviral transduction, instead, TCR-transgenic δ2 T cells responded less intensely (both in
specific signal and in background) than αβ T cells judging by the amount of secreted IFN-γ after
target recognition (fig. 4.30). δ2 T cells consistently showed very low levels of unspecific reactivity
as apparent by IFN-γ secretion in response to allogeneic control moDCs: With TCR-transgenic
δ2 T cells from donors 0112, 0506 and 1107 the median background level of IFN-γ in response to
control moDCs observed in 34 occasions involving moDCs from five different allogeneic donors
(0308, 1022, 1201, 1613 & 1918) was 31± 33 pg/ml (±SD, maximum 150 pg/ml, fig. 4.29 &
4.30). In contrast, αβ T cells produced 10-fold elevated levels of IFN-γ on average with a few
strong outliers (72–14,000 pg/ml, median 370 pg/ml) as a result of engaging control moDCs in
23 different occasions. This strikingly illustrates the very low unspecific reactivity of δ2 T cells
in an allogeneic context, in which αβ T cells most often secreted markedly more IFN-γ after
encountering HCMV-infected moDCs and sometimes even showed strong unspecific reactivity
(see fig. 4.28 for exemplary data). In an allogeneic setting, such as often the case in SOT
or HSCT, unspecific reactivity strictly needs to be avoided. Thus, depending on the context of
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Figure 4.31. HCMV strain specificity of the IE-1-specific, HLA class II-restricted TCR
RRKM18. A: Peptide titration of RRKM18-transgenic αβ T cells. HLA-matched control
mini-LCLs from donor F65 were loaded with IE-1 peptides no. 50, 51, 52, 123 or 124
from the 15-mer IE-1 peptide library (tab. 2.11) at concentrations ranging from 10−12 to
10−6 M. Peptide-loaded mini-LCLs were co-incubated overnight with an αβ T cell line from
donor 1107 that had been transduced with RRKM18-encoding retrovirus 13 days before
the assay and had been restimulated with antigen-expressing mini-LCL from donor 1021
six days before the assay. The graph shows absorption at 405 nm wavelength as readout of
an ELISA that evaluated concentration of IFN-γ in the co-culture supernatant. The mean
and standard deviation of triplicate samples are shown. B: Amino acids 191 to 240 of IE-1
protein from different HCMV strains. Sequences were obtained from NCBI’s GenBank
(https://www.ncbi.nlm.nih.gov/genbank/, accession numbers as depicted in 2nd column)
and translated into protein. Amino acid sequence of peptide no. 50 from the IE-1 library
used in this study is underlined and depicted in bold letters. Differences in IE-1 sequence
from AD169 are highlighted in red and indicated by a dot in the last line. The EFFT
epitope (IE-1213-225) is underlined and depicted in italic letters.
future clinical application (such as whether the T cell donor will be the patient, an HLA-matched
donor or an HLA-mismatched donor), TCR-transgenic δ2 T cells may qualify as preferable if the
intensity of both wanted and unwanted reactivities is taken into account.
4.4.5.4 Recognition of CMV-Δall in comparison to AD169
HCMV devoid of the immunoevasins US2, US3, US6 and US11 (CMV-Δall) elicited mildly
higher IFN-γ secretion by QPFM17-, YRIQ18- or YRIQ36-transgenic αβ or δ2 T cells than
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AD169 (1.4- to 1.7-fold, fig. 4.27). AGIL19 in combination with CD4 caused 0.8-fold decreased
or 2.5-fold increased IFN-γ release when expressed by αβ or δ2 T cells, respectively. In this
experiment, the same αβ and δ2 effector T cells transduced with AGIL19 and CD4 were also tested
on moDCs from another donor, releasing 1.3- and 1.1-fold more IFN-γ in response to CMV-Δall-
than AD169-infected moDCs (donor 1918, data not shown). Intriguingly, the opposite tendency
was observed for IE-1-specific TCRs: on average, αβ or δ2 T cells expressing SVMK6, SVMK27
or RRKM18 released half as much IFN-γ in response to CMV-Δall than to AD169 infection
(0.1- to 2.8-fold, median 0.5, one or two experiments per TCR and T cell population using
SVMK- or RRKM-specific TCRs, respectively, fig. 4.28 and data not shown). Overall, the
HLA-DR-restricted TCRs AGIL19, QPFM17, YRIQ18 and YRIQ36 as well as the HLA-DP-
restricted TCRs SVMK6 and SVMK27 seem to be considerably less affected by the effect of
immunoevasins US2, US3, US6 and US11 on peptide presentation (fig. 4.27 & 4.28, respectively)
than most HLA class I-restricted T cell clones and HLA-C*07:02-restricted TCRs (see section
4.3.2). This finding is in agreement with demonstrations that US2 and US11 do not target HLA
class I (Rehm et al., 2002), contradicting earlier research (Tomazin et al., 1999). The presented
results support clinical application of HCMV-specific, HLA class II-restricted TCRs because
HCMV does not seem capable in DCs to prevent presentation of viral peptides by HLA class II
molecules. An overview of all data collected on recognition of moDCs that were challenged with
CMV-Δall is provided in figures 4.29 & 4.30.
4.4.5.5 Role of CD4 co-receptor for function of HLA class II-restricted TCRs in transgenic
T cells
While TCR expression had not particularly depended on the presence of CD4 co-receptor in
transduced T cells (section 4.4.2), the importance of CD4 co-expression for the function of HLA
class II-restricted TCRs remained to be elucidated. In order to evaluate the effect of CD4 on
recognition of HCMV-infected moDCs by TCR-transgenic T cells, δ2 T cells from two donors
(0112 & 1107) were transduced with one of the two pp65-specific TCRs AGIL19 or EPDV21
or one of the two IE-1-specific TCRs EFFT22 or RRKM18 alone or in combination with CD4
co-receptor. The expression of CD4, if applicable, and each individual TCR are shown in figures
4.23 and 4.24 for donor 0112. Two days after the FACS analysis, these TCR-transgenic δ2 T
cells were co-incubated overnight with mature moDCs that had previously been infected with
AD169 or TB40-BAC4 for 48 hours. In general, co-transduction of CD4 had only a very minor
effect (0.4- to 1.4-fold IFN-γ secretion when CD4 was co-transduced, median 1.2, fig. 4.32).
The TCR EFFT22 was an exception: IFN-γ secretion in response to active HCMV preparations
was, unexpectedly, reduced when CD4 was co-transduced. Similar results were obtained with
the same T cell lines from donor 0112 when tested on moDCs from a different donor (0308, data
not shown). Since EFFT22 is the only TCR among the four discussed in this paragraph that
quite strongly suppressed expression of endogenous γδ TCRs in δ2 T cells (see fig. 4.23 and
4.24), EFFT22 may be less dependent on CD4 co-expression due to its inherent strength of TCR
expression.
In a replication of this experiment, the recognition of HCMV-infected moDCs by EFFT22-
transgenic δ2 T cell lines from another donor (1107) was tested (data not shown). In this case,
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δ2 T cells that had been transduced with retroviruses coding for EFFT22 and CD4 produced
almost identical levels of IFN-γ in response to HCMV-infected moDCs from donor 1613 than
EFFT22-transduced δ2 T cells. In summary, CD4 co-transduction had no or negligible effect
on the recognition of HCMV-infected moDCs. This somewhat unexpected result suggests CD4
independence of the HLA class II-restricted TCRs studied here. This will simplify clinical de-
velopment, since it appears that CD4 co-transduction is not necessary for generation of effective
Figure 4.32. Effect of CD4 co-transduction on the recognition of HCMV-infected moDCs by
δ2 T cell lines that express HLA class II-restricted TCRs. After immunomagnetic
separation, the αβ TCR– fraction had been stimulated with PAM before the cells were
transduced with AGIL19, EPDV21, EFFT22 or RRKM18. δ2 T cells were transduced with
TCR alone or together with CD4 co-receptor at a ratio of 2 to 1 of retroviral vector plasmid
transfected into packaging cells. CD4 transduction alone and empty retrovirus delivering
no transgene (“mock”) were used as controls. See figures 4.23 & 4.24 for FACS analysis
of TCR-transgenic T cells. 7 days after transduction, effector cells were co-incubated
overnight with differently treated moDCs at an e:t ratio of 20,000:10,000. Mature moDCs
had previously been infected with HCMV strain AD169 (solid blue bars) or TB40-BAC4
(solid green bars) at an MOI of 5 for 48 hours in the absence of cytokine supplementation
or had been treated correspondingly with UV-inactivated HCMV inoculum (hatched bars
in corresponding colours). Non-infected target cells were either loaded with corresponding
antigenic peptides (white bars) or left untreated (black bars) to serve as positive or negative
controls, respectively. For EPDV21, target cells were loaded with the pp65 peptide no. 57
(KVYL) instead of peptide no. 45 (EPDV, tab. 2.12) in this experiment because the
correct epitope of EPDV21 was identified later (see section 3.4.4); this explains the missing
positive control signal. The graph shows concentration of secreted IFN-γ in the supernatant
as evaluated by ELISA. The mean and standard deviation of triplicate samples are shown.
Representative results for one (0112) out of two δ2 T cell donors (the other was 1107;




HLA class II-restricted TCR-transgenic T cells specific for HCMV.
4.4.5.6 Differences in target cell recognition depending on the HCMV antigen:
pp65 vs. IE-1
Since pp65, but not IE-1, is contained in large quantities in HCMV virions (Büscher et al., 2015;
Reyda et al., 2014), it can be hypothesised that IE-1-specific T cells will preferentially respond
to moDCs which have been functionally infected and subsequently produce IE-1 protein. In
contrast, pp65-specific T cells will respond to any scavenging moDC, which has acquired viral
proteins through ingestion of inactivated virions, cellular debris and other viral protein-containing
material. Corroborating this hypothesis, UV irradiation greatly reduced recognition of HCMV-
infection by IE-1-specific, but not pp65-specific, TCR-transgenic δ2 T cells (see exemplary data
in fig. 4.27, 4.28 & 4.32 and summary in fig. 4.29 & 4.30).
For a more quantitative description of this effect, the ratio of secreted IFN-γ in response to
moDCs treated with infectious HCMV to secreted IFN-γ in response to moDCs treated with
UV-inactivated virus will here be designated active/inactive virus recognition ratio or, for short,
A/I ratio. Indeed, pp65- and IE-1-specific TCRs functionally differed from each other in their
A/I ratio. For AD169 and pp65-specific TCRs AGIL19 and EPDV21, the A/I ratio was 0.9
to 2.4 (median 1.5, fig. 4.32); for TB40-BAC4 and these two TCRs, it was 1.3 to 2.1 (median
1.7). In accordance with the hypothesis, the A/I ratio was higher for the IE-1-specific TCRs
EFFT22 and RRKM18, both with AD169 (2.2 to 5.7, median 2.8) and with TB40-BAC4 (1.1 to
3.9, median 2.4, fig. 4.32). A similar behaviour was observed earlier for HLA class II-restricted
CD4+ T cell clones (fig. 4.26).
To obtain a better overview, all experiments were collectively evaluated for their active/inactive
virus recognition (A/I) ratio (fig. 4.33 & 4.34). The general picture emerging from this analysis
is somewhat complex, but it appears to broadly support the view that pp65-specific T cell lines
reacted with similar strength to both types of target cells (A/I ratio ≈ 1) in most experiments,
whereas most IE-1-specific T cell lines reacted at least two times stronger to target cells that had
been treated with infectious AD169 than target cells that had been treated with UV-inactivated
AD169 (A/I ratio ≥ 2, fig. 4.33 A).
In general, TCR-transgenic αβ and δ2 T cell lines provided very comparable A/I ratios when
transduced with the same TCR, except for certain experiments with AGIL-, EPDV- and SVMK-
specific TCRs (fig. 4.33A & C). With some exceptions, relatively similar patterns were obtained
for viruses AD169 (fig. 4.33 A) and TB40-BAC4 (fig. 4.33 C).
The IFN-γ levels that were secreted by EFFT22- or EFFT50-transgenic T cell lines in response
to moDCs treated with infectious TB40-BAC4 were rather low (fig. 4.30), as discussed earlier
in section 4.4.5. Consequently, A/I ratios of EFFT22- or EFFT50-transgenic T cell lines for
TB40-BAC4 were markedly lower in comparison to AD169 (fig. 4.33 C vs. A, respectively).
Some A/I ratios of TCR-transgenic αβ cell lines, as observed with TCRs SVMK6 and SVMK27
for example, were presumably influenced by high background levels of IFN-γ secretion in response
to allogeneic moDCs irrespective of their treatment with HCMV (fig. 4.29 & 4.30). In order
142
4.4 Characterisation of HCMV-specific TCRs restricted by HLA class II
to eliminate this confounding factor, background-corrected A/I ratios were calculated using the
following formula:
corrected A/I ratio = IFN-γ(HCMV)− IFN-γ(Control)IFN-γ(HCMV +UV)− IFN-γ(Control) (3)
In accordance with the previous observation that TCR-transgenic δ2 T cell lines generally showed
low unspecific activation by control moDCs (judging by IFN-γ secretion, fig. 4.29 & 4.30), the
correction did not affect most of their A/I ratios, regardless of HCMV virus strain (AD169 or
TB40-BAC4, fig. 4.33 A vs. B or C vs. D), except for the combination of EFFT-specific T cells
and TB40-BAC4, where an elevation of some A/I values through correction was observed. In
contrast, TCR-transgenic αβ T cells were more strongly affected by the correction. In order to
avoid generating excessive values by the correction (values approaching infinity or reaching into
the negative), ratios were manually set to a predefined value in two instances: (I) If the amount
of IFN-γ secreted in response to control moDCs was higher than the one secreted in response
to moDCs treated with UV-inactivated HCMV, the corrected A/I ratio was set to 200; (II) If
the amount of IFN-γ secreted in response to control moDCs was higher than the one secreted in
response to moDCs treated with infectious HCMV, no detectable specific response to HCMV-
infected cells was assumed, and for purposes of graphical representation and non-parametric
analysis the corrected A/I ratio was set to 0.1.
Remarkably, A/I ratios obtained with TCR-transgenic αβ T cell lines expressing pp65-specific
TCRs were hardly affected by the correction, while most A/I ratios for αβ T cells obtained with
EPDV21 or any IE-1-specific TCR were (fig. 4.33). Among all pp65-specific TCRs, the amount of
IFN-γ secreted by TCR-transgenic αβ T cell lines in response to control moDCs ranged from 165
to 14,000 pg/ml (median 350± 4,700 pg/ml, fig. 4.29). If the two highest IFN-γ levels that had
been obtained with EPDV21 (7,000 pg/ml) and with QPFM17 (14,000 pg/ml) were excluded, the
strongest response to control moDCs was 440 pg/ml (median±SD = 310± 95 pg/ml). Combined
with the high levels of IFN-γ that the same cells generally secreted in response to HCMV-infected
moDCs (fig. 4.29), the correction did hardly affect the A/I ratios of αβ T cell lines expressing any
pp65-specific TCR, except for EPDV21 (fig. 4.33). IE-1-specific TCRs, however, mediated gen-
erally lower IFN-γ levels after TCR-transgenic αβ T cell lines had encountered HCMV-infected
moDCs, while causing relatively high reactivity of these cells to control moDCs (72–9,200 pg/ml,
median±SD = 1,400± 3,000 pg/ml, fig. 4.30). As a result, the correction affected A/I ratios
of αβ T cell lines expressing an IE-1-specific TCR more strongly than those expressing a pp65-
specific TCR, regardless of HCMV virus strain (AD169 or TB40-BAC4, fig. 4.33).
In order to cumulatively test whether pp65-specific TCRs differed from IE-1-specific TCRs,
all A/I values for a given HCMV strain (AD169 or TB40-BAC4) and a given type of transduced
T cells (αβ or δ2) were pooled in two groups according to the HCMV antigen and subjected to
statistical analysis (Mann-Whitney test). The medians of all A/I ratios for AD169 of αβ and
δ2 T cell lines that expressed a pp65-specific TCR were 1.00 and 0.93, respectively (fig. 4.34 A
& B). The corresponding median A/I values for IE-1-specific TCRs were 2.08 and 2.76, which
demonstrated that IE-1 recognition, but not pp65 recognition, was overall dependent on active
infection. Regardless of the TCR-transgenic T cell type (αβ vs. δ2), the difference between pp65
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Figure 4.33. Active/inactive virus recognition (A/I) ratios of TCR-transgenic αβ (blue circles)
and δ2 (orange squares) T cell lines for AD169 (graphs A & B) and TB40-BAC4
(graphs C & D). Every dot marks the ratio of IFN-γ secreted by a TCR-transgenic T cell line
in response to moDCs treated with infectious HCMV to IFN-γ secreted by identical effector
cells in response to moDCs treated with UV-inactivated virus in the same experiment (“A/I
ratio”, graphs A & C). For the corrected A/I ratio (graphs B & D), “background” IFN-γ
secreted in response to control moDCs was subtracted from IFN-γ secreted in response
to moDCs that had been treated with infectious HCMV or UV-inactivated virus, before
calculating the ratio. Corresponding formulas are displayed on top of each of the graphs.
The resulting ratios for TCRs that recognise the same epitope (tab. 4.2, e.g. YRIQ18
& YRIQ36) were pooled into groups (e.g. YRIQ). The bar marks the median of each
group. For groups marked with “§” one of the two adjustments has been applied for at
least one data point: (I) If the amount of IFN-γ secreted in response to control moDCs was
higher than the one secreted in response to moDCs treated with UV-inactivated HCMV,
the corrected ratio was set to an arbitrary upper cut-off value of 200; (II) If the amount of
IFN-γ secreted in response to control moDCs was higher than the one secreted in response
to moDCs treated with infectious HCMV, the corrected ratio was set to an arbitrary lower
cut-off value of 0.1. The dashed line indicates an A/I ratio of 1.
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Figure 4.34. Combined active/inactive virus recognition (A/I) ratios of TCR-transgenic αβ
T cell lines (blue) and δ2 T cell lines (orange) for AD169 (graphs A & B) and TB40-
BAC4 (graphs C & D). Every dot marks the ratio of IFN-γ secreted by a TCR-transgenic
T cell line in response to moDCs treated with infectious HCMV to IFN-γ secreted by
identical effector cells in response to moDCs treated with UV-inactivated virus in the same
experiment (“A/I ratio”). The A/I ratios for pp65-specific TCRs (filled symbols) and IE-1-
specific TCRs (empty symbols) were compared using a Mann-Whitney test for significance,
showing the respective P value within each graph.
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and IE-1 was highly significant (P<0.004, fig. 4.34 A & B).
For TB40-BAC4 the situation was similar, but due to the smaller number of experiments per-
formed with TCR-transgenic αβ T cells and TB40-BAC4-infected target cells the analysis had
reduced statistical strength in that situation (fig. 4.34 C). The median of the A/I ratios of TCR-
transgenic αβ T cells for TB40-BAC4 was 1.08 or 2.68 for pp65 or IE-1, respectively (P=0.033).
TCR-transgenic δ2 T cells had a median A/I ratio of 1.48 or 2.22 if they expressed a pp65-
specific or an IE-1-specific, HLA class II-restricted TCR, respectively (P=0.045, fig. 4.34 D).
While three of four median A/I values for pp65 were close to 1.0 (fig. 4.34 A, B & C), the median
pp65 A/I ratio was close to 1.5 for the combination of the TB40-BAC4 strain and δ2 T cells
(fig. 4.34 D). Thus, in this particular situation endogenous production of pp65 after infection
appeared to play a role in provision of antigen for T cell recognition. A possible explanation
is that TB40-BAC4 virions carry less pp65 protein than AD169-derived virions (Büscher et al.,
2015) and thus UV-inactivated TB40-BAC4 virions introduce less pp65 proteins into an infected
target cell than UV-inactivated AD169 at the same MOI. Consequently, DCs that were product-
ively infected with TB40-BAC4 will produce quantities of intracellularly derived pp65 peptides
that can detectably contribute to T cell recognition. A comparable increase in A/I ratios was
not observed with αβ T cells, which may be due to the low number of experiments that assessed
the recognition of TB40-BAC4 infection by pp65-specific, TCR-transgenic αβ T cells (fig. 4.34
C). In the case of HCMV strain AD169, newly synthesised pp65 may play a minor role in recog-
nition of infection by pp65 specific T cells, since these virions already introduce a large amount
of pp65 protein into infected cells (Varnum et al., 2004) providing an excess of antigen available
for presentation via HLA molecules. This may explain why most of αβ and δ2 T cell lines showed
an A/I ratio of approximately 1 in response to pp65 from AD169 (fig. 4.34 A & B).
In summary, figure 4.34 shows that pp65-specific, HLA class II-restricted TCRs most often
mediate a comparable IFN-γ response to active and inactive HCMV presented by moDCs. In
contrast, IE-1-specific, HLA class II-restricted TCRs conveyed an about 2- to 3-fold increased
sensitivity for active infection over inactive HCMV. Thus, a pp65-specific, HLA class II-restricted
T cell may be activated by an HLA class II-expressing target cell, such as DCs or monocytes,
that presents pp65-derived peptides as a result of infection with HCMV or endocytosis of cellular
debris or virions, which contained pp65 protein. An IE-1-specific, HLA class II-restricted T cell,
however, is likely activated by an HLA class II-expressing target cell predominantly if the latter
was infected with HCMV causing IE-1 production in the infected cell.
The amount of secreted IFN-γ by TCR-transgenic T cells specific for IE-1 was often markedly
lower than the amount of secreted IFN-γ by TCR-transgenic T cells specific for pp65 (fig. 4.30
vs. 4.29). This does not necessarily imply that IE-1-specific TCRs are less efficient than pp65-
specific TCRs in mediating effective antiviral action against HCMV-infected target cells by TCR-
transgenic T cells, but may indicate that protein levels of IE-1 are more limiting that those of the
particularly abundant protein pp65 in infected moDCs, which ultimately affects the abundance
of corresponding viral peptides presented on HLA class II molecules.
Taken together, HCMV-specific, HLA class II-restricted TCRs effectively mediated recognition
of moDCs that presented endogenously processed HCMV antigens. Unspecific reactivity was
occasionally observed when using αβ T cells for TCR transduction and partially mismatched
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moDCs as targets. This was most likely due to HLA alloreactivity, an expected and relevant
aspect that must be optimised for therapeutic application of TCR-transduced αβ T cells. Very
interestingly, when δ2 T cells were equipped with HCMV-specific, HLA class II-restricted TCRs,
such alloreactivity was absent. Thus, this combination of T cells and HCMV-specific TCRs by
TCR gene transfer is very attractive for therapy of HCMV in an allogeneic environment, such as
HSCT. HLA class II-restricted TCR-transgenic T cells may be used to complement HLA class




HCMV-specific T cells can be produced by transferring the genes of an HCMV-specific TCR into
primary T cells (Schub et al., 2009). This approach is a path to therapy of HCMV infection by
adoptive transfer of HCMV-specific T cells for immunocompromised patients that lack HCMV-
specific T cells even when the HSC donor is HCMV-negative (HCMV–) and therefore has no
HCMV-specific memory T cells. To put this idea into practice, HCMV-specific TCRs must be
identified, sequenced, and characterised. Ultimately, it must be evaluated whether the TCR, after
transfer into suitable effector cells, functionally, sensitively, and specifically recognises HCMV-
infected target cells. These tasks were addressed in the present study focussing on TCRs that
are restricted by different HLA class I and class II molecules in order to enable their therapeutic
use.
5.1 Epitopes, HLA restrictions and TCR sequences of HCMV-specific TCRs
Within this study, the TCR sequences of 9 HLA class I-restricted TCRs and 13 HLA class II-
restricted TCRs specific for one of the HCMV antigens pp65, IE-1 or UL28 were identified (tab.
4.2). pp65 is a structural protein that participates in the assembly of new virions and is the most
abundant protein of virions from WT strain AD169 (Reyda et al., 2014; Varnum et al., 2004).
Due to its high abundance in virions, it is not surprising that pp65 is an immunodominant anti-
gen against which most HCMV-positive (HCMV+) persons develop T cell responses (Sylwester
et al., 2005). In contrast, IE-1 was not identified as a component of virions (Büscher et al., 2015;
Varnum et al., 2004) or was contained at very low levels only (Reyda et al., 2014). IE-1 functions
as a transcriptional regulator and is essential for the expression of viral early proteins, which
drive viral DNA replication (Greaves and Mocarski, 1998; Marchini et al., 2001). While CD8+
T cell responses against the antigen IE-1 were also found in most HCMV+ persons, IE-1-specific
CD4+ T cell responses were only observed in a third of HCMV+ persons (Sylwester et al., 2005).
Recently, T cell clones specific for IE-1309-317 (CRV) and restricted by HLA-C*07:02 were
found to resist the immunomodulatory effect of HCMV’s immunoevasins (Ameres et al., 2014,
2013), which are known to down-regulate the expression of HLA class I molecules on infected
cells (Jones et al., 1995) and thereby impair T cell recognition. Since HLA-C*07:02 was less
affected by the four immunoevasins US2, US3, US6 and US11 in comparison to other HLA class
I molecules (Ameres et al., 2014, 2013), TCRs restricted by this HLA may be especially effic-
acious in controlling HCMV infection in individuals that possess this HLA allele. Thus, four
CRV-specific TCRs and five TCRs specific for the epitope UL28327-335 (FRC), which were also
restricted by HLA-C*07:02, were analysed and tested in this study. UL28/UL29 codes for an
IE protein that enhances IE gene expression and can activate major immediate-early promoter
(Mitchell et al., 2009).
To date, no complete TCRs specific for the epitopes CRV or FRC have been described. Re-
cently, 266 and 435 unique TCRβ sequences of HLA class I-restricted TCRs specific for FRC or
CRV, respectively, were published (Huth et al., 2019). These TCRβ sequences were identified by
deep sequencing of polyclonal, epitope-specific T cell lines that were selectively expanded from
HCMV+ donors. This publication confirmed the striking immunodominance of these specificit-
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ies in the CD8+ T cell repertoire, but did not address the TCRα repertoire. In contrast, in the
present work TCRα and TCRβ sequences of well characterised CRV- and FRC-specific CD8+
T cell clones were identified. All TCRβ sequences (V–CDR3–J) of FRC- or CRV-specific TCRs
listed in table 4.2 were already published by Huth et al. (2019) except for the TCRβ sequence
of CRV2. Huth et al. (2019), however, did not assess the function of the identified TCRs which
has been done for four FRC-specific and four CRV-specific TCRs in the present study.
Among HLA class II-restricted TCRs, six TCRs were specific for pp65 and five TCRs were
specific for IE-1. The pp65-specific TCRs were derived from CD4+ T cell clones that had been
established and incompletely characterised by Wiesner (2005) and Schub (2010). The epitopes
and HLA restrictions of a panel of IE-1-specific CD4+ T cell clones have been analysed in great
detail (Ameres et al., 2015). IE-1-specific CD4+ T cell clones were chosen for TCR isolation if
their HLA restriction had earlier been confirmed by HLA transfection (see Ameres et al., 2015).
Some sequences of HLA class II-restricted TCRs specific for gB, pp65or IE-1 were published,
but none of the sequences described in the present study (tab. 4.2) were known to code for an
HCMV-specific TCR before:
Abana et al. (2017) studied HLA-DRB1*07:01-restricted T cells specific for gB217-227 (DYSN)
or pp65177-191 (EPDV) by peptide/HLA class II multimer stainings ex vivo. The TCR EPDV21
which is described in this work is restricted by a different HLA class II complex (HLA-DQB1*03:01,
tab. 4.2). Abana et al. (2017) identified several TCRβ chains of DYSN-specific TCRs, but only
one TCRα-TCRβ pair, which was subsequently expressed in leukemic Jurkat cells and found to
mediate recognition of peptide-loaded target cells.
Crompton et al. (2008) also analysed HLA-DRB1*07:01-restricted, DSYN-specific T cell clones
from which they identified seven complete αβ TCRs and five more TCRβ sequences. These
TCRs were not recombinantly expressed in other T cells, but the parental T cell clones were
shown to recognise endogenously processed antigen presented by LCLs or HCMV-infected tar-
get cells. However, HLA-DRB1*07:01-restricted, DYSN-specific CD4+ T cells were shown to
cross-react with the alloantigen HLA-DR4, which may be a possible mechanism for the clinical
association between HCMV and GvHD after allo-HSCT (Elkington and Khanna, 2005). Thus,
DYSN-specific TCRs may not be safe to use in adoptive T cell therapy of HCMV disease.
Simon et al. (2014) described three complete αβ TCRs that are also restricted by HLA-DRB1*07:01
and specific for the epitopes pp65117-139 (PLKM) or pp65337-359 (VELR), but information about
the CDR3 of these TCRs was not shown. The TCR sequences were obtained from single CD4+
T cells that had been isolated from pp65-specific T cell lines by IFN-γ capture and magnetic
separation. The TCRs were recombinantly expressed in T cells by RNA transfection and medi-
ated recognition of peptide-loaded, HLA-transgenic K562 cells.
Schwele et al. (2012) published nine TCRβ sequences in total from T cell cultures that had been
stimulated with either pp65245-263 (TLGS) or IE-1269-288 (LTHI), but they did not verify HCMV-
specificity of these TCRs. Thus, some of the TCRβ sequences may not be specific for HCMV.
van Leeuwen et al. (2006) reported about 80 TCRβ sequences derived from CD4+ T cells that
had been isolated from PBMCs of SOT patients by stimulation with HCMV antigens and sub-
sequent IFN-γ capture and magnetic separation. Again, the antigen specificity of the TCRs was
not verified independently and thus the list of sequences may include non-HCMV-specific TCRβ
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chains.
The epitopes and HLA restrictions of six out of seven pp65-specific CD4+ T cell clones could
be determined (see fig. 4.7 & 4.8, as well as tab. 4.1). Each of these epitopes has already
been described, but some were allocated to HLA restrictions that were different from the HLA
restrictions identified here. This was the case for pp65509-523 (KYQE) described to be restric-
ted through DR1 or DR3 (Khattab et al., 1997; Li Pira et al., 2004; Slezak et al., 2007) and
pp65177-191 (EPDV) described to be restricted through DR7 (Li Pira et al., 2004). Misidentifica-
tion of their HLA restriction in previous studies seems possible, since the possibility of HLA-DQ
restriction was neither taken into account nor tested in those studies.
The epitope pp65109-123 (MSIY) that was reported earlier by this group (Wiesner et al., 2005)
for the same T cell clone used in the present study (F46P #40) could not be verified. Either the
putative HLA-DRB1*15:01 restriction or the epitope may have been wrongly identified because
neither MSIY/HLA-DRB1*15:01 tetramers could stain TCR-transgenic T cells, nor did these
cells recognise HLA-transgenic peptide-pulsed target cells (data not shown).
The epitopes and HLA restrictions of a large set of IE-1-specific CD4+ T cell clones, from
which the TCRs that are used in this study were derived, were analysed in detail by Ameres
et al. (2015). The only correction that is made necessary by the results presented here is the
HLA restriction of the SVMK-specific CD4+ T cell clones 1021M #6 and #90, and 1826M
#27: HLA-DPB1*03:01, but not HLA-DPB1*02:01 and DPB1*04:01, presented SVMK peptide
to TCR-transgenic T cells, which suggests that HLA-DPB1*14:01 and DPB1*20:01 may also
present the epitope due to their high homology to DPB1*03:01 (99.6% each Marsh et al., 2000).
However, this finding is based on a single experiment only and thus needs further confirmation.
It was previously described that HLA-DP allotypes are organised in groups that show related
behaviour in transplantation, and this correlates with their amino acid similarity (Fleischhauer
et al., 2012; Zino et al., 2003). Therefore, it is not unexpected that HLA-DP molecules from the
same group can present epitopes to the same T cells.
The expression of 9 HLA class I-restricted TCRs specific for UL28327-335 (FRC) or IE-1309-317
(CRV) and 12 HLA class II-restricted TCRs specific for various epitopes of either pp65 or IE-1
was analysed. All of those TCRs except for FRC86 could be transferred into primary T cells from
HCMV– healthy donors and were expressed on the cell surface (fig. 4.11-4.18 and 4.20-4.24). The
TCR KYQE16 was never transferred because no HLA-DQB1*05:01+ PBMC donor was available
from which moDCs could be derived for subsequent testing of TCR-transgenic effector T cells. 8
out of 9 HLA class I-restricted TCRs and 11 out of 12 HLA class II-restricted TCRs recognised
endogenously processed antigens that were presented by mini-LCLs, HCMV-infected fibroblasts
or HCMV-infected moDCs. Thus, a panel of functional HCMV-specific TCRs was established
that covers a variety of HLAs and could be further developed for clinical application (see tab.
4.2).
Based on the HLA allotypes that are covered by it, this panel allows to target HCMV by at least
one TCR in large proportions of different ethnicities (see tab. 5.1). Focussing on Caucasians, the
CRV- or FRC-specific TCRs that are restricted by HLA-C*07:02 could be applied in adoptive T
cell therapy in a quarter of patients, and the YSE-specific TCR, which is HLA-A*01:01-restricted,
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Table 5.1. HLA alleles and their phenotype frequency. Allele frequencies (AF) of HLA alleles
that are relevant to the TCRs tested in the present study among Caucasians (CAU), African
Americans (AFA) and Asian or Pacific Islanders (API) were gathered from Gragert et al.
(2013, HLA-A, -C, -DQB & -DRB) or Hollenbach et al. (2012, HLA-DPB). Percentages
of phenotype coverage were calculated by assuming distribution according to the Hardy-
Weinberg equilibrium: Population coverage (i.e. probability that a specific allele is present
in both or one of the two sets of chromosomes of a person) = (1 − (1 − AF) · (1 − AF)).
Population coverages are highlighted according to low (blue), medium (white) or high (red)
frequency.
HLA allele estimated population coverage [%]
AFA API CAU
A *01:01 9.1 13.8 29.2





DQB 1*03:01 33.6 33.6 35.41*05:01 27.5 15.5 21.9
DRB
1*13:01 10.5 6.3 12.0
1*13:02 14.1 7.1 9.1
1*15:01 5.4 15.8 24.2
3*01:01 24.9 9.2 26.8
3*02:02 46.8 37.9 36.2
3*03:01 18.4 21.7 9.2
5*01:01 26.9 22.1 24.3
to approximately 30% of patients. According to the HLA restrictions as listed in table 4.2, the
HCMV-specific, HLA class II-restricted TCRs could be applied to a proportion of Caucasian
patients ranging from 9% to 36% (Gragert et al., 2013, see tab. 5.1) depending on the individual
restricting element. Due to restriction by different HLA classes (I and II) as well as different
HLA class II isoforms (DP, DQ and DR), more than one HCMV-specific TCR may be applied
to patients that harbour the respective HLA alleles: The second and third most frequent HLA
haplotype in Caucasians include HLA-C*07:02 and DRB5*01:01 (Gragert et al., 2013) and thus
allow for the application of CRV- and FRC-specific TCRs, as well as EFFT22. For these frequent
haplotypes, a combined application of HLA class I and class II-restricted TCRs will therefore
be possible. The ninth most common Caucasian HLA haplotype includes HLA-DRB1*13:02 and
DRB3*03:01 (Gragert et al., 2013) which enables the usage of the TCRs QPFM17, YRIQ18,
YRIQ36 and AGIL19. Moreover, HLA heterozygosity may allow for the application of several
HCMV-specific TCRs at the same time.
5.2 δ2 T cells as recipients of HCMV-specific αβ TCRs
αβ TCR-transgenic γδ T cells have already been generated by others (van der Veken et al., 2009,
2006) in order to avoid the complication of mixed TCR dimers in TCR-transgenic αβ T cells
(Bendle et al., 2010; van Loenen et al., 2010). These γδ T cells, however, had been extensively
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purified by FACS and MACS of isolated PBMCs before the TCR genes were transferred (van der
Veken et al., 2009, 2006). In contrast, the protocol presented here involves only a single step of
immunomagnetic separation in order to deplete αβ TCR+ cells (αβ T cells) from the PBMC pre-
paration and leaves γδ T cells “untouched”. This avoids any interference with the functional state
of the γδ T cells due to activation of the TCR (e.g. by antibody-mediated cross-linking) or inac-
tivation of the TCR (e.g. by inhibiting contacts of TCR and target through antibody-mediated
blocking). When αβ T cells had not been removed prior to pamidronate (PAM) stimulation,
some of them apparently became susceptible to retroviral transduction and thereafter expressed
the transgenic TCR (fig. 4.9 & 4.15). Since no foreign antigens were present in the T cell cul-
ture except for residual trace amounts of FCS that cannot be entirely excluded, antigen-specific
activation of αβ T cells in T cell cultures stimulated with PAM is unlikely. However, it is a long
standing observation that a proportion of T cells will be activated ex vivo in the presence of cyto-
kines even if no specific antigen is present (Chu et al., 2013; Grimm et al., 1982). This bystander
activation cannot be totally avoided in standard T cell cultures and may have activated some αβ
T cells, which enabled their retroviral transduction.
In effector assays that evaluated the recognition of HCMV-infected target cells by PAM-stimu-
lated, TCR-transgenic T cell lines, it was not possible to distinguish the contribution of these
simultaneously transduced αβ T cells from the effect of the desired TCR-transgenic γδ T cells.
Thus, αβ T cells had to be removed from the culture prior to PAM stimulation in order to assess
the capability of TCR-transgenic γδ T cells alone. In contrast to van der Veken et al. (2009,
2006), who purified total γδ T cells that encompassed all the different natural subsets (δ1, δ2,
and others), PAM stimulation of αβ TCR-depleted PBMCs specifically expands Vδ2+ T cells
(Gober et al., 2003; Morita et al., 2007), which are the dominant γδ T cell population in peri-
pheral blood. Out of a range of 1 to 45 µM, 10 µM of PAM showed optimal proliferation of δ2 T
cells after three to seven days (fig. 4.9 A). Since susceptibility of δ2 T cells to retroviral trans-
duction was best after three days of PAM stimulation and then gradually decreased up to seven
days of PAM stimulation (fig. 4.9 D), the duration of PAM stimulation prior to retroviral trans-
duction was limited to three days. Shorter or longer periods of PAM stimulation were not tested.
The phenotype of δ2 T cells from three donors ex vivo was composed of roughly 20% naïve
(N), 25% central memory (CM), 40% effector memory (EM) and 15% EM re-expressing CD45RA
(EMRA) T cells (fig. 4.10 B). After PAM stimulation, the large majority of δ2 T cells from the
same three donors predominantly possessed either a CM or a EM phenotype, which is favourable
and likely increases the efficacy of a T cell product (Busch et al., 2016). For αβ T cells, transfer
of less-differentiated T cell subsets (N, CM) was highly correlated with clinical responses because
these T cell subsets were associated with superior T cell engraftment, persistence, and antitu-
mour immunity compared to TEM and TEMRA cells (Klebanoff et al., 2012). For δ2 T cells, it
remains unknown which phenotypic subpopulation likely confers best efficacy in adoptive T cell
therapy. If less-differentiated δ2 T cells are preferable, the established protocol represents an
effective and fast procedure to transfer αβ TCRs into δ2 T cells with a promising potential in
adoptive T cell therapy because the proportion of terminally-differentiated δ2 T cells was below
5% after three, five and seven days of PAM stimulation (fig. 4.10).
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Both HLA class I- and class II-restricted, HCMV-specific TCRs were expressed on a relatively
large proportion of δ2 T cells four to seven days after retroviral transduction (sections 4.3.1 &
4.4.2). TCRs specific for one of the epitopes CRV, FRC, YSE, AGIL, EFFT and YRIQ could be
stained by peptide-specific HLA class I or class II multimers, which is discussed in detail in the
paragraphs below. In parallel, expression of the majority of transgenic TCRs could be assessed by
antibodies that are specific for a particular Vβ domain (8 out of 9 HLA class I-restricted TCRs
and 7 out of 12 HLA class II-restricted TCRs). For some Vβ domains, like Vβ6, no specific
antibodies can be purchased at the moment, possibly because the epitopes of such Vβ-specific
antibodies are too similar to other Vβ domains. In this study, nine out of ten different Vβ-specific
antibodies (see tab. 2.14) provided good quality of staining. When the quality of staining with a
Vβ-specific antibody was poor (e.g. Vβ5.2) or the particular Vβ-specific antibody was not avail-
able (e.g. Vβ6), the expression of the TCR chains was assessed by staining with an antibody that
binds to any αβ TCR (antibodies are listed in tab. 2.14). However, the latter staining method
was only applicable to δ2 T cells because αβ T cells endogenously express another αβ TCR already.
αβ TCR-transgenic δ2 T cells offer the advantage that they can be stimulated by aminobisphos-
phonates in the absence of stimulation via the transgenic αβ TCR. However, this is only possible
when they express the endogenous γδ TCR and the transgenic αβ TCR simultaneously, as was
the case with most TCR-transgenic δ2 T cell lines after transduction with retroviruses coding for
an HLA class II-restricted TCR (fig. 4.20-4.24). If HCMV-specific, TCR-transgenic δ2 T cells
were applied to an HCMV– patient (prophylactic therapy) or an HCMV+ patient (preemptive
therapy) in the absence of HCMV infection or reactivation, these T cells could be maintained
or even expanded by periodical stimulation with clinically approved aminobisphosphonates, like
PAM.
Transduction with retroviruses coding for QPFM17 or EFFT22 resulted in an increased fraction
of δ2 T cells that expressed the transgenic αβ TCR, but not the endogenous (Vγ9)Vδ2 TCR (fig.
4.20, 4.23 & 4.24), possibly because these two TCRs competed exceptionally well for binding
to CD3. Thus, the ability to maintain and expand αβ TCR-transgenic δ2 T cell populations by
PAM stimulation in the absence of HCMV infection in vivo may negatively correlate with the
competitiveness of the particular TCR.
In αβ T cells, hazardous αβ TCR mis-pairing was reported after transfer of additional αβ TCR
genes into these cells: virus-specific T cell lines that had been transduced with an αβ TCR showed
neo-reactivity directed against allo-, but also auto-HLA which was sometimes as robust as re-
activity via the introduced or endogenous TCR against peptide pulsed target cells (van Loenen
et al., 2010). Introduction of only TCRα or TCRβ chains also resulted in neo-reactivity. This
was also observed in a mouse model, where it was found that self-reactive TCRs were formed
by introduced and endogenous TCR chains in transgenic T cells causing lethal autoimmunity
(Bendle et al., 2010). In contrast to αβ T cells, potentially harmful αβ TCR mis-pairing is not
expected to occur in γδ T cells because the αβ TCR cannot exchange chains with a γδ TCR
(Koning et al., 1987; Saito et al., 1988). This makes γδ T cells a safer alternative to αβ T cells.
Employing δ2 T cells in particular may even be safer than using total γδ T cells because the
endogenous specificity of δ2 T cells is directed towards IPP, HMB-PP and related antigens (re-
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viewed in Morita et al., 2007) and δ2 T cells have never been described to recognise a totally
different antigen. Also, the repertoire of Vγ9Vδ2 T cells is semi-invariant due to conserved TCR
usage (reviewed in Willcox et al., 2018). Thus, δ2 T cells may be considered a mono-specific
population, which is further supported by the observation that combining Vγ9 and Vδ2 chains
from different TCRs with each other did not alter their specificity, but even increased reactivity
of TCR-transgenic T cells (Gründer et al., 2012). In contrast, δ1 and δ3 T cells contain T cell
populations of different specificities and may thus be associated with unwanted off-target effects
once they are activated by the transgenic TCR.
Almost no unspecific reactivity and in particular no alloreactivity of TCR-transgenic, HLA
class II-restricted δ2 T cells from three different donors was observed in this study after testing
them against allogeneic target cells from five different donors in 34 different combinations of the
three factors TCR, T cell donor and moDC donor (fig. 4.29 & 4.30). In comparison, most TCR-
transgenic, HLA class II-restricted αβ T cells showed increased unspecific reactivity in response
to allogeneic control target cells. Occasionally, HLA class II-restricted, TCR-transgenic αβ T
cells even showed strong reactivity to target cells in comparison to equivalent δ2 T cells in the
same allogeneic setting (fig. 4.28). Strong reactivity of TCR-transgenic αβ T cells to allogeneic
control moDCs was probably due to alloreactivity and could not have been observed if autologous
target cells were used. Alloreactive T cell clones were shown to recognise a single peptide/allo-
HLA complex that was unique for each clone (Amir et al., 2011), so alloreactivity in the present
study was likely due to a minority of the TCR-transgenic αβ T cells that recognised a “foreign”
HLA loaded with a “self” peptide. This is highly relevant in an allogeneic transplant situation
because the recipient may develop GvHD (HSCT) or graft rejection (SOT) if alloreactive T cells
are transferred. Since δ2 T cells are not considered to be alloreactive, they harbour a safety
advantage in an allogeneic setting, which probably is why others use them as well (reviewed
in Fisher and Anderson, 2018; Pauza et al., 2018). δ2 T cells also have important functions of
relevance in virus control, such as direct killing of target cells and production of antiviral cytokines
(reviewed in Fisher and Anderson, 2018; Pauza et al., 2018; Zheng et al., 2013). However, they
may not have a functional repertoire comparable to αβ T cells and may not be able to produce
all TH cytokines.
5.3 CRV- and FRC-specific TCRs restricted by HLA-C*07:02
The expression of CRV- and FRC-specific TCRs after transfer of their genes into αβ or δ2 T
cells was assessed by HLA-C*07:02 streptamers. All four CRV-specific TCRs and 4 out of 5
FRC-specific TCRs were well expressed on αβ T cells (fig. 4.16 A & 4.18 A). The TCR CRV2
was also well expressed on δ2 T cells in the absence of CD8 (fig. 4.14). While ex vivo stain-
ing of CRV-specific CD8+ T cells by CRV/HLA-C*07:02 streptamers has already been reported
(Ameres et al., 2013; Schlott et al., 2018), the expression of FRC-specific TCRs has not been
analysed so far by peptide/HLA multimer analysis in the published literature. However, analyses
of this group showed that FRC multimer staining works well and reliably (X. Liang and A. Huth,
unpublished results).
HLA-C*07:02 is a promising HLA restriction to employ for T cell therapy of HCMV infection
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because CD8+ T cell clones that are restricted by this HLA allotype were able to strongly recog-
nise HCMV-infected fibroblasts despite the presence of immune evasive proteins (Ameres et al.,
2014, 2013). HCMV-specific CD8+ T cell clones that were restricted by various HLA-A or -B
allotypes were not able to elicit a comparable response in the presence of the four immunoevasins
US2, US3, US6 and US11. Even one of the immunoevasins US2 and US11 was potent enough to
strongly down-regulate HLA-A*02:01 and other HLA-A molecules on the surface of fibroblasts
and thereby evade T cell recognition (Ameres et al., 2014). The mechanism behind the down-
regulation of HLA surface expression is the dislocation of HLA class I α chains from the ER to
the cytosol, which is driven by US2 and US11, and their subsequent proteasomal degradation
(Jones and Sun, 1997; Wiertz et al., 1996). US2 and US11 were shown to directly interact with
the α2, α3 and cytoplasmic domains of HLA class I α chains (Barel et al., 2003a,b; Besold and
Plachter, 2008). These observations and the fact that these domains of HLA class I α chains
are polymorphic explain the allele specificity of HLA class I down-regulation by US2 and US11
(Barel et al., 2003a,b; Schust et al., 1999, 1998). HLA-C was predicted (Barel et al., 2003a,b) and
shown to be uniquely resistant to the effects of both US11 and US2 (Schust et al., 1998). The
functional relevance of HLA-C for T cell recognition of HCMV infection was shown by Ameres
et al. (2014) who confirmed the resistance of HLA-C*07:02 to US2 and US11. However, it re-
mains unclear whether other HLA-C alleles are similarly protected from US2 and US11.
Recognition of AD169-infected fibroblasts by CRV-specific, HLA-C*07:02-restricted CD8+ T
cells was reproduced using the two T cell clones 1010M #7 and F46M #36 (fig. 4.16 B II)
thereby confirming previous reports from this group (Ameres et al., 2014, 2013). In the present
study, both T cell clones were also shown to strongly recognise fibroblasts that had been infected
with HCMV WT strain Merlin (fig. 4.16 B II).
Each of the four CRV-specific and the four FRC-specific TCRs that were analysed in the
present study mediated strong recognition of peptide-loaded and CMV-Δall-infected fibroblasts,
despite low proportions of TCR-transgenic T cells among some of the T cell lines (fig. 4.16 &
4.18). However, neither TCR-transgenic T cells that expressed a CRV-specific TCR, nor those
that expressed a FRC-specific TCR recognised fibroblasts infected with AD169 or Merlin. In
contrast, fibroblasts infected with CMV-Δall, which is derived from AD169, but lacks the four
immunoevasins US2, US3, US6 and US11 (Besold et al., 2009), were strongly recognised by both
TCR-transgenic T cells and CRV-specific CD8+ T cell clones. Even T cell lines that were engin-
eered to express the TCR isolated from the CRV-specific T cell clone F46M #36 (i.e. CRV3),
which is highly sensitive to infection with WT HCMV, or 1013M #169 (i.e. CRV4) did not
recognise fibroblasts infected with AD169 or Merlin.
This insensitivity of HCMV-specific, HLA-C*07:02-restricted TCRs towardsWT strains of HCMV
was unexpected. Thus, several properties of TCR-transgenic T cells and T cell clones were ana-
lysed in order to identify the reason for this deficiency. The intensity of TCR expression on
CRV-specific T cell clones as well as their proportion of CRV streptamer+ T cells was com-
parable to that of TCR-transgenic T cells expressing CRV2 or its murinised variant CRV2mu,
as assessed by FACS analysis (fig. 4.17). Thus, TCR expression intensity and the propor-
tion of TCR-expressing T cells were considered unlikely to be the causes. Separation of CD8+
TCR-transgenic T cells in order to eliminate possible TCR-transgenic CD4+ Treg cells and their
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subsequent co-cultivation with AD169-infected fibroblasts did not enhance recognition of HCMV
infection (data not shown). Moreover, the levels of the anti-inflammatory cytokine IL-10 in the
supernatant of these co-cultures were generally low and not elevated due to AD169 infection.
The phenotype of TCR-transgenic T cells (≈75% TEM and ≈18% TCM) resembled that of the
CRV-specific T cell clones 1010M #7 and F46M #36 (>97% TEM), so an aberrant differentiation
of TCR-transgenic T cells was also unlikely to cause the insensitivity of TCR-transgenic T cells
towards target cells infected with WT HCMV.
The hypothesis remained that HCMV-specific, HLA-C*07:02-restricted T cell clones may be
selected into the memory repertoire in vivo depending on an unknown property that confers
enhanced sensitivity for HCMV-infected cells. CRV-specific CD8+ T cell clones, and the in vivo
T cells from which they were derived, may express activating receptors that enable the T cells
to overcome the effects of the immunoevasins, but that are not present on most other peripheral
T cells. Alternatively, the functional deficiency of TCR-transgenic T cells might be caused by
expression of inhibitory receptors that are triggered by AD169-infected fibroblasts, but are not
present on CRV-specific CD8+ T cell clones. However, it is not obvious why AD169, but not
AD169-derived CMV-Δall, would be able to engage this mechanism.
In order to test both hypotheses, the expression of the activating receptor NKG2D and the in-
hibitory receptors NKG2A and KIR2DL2/3 on TCR-transgenic T cells and CRV-specific CD8+
T cell clones was assessed. Both types of T cells neither expressed NKG2D (MFI ≤1,000 AU),
nor NKG2A (<0.3%). KIR2DL2/3 (CD158b) was not expressed by TCR-transgenic T cell lines
and T cell clone 1010M #7 CRV (≤0.3%), but 2.8% of the cells of T cell clone F46M #36 CRV
expressed KIR2DL2/3. However, this small fraction of CD158b+ cells did not prevent strong
recognition of AD169-infected fibroblasts by the T cell clone F46M #36 CRV (fig. 4.16 B II).
Since these analyses only covered three receptors out of many that could modulate T cell func-
tionality (reviewed in Hilton and Parham, 2017; Parham, 2005; Parham and Moffett, 2013),
the expression patterns of other inhibitory or activating receptors, such as LILRB1 and several
KIRs, remain to be evaluated in order to elucidate the deficiency of TCR-transgenic T cells or
the advantage of CRV-specific CD8+ T cell clones. If any one receptor or other molecule could
be identified as the root cause, this would greatly help assessing whether the generation of TCR-
engineered T cells for adoptive T cell therapy can be optimised in a way to take advantage of
these important HLA-C-restricted TCR specificities.
A lack of natural regulation of transgenic TCRs may also impair sensitivity towards WT strains
of HCMV. TCR internalisation, resulting in transiently reduced TCR surface expression, usually
limits the intensity and duration of signalling as a result of natural TCR engagement (Itoh et al.,
1999; Valitutti et al., 1995). The retroviral vector MP71 that was used for delivery of TCR genes
in the present study yields stable, high-level transgene expression in T lymphocytes (Engels et al.,
2003) and may thus prevent effective limitation of TCR signalling. Although it may seem counter-
intuitive, down-regulation of TCR expression may be necessary for an optimal T cell response,
as indicated by a study of Eyquem et al. (2017), who showed that targeting gene transfer of a
chimeric antigen receptor (CAR) to the TRAC locus enhances tumour rejection in comparison
to “random” retroviral gene insertion. Therefore, placing the transgenic HCMV-specific TCR
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under the regulation of a natural TCR promoter may rescue sensitivity of TCR-transgenic T
cells towards target cells infected with WT strains of HCMV. However, this remains speculative
and requires further investigation.
5.4 Expression of HCMV-specific HLA class II-restricted TCRs on primary T cells
The intensity of TCR expression and the proportion of TCR-expressing T cells were assessed by
staining with TCR-specific antibodies and, if available, with peptide/HLA-specific multimers.
The TCRs AGIL19, QPFM17, EPDV21, EFFT22, EFFT50, RRKM18, SVMK6 and SVMK27
could be well expressed on δ2 T cells and most of them also on αβ T cells (fig. 4.20, 4.23 &
4.24 and summary provided in tab. 4.3). In contrast, EIMA236, YRIQ18 and YRIQ36 were
expressed on a comparatively small population of δ2 T cells (fig. 4.21 & 4.22).
No Vβ6 (TRBV7)-specific antibody was commercially available for staining the variable domain
of the TCRβ chains of YRIQ18, YRIQ36, RRKM18 and EFFT50. Instead, specific peptide/HLA
class II tetramers and an antibody that binds to any αβ TCR were used. However, three out of six
peptide/HLA tetramers either failed to refold in presence of peptide (KRKM/HLA-DRB3*02:02)
or refolded only sub-optimally (QPFM/HLA-DRB1*13:02 and MSIY/HLA-DRB1*15:01) during
production by the manufacturer Immunaware (Copenhagen, Denmark), as described in sections
2.8 and 4.4.2. HLA-DRB3*02:02 monomers were deliberately refolded in the presence of KRKM
and not RRKM peptide, because the TCR RRKM18 and its parental T cell clone F65M #18
showed superior sensitivity for KRKM (fig. 4.31 A). The reason for the difficulties with refolding
HLA monomers is not entirely clear, but may be attributed to a wrong allocation of epitope
and/or HLA restriction in at least one case (MSIY/HLA-DRB1*15:01), since neither could be
precisely determined for the TCR MSIY40. As a result of the erroneous HLA monomer refolding,
KRKM/HLA-DRB3*02:02 was not delivered, QPFM/HLA-DRB1*13:02 failed to stain CD4+ T
cell clone F46P #17 QPFM and MSIY/HLA-DRB1*15:01 failed to stain MSIY40-transgenic T
cells (data not shown).
Of the three HLA class II tetramers whose monomers had refolded well, EFFT/HLA-DRB5*01:01
and AGIL/HLA-DRB3*03:01 provided stainings of high quality (fig. 4.24). Similar stainings of
respective ex vivo T cell populations were reported by Braendstrup et al. (2013, 2014) for the epi-
tope IE-1211-225 restricted by HLA-DRB5*01:01. Their IE-1211-225/HLA-DRB5*01:01 tetramers
likely stained T cells that are specific for IE-1213-225 (EFFT) as presented here because the latter
was identified as the minimal epitope (Ameres et al., 2015). CD4+ T cells specific for pp65489-503
(AGIL) have also been stained ex vivo with tetramers previously (Pachnio et al., 2016), but these
employed HLA-DRB3*02:02 instead of DRB3*03:01 as used here. In accordance with experi-
ments that assessed the HLA restriction of the T cell clone F46P #45 (fig. 4.7 C), this supports
the hypothesis that AGIL may be presented by HLA-DRB3*02:02 as well as DRB3*03:01 and
may be recognised on both HLA allotypes by AGIL-specific T cell clones including F46P #19
and #45. These previously reported multimer stainings (Braendstrup et al., 2013, 2014; Pachnio
et al., 2016) demonstrated the presence of particular HCMV-specific T cell populations ex vivo,
but in the work presented here the functional expression of such TCRs after gene transfer into
primary T cells is shown for the first time.
In contrast to the high quality stainings with EFFT- or AGIL-specific HLA tetramers, few cells
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of a YRIQ18-transgenic αβ or δ2 T cell line stained positive for YRIQ/HLA-DRB1*13:02 tet-
ramer (fig. 4.22). However, due to the lack of a suitable negative control, the quality of this
tetramer staining and the proportion of stained cells cannot be properly judged and require fur-
ther investigation. Staining with an αβ TCR-specific antibody confirmed the small proportions
of δ2 T cells that expressed either YRIQ18 or YRIQ36. Thus, expression of those two TCRs was
poor in comparison to most other HLA class II-restricted TCRs, possibly because YRIQ18 and
YRIQ36 poorly compete with the endogenous γδ TCR for binding of CD3, which is an important
prerequisite for strong surface expression of a transgenic TCR (Ahmadi et al., 2011).
In summary, multiple HCMV-specific TCRs derived from CD4+ T cell clones could be trans-
genically expressed in primary T cells for the first time. HLA class II multimer stainings were
successfully used for a subset of epitopes only, but this is expected because HLA class II multimers
remain a reagent that is difficult to produce and use (Braendstrup et al., 2013, 2014).
5.5 Recognition of HCMV-infected target cells through HLA class II-restricted
TCRs
DCs represent an important target for HCMV-specific CD4+ T cells in order to control HCMV
reactivation (Jackson et al., 2017), since the latency reservoir of HCMV is formed by CD34+
hematopoietic progenitor cells (HPCs) and cells of the myeloid lineage (Kondo et al., 1994; Sin-
clair and Sissons, 2006; Sindre et al., 1996). DCs are professional antigen-presenting cells that
possess the unique ability to prime naïve T cells, but are also able to reactivate memory T cells.
They are a natural interaction partner of HLA class II-restricted T cells because of their central
role in initiating immune responses and their constitutive expression of HLA class II complexes.
Since monocyte-derived dendritic cells (moDCs) can be differentiated from peripheral blood
monocytes by stimulation with IL4 and GM-CSF and they can be productively infected with
HCMV (Moutaftsi et al., 2002; Riegler et al., 2000; Sénéchal et al., 2004), moDCs were chosen
as target cells to evaluate the recognition of HCMV infection through HLA class II-restricted
TCRs. In vitro differentiated moDCs exhibit an interstitial/dermal DC phenotype (Duperrier
et al., 2000; Grassi et al., 1998) and thus closely mimic an in vivo DC population. More recent
protocols of in vitro moDC differentiation include the additional use of synthetic TLR agonists
(Lichtenegger et al., 2012; Spranger et al., 2010) that mimic natural conditions, in which danger
signals are delivered by infection (Matzinger, 1994). But since HCMV infection probably delivers
its own danger signals to the infected cells, such as viral DNA that may activate TLR9, this was
not considered necessary here.
Fibroblasts that were used as target cells to test HLA class I-restricted TCRs are no adequate
target cells for testing HLA class II-restricted TCRs, because fibroblasts usually do not express
HLA class II, although stimulation with IFN-γ can promote HLA class II expression to some
extent (Pober et al., 1983; Stevanovic et al., 2013).
Contradictory data was reported on the susceptibility of moDCs to HCMV infection owing to
different maturation status of the DCs and differently propagated HCMV virus strains. How-
ever, Sénéchal et al. (2004) were able to draw a conclusive summary: immature moDCs were
most susceptible to HCMV propagated on endothelial cells (35-70% infected DCs at MOI = 1),
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while infection by HCMV propagated on fibroblasts was very inefficient. In contrast, mature
DCs were efficiently infected by both types of HCMV preparations, but at a lower efficiency
(15-30% infected DCs at MOI = 1) than immature moDCs. Some of these observations were
confirmed by others as well: TB40/E propagated on human foreskin fibroblasts better infected
immature than mature moDCs (Moutaftsi et al., 2002); moDCs were fully permissive for HCMV
infection when endothelial cell-adapted HCMV strains were applied, irrespectively of their stage
of maturation, but viral replication was abrogated at the level of IE and/or E gene expression
when fibroblast-adapted strains were used (Beck et al., 2003); the infection rate of immature
moDCs was negligible with fibroblast-adapted HCMV strains, but 80-90% were susceptible to
HCMV strains that had been propagated in endothelial cell culture (Riegler et al., 2000).
Since the HCMV virus preparations that were used in the present study had exclusively been
propagated on fibroblasts, moDCs were matured prior to infection with HCMV at an MOI of 5
to achieve a sufficient population of HCMV-infected moDCs.
HCMV infection decreases the expression of co-stimulatory molecules, like CD40, CD80 and
CD86, and of HLA class I and class II complexes on DCs (Grigoleit et al., 2002; Hertel et al.,
2003; Moutaftsi et al., 2002). CD86 and HLA class II molecules, however, may be less affected
than CD40, CD80 and HLA class I molecules (Beck et al., 2003; Moutaftsi et al., 2002). Sénéchal
et al. (2004) observed a decreased expression of CD80, CD86, HLA class I and class II on imma-
ture moDCs after HCMV infection, too, but the latter had comparatively little effect on mature
moDCs. HCMV was also shown to decrease the expression of various adhesion molecules, such
as CD11c, CD33, CD54, CD58 (Beck et al., 2003) and ICAM-1 (Hertel et al., 2003), on infected
DCs.
Probably as a result of the down-regulation of co-stimulatory, adhesion, and HLA molecules,
the stimulatory activity of DCs to autologous (Moutaftsi et al., 2002; Raftery et al., 2001) and
allogeneic T cells (Grigoleit et al., 2002; Hertel et al., 2003; Sénéchal et al., 2004) was im-
paired by HCMV infection. CD83, which is an important marker molecule for mature DCs and
provides co-stimulation to T cells (Aerts-Toegaert et al., 2007), may play a special role in in-
hibition of the immunostimulatory activity of HCMV-infected DCs: the expression of CD83 was
strongly decreased on HCMV-infected, mature moDCs, while cell-free supernatants from these
cells contained a significantly increased amount of soluble CD83 in comparison to uninfected,
mature moDCs (Sénéchal et al., 2004). Decreased expression of CD83 on HCMV-infected, ma-
ture DCs was also reported by Hertel et al. (2003). The inhibitory effect of soluble CD83 on DC
stimulatory activity could be abrogated by immunodepletion of CD83 from the supernatant of
HCMV-infected moDCs (Sénéchal et al., 2004).
In accordance with observations of reduced immunostimulatory capacity of infected DC cultures,
the immunoevasins US2 and US3 of HCMV were reported to target the HLA class II molecules
for degradation (Hegde et al., 2002; Tomazin et al., 1999) in a similar way than HLA class I
molecules are affected (Hegde and Johnson, 2003). These studies were conducted using the as-
trocytoma/glioblastoma cell line U373-MG that was induced to express HLA class II molecules
either by IFN-γ or by transfection with the class II transactivator gene (CIITA). However, the
previously reported effect of US2 on HLA class II DRα could not be confirmed in moDCs that
naturally express HLA class II molecules (Rehm et al., 2002). These contradictory results may
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be caused by discrepancies in delivering the viral immunoevasins and enforcing their expression,
as well as the difference in cell types. However, it remains somewhat surprising that US2 was
reported to cause degradation of both HLA-DRα and DMα (Tomazin et al., 1999), which share
only 27% and 24% amino acid homology with HLA-A, respectively, while HLA-C and HLA-G
that share about 80% of their sequences with HLA-A (Tomazin et al., 1999) were resistant to
the effects of both US2 and US11 (Schust et al., 1998).
In order to assess the effect of the immunoevasins US2, US3, US6 and US11 on peptide present-
ation via HLA class II, the AD169-derived virus strain CMV-Δall, which is devoid of these four
immunoevasins (Besold et al., 2009), was used to infect moDCs. HCMV-specific, HLA class
II-restricted T cell lines mainly produced a comparable amount of IFN-γ in response to moDCs
that were infected with AD169 or CMV-Δall. YRIQ-, QPFM- and AGIL-specific TCRs medi-
ated a slightly stronger recognition of moDCs infected with CMV-Δall than moDCs infected with
AD169 (1.4-, 1.5- and 1.4-fold increased IFN-γ levels, fig. 4.29). However, neither RRKM- nor
SVMK-specific TCRs elicited higher IFN-γ levels in response to infection with CMV-Δall when
compared with AD169 (fig. 4.30). The sensitivity of EFFT-specific TCRs was not tested against
CMV-Δall. This difference in sensitivity of pp65- and IE-1-specific T cell lines for infection with
CMV-Δall may not be solely explained by the lack of the four immunoevasins, but may also
be caused by a high content of pp65 in virus preparations (Varnum et al., 2004). If virus pre-
parations of the strain CMV-Δall carried more non-infectious enveloped particles (NIEPs) and
dense bodies than preparations of AD169, this would increase the sensitivity of pp65-specific,
but not IE-1-specific, T cells towards CMV-Δall-infected moDCs. Dense bodies are virus-like
structures lacking viral DNA that are readily taken up by antigen-presenting cells, followed by
processing and presentation of their antigenic material (Pepperl et al., 2000; Pepperl-Klindworth
et al., 2003).
In summary, moDCs infected with CMV-Δall were not recognised more strongly than moDCs
that were infected with AD169 by HCMV-specific, TCR-transgenic T cell lines. Thus, the im-
munoevasins US2, US3, US6 and US11 may have a minor or no effect on peptide presentation
via HLA class II in mature moDCs.
The functionality of the HCMV-specific, HLA class II-restricted TCRs AGIL19, EPDV21,
EFFT22 and RRKM18 was independent of CD4 co-expression, since HCMV-infected moDCs
were recognised similarly well by TCR-transgenic δ2 T cells irrespective of CD4 co-transduction
(fig. 4.32). The dependency of SVMK-specific TCRs on CD4 co-expression was not evaluated
in the same way by CD4 co-transduction, but δ2 T cells that were only transduced with these
TCRs mediated strong recognition of HCMV-infected moDCs (fig. 4.28). This indicates that
the two SVMK-specific TCRs work well in the absence of CD4 co-receptor. All YRIQ-specific
TCR-transgenic T cell lines, whose function was assessed in this study, had been co-transduced
with CD4, so the dependency of YRIQ18 and YRIQ36 on co-expression of CD4 could not be
evaluated. Regarding the TCR QPFM17, in two of three experiments only T cells co-transduced
with TCR and CD4 were tested, resulting in good recognition of infected cells, but similar and
even stronger recognition was achieved in a third experiment with αβ T cells and δ2 T cells,
respectively, transduced with TCR but not CD4 (fig. 4.29). Thus, CD4 co-expression appeared
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not necessary for this TCR either.
In summary, there was no evidence that recognition of HCMV-infected moDCs by HLA class
II-restricted TCRs depended on expression of CD4. This finding is in accordance with a study by
van der Veken et al. (2006) who assessed the effector functions of γδ T cells that expressed an HLA
class II-restricted TCR specific for the minor histocompatibility antigen HA-2 in the presence or
absence of CD4 co-expression. They found that CD4 co-transduction did not increase IFN-γ se-
cretion by TCR-transgenic γδ T cells, but antigen-specific lysis was approximately doubled when
CD4 was co-expressed. Whether the HCMV-specific, HLA class II-restricted TCRs presented
here rely on CD4 co-expression for enhancement of their cytotoxic efficacy remains to be elucid-
ated.
Murine αβ T cells were reported to be able to detect even a single peptide/MHC class II complex
on the surface of an antigen-presenting cell (Irvine et al., 2002). This sensitivity highly depends
on the co-receptor CD4 (Irvine et al., 2002; Krogsgaard et al., 2005), which enhances the respons-
iveness of CD4+ TH cells by recruiting the tyrosine kinase Lck (Li et al., 2004). However, the
recognition of professional APCs, like DCs, may be independent of CD4 expression if sufficient
co-stimulation is provided through other molecules, like CD28, which may compensate for a lack
of CD4. In δ2 T cells, the activating receptor NKG2D may also help overcoming the activation
threshold in recognition of HCMV-infected DCs. At least in CD8+ T cells, NKG2D can have an
important co-stimulatory function (Rajasekaran et al., 2010).
10 out of 13 HLA class II-restricted TCRs specific for pp65 or IE-1 that were tested within
the present study conveyed sensitivity for HCMV-infected moDCs to TCR-transgenic T cells
(fig. 4.29 & 4.30). The recognition of HCMV-infected moDCs mediated by the remaining three
TCRs was not assessed due to a lack of HLA-matched moDCs (KYQE16), a lack of mini-LCL
recognition (EIMA236) or unresolved HLA restriction (MSIY40).
pp65-specific TCRs that are restricted by HLA class II generally evoked strong IFN-γ secretion
by TCR-transgenic T cells regardless of the T cell type that received the TCR genes (αβ vs. δ2,
fig. 4.29). In contrast, the amount of secreted IFN-γ by TCR-transgenic T cells specific for IE-1
was often more modest (fig. 4.30). This does not necessarily imply that IE-1-specific TCRs were
less efficient than pp65-specific TCRs. pp65 is contained in large quantities in HCMV virions
but very little, if any, IE-1 protein (Büscher et al., 2015; Reyda et al., 2014). Moreover, in vitro
propagation of AD169 generates NIEPs in amounts nearly equivalent to virions (Gibson and
Irmiere, 1984) and dense bodies, which are mainly composed of pp65 (>60%, Varnum et al.,
2004). Thus, HCMV stock preparations deliver a large amount of pp65 but little IE-1 into in-
fected cells. IE-1 protein is among the first to be expressed after infection and its production
peaks at three days p.i. in moDCs (Fish et al., 1995). Nevertheless, at two days p.i., when the
recognition of HCMV-infected moDCs by HCMV-specific T cell lines was tested, much higher
levels of pp65 protein than IE-1 protein were likely available to HCMV-treated moDCs for pro-
cessing and presentation, which would explain the difference in IFN-γ secretion between pp65-
and IE-1-specific T cells.
Proteins of intracellular and extracellular origin both have a role to play in control of infec-
tion. In most infections, the task of DCs is to take up exogenous pathogenic material in order
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to prime naïve T cells and activate memory T cells. In the special situation of HCMV, DCs
can be infected themselves and are thus part of the viral replication cycle (Gerna et al., 2005;
Jahn et al., 1999; Sénéchal et al., 2004). Therefore, it becomes instrumental to distinguish two
situations: recognition of DCs that have taken up exogenous viral material, and recognition of
DCs that have themselves become infected and intracellularly produce viral antigen.
This distinction is difficult to perform, but different tools are available. Those may include bio-
chemical inhibitors of transcription and translation, such as actinomycin D or cycloheximide.
Recently, both compounds were applied in a sequential manner, which allows expression of viral
genes whose transcription is independent of de novo synthesis of viral proteins, in order to study
T cell recognition of early viral products (Hesse et al., 2013). But these compounds have severe
disadvantages as they strongly interfere with many biochemical processes of antigen-presenting
cells. In the experimental HCMV system, it is hard or impossible to achieve endogenous viral
gene expression after infection without co-transfer of protein during infection. Even if dense
bodies would be separated from functional virus by density centrifugation (Irmiere and Gibson,
1983; Talbot and Almeida, 1977), a large amount of viral protein would enter the cell as a com-
ponent of infectious virions. Therefore, the method chosen here was a simple but effective one: to
inactivate HCMV particles by UV irradiation, which introduces damage to viral DNA abolishing
gene expression from the viral genome. This method has often been used to distinguish the ef-
fects of intact virions or UV-inactivated virions on target cells and subsequent T cell recognition
(Frascaroli et al., 2018; Jackson et al., 2017; Moutaftsi et al., 2002; Sénéchal et al., 2004).
Although peptides that are presented on HLA class II complexes are generally believed to ori-
ginate from exogenous sources, peptides derived from endogenous proteins can also be presented
efficiently on HLA class II complexes (reviewed in Crotzer and Blum, 2010). Thus, viral proteins
that are translated in an infected cell and viral proteins from exogenous sources both contribute
to the abundance of viral peptides for presentation by HLA class II complexes.
The active/inactive virus recognition ratio (abbreviated as A/I ratio, see section 4.4.5.6) was
calculated to provide an overview whether HCMV-specific, TCR-transgenic T cells preferentially
responded to HCMV-infected moDCs or to scavenging moDCs, which had acquired viral proteins
through ingestion of extracellular material, but were not functionally infected with HCMV. These
calculations showed that pp65-specific, HLA class II-restricted TCRs had similar sensitivity for
HCMV-infected moDCs and for moDCs that were treated with UV-inactivated virus (A/I ratio
≈ 1, fig. 4.34). In contrast, IE-1-specific, HLA class II-restricted TCRs reacted more strongly
in the active than the inactive situation (A/I ratio ≥ 2). This observation was highly significant
for infection with AD169 (P<0.004, fig. 4.34 A & B) and also significant for infection with
TB40-BAC4 (P<0.05, fig. 4.34 C & D) – in both cases regardless of the type of TCR-transgenic
T cells (αβ vs. δ2). Thus, pp65-specific, HLA class II-restricted TCRs mediate recognition of
antigen-expressing target cells irrespective of the antigen source, whereas IE-1-specific, HLA class
II-restricted TCRs predominantly mediate recognition of bona fide infected target cells.
The benefit of IE-1-specific T cells that selectively recognise true infection is that such cells will
only mobilise a response against cells that carry the virus and may be capable of producing new
virions. Potentially, T cells that recognise cells which have taken up ubiquitous extracellular
antigen may be able to create damage by too broad and indiscriminate activation – especially in
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a therapeutic situation where HCMV infection is already widespread in an organ or in the body.
In case of massive viral disease, adoptive T cell therapy can be toxic due to overreaction, as an
example from EBV shows (Khanna et al., 1999). Therefore, it is useful that HCMV-specific,
HLA class II-restricted TCRs with different patterns of reactivity are now available to develop
adoptive immunotherapy in different clinical situations.
However, it is not clear yet which T cell specificities are protective against HCMV in humans.
Studies by Bunde et al. (2005) and Gratama et al. (2008) suggest that IE-1-specific but not
pp65-specific CD8+ T cells may protect from HCMV disease. IE-1-specific T cells have the
advantage that they may be able to recognise viral reactivation from latency at an early stage.
In contrast, pp65-specific T cells may be able to recognise freshly infected cells more potently
because pp65 that is contained in the virion is transferred into the infected cell and may be im-
mediately available for T cell recognition (see Hesse et al., 2013; Riddell et al., 1993, for CD8+ T
cells). pp65-specific T cells may also be less limited in their function as their antigen is produced
at higher amounts and they may therefore mobilise a stronger response supported by antigen
presentation by bystander cells. On the other hand, this will mainly happen late in the infectious
cycle. In the end, these different temporal and quantitative patterns of T cell recognition may
be complementary, and an optimally functional T cell response against HCMV may require a
combination of T cells specific for antigens of different classes, such as IE-1 and pp65. This
question remains to be answered by future investigations.
In order to correct the A/I ratios for background due to alloreactivity, such individual back-
grounds were subtracted from the A and I values (see section 4.4.5.6, equation 3). As expected,
the A/I ratios of TCR-transgenic δ2 T cell lines were little affected by the correction (fig. 4.33)
because their background reactivity was very low (fig. 4.29 & 4.30). In contrast, TCR-transgenic
αβ T cell lines were more strongly affected by the correction since their background reactivity
was slightly increased in general and occasionally even strongly increased. The A/I ratios of
IE-1-specific αβ T cell lines were more strongly affected by the correction than the ratios of pp65-
specific αβ T cell lines (fig. 4.33) usually because the amounts of cytokine secreted in response
to pp65 were higher than those in response to IE-1, as discussed above.
5.6 Development of HCMV-specific TCRs for adoptive T cell therapy
At present, the majority of clinical trials in adoptive T cell therapy focusses on generating
HCMV-specific T cells from HCMV-positive donors, who provide an established repertoire of
virus-specific memory T cells (https://clinicaltrials.gov, identifier: NCT02227641, NCT01325636
and NCT02985775, accessed on 07.05.19). However, about half of the population of industri-
alised countries is HCMV– (reviewed in Cannon et al., 2010), so there is a profound need for
clinically feasible protocols to generate HCMV-specific T cells from HCMV– donors. This can
be achieved by priming naïve T cells in vitro (Hanley et al., 2009, 2015; Jedema et al., 2011),
but the protocols are exceedingly time-consuming and complicated and the resulting T cells have
unusual properties and unclear efficacy. Alternatively, HCMV– HSCT donors or SOT recipients
may be vaccinated to generate HCMV-specific T cell immunity, but the antigen components
that would provide protective immunity remain unknown (reviewed in Diamond et al., 2018).
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Moreover, no vaccine has yet been licensed (Schleiss, 2016), although numerous clinical trials are
ongoing (reviewed in Diamond et al., 2018).
Thus, the transfer of genes of HCMV-specific TCRs emerges as the most reliable method to
obtain HCMV-specific T cells from HCMV– donors in a timely, qualitatively and quantitatively
appropriate fashion. Moreover, TCR gene transfer may be used to generate HCMV-specific T
cells of defined specificity from an HCMV+ HSCT donor or SOT recipient if the existing T cells
do not suffice to control HCMV infection. At the moment, only one registered clinical trial
(NCT02988258, accessed on 07.05.19) employs gene transfer of a pp65-specific, HLA-A*02:01-
restricted TCR into T cells from HCMV– donors. However, HLA-A*02:01 is particularly sus-
ceptible to the effects of HCMV’s immunoevasins (Ameres et al., 2014, 2013) and pp65-specific
CD8+ T cells may not be able to confer protection from HCMV disease (Bunde et al., 2005;
Gratama et al., 2008), as described earlier. Thus, TCRs that may confer protection from HCMV
infection and reactivation need to be identified and thoroughly characterised in order to enable
the generation of efficacious HCMV-specific T cells.
In this study, the expression and function of 8 HLA class I-restricted TCRs and 10 HLA class
II-restricted TCRs specific for one of the HCMV antigens pp65, IE-1 or UL28 were successfully
established. Among the CRV (IE-1309-317)-specific TCRs, CRV2 was outstanding because its
expression was high even in CD8– cells (fig. 4.16 A) and its affinity for CRV streptamers was
comparable to that of a CRV-specific T cell clone (fig. 4.17). Of the FRC (UL28327-335)-specific
TCRs, FRC1 showed the largest fraction of TCR+ CD8– T cells and FRC32 showed the most
intense FRC streptamer staining (fig. 4.18 A). All of the HLA-C*07:02-restricted TCRs either
specific for the epitope CRV or FRC conveyed sensitivity for target cells infected with the virus
strain CMV-Δall, but not AD169 or Merlin (fig. 4.16 B & 4.18 B). For an efficacious applic-
ation by transfer of TCR genes in adoptive T cell therapy against HCMV infection, this lack
of sensitivity needs to be further investigated and the function of the T cells needs to be improved.
Among the HLA class II-restricted TCRs specific for either pp65 or IE-1, some TCRs showed
extraordinary properties that may be useful in adoptive T cell therapy of HCMV infection. δ2 T
cells that were transduced with retroviruses coding for one of the two TCRs QPFM17 or EFFT22
showed a relatively high proportion of Vδ2– αβ TCR+ cells (fig. 4.20 & 4.23) in comparison to all
other HLA class II-restricted TCRs tested in this study. This may indicate that QPFM17 and
EFFT22 efficiently competed for CD3, which is limiting for the expression of a transgenic TCR
and the conveyed antigen-specific T cell function (Ahmadi et al., 2011). In contrast to other HLA
class II-restricted TCRs that presumably compete less successfully for CD3 complexes, QPFM17
and EFFT22 are well expressed on transgenic T cells and thus favourable TCRs for application
in adoptive T cell therapy.
Of all HLA class II-restricted TCRs specific for either pp65 or IE-1, AGIL19 mediated the
strongest IFN-γ secretion by both TCR-transgenic αβ and δ2 T cells in response to AD169-
treated moDCs (fig. 4.29 & 4.30). This may partly be caused by the high amount of pp65 in
AD169 propagated on fibroblasts (Gibson and Irmiere, 1984; Varnum et al., 2004). But since
other pp65-specific TCRs did not mediate comparable IFN-γ secretion by TCR-transgenic T cells
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in response to AD169, AGIL19 may be an especially sensitive TCR possibly due to enhanced
affinity. High competitiveness for binding of CD3 unlikely explains the increased sensitivity of
AGIL19 because QPFM17 which apparently competed well for binding of CD3 (described in the
previous paragraph) did not confer an increased sensitivity for HCMV infection. Alternatively,
AGIL peptides may be more abundantly presented by HCMV-infected moDCs than other pep-
tides, which could explain the increased sensitivity of AGIL19. Differences in peptide processing
and peptide/HLA stability may influence peptide abundance, but were too difficult to measure
at this point.
In addition to its high sensitivity for pp65, the HLA restriction of AGIL19 (DRB3*02:02 and
DRB3*03:01) implies an excellent coverage of various ethnicities (36-47% for DRB3*02:02 and
9-18% for DRB3*03:01, see tab. 5.1) making AGIL19 a promising TCRs for broad application
in adoptive T cell therapy.
The HLA class II-restricted TCR RRKM18 had a particular pattern of HCMV strain prefer-
ence. It consistently mediated higher levels of IFN-γ secretion in response to moDCs infected
with TB40-BAC4 than moDCs infected with AD169 (fig. 4.30). This was due to a higher affin-
ity of RRKM18-transgenic T cells for the epitope variant KRKM IYMC YRNV EFF (IE-1201-215) as
expressed by HCMV strain Davis than for RRKM MYMC YRNI EFF as expressed by HCMV strains
AD169, Towne, Merlin and strain W (fig. 4.31). Since RRKM18 also mediated recognition of
moDCs infected with TB40-BAC4 (KRKM IYMC YRNV EFF) and moDCs pulsed with the 15mer
peptide derived from HCMV strain Davis, it may also mediate recognition of moDCs infected
with HCMV strain Toledo (KRKM MYMC YRNV EFF). If this could be confirmed by future ana-
lyses, RRKM18 may confer increased sensitivity for HCMV strains TB40/E, Toledo and Davis
to TCR-transgenic T cells, which is a unique property among the HLA class II-restricted TCRs
studied here. Consequently, particular HCMV strains that are less susceptible to detection by
other HLA class II-restricted TCRs tested in this study may be preferentially targeted with the
help of RRKM18. Moreover, RRKM18 is restricted by HLA-DRB3*02:02, which is present in
more than a third of Caucasian, African American and Asian or Pacific Islanders (tab. 5.1), and
may thus be applicable to a broad range of patients.
The impact of differences among various HCMV strains on T cell recognition of infection still
remains largely unknown. There are some publications about HCMV-specific T cells that show
the impact of such variants on T cell recognition: Smith et al. (2016) showed this for various
CD8+ T cell epitopes including IE-1199-207 (EL RRKM MYM vs. EL KRKM IYM) and two related
epitopes (IE-1198-206 and IE-1201-210), which interestingly overlap with the CD4+ T cell epitope
RRKM (IE-1201-215) that was just discussed. They reported that some of the HCMV-specific T
cell responses were strain-specific. In contrast, earlier work of this group has shown that some
HCMV-specific CD8+ T cells can recognise HCMV strain variants equally well (CRVL CCYV L
vs. CRVL CCYI L, IE-1309-317, see Ameres et al., 2013). Unfortunately, recognition of genetically
different HCMV strains by CD4+ T cells is even less clear than recognition by CD8+ T cells, but
this topic will hopefully be addressed by future research as genetic information about HCMV
strain variation becomes available (Renzette et al., 2011, 2015).
Since HLA-DP was historically difficult to type, it is often not matched in allo-HSCT (Fleis-
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chhauer et al., 2012) and thus a potential source of alloreactivity. Although HLA-DP mismatch
increases the risk for mortality and severe GvHD after allo-HSCT (Fleischhauer et al., 2012; Zino
et al., 2003), it may also be beneficial to kill leukemia cells by alloreactive T cells (Graft-versus-
leukemia, GvL) that are restricted by HLA-DP. Therefore, HLA-DP requires special considera-
tion in allo-HSCT.
HLA-DP-restricted T cells have been studied less frequently than DR- and DQ-restricted T cells.
This work identifies the first HCMV-specific TCRs that are restricted by HLA-DP. In contrast
to HLA-DR and -DQ, DP is less polymorphic and the repertoires of its α and β chains are dom-
inated by one allele each: HLA-DPA1*01:03 and DPB1*04:01 with frequencies of 81.9% and
43.9%, respectively (Hollenbach et al., 2012, Caucasian population). Both HLA-DP-restricted
TCRs that were identified and tested in this study are not restricted by the dominant allele
HLA-DPB1*04:01, but by DPB1*03:01 which is the fourth most frequent HLA-DPB1 allele in
Caucasians (10.1%, see Hollenbach et al., 2012).
Each of the two SVMK-specific, HLA class II-restricted TCRs conveyed a strong sensitivity for
infection with AD169 or TB40-BAC4 to TCR-transgenic T cells (fig. 4.30). Among IE-1-specific
TCRs, the IFN-γ levels secreted by TCR-transgenic δ2 T cells were exceptionally high. Evalu-
ation of the function of SVMK6 and SVMK27, however, was only performed with one cell line
per TCR and T cell subpopulation each, so more experiments are required to ensure the obtained
data were no exception. If the strength of both SVMK-specific TCRs could be confirmed, they
may yield a great potential for detecting HCMV-infected target cells that express HLA class II
molecules, like professional APCs. Both TCRs are restricted by HLA-DPB1*03:01 that is present
in a large proportion of Caucasians (19.2%, see tab. 5.1). Additionally, patients that harbour
either DPB1*14:01 or DPB1*20:01, both of which share a high degree of homology with HLA-
DPB1*03:01 (99.6% homology each, Marsh et al., 2000), may also benefit from SVMK-specific
T cells (2.3% or 1.1% of Caucasians, respectively, see tab. 5.1).
Zino et al. (2003, 2007) redefined HLA-DP matching in a group-specific instead of an allele-
specific manner and sorted HLA-DPB1 alleles into three groups associated with high, intermedi-
ate or low immunogenicity, as presumed on the basis of a shared alloreactive T cell epitope (TCE3,
see Crocchiolo et al., 2009). The purpose of this grouping was to identify HLA-DPB1 mismatches
that might be tolerated (“permissive mismatch”) and those that would increase risks (“non-
permissive mismatch”) after allo-HSCT (Fleischhauer et al., 2012), and indeed non-permissive
mismatches were associated with a significantly higher risk of adverse outcome than permissive
mismatches (Crocchiolo et al., 2009; Zino et al., 2003). HLA-DPB1*03:01, DPB1*14:01 and
DPB1*45:01 were allocated to the TCE3 group no. 2 with total frequencies of 14.3%, 7.5% and
6.0% in the “white”, Asian and African population, respectively (Zino et al., 2003). Regardless of
the apparent sequence similarity to HLA-DPB1*03:01, Zino et al. (2003) allocated DPB1*20:01
to TCE3 group no. 3, which also contained the dominant allele HLA-DPB1*04:01.
In general, HCMV-specific TCRs can be transferred into various subpopulations of T lympho-
cytes. As shown for such TCRs described in the present study, αβ T cells and δ2 T cells recognise
HCMV infection if equipped with an HLA class I- or class II-restricted TCR. Depending on the
phenotype of the receiving T cell population, the transfer of TCR genes could direct cytotoxicity
of CTLs to target cells or promote T cell help to establish and maintain HCMV immunity.
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As described earlier, pp65-specific, HLA class II-restricted TCRs mediated the recognition of
both HCMV-infected DCs and DCs that were not infected but presented viral peptides derived
from exogenous material equally well (fig. 4.34). If a pp65-specific, HLA class II-restricted
TCR is transferred into CD8+ CTLs, these cells will kill HCMV-infected APCs and could thus
prevent viral dissemination by hematopoietic and other HLA class II-expressing cells. On the
other hand, they would also kill APCs that were not infected but have taken up viral antigens
from exogenous sources thereby curtailing HCMV-specific immune responses that depend on the
professional presentation of viral antigens to T and B cells. Thus, pp65-specific TCRs may be
best put to use by transferring them into CD4+ TH cells that will subsequently provide help to
other HCMV-specific immune cells after encountering HLA class II-expressing APCs.
In contrast, IE-1-specific, HLA class II-restricted TCRs preferentially mediated recognition of
HCMV-infected DCs, but not DCs that presented viral peptides derived from exogenous sources
(fig. 4.34). By sparing APCs that have not been infected, but present peptides derived from
HCMV antigens nonetheless, these APCs will remain available for initiating and promoting im-
mune responses against HCMV infection and will thus strengthen HCMV immunity. However,
the genes of IE-1-specific, HLA class II-restricted TCRs may also be transferred into CD8+
CTLs to selectively kill HCMV-infected, HLA class II-expressing APCs, which is important to
limit viral dissemination and prevent shedding of virus. Since the latency reservoir is formed by
CD34+ HPCs and cells of the myeloid lineage (Kondo et al., 1994; Sinclair and Sissons, 2006;
Sindre et al., 1996) all of which express HLA class II molecules, reactivation of HCMV in those
cells may be detected early by IE-1-specific, HLA class II-restricted T cells, which could prevent
release of virus progeny.
Synergistic effects may even be obtained by combining CD8+ T cells engineered to express an
HCMV-specific, HLA class I-restricted TCR with CD4+ T cells engineered to express an HCMV-
specific, HLA class II-restricted TCR. This hypothesis is supported by a synergistic anti-tumour
effect observed with CD4+ and CD8+ T cells that were engineered to express the same CAR
in a murine leukemia model (Sommermeyer et al., 2016) and the efficient treatment of human
leukemia patients with CAR-engineered T cells of a defined CD4:CD8 ratio (Turtle et al., 2016).
It will be important to determine what may be an optimal composition of HCMV-specific T
cells that will respond to HLA class I- and class II-expressing target cells and whether there is a
combination of certain TCRs that is particularly protective.
In order to successfully control HCMV infection and reactivation in immunocompromised
patients after adoptive T cell transfer, specificities that correlate with protection from HCMV
disease remain to be determined. Moreover, the efficacy and toxicity profiles of αβ T cells and
δ2 T cells have to be compared to decide which T cell subset is better suited for application in
adoptive T cell therapy in the long run. Both questions must ultimately be answered in clinical
trials.
Within the next decades, HCMV will remain a serious threat to immunocompromised individuals.
A new and promising virostatic compound has been discovered (Letermovir, see Marty et al.,
2017), but HCMV may develop resistances against it. On the other hand, big clinical studies
have been initiated (“CORDIS”: EU-funded, multi-national trial, targeting CMV, EBV and
Adenovirus) to establish adoptive T cell transfer as treatment for refractory viral infection post-
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HSCT. However, as previously mentioned, such trials only include HCMV+ HSCT donors to date,
but a solution for HCMV– HSCT donors, whose HCMV+ recipients are at higher risk of viral
reactivation (Ganepola et al., 2007; Ljungman et al., 2014), is urgently needed. Recombinant
antigen receptor techniques have now been established in clinical application due to many studies
on CD19-specific CARs and their excellent success (Chow et al., 2018; Kochenderfer et al., 2015;
Schuster et al., 2017). Thus, adoptive immunotherapy using TCR-transgenic T cells will be easier
to perform in the future because the production of genetically engineered T cells will become
much more widespread and commonplace. Therefore, HCMV-specific TCR therapy stands a
realistic chance of becoming clinical routine in the future, potentially as part of a platform
of multiple virus- and tumour-specific TCRs that will be available as libraries to choose from
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A/I ratio Active/inactive virus recognition ratio
AIDS Acquired immunodeficiency syndrome
ALP Alkaline phosphatase
APC Allophycocyanin










C (terminus) Carboxy (terminus)
CAR Chimeric antigen receptor
Cat.No. Catalogue number
CD Cluster of differentiation (cell surface marker)
cDNA Complementary desoxyribonucleic acid
CDR Complementarity determining region
CIITA (HLA) Class II transactivator
CM Central memory (T cell subpopulation)









DOI Digital object idenfifier
DP Double-positive (for CD4 and CD8 co-receptor)
EBV Epstein-Barr virus (HHV-4)
EC50 Half maximal effective concentration
EDTA Ethylenediaminetetraacetic acid
e.g. Latin: exempli gratia (meaning “for example”)
ELISA Enzyme-linked immunosorbent assay
EM Effector memory (T cell subpopulation)
EMRA Effector memory (T cell subpopulation), re-expressing CD45RA
ER Endoplasmic reticulum
ERAAP ER aminopeptidase associated with antigen processing
e:t (ratio) Effector-to-target (ratio)
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Abbreviation Full name
et al. Latin: et alii (meaning “and others”)
FACS Fluorescence-activated cell sorting
FBS Fetal bovine serum (also called FCS)





GFP Green fluorescent protein
GM-CSF Granulocyte-macrophage colony-stimulating factor
GMP Good manufacturing practice
gp Glycoprotein
GTP Guanosine triphosphate
GTPase Enzyme that binds and hydrolyses GTP
GvHD Graft-versus-host disease
GvL Graft-versus-leukemia
Gy Gray (unit of energy dose, e.g. for ionising radiation; Gy = J/kg
HCMV Human cytomegalovirus
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HHV Human herpes virus
HIV Human immunodeficiency virus
HLA Human leukocyte antigen
HMB-PP (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate
HPC Hematopoietic progenitor cell
HS Human serum
HSC Hematopoietic stem cell
HSCT Hematopoietic stem cell transplantation
IC50 Half maximal inhibitory concentration
ICOS Inducible co-stimulator
i.e. Latin: id est (meaning “that is to say”)
IE Immediate-early




IMGT International ImMunoGeneTics information system
(http://www.imgt.org/, founder and director: Marie-Paule Lefranc,
Montpellier, France)
IPP Isopentenyl pyrophosphate
IRES Internal ribosome entry site
ITAM Immunoreceptor tyrosine-based activation motif
J Joining
kb Kilobases (or kilo base pairs)
kDa Kilodalton
KIR Killer cell immunoglobulin-like receptor
L Ligand (e.g. CD40L)
LCL Lymphoblastoid cell line
LILRB1 Leukocyte immunoglobulin-like receptor subfamily B member 1
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Abbreviation Full name
LPS Lipopolysaccharide
LTR Long terminal repeat
MACS Magnetic-activated cell sorting
M-CSF Macrophage colony-stimulating factor
MCMV Murine cytomegalovirus
MEP pathway 2-C-methyl-D-erythritol 4-phosphate pathway
MFI Mean fluorescence intensity
MHC Major histocompatibility complex
mini-EBV Genetically modified Epstein Barr Virus that contains a reduced set
of viral genes but all necessary genes and elements for transformation
of primary B cells
mini-LCL Lymphoblastoid cell line created by using mini-EBV
mio Million (106)
miRNA Micro-ribonucleic acid (non-coding)
moDC Monocyte-derived dendritic cell
MOI Multiplicity of infection
mRNA Messenger ribonucleic acid
mu Murinised
MVA Modified vaccinia Ankara
N Naïve (T cell subpopulation)
N (terminus) Amino (terminus)
n/a Not applicable
NCBI National Center for Biotechnology Information
https://www.ncbi.nlm.nih.gov
n.d. Not determined
NEAA Non-essential amino acids
NK cell Natural killer cell
NOD Nuclear oligomerisation domain
nt Nucleotide
ORF Open reading frame
P2A Picornavirus ’self-cleaving’ 2A peptide
PAM Pamidronate
PAMP Pathogen-associated molecular pattern
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
pCMV Human cytomegalovirus immediate-early enhancer and promoter
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Abbreviation Full name
PRR Pattern recognition receptor
rhu Recombinant human
RNA Ribonucleic acid
rpm Revolutions per minute
RPMI Roswell Park Memorial Institute (cell culture medium)
SD Standard deviation
SSC Side scatter
SOT Solid organ transplantation
SP Single-positive (for CD4 and CD8 co-receptor)
T Thymidine
Tab. Table
TAE Tris, acetate & EDTA
TAP Transporter associated with antigen processing
TCID50 50% infectious tissue culture dose
TCR T cell receptor
TH cell Helper T cell or T helper cell
TLR Toll-like receptor








v/v Volume per volume
w/v Weight per volume
WT Wild-type




Zu allererst möchte ich meinen Eltern für ihre bedingungslose Unterstützung in vielerlei Hinsicht
danken. Ohne ihre unermüdliche Hilfe und ihr Vertrauen hätte ich mein Studium, diese Pro-
motion und viele andere Herausforderungen im Leben nicht geschafft. Auch meiner Schwester
möchte ich von ganzem Herzen für ihre Hilfe, Aufmunterungen und Lehren aus ihren eigenen
Lebenserfahrungen danken. Ohne euch wäre diese Arbeit nicht möglich gewesen und ich hätte
dieses Ziel nicht erreicht!
Andreas Moosmann möchte ich herzlich für seine Betreuung, Hilfsbereitschaft und die un-
zähligen Erklärungen und Diskussionen danken, die er mir während der Promotion hat zuteil
werden lassen. Auch für das in mich gesetzte Vertrauen, sein Verständnis und die mir von ihm
vermittelte Freiheit in der Ausführung meiner Aufgaben möchte ich ihm danken.
Wolfgang Hammerschmidt, Josef Mautner und Christina Zielinski möchte ich für ihre be-
ratende Unterstützung als Mitglieder des Promotionskomitees, sowie ihre Hilfe in mancherlei
organisatorischer oder experimenteller Hinsicht danken.
Horst Domdey möchte ich für seine Bereitschaft danken diese Arbeit als Fachvertreter der Fak-
ultät für Chemie und Pharmazie zu betreuen und sie als Gutachter zu bewerten.
Für Reagenzien, ohne die einige Experimente nicht möglich oder ungleich schwieriger gewesen
wären, möchte ich mich bei Josef Mautner, Michael Neuenhahn, Fabian Schlott, Dirk Busch,
Kilian Schober, Bodo Plachter und meinen ehemaligen sowie derzeitigen Kollegen aus Andreas’
Arbeitsgruppe bedanken.
Mein Dank gilt allen Blutspendern, die viele Experimente durch ihre Spendebereitschaft erst
möglich gemacht haben. Insbesonders möchte ich Kathrin Gärtner und Paulina Mrozek-Gorska
für die häufigen Blutspenden danken. Außerdem möchte ich mich bei allen Mitgliedern der
Abteilung Genvektoren bedanken, die mich im Lauf der Zeit unterstützt haben und mir bei
verschiedenen Herausforderungen geholfen haben. Dabei möchte ich insbesonders Larissa Mar-
tin für ihre Unterstützung, Hilfsbereitschaft und motivierenden Worte danken. Ebenso möchte
ich Andreas von Kries für seine tatkräftige Unterstützung und seinen Fleiß während der Durch-
führung seines Praxissemesters und seiner Bachelorarbeit in meiner Obhut danken.
Außerdem möchte ich mich besonders bei Manuel Diehl, Larissa Martin, Bettina von Neubeck,
Corinna Hüls, Markus Lechner, Alexandra Hollaus und allen Mitgliedern der Graduate School
des SFB-TR36 für die gute Zeit, die wir zusammen hatten, bedanken.
Ich möchte mich bei meinen Freunden für ihr Verständnis, ihre Unterstützung, die Ablenkung
in der Freizeit und vor allem ihre langjährige Freundschaft bedanken.
Zu guter Letzt, möchte ich mich von ganzem Herzen bei meiner Frau bedanken, die mich oft
ermuntert, ertragen und dabei stets an mich geglaubt hat. Ohne ihr Einfühlungsvermögen, ihre
Geduld und Unterstützung wäre die Zeit außerhalb des Labors nicht so schön gewesen, wie sie
war.
197

